The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT JJ NNS O
perpetual perpetual 0 0 0 0 0 0 0 0 9 0 NONE DT JJ NNS IN O
movements movements 0 0 0 0 0 0 0 0 9 0 DT JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
anaphase. anaphase. 0 0 0 0 0 0 0 0 9 0 NNS IN NNP NNP NNP B_TIMEXCCP
Maiato Maiato 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lince-Faria Lince-Faria 1 0 1 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Instituto Instituto 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biologia Biologia 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NN O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NN -NONE- O
e e 0 0 0 0 0 0 0 0 1 0 NNP NNP NN -NONE- NNP O
Celular, Celular, 1 0 0 0 1 0 0 0 8 0 NNP NN -NONE- NNP VBP O
Universidade Universidade 1 0 0 0 0 0 0 0 12 0 NN -NONE- NNP VBP -NONE- O
do do 0 0 0 0 0 0 0 0 2 0 -NONE- NNP VBP -NONE- NNP O
Porto, Porto, 1 0 0 0 1 0 0 0 6 0 NNP VBP -NONE- NNP VBP O
Rua Rua 1 0 0 0 0 0 0 0 3 0 VBP -NONE- NNP VBP NNP O
do do 0 0 0 0 0 0 0 0 2 0 -NONE- NNP VBP NNP NNP O
Campo Campo 1 0 0 0 0 0 0 0 5 0 NNP VBP NNP NNP CD O
Alegre Alegre 1 0 0 0 0 0 0 0 6 0 VBP NNP NNP CD CD O
823, 823, 0 0 0 0 1 0 0 1 4 0 NNP NNP CD CD JJ O
4150-180, 4150-180, 0 0 1 0 1 0 0 1 9 0 NNP CD CD JJ NNP O
Porto, Porto, 1 0 0 0 1 0 0 0 6 0 CD CD JJ NNP NNP O
Portugal. Portugal. 1 0 0 0 0 0 0 0 9 0 CD JJ NNP NNP NNP O
maiato@ibmc.up.pt maiato@ibmc.up.pt 0 0 0 0 0 0 0 0 17 0 JJ NNP NNP NNP CD O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CD IN O
One One 1 0 0 0 0 0 0 0 3 0 NNP NNP CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP CD IN DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 IN DT RBS JJ NNS O
extraordinary extraordinary 0 0 0 0 0 0 0 0 13 0 DT RBS JJ NNS IN O
events events 0 0 0 0 0 0 0 0 6 0 RBS JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
lifetime lifetime 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN VBZ O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT VBN NN O
coordinated coordinated 0 0 0 0 0 0 0 0 11 0 VBZ DT VBN NN IN O
separation separation 0 0 0 0 0 0 0 0 10 0 DT VBN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN NNS O
sister sister 0 0 0 0 0 0 0 0 6 0 NN IN NN NNS IN O
chromatids chromatids 0 0 0 0 0 0 0 0 10 0 IN NN NNS IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NN NNS IN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NNP NNP O
division. division. 0 0 0 0 0 0 0 0 9 0 IN NN NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ RB DT O
truly truly 0 0 0 0 0 0 0 0 5 0 NNP VBZ RB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ RB DT NN IN O
essence essence 0 0 0 0 0 0 0 0 7 0 RB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ JJ O
entire entire 0 0 0 0 0 0 0 0 6 0 IN DT JJ JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NN CC B_TIMEXCCP
process process 0 0 0 0 0 0 0 0 7 0 JJ JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
reason reason 0 0 0 0 0 0 0 0 6 0 CC DT NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJS NN O
most most 0 0 0 0 0 0 0 0 4 0 IN DT JJS NN JJ O
profound profound 0 0 0 0 0 0 0 0 8 0 DT JJS NN JJ NNS O
morphological morphological 0 0 0 0 0 0 0 0 13 0 JJS NN JJ NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 NN JJ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN CC O
cytoskeleton cytoskeleton 0 0 0 0 0 0 0 0 12 0 NNS IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 NN CC JJ NN WDT O
organization organization 0 0 0 0 0 0 0 0 12 0 CC JJ NN WDT DT O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN WDT DT NN MD O
cell cell 0 0 0 0 0 0 0 0 4 0 WDT DT NN MD RB O
may may 0 0 0 0 0 0 0 0 3 0 DT NN MD RB NNP O
ever ever 0 0 0 0 0 0 0 0 4 0 NN MD RB NNP PRP O
experience. experience. 0 0 0 0 0 0 0 0 11 0 MD RB NNP PRP DT O
It It 1 0 0 0 0 0 0 0 2 0 RB NNP PRP DT NNS O
all all 0 0 0 0 0 0 0 0 3 0 NNP PRP DT NNS IN O
occurs occurs 0 0 0 0 0 0 0 0 6 0 PRP DT NNS IN DT O
within within 0 0 0 0 0 0 0 0 6 0 DT NNS IN DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT RB JJ O
very very 0 0 0 0 0 0 0 0 4 0 IN DT RB JJ NN O
short short 0 0 0 0 0 0 0 0 5 0 DT RB JJ NN NN O
time time 0 0 0 0 0 0 0 0 4 0 RB JJ NN NN VBN O
window window 0 0 0 0 0 0 0 0 6 0 JJ NN NN VBN IN O
known known 0 0 0 0 0 0 0 0 5 0 NN NN VBN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 NN VBN IN NNP IN O
"anaphase", "anaphase", 0 0 0 0 1 0 0 0 11 0 VBN IN NNP IN IN B_TIMEXCCP
as as 0 0 0 0 0 0 0 0 2 0 IN NNP IN IN DT O
if if 0 0 0 0 0 0 0 0 2 0 NNP IN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN IN DT NN VBD O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN VBD VBN O
had had 0 0 0 0 0 0 0 0 3 0 DT NN VBD VBN DT O
spent spent 0 0 0 0 0 0 0 0 5 0 NN VBD VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD VBN DT NN IN O
rest rest 0 0 0 0 0 0 0 0 4 0 VBN DT NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN VBG O
existence existence 0 0 0 0 0 0 0 0 9 0 IN PRP$ NN VBG RB O
getting getting 0 0 0 0 0 0 0 0 7 0 PRP$ NN VBG RB IN O
ready ready 0 0 0 0 0 0 0 0 5 0 NN VBG RB IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBG RB IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 RB IN DT NN IN O
moment moment 0 0 0 0 0 0 0 0 6 0 IN DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NN O
ultimate ultimate 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN IN O
act act 0 0 0 0 0 0 0 0 3 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CC O
survival. survival. 0 0 0 0 0 0 0 0 9 0 NN IN NNP CC EX O
And And 1 0 0 0 0 0 0 0 3 0 IN NNP CC EX VBZ O
there there 0 0 0 0 0 0 0 0 5 0 NNP CC EX VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 CC EX VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 EX VBZ DT JJ NN O
good good 0 0 0 0 0 0 0 0 4 0 VBZ DT JJ NN IN O
reason reason 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN DT O
this: this: 0 0 0 0 0 0 0 0 5 0 NN IN NN DT NN O
no no 0 0 0 0 0 0 0 0 2 0 IN NN DT NN IN O
space space 0 0 0 0 0 0 0 0 5 0 NN DT NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NNP NNP O
mistakes. mistakes. 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP IN O
Problems Problems 1 0 0 0 0 0 0 0 8 0 IN NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NN IN NNS IN NN O
during during 0 0 0 0 0 0 0 0 6 0 IN NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN VBP O
division division 0 0 0 0 0 0 0 0 8 0 IN NN NN VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN NN VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBP VBN VBN IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 VBP VBN VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBN VBN IN JJ DT O
aneuploidy, aneuploidy, 0 0 0 0 1 0 0 0 11 0 VBN IN JJ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN JJ DT JJ NN O
common common 0 0 0 0 0 0 0 0 6 0 JJ DT JJ NN VBN O
feature feature 0 0 0 0 0 0 0 0 7 0 DT JJ NN VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 JJ NN VBN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN VBN IN NNS CC O
cancers cancers 0 0 0 0 0 0 0 0 7 0 VBN IN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC JJ JJ O
several several 0 0 0 0 0 0 0 0 7 0 NNS CC JJ JJ NN O
birth birth 0 0 0 0 0 0 0 0 5 0 CC JJ JJ NN CC O
defects, defects, 0 0 0 0 1 0 0 0 8 0 JJ JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NN O
main main 0 0 0 0 0 0 0 0 4 0 CC DT JJ NN IN O
cause cause 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
spontaneous spontaneous 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN IN O
abortion abortion 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
humans. humans. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
paper, paper, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP RB O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP RB VB O
critically critically 0 0 0 0 0 0 0 0 10 0 NN PRP RB VB DT O
review review 0 0 0 0 0 0 0 0 6 0 PRP RB VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 VB DT NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN NN O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NNS IN NN NN NN B_TIMEXCCP
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN NN NN NN WDT O
motion motion 0 0 0 0 0 0 0 0 6 0 NN NN NN WDT VBN O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT VBN DT O
resisted resisted 0 0 0 0 0 0 0 0 8 0 NN WDT VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBN DT NN IN O
scrutiny scrutiny 0 0 0 0 0 0 0 0 8 0 VBN DT NN IN JJR O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJR IN O
more more 0 0 0 0 0 0 0 0 4 0 NN IN JJR IN CD O
than than 0 0 0 0 0 0 0 0 4 0 IN JJR IN CD NNS O
100 100 0 0 0 0 0 0 1 1 3 0 JJR IN CD NNS IN O
years years 0 0 0 0 0 0 0 0 5 0 IN CD NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN JJ IN O
research, research, 0 0 0 0 1 0 0 0 9 0 NNS IN JJ IN NN O
as as 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN IN O
part part 0 0 0 0 0 0 0 0 4 0 JJ IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN TO O
tribute tribute 0 0 0 0 0 0 0 0 7 0 IN DT NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN NN O
pioneering pioneering 0 0 0 0 0 0 0 0 10 0 TO DT NN NN IN O
work work 0 0 0 0 0 0 0 0 4 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
Miguel Miguel 1 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NNP O
Mota. Mota. 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
20306325 20306325 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NNP O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 NONE DT NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT NN NNP NNP NNP B_TIMEXCCP
Damelin Damelin 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bestor Bestor 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
TH. TH. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Genetics Genetics 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Development, Development, 1 0 0 0 1 0 0 0 12 0 NNP CC NNP NNP IN O
College College 1 0 0 0 0 0 0 0 7 0 CC NNP NNP IN NNPS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNPS CC O
Physicians Physicians 1 0 0 0 0 0 0 0 10 0 NNP IN NNPS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNPS CC NNS IN O
Surgeons Surgeons 1 0 0 0 0 0 0 0 8 0 NNPS CC NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NNS IN NNP NNP O
Columbia Columbia 1 0 0 0 0 0 0 0 8 0 NNS IN NNP NNP CD O
University, University, 1 0 0 0 1 0 0 0 11 0 IN NNP NNP CD NNP O
701 701 0 0 0 0 0 0 1 1 3 0 NNP NNP CD NNP CD O
W. W. 1 1 0 0 0 0 0 0 2 0 NNP CD NNP CD -NONE- O
168th 168th 0 0 0 0 0 0 0 1 5 0 CD NNP CD -NONE- NNP O
St., St., 1 0 0 0 1 0 0 0 4 0 NNP CD -NONE- NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 CD -NONE- NNP NNP NNP O
York, York, 1 0 0 0 1 0 0 0 5 0 -NONE- NNP NNP NNP CD O
NY NY 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
10032, 10032, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NN O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 NNP NNP NN NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP NN NN NNS NN B_TIMEXCCP
delays delays 0 0 0 0 0 0 0 0 6 0 NN NN NNS NN IN O
entry entry 0 0 0 0 0 0 0 0 5 0 NN NNS NN IN NN O
into into 0 0 0 0 0 0 0 0 4 0 NNS NN IN NN IN O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 NN IN NN IN DT O
until until 0 0 0 0 0 0 0 0 5 0 IN NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN DT NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 DT NNS VBP VBN NNP O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN NNP NNP O
disentangled. disentangled. 0 0 0 0 0 0 0 0 13 0 VBP VBN NNP NNP IN O
Deficiency Deficiency 1 0 0 0 0 0 0 0 10 0 VBN NNP NNP IN CC O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NNP IN CC NN IN O
bypass bypass 0 0 0 0 0 0 0 0 6 0 IN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 IN DT NN NN MD O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT NN NN MD VB B_TIMEXCCP
can can 0 0 0 0 0 0 0 0 3 0 NN NN MD VB NN O
cause cause 0 0 0 0 0 0 0 0 5 0 NN MD VB NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 MD VB NN NN CC O
breakage breakage 0 0 0 0 0 0 0 0 8 0 VB NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
nondisjunction nondisjunction 0 0 0 0 0 0 0 0 14 0 NN CC NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 CC NN IN JJ WDT O
mitosis, mitosis, 0 0 0 0 1 0 0 0 8 0 NN IN JJ WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 IN JJ WDT NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 JJ WDT NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 WDT NNS IN NN CC O
aneuploidy aneuploidy 0 0 0 0 0 0 0 0 10 0 NNS IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN CC NN NNS IN O
rearrangements rearrangements 0 0 0 0 0 0 0 0 14 0 CC NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
daughter daughter 0 0 0 0 0 0 0 0 8 0 IN DT NN NNP DT O
cells. cells. 0 0 0 0 0 0 0 0 6 0 DT NN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT NN IN O
deficiency deficiency 0 0 0 0 0 0 0 0 10 0 NNP DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 IN DT NN NN VBZ O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 DT NN NN VBZ VBN B_TIMEXCCP
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
reported reported 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NN CC O
lung lung 0 0 0 0 0 0 0 0 4 0 VBN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NN CC NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 CC NN NN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NNS CC O
lines lines 0 0 0 0 0 0 0 0 5 0 NN NN NNS CC MD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNS CC MD VB TO O
contribute contribute 0 0 0 0 0 0 0 0 10 0 CC MD VB TO DT O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VB TO DT NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 TO DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS WDT O
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 IN NN NNS WDT RB O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT RB VBP O
commonly commonly 0 0 0 0 0 0 0 0 8 0 NNS WDT RB VBP IN O
occur occur 0 0 0 0 0 0 0 0 5 0 WDT RB VBP IN PRP$ O
during during 0 0 0 0 0 0 0 0 6 0 RB VBP IN PRP$ NNP O
tumour tumour 0 0 0 0 0 0 0 0 6 0 VBP IN PRP$ NNP NNP O
progression. progression. 0 0 0 0 0 0 0 0 12 0 IN PRP$ NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 PRP$ NNP NNP NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN VBZ B_TIMEXCCP
deficiency deficiency 0 0 0 0 0 0 0 0 10 0 NNP NN NN VBZ RB O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN VBZ RB VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 VBZ RB VBN VBN IN O
documented documented 0 0 0 0 0 0 0 0 10 0 RB VBN VBN IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN VBN NN O
cultured cultured 0 0 0 0 0 0 0 0 8 0 VBN IN VBN NN CC O
stem stem 0 0 0 0 0 0 0 0 4 0 IN VBN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBN NN CC NN NN O
progenitor progenitor 0 0 0 0 0 0 0 0 10 0 NN CC NN NN CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 CC NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN CC NN NN NNS O
stem stem 0 0 0 0 0 0 0 0 4 0 CC NN NN NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP JJ TO O
likely likely 0 0 0 0 0 0 0 0 6 0 NNS VBP JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 JJ TO VB VBN IN O
derived derived 0 0 0 0 0 0 0 0 7 0 TO VB VBN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 VB VBN IN NN CC O
stem stem 0 0 0 0 0 0 0 0 4 0 VBN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN NNS O
progenitor progenitor 0 0 0 0 0 0 0 0 10 0 NN CC NN NNS WDT O
cells cells 0 0 0 0 0 0 0 0 5 0 CC NN NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT VBP DT O
lack lack 0 0 0 0 0 0 0 0 4 0 NNS WDT VBP DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 WDT VBP DT JJ NN O
effective effective 0 0 0 0 0 0 0 0 9 0 VBP DT JJ NN NNP O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 DT JJ NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NN B_TIMEXCCP
An An 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN NN O
inefficient inefficient 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NN NN O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 NNP NN NN NN VBZ O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN NN NN VBZ JJ B_TIMEXCCP
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ TO O
likely likely 0 0 0 0 0 0 0 0 6 0 NN VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB DT O
be be 0 0 0 0 0 0 0 0 2 0 JJ TO VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT NN IN O
source source 0 0 0 0 0 0 0 0 6 0 VB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN DT NN NNS WDT O
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 DT NN NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNS WDT VBP JJ NNS O
common common 0 0 0 0 0 0 0 0 6 0 WDT VBP JJ NNS IN O
features features 0 0 0 0 0 0 0 0 8 0 VBP JJ NNS IN JJS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 NNS IN JJS JJ CC O
tumours, tumours, 0 0 0 0 1 0 0 0 8 0 IN JJS JJ CC DT O
but but 0 0 0 0 0 0 0 0 3 0 JJS JJ CC DT NN O
an an 0 0 0 0 0 0 0 0 2 0 JJ CC DT NN NN O
inefficient inefficient 0 0 0 0 0 0 0 0 11 0 CC DT NN NN NN O
decatenation decatenation 0 0 0 0 0 0 0 0 12 0 DT NN NN NN IN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN NN NN IN NN B_TIMEXCCP
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN IN NN NN NNS O
stem stem 0 0 0 0 0 0 0 0 4 0 IN NN NN NNS MD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS MD RB O
could could 0 0 0 0 0 0 0 0 5 0 NN NNS MD RB VB O
also also 0 0 0 0 0 0 0 0 4 0 NNS MD RB VB DT O
provide provide 0 0 0 0 0 0 0 0 7 0 MD RB VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 RB VB DT JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN IN O
target target 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NNP NNP O
chemotherapy. chemotherapy. 0 0 0 0 0 0 0 0 13 0 NN IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
17211475 17211475 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2360007 PMC2360007 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Mathematical Mathematical 1 0 0 0 0 0 0 0 12 0 NONE NONE JJ NNS IN O
models models 0 0 0 0 0 0 0 0 6 0 NONE JJ NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 phase IN DT NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNP O
Saccharomyces Saccharomyces 1 0 0 0 0 0 0 0 13 0 NN IN NNP NNP NNP O
cerevisiae. cerevisiae. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NNP O
Britton Britton 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
NF, NF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wheals Wheals 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
AE. AE. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Mathematics, Mathematics, 1 0 0 0 1 0 0 0 12 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Bath, Bath, 1 0 0 0 1 0 0 0 5 0 NNP IN NNP NNP NNP O
England. England. 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNS O
Three Three 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS IN O
models models 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT VBG NN O
budding budding 0 0 0 0 0 0 0 0 7 0 IN DT VBG NN NNS O
yeast, yeast, 0 0 0 0 1 0 0 0 6 0 DT VBG NN NNS -NONE- O
Saccharomyces Saccharomyces 1 0 0 0 0 0 0 0 13 0 VBG NN NNS -NONE- WDT O
cerevisiae, cerevisiae, 0 0 0 0 1 0 0 0 11 0 NN NNS -NONE- WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 NNS -NONE- WDT VBP DT O
include include 0 0 0 0 0 0 0 0 7 0 -NONE- WDT VBP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBP DT JJ NNP O
reversible reversible 0 0 0 0 0 0 0 0 10 0 VBP DT JJ NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 phase DT JJ NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 JJ NNP NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NNP NN IN JJ VBP O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 NN IN JJ VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 IN JJ VBP NNP NNP O
presented. presented. 0 0 0 0 0 0 0 0 10 0 JJ VBP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBP NNP NNP NN VBZ O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBZ NNS O
gives gives 0 0 0 0 0 0 0 0 5 0 NNP NN VBZ NNS IN O
estimates estimates 0 0 0 0 0 0 0 0 9 0 NN VBZ NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBZ NNS IN JJ NNS O
various various 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NNS IN O
quantities quantities 0 0 0 0 0 0 0 0 10 0 IN JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
biological biological 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NN JJ O
interest, interest, 0 0 0 0 1 0 0 0 9 0 IN JJ NN JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 JJ NN JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
probability probability 0 0 0 0 0 0 0 0 11 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN TO O
entry entry 0 0 0 0 0 0 0 0 5 0 NN IN NN TO CC O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN TO CC NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 TO CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN IN O
exit exit 0 0 0 0 0 0 0 0 4 0 NN IN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 IN DT NNP NNP DT B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 DT NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
average average 0 0 0 0 0 0 0 0 7 0 NNP DT JJ NN IN O
duration duration 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 IN DT NNP NNP DT B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 DT NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP DT NN NN IN O
time time 0 0 0 0 0 0 0 0 4 0 DT NN NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN VBG NNS O
cycling cycling 0 0 0 0 0 0 0 0 7 0 NN IN VBG NNS CC O
daughters daughters 0 0 0 0 0 0 0 0 9 0 IN VBG NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 VBG NNS CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NN VBG O
population population 0 0 0 0 0 0 0 0 10 0 CC DT NN VBG NN O
doubling doubling 0 0 0 0 0 0 0 0 8 0 DT NN VBG NN IN O
time time 0 0 0 0 0 0 0 0 4 0 NN VBG NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN VBG JJ O
cycling cycling 0 0 0 0 0 0 0 0 7 0 NN IN VBG JJ NN O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN VBG JJ NN IN O
none none 0 0 0 0 0 0 0 0 4 0 VBG JJ NN IN WDT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 IN WDT VBZ RB NNP O
easily easily 0 0 0 0 0 0 0 0 6 0 WDT VBZ RB NNP NNP O
measurable. measurable. 0 0 0 0 0 0 0 0 11 0 VBZ RB NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 RB NNP NNP CD JJ O
3309476 3309476 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Reappraisal Reappraisal 1 0 0 0 0 0 0 0 11 0 NONE NONE NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNP IN JJ NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 arrest NNP IN JJ NN CC B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
synchronization synchronization 0 0 0 0 0 0 0 0 15 0 NN CC NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
lovastatin. lovastatin. 0 0 0 0 0 0 0 0 11 0 NN IN NNP NNP NNP O
Cooper Cooper 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Microbiology Microbiology 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Immunology, Immunology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Michigan Michigan 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
School, School, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Ann Ann 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Arbor, Arbor, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP CD O
MI MI 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
48109-0620, 48109-0620, 0 0 1 0 1 0 0 1 11 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
cooper@umich.edu cooper@umich.edu 0 0 0 0 0 0 0 0 16 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN IN O
proposed proposed 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBN VBN IN NN NNS O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 arrests VBN IN NN NNS NNS O
arrests arrests 0 0 0 0 0 0 0 0 7 0 IN NN NNS NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NNS NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 IN DT NN IN DT B_TIMEXCCP
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
division division 0 0 0 0 0 0 0 0 8 0 IN DT NN NN CC O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 DT NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN CC IN NN IN O
release release 0 0 0 0 0 0 0 0 7 0 CC IN NN IN NN O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN NN NN O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 0 NN IN NN NN NNS O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 IN NN NN NNS DT O
produces produces 0 0 0 0 0 0 0 0 8 0 NN NN NNS DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT VBN NNP O
synchronized synchronized 0 0 0 0 0 0 0 0 12 0 NNS DT VBN NNP NNP O
culture. culture. 0 0 0 0 0 0 0 0 8 0 DT VBN NNP NNP JJ O
A A 1 1 0 0 0 0 0 0 1 0 VBN NNP NNP JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 NNP NNP JJ NN IN O
method method 0 0 0 0 0 0 0 0 6 0 NNP JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN JJ O
methocel methocel 0 0 0 0 0 0 0 0 8 0 NN IN NN JJ VBZ O
time-lapse-videography time-lapse-videography 0 0 1 0 0 0 0 0 22 0 IN NN JJ VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN JJ VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 JJ VBZ VBN VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 VBZ VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB NN O
analyse analyse 0 0 0 0 0 0 0 0 7 0 VBN TO VB NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 TO VB NN NN NNS O
division division 0 0 0 0 0 0 0 0 8 0 VB NN NN NNS VBG O
patterns patterns 0 0 0 0 0 0 0 0 8 0 NN NN NNS VBG NN O
following following 0 0 0 0 0 0 0 0 9 0 NN NNS VBG NN NNP O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 0 NNS VBG NN NNP NNP O
treatment. treatment. 0 0 0 0 0 0 0 0 10 0 VBG NN NNP NNP IN O
Release Release 1 0 0 0 0 0 0 0 7 0 NN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNS O
L1210 L1210 1 1 0 0 0 0 0 1 5 0 NNP IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NN NN O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 0 NNS IN NN NN VBD O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 IN NN NN VBD TO O
failed failed 0 0 0 0 0 0 0 0 6 0 NN NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB VBN O
produce produce 0 0 0 0 0 0 0 0 7 0 VBD TO VB VBN NNP O
synchronized synchronized 0 0 0 0 0 0 0 0 12 0 TO VB VBN NNP NNP O
divisions. divisions. 0 0 0 0 0 0 0 0 10 0 VB VBN NNP NNP NN O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 VBN NNP NNP NN TO O
contrary contrary 0 0 0 0 0 0 0 0 8 0 NNP NNP NN TO JJR O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO JJR JJ O
earlier earlier 0 0 0 0 0 0 0 0 7 0 NN TO JJR JJ NN O
proposals, proposals, 0 0 0 0 1 0 0 0 10 0 TO JJR JJ NN VBD O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 0 JJR JJ NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 JJ NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 arrest NN VBD RB VB NNS O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBD RB VB NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 RB VB NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VB NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 IN DT JJ NN IN B_TIMEXCCP
amount amount 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
DNA. DNA. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP IN O
Analysis Analysis 1 0 0 0 0 0 0 0 8 0 IN NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNS O
previous previous 0 0 0 0 0 0 0 0 8 0 NNP IN JJ NNS IN O
reports reports 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP CC O
'synchronization' 'synchronization' 0 0 0 0 0 1 0 0 17 0 NNS IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NN O
growth-arrest growth-arrest 0 0 1 0 0 0 0 0 13 0 NNP CC JJ NN DT O
support support 0 0 0 0 0 0 0 0 7 0 CC JJ NN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 JJ NN DT NNP NNP O
findings. findings. 0 0 0 0 0 0 0 0 9 0 NN DT NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 DT NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
concluded concluded 0 0 0 0 0 0 0 0 9 0 NNP VBZ VBN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NN DT O
lovastatin lovastatin 0 0 0 0 0 0 0 0 10 0 VBN IN NN DT NNS O
neither neither 0 0 0 0 0 0 0 0 7 0 IN NN DT NNS -NONE- O
synchronizes synchronizes 0 0 0 0 0 0 0 0 12 0 NN DT NNS -NONE- CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 DT NNS -NONE- CC NNS O
nor nor 0 0 0 0 0 0 0 0 3 arrests NNS -NONE- CC NNS NNS O
arrests arrests 0 0 0 0 0 0 0 0 7 0 -NONE- CC NNS NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 CC NNS NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
G1-phase G1-phase 1 0 1 0 0 0 0 1 8 0 IN DT NN IN DT B_TIMEXCCP
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
division division 0 0 0 0 0 0 0 0 8 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP CD O
Copyright Copyright 1 0 0 0 0 0 0 0 9 0 NN NNP NNP CD NNP O
2002 2002 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NNP NNP O
Elsevier Elsevier 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Science Science 1 0 0 0 0 0 0 0 7 0 CD NNP NNP NNP NNP O
Ltd. Ltd. 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
12175675 12175675 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NN O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 NONE DT NN NN NNP B_TIMEXCCP
DNA-damage DNA-damage 1 0 1 0 0 0 0 0 10 0 DT NN NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NNP B_TIMEXCCP
O'Connell O'Connell 1 0 0 0 0 1 0 0 9 0 NN NNP NNP NNP NNP O
MJ, MJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Walworth Walworth 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
NC, NC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Carr Carr 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
AM. AM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Trescowthick Trescowthick 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Laboratories, Laboratories, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
Peter Peter 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
MacCallum MacCallum 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Locked Locked 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CD O
Bag Bag 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD JJ O
1, 1, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD JJ NN O
A'Beckett A'Beckett 1 0 0 0 0 1 0 0 9 0 NNP CD JJ NN NN O
Street, Street, 1 0 0 0 1 0 0 0 7 0 CD JJ NN NN NNP O
Melbourne, Melbourne, 1 0 0 0 1 0 0 0 10 0 JJ NN NN NNP CD O
Victoria Victoria 1 0 0 0 0 0 0 0 8 0 NN NN NNP CD NNP O
8006, 8006, 0 0 0 0 1 0 0 1 5 0 NN NNP CD NNP NNP O
Australia. Australia. 1 0 0 0 0 0 0 0 10 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN NNS O
damage damage 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNS JJ O
causes causes 0 0 0 0 0 0 0 0 6 0 NNP NN NNS JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 NN NNS JJ NN IN O
delay delay 0 0 0 0 0 0 0 0 5 0 NNS JJ NN IN NNP O
before before 0 0 0 0 0 0 0 0 6 0 JJ NN IN NNP NNP O
S S 1 1 0 0 0 0 0 0 1 0 NN IN NNP NNP IN B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NNP NNP IN NN CC O
replication replication 0 0 0 0 0 0 0 0 11 0 NNP IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NNP O
before before 0 0 0 0 0 0 0 0 6 0 NN CC IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 CC IN NNP NNP VBZ B_TIMEXCCP
This This 1 0 0 0 0 0 0 0 4 0 IN NNP NNP VBZ DT O
involves involves 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 VBZ DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB VBN O
highly highly 0 0 0 0 0 0 0 0 6 0 NN IN RB VBN NNS O
conserved conserved 0 0 0 0 0 0 0 0 9 0 IN RB VBN NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 RB VBN NNS IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBN NNS IN NN NNP O
sense sense 0 0 0 0 0 0 0 0 5 0 NNS IN NN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN NN NNP NN CC O
damage damage 0 0 0 0 0 0 0 0 6 0 NN NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ DT O
signal signal 0 0 0 0 0 0 0 0 6 0 NN CC JJ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC JJ DT JJ NNP O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 JJ DT JJ NNP NNP O
machinery. machinery. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP IN O
Kinases Kinases 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP IN VBD O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNP IN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP IN VBD RB VBN O
initially initially 0 0 0 0 0 0 0 0 9 0 IN VBD RB VBN IN O
discovered discovered 0 0 0 0 0 0 0 0 10 0 VBD RB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN NN O
yeast yeast 0 0 0 0 0 0 0 0 5 0 VBN IN NN NN NNS O
model model 0 0 0 0 0 0 0 0 5 0 IN NN NN NNS VBP O
systems systems 0 0 0 0 0 0 0 0 7 0 NN NN NNS VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP RB VBN O
recently recently 0 0 0 0 0 0 0 0 8 0 NNS VBP RB VBN RP O
been been 0 0 0 0 0 0 0 0 4 0 VBP RB VBN RP TO O
shown shown 0 0 0 0 0 0 0 0 5 0 RB VBN RP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN RP TO VB DT O
regulate regulate 0 0 0 0 0 0 0 0 8 0 RP TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
regulators regulators 0 0 0 0 0 0 0 0 10 0 VB DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NNS O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 NNS IN JJ NNS CC O
kinases kinases 0 0 0 0 0 0 0 0 7 0 IN JJ NNS CC TO O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNS CC TO NN DT O
control control 0 0 0 0 0 0 0 0 7 0 CC TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN IN O
stability stability 0 0 0 0 0 0 0 0 9 0 NN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
p53. p53. 0 0 0 0 0 0 0 1 4 0 NN IN NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 IN NNP NNP VBZ DT O
shows shows 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NN IN O
importance importance 0 0 0 0 0 0 0 0 10 0 VBZ DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN VBG NN O
maintaining maintaining 0 0 0 0 0 0 0 0 11 0 NNS IN VBG NN NNP O
genome genome 0 0 0 0 0 0 0 0 6 0 IN VBG NN NNP NNP O
stability. stability. 0 0 0 0 0 0 0 0 10 0 VBG NN NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 NN NNP NNP PRP VBZ O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ JJ O
discuss discuss 0 0 0 0 0 0 0 0 7 0 NNP PRP VBZ JJ NNS O
recent recent 0 0 0 0 0 0 0 0 6 0 PRP VBZ JJ NNS IN O
data data 0 0 0 0 0 0 0 0 4 0 VBZ JJ NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN JJ CC O
yeast yeast 0 0 0 0 0 0 0 0 5 0 NNS IN JJ CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NNS WDT O
metazoans metazoans 0 0 0 0 0 0 0 0 9 0 JJ CC NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 CC NNS WDT VBP DT O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNS WDT VBP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBP DT JJ NN O
remarkable remarkable 0 0 0 0 0 0 0 0 10 0 VBP DT JJ NN IN O
conservation conservation 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
organization organization 0 0 0 0 0 0 0 0 12 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
G2 G2 1 1 0 0 0 0 0 1 2 0 IN DT NNP NNP NN B_TIMEXCCP
DNA-damage DNA-damage 1 0 1 0 0 0 0 0 10 0 DT NNP NNP NN NNP O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NNP NNP B_TIMEXCCP
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
10856933 10856933 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Chromosome Chromosome 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP NN IN O
topology topology 0 0 0 0 0 0 0 0 8 0 NONE NNP NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN NNP O
interphase interphase 0 0 0 0 0 0 0 0 10 0 IN JJ NN NNP NNP B_TIMEXCCP
nuclei. nuclei. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNP O
Haaf Haaf 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Schmid Schmid 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Genetics, Genetics, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Stanford Stanford 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
California California 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
94305. 94305. 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP NNP CD O
Since Since 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD WRB O
1968, 1968, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD WRB NNS O
when when 0 0 0 0 0 0 0 0 4 0 NNP CD WRB NNS VBD O
Comings Comings 1 0 0 0 0 0 0 0 7 0 CD WRB NNS VBD DT O
published published 0 0 0 0 0 0 0 0 9 0 WRB NNS VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBD DT NN NN O
pioneering pioneering 0 0 0 0 0 0 0 0 10 0 VBD DT NN NN IN O
paper paper 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
"the "the 0 0 0 0 0 0 0 0 4 0 NN IN NNP NN IN O
rationale rationale 0 0 0 0 0 0 0 0 9 0 IN NNP NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNP NN IN DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT VBN NN O
ordered ordered 0 0 0 0 0 0 0 0 7 0 IN DT VBN NN IN O
arrangement arrangement 0 0 0 0 0 0 0 0 11 0 DT VBN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN IN O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NN IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 IN DT NN NN JJ O
nucleus," nucleus," 0 0 0 0 1 0 0 0 9 0 DT NN NN JJ NNS O
technical technical 0 0 0 0 0 0 0 0 9 0 NN NN JJ NNS VBP O
methods methods 0 0 0 0 0 0 0 0 7 0 NN JJ NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP VBN RB O
progressed progressed 0 0 0 0 0 0 0 0 10 0 NNS VBP VBN RB CC O
tremendously tremendously 0 0 0 0 0 0 0 0 12 0 VBP VBN RB CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 VBN RB CC VBN PRP$ O
improved improved 0 0 0 0 0 0 0 0 8 0 RB CC VBN PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 CC VBN PRP$ NN IN O
understanding understanding 0 0 0 0 0 0 0 0 13 0 VBN PRP$ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN NN NNP O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN IN NN NNP NNP O
organization. organization. 0 0 0 0 0 0 0 0 13 0 IN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN IN O
existence existence 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN RB VBN O
highly highly 0 0 0 0 0 0 0 0 6 0 NN IN RB VBN JJ O
ordered ordered 0 0 0 0 0 0 0 0 7 0 IN RB VBN JJ NNS O
organizational organizational 0 0 0 0 0 0 0 0 14 0 RB VBN JJ NNS IN O
patterns patterns 0 0 0 0 0 0 0 0 8 0 VBN JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN VBZ O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN VBZ NNS O
nucleus nucleus 0 0 0 0 0 0 0 0 7 0 DT NN VBZ NNS TO O
appears appears 0 0 0 0 0 0 0 0 7 0 NN VBZ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ NNS TO VB IN O
be be 0 0 0 0 0 0 0 0 2 0 NNS TO VB IN DT O
beyond beyond 0 0 0 0 0 0 0 0 6 0 TO VB IN DT NN O
any any 0 0 0 0 0 0 0 0 3 0 VB IN DT NN CC O
doubt doubt 0 0 0 0 0 0 0 0 5 0 IN DT NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN CC PRP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 CC PRP VBZ JJ TO O
difficult difficult 0 0 0 0 0 0 0 0 9 0 PRP VBZ JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO NN DT O
escape escape 0 0 0 0 0 0 0 0 6 0 JJ TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN IN O
conclusion conclusion 0 0 0 0 0 0 0 0 10 0 NN DT NN IN NN O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN IN NN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN NN NN NN VBZ O
topology topology 0 0 0 0 0 0 0 0 8 0 NN NN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ IN O
important important 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN NN O
complex complex 0 0 0 0 0 0 0 0 7 0 IN DT NN NN IN O
regulation regulation 0 0 0 0 0 0 0 0 10 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ VBD O
many many 0 0 0 0 0 0 0 0 4 0 IN DT JJ VBD CC O
varied varied 0 0 0 0 0 0 0 0 6 0 DT JJ VBD CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 JJ VBD CC VBN JJ O
interrelated interrelated 0 0 0 0 0 0 0 0 12 0 VBD CC VBN JJ NNP O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 CC VBN JJ NNP NNP O
processes. processes. 0 0 0 0 0 0 0 0 10 0 VBN JJ NNP NNP PRP O
However, However, 1 0 0 0 1 0 0 0 8 0 JJ NNP NNP PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP PRP VBZ JJ NN O
worth worth 0 0 0 0 0 0 0 0 5 0 PRP VBZ JJ NN WDT O
emphasizing emphasizing 0 0 0 0 0 0 0 0 11 0 VBZ JJ NN WDT DT O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT DT RB O
a a 0 0 0 0 0 0 0 0 1 0 NN WDT DT RB JJ O
universally universally 0 0 0 0 0 0 0 0 11 0 WDT DT RB JJ NN O
valid valid 0 0 0 0 0 0 0 0 5 0 DT RB JJ NN IN O
principle principle 0 0 0 0 0 0 0 0 9 0 RB JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NN VBZ O
arrangement arrangement 0 0 0 0 0 0 0 0 11 0 IN NN NN VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 NN NN VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VB JJ O
exist exist 0 0 0 0 0 0 0 0 5 0 VBZ RB VB JJ NN O
and, and, 0 0 0 0 1 0 0 0 4 0 RB VB JJ NN DT O
therefore, therefore, 0 0 0 0 1 0 0 0 10 0 VB JJ NN DT NN O
any any 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN IN O
generalization generalization 0 0 0 0 0 0 0 0 14 0 NN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS MD O
patterns patterns 0 0 0 0 0 0 0 0 8 0 IN NN NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB NNP NNP O
misleading. misleading. 0 0 0 0 0 0 0 0 11 0 MD VB NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 VB NNP NNP NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NN VBG O
order order 0 0 0 0 0 0 0 0 5 0 NNS IN NN VBG TO O
according according 0 0 0 0 0 0 0 0 9 0 IN NN VBG TO WDT O
to to 0 0 0 0 0 0 0 0 2 0 NN VBG TO WDT DT O
which which 0 0 0 0 0 0 0 0 5 0 VBG TO WDT DT VBZ O
the the 0 0 0 0 0 0 0 0 3 0 TO WDT DT VBZ VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 WDT DT VBZ VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT VBZ VBP VBN NN O
arranged arranged 0 0 0 0 0 0 0 0 8 0 VBZ VBP VBN NN DT O
inside inside 0 0 0 0 0 0 0 0 6 0 VBP VBN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN NN DT NN VBP O
nucleus nucleus 0 0 0 0 0 0 0 0 7 0 NN DT NN VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 DT NN VBP JJ NN O
manifold: manifold: 0 0 0 0 0 0 0 0 9 0 NN VBP JJ NN NNP O
(1) (1) 0 0 0 0 0 0 0 1 3 0 VBP JJ NN NNP VBZ O
Individual Individual 1 0 0 0 0 0 0 0 10 0 JJ NN NNP VBZ NN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NN NNP VBZ NN IN O
remain remain 0 0 0 0 0 0 0 0 6 0 NNP VBZ NN IN RB O
in in 0 0 0 0 0 0 0 0 2 0 VBZ NN IN RB VBN O
spatially spatially 0 0 0 0 0 0 0 0 9 0 NN IN RB VBN NNS O
separated separated 0 0 0 0 0 0 0 0 9 0 IN RB VBN NNS IN O
domains domains 0 0 0 0 0 0 0 0 7 0 RB VBN NNS IN JJ O
throughout throughout 0 0 0 0 0 0 0 0 10 0 VBN NNS IN JJ NN O
interphase, interphase, 0 0 0 0 1 0 0 0 11 0 NNS IN JJ NN DT O
preventing preventing 0 0 0 0 0 0 0 0 10 0 IN JJ NN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 JJ NN DT NN IN O
intermingling intermingling 0 0 0 0 0 0 0 0 13 0 NN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT VBN NNP O
decondensed decondensed 0 0 0 0 0 0 0 0 11 0 IN DT VBN NNP NNP O
euchromatin. euchromatin. 0 0 0 0 0 0 0 0 12 0 DT VBN NNP NNP NNP O
(2) (2) 0 0 0 0 0 0 0 1 3 0 VBN NNP NNP NNP NNS O
Chromosome Chromosome 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNS WDT O
regions regions 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNS WDT NN VBP O
contain contain 0 0 0 0 0 0 0 0 7 0 NNS WDT NN VBP NN O
constitutive constitutive 0 0 0 0 0 0 0 0 12 0 WDT NN VBP NN NN O
heterochromatin heterochromatin 0 0 0 0 0 0 0 0 15 0 NN VBP NN NN IN O
associate associate 0 0 0 0 0 0 0 0 9 0 VBP NN NN IN JJR O
into into 0 0 0 0 0 0 0 0 4 0 NN NN IN JJR NNP O
larger larger 0 0 0 0 0 0 0 0 6 0 NN IN JJR NNP NNP O
chromocenters. chromocenters. 0 0 0 0 0 0 0 0 14 0 IN JJR NNP NNP NNP O
(3) (3) 0 0 0 0 0 0 0 1 3 0 JJR NNP NNP NNP JJS O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP JJS NN O
most most 0 0 0 0 0 0 0 0 4 0 NNP NNP JJS NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP JJS NN NNS JJ O
types types 0 0 0 0 0 0 0 0 5 0 JJS NN NNS JJ NNS O
direct direct 0 0 0 0 0 0 0 0 6 0 NN NNS JJ NNS IN O
associations associations 0 0 0 0 0 0 0 0 12 0 NNS JJ NNS IN NN O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN NN NNS O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNS IN O
domains domains 0 0 0 0 0 0 0 0 7 0 IN NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ NNS O
homologous homologous 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN JJ NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP RB NNP O
not not 0 0 0 0 0 0 0 0 3 0 NNS VBP RB NNP NNP O
observed. observed. 0 0 0 0 0 0 0 0 9 0 VBP RB NNP NNP NNS O
In In 1 0 0 0 0 0 0 0 2 0 RB NNP NNP NNS JJ O
others others 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS JJ JJ O
homologous homologous 0 0 0 0 0 0 0 0 10 0 NNP NNS JJ JJ NNS O
heterochromatic heterochromatic 0 0 0 0 0 0 0 0 15 0 NNS JJ JJ NNS VBP O
regions regions 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS VBP TO O
tend tend 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBP TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBP TO VB VBN -NONE- O
paired paired 0 0 0 0 0 0 0 0 6 0 TO VB VBN -NONE- -NONE- O
preferentially. preferentially. 0 0 0 0 0 0 0 0 15 0 VB VBN -NONE- -NONE- NNP O
(4) (4) 0 0 0 0 0 0 0 1 3 0 VBN -NONE- -NONE- NNP VBZ O
Interphase Interphase 1 0 0 0 0 0 0 0 10 0 -NONE- -NONE- NNP VBZ VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 -NONE- NNP VBZ VBP RB O
do do 0 0 0 0 0 0 0 0 2 0 NNP VBZ VBP RB VB O
not not 0 0 0 0 0 0 0 0 3 0 VBZ VBP RB VB RB O
float float 0 0 0 0 0 0 0 0 5 0 VBP RB VB RB IN O
freely freely 0 0 0 0 0 0 0 0 6 0 RB VB RB IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VB RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN PRP O
nucleoplasm; nucleoplasm; 0 0 0 0 0 0 0 0 12 0 IN DT NN PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 DT NN PRP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN PRP VBP VBN TO O
associated associated 0 0 0 0 0 0 0 0 10 0 PRP VBP VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO NN NNS O
varying varying 0 0 0 0 0 0 0 0 7 0 VBN TO NN NNS IN O
degrees degrees 0 0 0 0 0 0 0 0 7 0 TO NN NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN CC O
membrane membrane 0 0 0 0 0 0 0 0 8 0 DT JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 NN CC JJ NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 CC JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP O
scaffold. scaffold. 0 0 0 0 0 0 0 0 9 0 DT JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
number number 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNS O
attachment attachment 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS IN O
sites sites 0 0 0 0 0 0 0 0 5 0 IN NN NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN DT NN O
each each 0 0 0 0 0 0 0 0 4 0 NNS IN DT NN TO O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 IN DT NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 TO DT JJ NN VBZ O
membrane membrane 0 0 0 0 0 0 0 0 8 0 DT JJ NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ RB NNP O
relatively relatively 0 0 0 0 0 0 0 0 10 0 NN VBZ RB NNP NNP O
low. low. 0 0 0 0 0 0 0 0 4 0 VBZ RB NNP NNP NNP O
(5) (5) 0 0 0 0 0 0 0 1 3 0 RB NNP NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS IN O
positions positions 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNS CC O
centromeres centromeres 0 0 0 0 0 0 0 0 11 0 NNS IN NNS CC JJ O
(and (and 0 0 0 0 0 0 0 0 4 0 IN NNS CC JJ NN O
pericentromeric pericentromeric 0 0 0 0 0 0 0 0 15 0 NNS CC JJ NN VBP O
heterochromatin) heterochromatin) 0 0 0 0 0 0 0 0 16 0 CC JJ NN VBP NN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NN VBP NN CC O
nonrandom nonrandom 0 0 0 0 0 0 0 0 9 0 NN VBP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBP NN CC JJ IN O
characteristic characteristic 0 0 0 0 0 0 0 0 14 0 NN CC JJ IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC JJ IN DT NN O
each each 0 0 0 0 0 0 0 0 4 0 JJ IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
type. type. 0 0 0 0 0 0 0 0 5 0 DT NN NNP NNP VBD O
Specific Specific 1 0 0 0 0 0 0 0 8 0 NN NNP NNP VBD NNS O
centromere centromere 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD NNS VBP O
movements movements 0 0 0 0 0 0 0 0 9 0 NNP VBD NNS VBP IN O
occur occur 0 0 0 0 0 0 0 0 5 0 VBD NNS VBP IN DT O
during during 0 0 0 0 0 0 0 0 6 0 NNS VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN IN O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 DT NN NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN JJ CC O
differentiation, differentiation, 0 0 0 0 1 0 0 0 16 0 NN IN JJ CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC IN JJ O
under under 0 0 0 0 0 0 0 0 5 0 JJ CC IN JJ JJ O
certain certain 0 0 0 0 0 0 0 0 7 0 CC IN JJ JJ NNP O
pathophysiological pathophysiological 0 0 0 0 0 0 0 0 18 0 IN JJ JJ NNP NNP O
conditions. conditions. 0 0 0 0 0 0 0 0 11 0 JJ JJ NNP NNP NNP O
(6) (6) 0 0 0 0 0 0 0 1 3 0 JJ NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NN O
telomeric telomeric 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NNP JJ NN NNS VBP O
ends ends 0 0 0 0 0 0 0 0 4 0 JJ NN NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP RB JJ O
particularly particularly 0 0 0 0 0 0 0 0 12 0 NNS VBP RB JJ TO O
prone prone 0 0 0 0 0 0 0 0 5 0 VBP RB JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO VB IN O
associate associate 0 0 0 0 0 0 0 0 9 0 JJ TO VB IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 TO VB IN JJ JJ O
certain certain 0 0 0 0 0 0 0 0 7 0 VB IN JJ JJ NN O
somatic somatic 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NNS CC O
types types 0 0 0 0 0 0 0 0 5 0 JJ NN NNS CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS CC IN JJ NN O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 CC IN JJ NN NNP O
prophase prophase 0 0 0 0 0 0 0 0 8 0 IN JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
(7) (7) 0 0 0 0 0 0 0 1 3 0 NN NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
arrangement arrangement 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNP O
repetitive repetitive 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNP NNS O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NNS VBZ O
families families 0 0 0 0 0 0 0 0 8 0 JJ NNP NNS VBZ TO O
appears appears 0 0 0 0 0 0 0 0 7 0 NNP NNS VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBZ TO VB DT O
determine determine 0 0 0 0 0 0 0 0 9 0 VBZ TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
structural structural 0 0 0 0 0 0 0 0 10 0 VB DT JJ NN IN O
framework framework 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
interphase interphase 0 0 0 0 0 0 0 0 10 0 IN DT NN NNP NNP O
nucleus. nucleus. 0 0 0 0 0 0 0 0 8 0 DT NN NNP NNP NN O
Different Different 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 NNP NN NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 NNS IN CD NN MD O
organism organism 0 0 0 0 0 0 0 0 8 0 IN CD NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 CD NN MD VB VBN O
exhibit exhibit 0 0 0 0 0 0 0 0 7 0 NN MD VB VBN NNS O
marked marked 0 0 0 0 0 0 0 0 6 0 MD VB VBN NNS IN O
differences differences 0 0 0 0 0 0 0 0 11 0 VB VBN NNS IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 VBN NNS IN PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 NNS IN PRP$ JJ NNP O
repetitive repetitive 0 0 0 0 0 0 0 0 10 0 IN PRP$ JJ NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 PRP$ JJ NNP NNP VBZ O
framework, framework, 0 0 0 0 1 0 0 0 10 0 JJ NNP NNP VBZ NNS O
whereas whereas 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP VBZ NNS IN VBP O
that that 0 0 0 0 0 0 0 0 4 0 VBZ NNS IN VBP IN O
are are 0 0 0 0 0 0 0 0 3 0 NNS IN VBP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN VBP IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 VBP IN DT JJ VBN O
identical identical 0 0 0 0 0 0 0 0 9 0 IN DT JJ VBN NN O
differentiated differentiated 0 0 0 0 0 0 0 0 14 0 DT JJ VBN NN CC O
state state 0 0 0 0 0 0 0 0 5 0 JJ VBN NN CC DT O
or or 0 0 0 0 0 0 0 0 2 0 VBN NN CC DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN CC DT JJ NN O
identical identical 0 0 0 0 0 0 0 0 9 phase CC DT JJ NN IN O
phase phase 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NN RB O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN RB VBP O
often often 0 0 0 0 0 0 0 0 5 0 NN NN RB VBP JJ O
show show 0 0 0 0 0 0 0 0 4 0 NN RB VBP JJ NN O
comparable comparable 0 0 0 0 0 0 0 0 10 0 RB VBP JJ NN NNS O
interphase interphase 0 0 0 0 0 0 0 0 10 0 VBP JJ NN NNS RB O
patterns patterns 0 0 0 0 0 0 0 0 8 0 JJ NN NNS RB IN O
even even 0 0 0 0 0 0 0 0 4 0 NN NNS RB IN RB O
in in 0 0 0 0 0 0 0 0 2 0 NNS RB IN RB JJ O
evolutionarily evolutionarily 0 0 0 0 0 0 0 0 14 0 RB IN RB JJ NNP O
distant distant 0 0 0 0 0 0 0 0 7 0 IN RB JJ NNP NNP O
species. species. 0 0 0 0 0 0 0 0 8 0 RB JJ NNP NNP NNP O
(8) (8) 0 0 0 0 0 0 0 1 3 0 JJ NNP NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP JJ NNS O
various various 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NNS IN O
steps steps 0 0 0 0 0 0 0 0 5 0 NNP JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
ribosome ribosome 0 0 0 0 0 0 0 0 8 0 NNS IN NN NN VB O
biogenesis biogenesis 0 0 0 0 0 0 0 0 10 0 IN NN NN VB NN O
take take 0 0 0 0 0 0 0 0 4 0 NN NN VB NN IN O
place place 0 0 0 0 0 0 0 0 5 0 NN VB NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VB NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
precise precise 0 0 0 0 0 0 0 0 7 0 IN DT NN NN IN O
fashion fashion 0 0 0 0 0 0 0 0 7 0 DT NN NN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 NN NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ JJ O
separate separate 0 0 0 0 0 0 0 0 8 0 IN DT JJ JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NN DT O
domain, domain, 0 0 0 0 1 0 0 0 7 0 JJ JJ NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNP NNP O
nucleolus. nucleolus. 0 0 0 0 0 0 0 0 10 0 NN DT NNP NNP RB O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP RB JJ O
topologically topologically 0 0 0 0 0 0 0 0 13 0 NNP NNP RB JJ NN O
well-defined well-defined 0 0 1 0 0 0 0 0 12 0 NNP RB JJ NN NNS O
nucleolar nucleolar 0 0 0 0 0 0 0 0 9 0 RB JJ NN NNS VBP O
substructures substructures 0 0 0 0 0 0 0 0 13 0 JJ NN NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 NNS VBP VBN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 VBP VBN IN NNP NN O
rDNA rDNA 0 0 0 0 0 0 0 0 4 0 VBN IN NNP NN CC O
transcription transcription 0 0 0 0 0 0 0 0 13 0 IN NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NNP O
pre-rRNA pre-rRNA 0 0 1 0 0 0 0 0 8 0 NN CC NNP NNP NNP O
processing. processing. 0 0 0 0 0 0 0 0 11 0 CC NNP NNP NNP NNP O
(9) (9) 0 0 0 0 0 0 0 1 3 0 NNP NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN IN O
compartmentalization compartmentalization 0 0 0 0 0 0 0 0 20 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ CC O
transcriptional transcriptional 0 0 0 0 0 0 0 0 15 0 NN IN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN NNS O
processing processing 0 0 0 0 0 0 0 0 10 0 JJ CC NN NNS VBZ O
events events 0 0 0 0 0 0 0 0 6 0 CC NN NNS VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NN NNS VBZ RB JJ O
also also 0 0 0 0 0 0 0 0 4 0 NNS VBZ RB JJ IN O
evident evident 0 0 0 0 0 0 0 0 7 0 VBZ RB JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
rest rest 0 0 0 0 0 0 0 0 4 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
nucleus. nucleus. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP PRP O
However, However, 1 0 0 0 1 0 0 0 8 0 DT NNP NNP PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP PRP VBZ RB RB O
not not 0 0 0 0 0 0 0 0 3 0 PRP VBZ RB RB VBN O
yet yet 0 0 0 0 0 0 0 0 3 0 VBZ RB RB VBN IN O
known known 0 0 0 0 0 0 0 0 5 0 RB RB VBN IN DT O
if if 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT IN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN DT IN NN NNS O
situ situ 0 0 0 0 0 0 0 0 4 0 DT IN NN NNS IN O
sites sites 0 0 0 0 0 0 0 0 5 0 IN NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN CC O
transcription transcription 0 0 0 0 0 0 0 0 13 0 NNS IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP NN O
RNA RNA 1 1 0 0 0 0 0 0 3 0 NN CC NNP NN IN O
processing processing 0 0 0 0 0 0 0 0 10 0 CC NNP NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNP NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
particular particular 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN NN O
(nonribosomal) (nonribosomal) 0 0 0 0 0 0 0 0 14 0 DT JJ NN NN CC O
gene gene 0 0 0 0 0 0 0 0 4 0 JJ NN NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 NN NN CC NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 NN CC NN NN VBP O
family family 0 0 0 0 0 0 0 0 6 0 CC NN NN VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP RB NNP O
actually actually 0 0 0 0 0 0 0 0 8 0 NN VBP RB NNP NNP O
adjacent. adjacent. 0 0 0 0 0 0 0 0 9 0 VBP RB NNP NNP NNP O
(10) (10) 0 0 0 0 0 0 0 1 4 0 RB NNP NNP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBZ O
replication replication 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB RB O
precisely precisely 0 0 0 0 0 0 0 0 9 0 NN VBZ RB RB VBN O
spatiotemporally spatiotemporally 0 0 0 0 0 0 0 0 16 0 VBZ RB RB VBN IN O
regulated regulated 0 0 0 0 0 0 0 0 9 0 RB RB VBN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 RB VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
nucleus. nucleus. 0 0 0 0 0 0 0 0 8 0 IN DT NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP NN VBZ O
replication replication 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBZ VBP O
domains domains 0 0 0 0 0 0 0 0 7 0 NNP NN VBZ VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN VBZ VBP VBN IN O
immobilized immobilized 0 0 0 0 0 0 0 0 11 0 VBZ VBP VBN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NNP O
matrix.(ABSTRACT matrix.(ABSTRACT 0 0 0 0 0 0 0 0 16 0 DT JJ NN NNP NNP O
TRUNCATED TRUNCATED 1 1 0 0 0 0 0 0 9 0 JJ NN NNP NNP CD O
AT AT 1 1 0 0 0 0 0 0 2 0 NN NNP NNP CD NNP O
400 400 0 0 0 0 0 0 1 1 3 0 NNP NNP CD NNP NNP O
WORDS) WORDS) 1 1 0 0 0 0 0 0 6 0 NNP CD NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 CD NNP NNP CD JJ O
1988281 1988281 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Mitosis. Mitosis. 1 0 0 0 0 0 0 0 8 0 NONE NONE NNP NNP NNP B_TIMEXCCP
McIntosh McIntosh 1 0 0 0 0 0 0 0 8 0 NONE NNP NNP NNP NNP O
JR, JR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Koonce Koonce 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
MP. MP. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Molecular, Molecular, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP CC O
Cellular, Cellular, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Developmental Developmental 1 0 0 0 0 0 0 0 13 0 NNP CC NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Colorado, Colorado, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Boulder Boulder 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
80309. 80309. 0 0 0 0 0 0 0 1 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Data Data 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NN DT O
describe describe 0 0 0 0 0 0 0 0 8 0 NNP IN NN DT DT O
both both 0 0 0 0 0 0 0 0 4 0 IN NN DT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN DT DT NN CC O
structure structure 0 0 0 0 0 0 0 0 9 0 DT DT NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
physiology physiology 0 0 0 0 0 0 0 0 10 0 CC DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN VBP B_TIMEXCCP
spindle spindle 0 0 0 0 0 0 0 0 7 0 DT JJ NN VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 JJ NN VBP NNP NNP O
reviewed. reviewed. 0 0 0 0 0 0 0 0 9 0 NN VBP NNP NNP IN O
Some Some 1 0 0 0 0 0 0 0 4 0 VBP NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNS WDT O
molecules molecules 0 0 0 0 0 0 0 0 9 0 IN DT NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 DT NNS WDT VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNS WDT VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 WDT VBP VBN VBN TO O
shown shown 0 0 0 0 0 0 0 0 5 0 VBP VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB DT O
play play 0 0 0 0 0 0 0 0 4 0 VBN TO VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VB DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBP O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 NN IN NN VBP JJ B_TIMEXCCP
are are 0 0 0 0 0 0 0 0 3 0 IN NN VBP JJ CC O
tabulated, tabulated, 0 0 0 0 1 0 0 0 10 0 NN VBP JJ CC WRB O
and and 0 0 0 0 0 0 0 0 3 0 VBP JJ CC WRB NN O
how how 0 0 0 0 0 0 0 0 3 0 JJ CC WRB NN MD O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 CC WRB NN MD VB B_TIMEXCCP
might might 0 0 0 0 0 0 0 0 5 0 WRB NN MD VB VBZ O
work work 0 0 0 0 0 0 0 0 4 0 NN MD VB VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 MD VB VBZ NNP NNP O
considered. considered. 0 0 0 0 0 0 0 0 11 0 VB VBZ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 VBZ NNP NNP CD JJ O
2683078 2683078 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Polyribosome Polyribosome 1 0 0 0 0 0 0 0 12 0 NONE NONE NNP NN IN O
disaggregation disaggregation 0 0 0 0 0 0 0 0 14 0 NONE NNP NN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 NNP NN IN NNP NNP O
metaphase. metaphase. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP NNP B_TIMEXCCP
Scharff Scharff 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
MD, MD, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Robbins Robbins 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
E. E. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Polyribosomes Polyribosomes 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN VBN IN O
examined examined 0 0 0 0 0 0 0 0 8 0 NNP IN VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN DT JJ O
both both 0 0 0 0 0 0 0 0 4 0 VBN IN DT JJ NN O
sucrose-gradient sucrose-gradient 0 0 1 0 0 0 0 0 16 0 IN DT JJ NN CC O
analysis analysis 0 0 0 0 0 0 0 0 8 0 DT JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
electron electron 0 0 0 0 0 0 0 0 8 0 NN CC NN NN NN O
microscopy microscopy 0 0 0 0 0 0 0 0 10 0 CC NN NN NN IN O
disaggregate disaggregate 0 0 0 0 0 0 0 0 12 0 NN NN NN IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN NN IN O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NN IN NN IN DT B_TIMEXCCP
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT JJ O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT JJ NNP O
normal normal 0 0 0 0 0 0 0 0 6 0 IN DT JJ NNP NNS O
HeLa HeLa 1 0 0 0 0 0 0 0 4 0 DT JJ NNP NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNS CC DT VBN O
those those 0 0 0 0 0 0 0 0 5 0 NNS CC DT VBN IN O
arrested arrested 0 0 0 0 0 0 0 0 8 0 CC DT VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT VBN IN NN IN O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 VBN IN NN IN NN B_TIMEXCCP
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN NNP NNP O
colchicine. colchicine. 0 0 0 0 0 0 0 0 11 0 NN IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
5907291 5907291 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Chromosome Chromosome 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP NNP NN O
segregation: segregation: 0 0 0 0 0 0 0 0 12 0 NONE NNP NNP NN NN O
playing playing 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN IN O
polo polo 0 0 0 0 0 0 0 0 4 0 NNP NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP NNP B_TIMEXCCP
Weitzer Weitzer 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Uhlmann Uhlmann 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
F. F. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Chromosome Chromosome 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Segregation Segregation 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
UK UK 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
London London 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CD O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP CD NNS O
44 44 0 0 0 0 0 0 1 1 2 0 NNP NNP CD NNS NNP O
Lincoln's Lincoln's 1 0 0 0 0 1 0 0 9 0 NNP CD NNS NNP NNP O
Inn Inn 1 0 0 0 0 0 0 0 3 0 CD NNS NNP NNP NNP O
Fields, Fields, 1 0 0 0 1 0 0 0 7 0 NNS NNP NNP NNP CD O
WC2A WC2A 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP CD -NONE- O
3PX, 3PX, 0 1 0 0 1 0 0 1 4 0 NNP NNP CD -NONE- NNP O
London, London, 1 0 0 0 1 0 0 0 7 0 NNP CD -NONE- NNP NNP O
United United 1 0 0 0 0 0 0 0 6 0 CD -NONE- NNP NNP NNP O
Kingdom. Kingdom. 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
During During 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
mitosis, mitosis, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP IN JJS B_TIMEXCCP
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 NNP IN JJS JJ NN O
eukaryotes, eukaryotes, 0 0 0 0 1 0 0 0 11 0 IN JJS JJ NN VBZ O
cohesin cohesin 0 0 0 0 0 0 0 0 7 0 JJS JJ NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ VBN IN O
removed removed 0 0 0 0 0 0 0 0 7 0 NN VBZ VBN IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NNS IN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 VBN IN NNS IN CD O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN CD NNP O
two two 0 0 0 0 0 0 0 0 3 0 NNS IN CD NNP NNP O
steps. steps. 0 0 0 0 0 0 0 0 6 0 IN CD NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 CD NNP NNP NN IN O
paper paper 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
March March 1 0 0 0 0 0 0 0 5 0 IN DT NNP NN IN O
issue issue 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NN IN NNP NNP NNS O
Cell Cell 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNS JJ O
identifies identifies 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS JJ NN O
Polo-like Polo-like 1 0 1 0 0 0 0 0 9 0 NNP NNS JJ NN IN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NNS JJ NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
key key 0 0 0 0 0 0 0 0 3 0 IN DT JJ NN IN O
regulator regulator 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN WDT O
step step 0 0 0 0 0 0 0 0 4 0 DT JJ NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBZ RB O
releases releases 0 0 0 0 0 0 0 0 8 0 NN WDT VBZ RB IN O
much much 0 0 0 0 0 0 0 0 4 0 WDT VBZ RB IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBZ RB IN NN IN O
cohesin cohesin 0 0 0 0 0 0 0 0 7 0 RB IN NN IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 IN NN IN NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 NN IN NNP NNP IN B_TIMEXCCP
Comment Comment 1 0 0 0 0 0 0 0 7 0 IN NNP NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP DT O
Splitting Splitting 1 0 0 0 0 0 0 0 9 0 NNP IN NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 IN NNP DT NNP NN O
chromosome: chromosome: 0 0 0 0 0 0 0 0 11 0 NNP DT NNP NN DT O
cutting cutting 0 0 0 0 0 0 0 0 7 0 DT NNP NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NNS WDT O
ties ties 0 0 0 0 0 0 0 0 4 0 NN DT NNS WDT IN O
that that 0 0 0 0 0 0 0 0 4 0 DT NNS WDT IN JJR O
bind bind 0 0 0 0 0 0 0 0 4 0 NNS WDT IN JJR NNP O
sister sister 0 0 0 0 0 0 0 0 6 0 WDT IN JJR NNP NNP O
chromatids. chromatids. 0 0 0 0 0 0 0 0 11 0 IN JJR NNP NNP CD O
[Science. [Science. 0 0 0 0 0 0 0 0 9 0 JJR NNP NNP CD -NONE- O
2000] 2000] 0 0 0 0 0 0 0 1 5 0 NNP NNP CD -NONE- CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP CD -NONE- CD JJ O
11970886 11970886 0 0 0 0 0 0 1 1 8 0 CD -NONE- CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 -NONE- CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Delaying Delaying 1 0 0 0 0 0 0 0 8 0 NONE NONE VBG NN NN O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NONE VBG NN NN NNS B_TIMEXCCP
progression progression 0 0 0 0 0 0 0 0 11 0 VBG NN NN NNS NNS O
rescues rescues 0 0 0 0 0 0 0 0 7 0 NN NN NNS NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NNS NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNS NNS IN JJ NN O
heat-induced heat-induced 0 0 1 0 0 0 0 0 12 0 NNS IN JJ NN NNP O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 IN JJ NN NNP NNP B_TIMEXCCP
hypertoxicity. hypertoxicity. 0 0 0 0 0 0 0 0 14 0 JJ NN NNP NNP NNP O
VanderWaal VanderWaal 1 0 0 0 0 0 0 0 10 0 NN NNP NNP NNP NNP O
RP, RP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Griffith Griffith 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
CL, CL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wright Wright 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
WD, WD, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Borrelli Borrelli 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
MJ, MJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Roti Roti 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
JL. JL. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Washington Washington 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Mallinckrodt Mallinckrodt 1 0 0 0 0 0 0 0 12 0 IN NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Radiology, Radiology, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
Radiation Radiation 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Oncology Oncology 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP IN O
Section Section 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
St. St. 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Louis, Louis, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Missouri, Missouri, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN WDT O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN WDT DT O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN WDT DT NN VBZ O
cell cell 0 0 0 0 0 0 0 0 4 0 WDT DT NN VBZ PRP O
protects protects 0 0 0 0 0 0 0 0 8 0 DT NN VBZ PRP IN O
itself itself 0 0 0 0 0 0 0 0 6 0 NN VBZ PRP IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VBZ PRP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 PRP IN DT JJ NNS O
lethal lethal 0 0 0 0 0 0 0 0 6 0 IN DT JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
heat heat 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN CC O
shock shock 0 0 0 0 0 0 0 0 5 0 IN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 NN CC JJ JJ NNS O
stress-inducing stress-inducing 0 0 1 0 0 0 0 0 15 0 CC JJ JJ NNS VBZ O
agents agents 0 0 0 0 0 0 0 0 6 0 JJ JJ NNS VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 JJ NNS VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBZ DT NN IN O
subject subject 0 0 0 0 0 0 0 0 7 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
much much 0 0 0 0 0 0 0 0 4 0 NN IN JJ NNP NNP O
research. research. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP VBP VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP VBN DT NN IN O
relationship relationship 0 0 0 0 0 0 0 0 12 0 VBN DT NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN JJ NN O
heat-induced heat-induced 0 0 1 0 0 0 0 0 12 0 NN IN JJ NN TO O
damage damage 0 0 0 0 0 0 0 0 6 0 IN JJ NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN TO NNP NN NN O
replication replication 0 0 0 0 0 0 0 0 11 0 TO NNP NN NN CC O
machinery machinery 0 0 0 0 0 0 0 0 9 0 NNP NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NNS O
lethal lethal 0 0 0 0 0 0 0 0 6 0 CC DT JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
heat heat 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN IN O
shock, shock, 0 0 0 0 1 0 0 0 6 0 IN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NN IN NN NN WDT B_TIMEXCCP
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NN NN WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBP RBR O
are are 0 0 0 0 0 0 0 0 3 0 NN WDT VBP RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 WDT VBP RBR JJ TO O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 VBP RBR JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RBR JJ TO VB NN O
heat heat 0 0 0 0 0 0 0 0 4 0 JJ TO VB NN IN O
shock shock 0 0 0 0 0 0 0 0 5 0 TO VB NN IN DT O
than than 0 0 0 0 0 0 0 0 4 0 VB NN IN DT NNP O
either either 0 0 0 0 0 0 0 0 6 0 NN IN DT NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN DT NNP CC NNP B_TIMEXCCP
or or 0 0 0 0 0 0 0 0 2 0 DT NNP CC NNP NNP O
G2. G2. 1 1 0 0 0 0 0 1 3 0 NNP CC NNP NNP VBD B_TIMEXCCP
We We 1 0 0 0 0 0 0 0 2 0 CC NNP NNP VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NN NNS O
maintaining maintaining 0 0 0 0 0 0 0 0 11 0 VBD IN NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ WDT O
aphidicolin, aphidicolin, 0 0 0 0 1 0 0 0 12 0 NNS IN JJ WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 IN JJ WDT NNS DT O
prevents prevents 0 0 0 0 0 0 0 0 8 0 JJ WDT NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 WDT NNS DT NN IN O
passage passage 0 0 0 0 0 0 0 0 7 0 NNS DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 IN NNS IN JJ MD O
S-phase, S-phase, 1 0 1 0 1 0 0 0 8 0 NNS IN JJ MD VB B_TIMEXCCP
can can 0 0 0 0 0 0 0 0 3 0 IN JJ MD VB JJ O
rescue rescue 0 0 0 0 0 0 0 0 6 0 JJ MD VB JJ NNP O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 MD VB JJ NNP NNS B_TIMEXCCP
HeLa HeLa 1 0 0 0 0 0 0 0 4 0 VB JJ NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NNP NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNS O
lethal lethal 0 0 0 0 0 0 0 0 6 0 IN DT JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNP O
heat heat 0 0 0 0 0 0 0 0 4 0 NNS IN NN NNP NNP O
shock. shock. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNP O
When When 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
S-phase, S-phase, 1 0 1 0 1 0 0 0 8 0 NNP NNP NNP NNP VBZ O
HeLa HeLa 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP VBZ VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN IN O
held held 0 0 0 0 0 0 0 0 4 0 VBZ VBD VBN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN CD NN O
5-6 5-6 0 0 1 0 0 0 0 1 3 0 VBN IN CD NN IN O
h h 0 0 0 0 0 0 0 0 1 0 IN CD NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN CD NNP O
3 3 0 0 0 0 0 0 1 1 1 0 NN IN CD NNP NN O
microM microM 0 0 0 0 0 0 0 0 6 0 IN CD NNP NN DT O
aphidicolin aphidicolin 0 0 0 0 0 0 0 0 11 0 CD NNP NN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT VBN JJ O
measured measured 0 0 0 0 0 0 0 0 8 0 NN DT VBN JJ NN O
clonogenic clonogenic 0 0 0 0 0 0 0 0 10 0 DT VBN JJ NN VBD O
survival survival 0 0 0 0 0 0 0 0 8 0 VBN JJ NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD JJ TO O
similar similar 0 0 0 0 0 0 0 0 7 0 NN VBD JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBD JJ TO DT IN O
that that 0 0 0 0 0 0 0 0 4 0 JJ TO DT IN RB O
for for 0 0 0 0 0 0 0 0 3 0 TO DT IN RB VBG O
exponentially exponentially 0 0 0 0 0 0 0 0 13 0 DT IN RB VBG NNP O
growing growing 0 0 0 0 0 0 0 0 7 0 IN RB VBG NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 RB VBG NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 VBG NNP NNP VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ NNP IN O
known, known, 0 0 0 0 1 0 0 0 6 0 NNP VBZ NNP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBZ NNP IN NN NN O
heat heat 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN NNS O
shock shock 0 0 0 0 0 0 0 0 5 0 IN NN NN NNS NN O
induces induces 0 0 0 0 0 0 0 0 7 0 NN NN NNS NN CC O
denaturation denaturation 0 0 0 0 0 0 0 0 12 0 NN NNS NN CC VBG O
or or 0 0 0 0 0 0 0 0 2 0 NNS NN CC VBG IN O
unfolding unfolding 0 0 0 0 0 0 0 0 9 0 NN CC VBG IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC VBG IN JJ NN O
proteins, proteins, 0 0 0 0 1 0 0 0 9 0 VBG IN JJ NN PRP O
rendering rendering 0 0 0 0 0 0 0 0 9 0 IN JJ NN PRP JJR O
them them 0 0 0 0 0 0 0 0 4 0 JJ NN PRP JJR JJ O
less less 0 0 0 0 0 0 0 0 4 0 NN PRP JJR JJ CC O
soluble soluble 0 0 0 0 0 0 0 0 7 0 PRP JJR JJ CC RBR O
and and 0 0 0 0 0 0 0 0 3 0 JJR JJ CC RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 JJ CC RBR JJ TO O
likely likely 0 0 0 0 0 0 0 0 6 0 CC RBR JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 RBR JJ TO JJ IN O
co-isolate co-isolate 0 0 1 0 0 0 0 0 10 0 JJ TO JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 TO JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NNP O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP O
matrix. matrix. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 JJ NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN VBN O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN VBN VBG O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 VBP IN VBN VBG IN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN VBN VBG IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBN VBG IN NNS VBN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 VBG IN NNS VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 IN NNS VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN -NONE- O
replication replication 0 0 0 0 0 0 0 0 11 0 IN NNP NN -NONE- -NONE- O
(PCNA, (PCNA, 0 1 0 0 1 0 0 0 6 0 NNP NN -NONE- -NONE- CC O
RPA, RPA, 1 1 0 0 1 0 0 0 4 0 NN -NONE- -NONE- CC VB O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC VB JJ O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 -NONE- CC VB JJ IN O
A), A), 1 1 0 0 1 0 0 0 3 0 CC VB JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VB JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NNS O
matrix, matrix, 0 0 0 0 1 0 0 0 7 0 DT JJ NN NNS IN O
correlates correlates 0 0 0 0 0 0 0 0 10 0 JJ NN NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN NN IN O
lethality lethality 0 0 0 0 0 0 0 0 9 0 NNS IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NN IN JJ NNS VBG B_TIMEXCCP
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBG NN O
following following 0 0 0 0 0 0 0 0 9 0 JJ NNS VBG NN NN O
heat heat 0 0 0 0 0 0 0 0 4 0 NNS VBG NN NN IN O
shock shock 0 0 0 0 0 0 0 0 5 0 VBG NN NN IN CD O
under under 0 0 0 0 0 0 0 0 5 0 NN NN IN CD JJ O
four four 0 0 0 0 0 0 0 0 4 0 NN IN CD JJ JJ O
different different 0 0 0 0 0 0 0 0 9 0 IN CD JJ JJ NNP O
experimental experimental 0 0 0 0 0 0 0 0 12 0 CD JJ JJ NNP NNP O
conditions. conditions. 0 0 0 0 0 0 0 0 11 0 JJ JJ NNP NNP DT O
Specifically, Specifically, 1 0 0 0 1 0 0 0 13 0 JJ NNP NNP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNS IN O
amounts amounts 0 0 0 0 0 0 0 0 7 0 NNP DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NN O
RPA, RPA, 1 1 0 0 1 0 0 0 4 0 NNS IN JJ NN CC O
PCNA, PCNA, 1 1 0 0 1 0 0 0 5 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN DT O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN CC NN DT VBN O
A A 1 1 0 0 0 0 0 0 1 0 CC NN DT VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN DT VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 DT VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NN O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN WRB O
matrix matrix 0 0 0 0 0 0 0 0 6 0 DT JJ NN WRB NNS O
when when 0 0 0 0 0 0 0 0 4 0 JJ NN WRB NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN WRB NNS VBN NN O
resumed resumed 0 0 0 0 0 0 0 0 7 0 WRB NNS VBN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 NNS VBN NN IN JJ O
through through 0 0 0 0 0 0 0 0 7 0 VBN NN IN JJ VBN O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NN IN JJ VBN IN B_TIMEXCCP
correlated correlated 0 0 0 0 0 0 0 0 10 0 IN JJ VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 JJ VBN IN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 VBN IN NN NNP JJ O
killing. killing. 0 0 0 0 0 0 0 0 8 0 IN NN NNP JJ VBN O
Heat-induced Heat-induced 1 0 1 0 0 0 0 0 12 0 NN NNP JJ VBN VBG O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 NNP JJ VBN VBG IN O
binding binding 0 0 0 0 0 0 0 0 7 0 JJ VBN VBG IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN VBG IN JJ NNS O
nuclear nuclear 0 0 0 0 0 0 0 0 7 0 VBG IN JJ NNS VBN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN JJ NNS VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NNS IN O
aspects aspects 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NNP NNP O
metabolism, metabolism, 0 0 0 0 1 0 0 0 11 0 IN NNP NNP NNP NNP O
(Mrell, (Mrell, 0 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP VBP O
PDI), PDI), 1 1 0 0 1 0 0 0 5 0 NNP NNP NNP VBP RB O
do do 0 0 0 0 0 0 0 0 2 0 NNP NNP VBP RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NNP VBP RB VB DT O
show show 0 0 0 0 0 0 0 0 4 0 VBP RB VB DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 RB VB DT NNP NNP O
correlation. correlation. 0 0 0 0 0 0 0 0 12 0 VB DT NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 DT NNP NNP NNS NN O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS NN DT O
support support 0 0 0 0 0 0 0 0 7 0 NNP NNS NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS NN DT NN IN O
hypothesis hypothesis 0 0 0 0 0 0 0 0 10 0 NN DT NN IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ NNS O
heat-induced heat-induced 0 0 1 0 0 0 0 0 12 0 NN IN JJ NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
binding binding 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS VBN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN IN NNS VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 IN NNS VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNS VBN IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN NNS O
replication replication 0 0 0 0 0 0 0 0 11 0 IN NNP NN NNS VBP O
factories factories 0 0 0 0 0 0 0 0 9 0 NNP NN NNS VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP DT RB O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT RB JJ O
potentially potentially 0 0 0 0 0 0 0 0 11 0 VBP DT RB JJ NN O
lethal lethal 0 0 0 0 0 0 0 0 6 0 DT RB JJ NN WDT O
lesions, lesions, 0 0 0 0 1 0 0 0 8 0 RB JJ NN WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 JJ NN WDT NN VBD O
become become 0 0 0 0 0 0 0 0 6 0 NN WDT NN VBD TO O
fixed fixed 0 0 0 0 0 0 0 0 5 0 WDT NN VBD TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO JJ NNS O
lethal lethal 0 0 0 0 0 0 0 0 6 0 VBD TO JJ NNS IN O
lesions lesions 0 0 0 0 0 0 0 0 7 0 TO JJ NNS IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NNS IN JJ NN CC B_TIMEXCCP
progression progression 0 0 0 0 0 0 0 0 11 0 IN JJ NN CC VBP O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NN CC VBP JJ IN O
repairable repairable 0 0 0 0 0 0 0 0 10 0 CC VBP JJ IN JJ O
if if 0 0 0 0 0 0 0 0 2 0 VBP JJ IN JJ NN O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 JJ IN JJ NN VBZ B_TIMEXCCP
progression progression 0 0 0 0 0 0 0 0 11 0 IN JJ NN VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ NNP NNP O
delayed. delayed. 0 0 0 0 0 0 0 0 8 0 NN VBZ NNP NNP CD O
Copyright Copyright 1 0 0 0 0 0 0 0 9 0 VBZ NNP NNP CD -NONE- O
2001 2001 0 0 0 0 0 0 1 1 4 0 NNP NNP CD -NONE- NNP O
Wiley-Liss, Wiley-Liss, 1 0 1 0 1 0 0 0 11 0 NNP CD -NONE- NNP NNP O
Inc. Inc. 1 0 0 0 0 0 0 0 4 0 CD -NONE- NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 -NONE- NNP NNP CD JJ O
11268003 11268003 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
TELOPHASE TELOPHASE 1 1 0 0 0 0 0 0 9 0 NONE NONE NN NN IN B_TIMEXCCP
SEGREGATION SEGREGATION 1 1 0 0 0 0 0 0 11 0 NONE NN NN IN NNP O
OF OF 1 1 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
CHROMOSOMES CHROMOSOMES 1 1 0 0 0 0 0 0 11 0 NN IN NNP NNP NNP O
AND AND 1 1 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
AMITOSIS. AMITOSIS. 1 1 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
MOLE MOLE 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
BAJER BAJER 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Cases Cases 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NN O
"distributive "distributive 0 0 0 0 0 0 0 0 13 0 NNP IN JJ NN NN O
c-mitosis" c-mitosis" 0 0 1 0 0 0 0 0 10 0 IN JJ NN NN NN B_TIMEXCCP
(the (the 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN VBZ O
term term 0 0 0 0 0 0 0 0 4 0 NN NN NN VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 NN NN VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VB IN O
mean mean 0 0 0 0 0 0 0 0 4 0 VBZ RB VB IN NN O
that that 0 0 0 0 0 0 0 0 4 0 RB VB IN NN VBZ O
colchicine colchicine 0 0 0 0 0 0 0 0 10 0 VB IN NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 IN NN VBZ VBN -NONE- O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN -NONE- IN O
used) used) 0 0 0 0 0 0 0 0 5 0 VBZ VBN -NONE- IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBN -NONE- IN NN NN O
plant plant 0 0 0 0 0 0 0 0 5 0 -NONE- IN NN NN VBP O
endosperm endosperm 0 0 0 0 0 0 0 0 9 0 IN NN NN VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP JJ IN O
described, described, 0 0 0 0 1 0 0 0 10 0 NN VBP JJ IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 VBP JJ IN WDT DT O
which which 0 0 0 0 0 0 0 0 5 0 JJ IN WDT DT VBZ O
the the 0 0 0 0 0 0 0 0 3 0 IN WDT DT VBZ IN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 WDT DT VBZ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT VBZ IN NN NN O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 VBZ IN NN NN JJ B_TIMEXCCP
type type 0 0 0 0 0 0 0 0 4 0 IN NN NN JJ NN O
(two-chromatid (two-chromatid 0 0 1 0 0 0 0 0 14 0 NN NN JJ NN VBP O
chromosomes) chromosomes) 0 0 0 0 0 0 0 0 12 0 NN JJ NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 JJ NN VBP VBN IN O
distributed distributed 0 0 0 0 0 0 0 0 11 0 NN VBP VBN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 VBP VBN IN NN IN O
random random 0 0 0 0 0 0 0 0 6 0 VBN IN NN IN IN O
because because 0 0 0 0 0 0 0 0 7 0 IN NN IN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN IN IN JJ NN O
phragmoplast phragmoplast 0 0 0 0 0 0 0 0 12 0 IN IN JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN JJ O
process process 0 0 0 0 0 0 0 0 7 0 IN DT NN JJ TO O
similar similar 0 0 0 0 0 0 0 0 7 0 DT NN JJ TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO NNP NNP O
non-disjunction. non-disjunction. 0 0 1 0 0 0 0 0 16 0 JJ TO NNP NNP VBZ O
There There 1 0 0 0 0 0 0 0 5 0 TO NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT NN O
some some 0 0 0 0 0 0 0 0 4 0 NNP VBZ DT NN IN O
evidence evidence 0 0 0 0 0 0 0 0 8 0 VBZ DT NN IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ NNS O
chromosmal chromosmal 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS MD O
fibres fibres 0 0 0 0 0 0 0 0 6 0 IN JJ NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 JJ NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN IN O
formed formed 0 0 0 0 0 0 0 0 6 0 MD VB VBN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 VB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
phragmoplast phragmoplast 0 0 0 0 0 0 0 0 12 0 IN DT NN IN JJ O
under under 0 0 0 0 0 0 0 0 5 0 DT NN IN JJ NN O
special special 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN IN O
circumstances; circumstances; 0 0 0 0 0 0 0 0 14 0 IN JJ NN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 JJ NN IN JJ NN O
"distributive "distributive 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN DT O
c-mitosis" c-mitosis" 0 0 1 0 0 0 0 0 10 0 IN JJ NN DT NNS B_TIMEXCCP
some some 0 0 0 0 0 0 0 0 4 0 JJ NN DT NNS VBP O
kinetochores kinetochores 0 0 0 0 0 0 0 0 12 0 NN DT NNS VBP JJ O
show show 0 0 0 0 0 0 0 0 4 0 DT NNS VBP JJ NNS O
active active 0 0 0 0 0 0 0 0 6 0 NNS VBP JJ NNS JJ O
movements movements 0 0 0 0 0 0 0 0 9 0 VBP JJ NNS JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 JJ NNS JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNS JJ TO NN IN O
cooperation cooperation 0 0 0 0 0 0 0 0 11 0 JJ TO NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 TO NN IN JJ NNS O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNS VBN O
fibres fibres 0 0 0 0 0 0 0 0 6 0 IN JJ NNS VBN IN O
formed formed 0 0 0 0 0 0 0 0 6 0 JJ NNS VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
phragmoplast; phragmoplast; 0 0 0 0 0 0 0 0 13 0 IN DT NN IN JJ O
while while 0 0 0 0 0 0 0 0 5 0 DT NN IN JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN IN O
chromosomes, chromosomes, 0 0 0 0 1 0 0 0 12 0 IN JJ NN IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NN IN VBN IN PRP$ O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN PRP$ NNS O
their their 0 0 0 0 0 0 0 0 5 0 VBN IN PRP$ NNS CC O
arrangements arrangements 0 0 0 0 0 0 0 0 12 0 IN PRP$ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 PRP$ NNS CC JJ VBP O
shape, shape, 0 0 0 0 1 0 0 0 6 0 NNS CC JJ VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 CC JJ VBP VBN IN O
moved moved 0 0 0 0 0 0 0 0 5 0 JJ VBP VBN IN DT O
without without 0 0 0 0 0 0 0 0 7 0 VBP VBN IN DT NN O
any any 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
kinetochores. kinetochores. 0 0 0 0 0 0 0 0 13 0 NN IN NNP NNP NNS O
Some Some 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ VBP O
phragmoplast phragmoplast 0 0 0 0 0 0 0 0 12 0 IN DT JJ VBP DT O
have have 0 0 0 0 0 0 0 0 4 0 DT JJ VBP DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 JJ VBP DT JJS NNS O
fastest fastest 0 0 0 0 0 0 0 0 7 0 VBP DT JJS NNS VBG O
movements movements 0 0 0 0 0 0 0 0 9 0 DT JJS NNS VBG IN O
occurring occurring 0 0 0 0 0 0 0 0 9 0 JJS NNS VBG IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBG IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 VBG IN NNP NNP NNS B_TIMEXCCP
Some Some 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNS VBP O
cases cases 0 0 0 0 0 0 0 0 5 0 NNP NNP NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP VBN IN O
described described 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 VBP VBN IN WDT DT O
which which 0 0 0 0 0 0 0 0 5 0 VBN IN WDT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN WDT DT NN VBZ O
phragmoplast phragmoplast 0 0 0 0 0 0 0 0 12 0 WDT DT NN VBZ NN O
divides divides 0 0 0 0 0 0 0 0 7 0 DT NN VBZ NN CC O
telophase telophase 0 0 0 0 0 0 0 0 9 0 NN VBZ NN CC NN B_TIMEXCCP
and and 0 0 0 0 0 0 0 0 3 0 VBZ NN CC NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NN CC NN NN IN B_TIMEXCCP
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 CC NN NN IN CD O
into into 0 0 0 0 0 0 0 0 4 0 NN NN IN CD CC O
two two 0 0 0 0 0 0 0 0 3 0 NN IN CD CC JJR O
or or 0 0 0 0 0 0 0 0 2 0 IN CD CC JJR NNS O
more more 0 0 0 0 0 0 0 0 4 0 CD CC JJR NNS CC O
groups groups 0 0 0 0 0 0 0 0 6 0 CC JJR NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJR NNS CC NNS DT O
moves moves 0 0 0 0 0 0 0 0 5 0 NNS CC NNS DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 CC NNS DT NNS DT O
pieces pieces 0 0 0 0 0 0 0 0 6 0 NNS DT NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 DT NNS DT JJ NN O
considerable considerable 0 0 0 0 0 0 0 0 12 0 NNS DT JJ NN NNP O
distance distance 0 0 0 0 0 0 0 0 8 0 DT JJ NN NNP NNP O
apart. apart. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
similar similar 0 0 0 0 0 0 0 0 7 0 NNP DT JJ NN DT O
way, way, 0 0 0 0 1 0 0 0 4 0 DT JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN MD O
phragmoplast phragmoplast 0 0 0 0 0 0 0 0 12 0 NN DT NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 DT NN MD VB RB O
divide divide 0 0 0 0 0 0 0 0 6 0 NN MD VB RB VBN O
newly newly 0 0 0 0 0 0 0 0 5 0 MD VB RB VBN NN O
formed formed 0 0 0 0 0 0 0 0 6 0 VB RB VBN NN NNP O
restitution restitution 0 0 0 0 0 0 0 0 11 0 RB VBN NN NNP NNP O
nuclei. nuclei. 0 0 0 0 0 0 0 0 7 0 VBN NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN NNS O
phenomenon phenomenon 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NNS TO O
leads leads 0 0 0 0 0 0 0 0 5 0 NNP NN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS TO DT NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 TO DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NN CC O
numbers, numbers, 0 0 0 0 1 0 0 0 8 0 IN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
course course 0 0 0 0 0 0 0 0 6 0 CC DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN PRP O
process process 0 0 0 0 0 0 0 0 7 0 IN DT NN PRP VBZ O
itself itself 0 0 0 0 0 0 0 0 6 0 DT NN PRP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN PRP VBZ JJ IN O
reminiscent reminiscent 0 0 0 0 0 0 0 0 11 0 PRP VBZ JJ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN NNP NNP O
amitosis. amitosis. 0 0 0 0 0 0 0 0 9 0 JJ IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
14342832 14342832 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC2106614 PMC2106614 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NONE NONE O
Assessment Assessment 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NONE NNP CC NNS IN O
challenges challenges 0 0 0 0 0 0 0 0 10 0 NNP CC NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NNS IN NN VBG O
ligand ligand 0 0 0 0 0 0 0 0 6 0 NNS IN NN VBG IN O
docking docking 0 0 0 0 0 0 0 0 7 0 IN NN VBG IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 NN VBG IN JJ NNS O
comparative comparative 0 0 0 0 0 0 0 0 11 0 VBG IN JJ NNS IN O
models models 0 0 0 0 0 0 0 0 6 0 IN JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ VBN O
g-protein g-protein 0 0 1 0 0 0 0 0 9 0 NNS IN JJ VBN NNP O
coupled coupled 0 0 0 0 0 0 0 0 7 0 IN JJ VBN NNP NNP O
receptors. receptors. 0 0 0 0 0 0 0 0 10 0 JJ VBN NNP NNP NNP O
Nguyen Nguyen 1 0 0 0 0 0 0 0 6 0 VBN NNP NNP NNP NNP O
ED, ED, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Norn Norn 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Frimurer Frimurer 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
TM, TM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Meiler Meiler 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Structural Structural 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
Vanderbilt Vanderbilt 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Nashville, Nashville, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Tennessee, Tennessee, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP RB O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP RB VBG O
rapidly rapidly 0 0 0 0 0 0 0 0 7 0 NNP NNP RB VBG NN O
increasing increasing 0 0 0 0 0 0 0 0 10 0 NNP RB VBG NN IN O
number number 0 0 0 0 0 0 0 0 6 0 RB VBG NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBG NN IN NN NNP O
high-resolution high-resolution 0 0 1 0 0 0 0 0 15 0 NN IN NN NNP NNS O
X-ray X-ray 1 0 1 0 0 0 0 0 5 0 IN NN NNP NNS IN O
structures structures 0 0 0 0 0 0 0 0 10 0 NN NNP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ VBN O
G-protein G-protein 1 0 1 0 0 0 0 0 9 0 NNS IN JJ VBN NNS O
coupled coupled 0 0 0 0 0 0 0 0 7 0 IN JJ VBN NNS -NONE- O
receptors receptors 0 0 0 0 0 0 0 0 9 0 JJ VBN NNS -NONE- VBZ O
(GPCRs) (GPCRs) 0 0 0 0 0 0 0 0 7 0 VBN NNS -NONE- VBZ DT O
creates creates 0 0 0 0 0 0 0 0 7 0 NNS -NONE- VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBZ DT JJ NN O
unique unique 0 0 0 0 0 0 0 0 6 0 VBZ DT JJ NN TO O
opportunity opportunity 0 0 0 0 0 0 0 0 11 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB JJ O
employ employ 0 0 0 0 0 0 0 0 6 0 NN TO VB JJ NN O
comparative comparative 0 0 0 0 0 0 0 0 11 0 TO VB JJ NN CC O
modeling modeling 0 0 0 0 0 0 0 0 8 0 VB JJ NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBG TO O
docking docking 0 0 0 0 0 0 0 0 7 0 NN CC VBG TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CC VBG TO VB JJ O
provide provide 0 0 0 0 0 0 0 0 7 0 VBG TO VB JJ NN O
valuable valuable 0 0 0 0 0 0 0 0 8 0 TO VB JJ NN IN O
insight insight 0 0 0 0 0 0 0 0 7 0 VB JJ NN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CC O
function function 0 0 0 0 0 0 0 0 8 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN VBG O
ligand ligand 0 0 0 0 0 0 0 0 6 0 NN CC NN VBG NNS O
binding binding 0 0 0 0 0 0 0 0 7 0 CC NN VBG NNS IN O
determinants determinants 0 0 0 0 0 0 0 0 12 0 NN VBG NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBG NNS IN NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 NNS IN NN NN TO O
receptors, receptors, 0 0 0 0 1 0 0 0 10 0 IN NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB IN O
assist assist 0 0 0 0 0 0 0 0 6 0 NN TO VB IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 TO VB IN JJ NN O
virtual virtual 0 0 0 0 0 0 0 0 7 0 VB IN JJ NN CC O
screening screening 0 0 0 0 0 0 0 0 9 0 IN JJ NN CC TO O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN CC TO VB CC O
design design 0 0 0 0 0 0 0 0 6 0 CC TO VB CC VB O
and and 0 0 0 0 0 0 0 0 3 0 TO VB CC VB NN O
optimize optimize 0 0 0 0 0 0 0 0 8 0 VB CC VB NN NNP O
drug drug 0 0 0 0 0 0 0 0 4 0 CC VB NN NNP NNP O
candidates. candidates. 0 0 0 0 0 0 0 0 11 0 VB NN NNP NNP JJ O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP JJ NN O
low low 0 0 0 0 0 0 0 0 3 0 NNP NNP JJ NN NN O
sequence sequence 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN IN O
identity identity 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 NN NN IN JJ JJ O
receptors, receptors, 0 0 0 0 1 0 0 0 10 0 NN IN JJ JJ NN O
conformational conformational 0 0 0 0 0 0 0 0 14 0 IN JJ JJ NN CC O
flexibility, flexibility, 0 0 0 0 1 0 0 0 12 0 JJ JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
chemical chemical 0 0 0 0 0 0 0 0 8 0 NN CC JJ NN IN O
diversity diversity 0 0 0 0 0 0 0 0 9 0 CC JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS JJ O
ligands ligands 0 0 0 0 0 0 0 0 7 0 NN IN NNS JJ DT O
present present 0 0 0 0 0 0 0 0 7 0 IN NNS JJ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNS JJ DT JJ NN O
enormous enormous 0 0 0 0 0 0 0 0 8 0 JJ DT JJ NN TO O
challenge challenge 0 0 0 0 0 0 0 0 9 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NN TO VB NN NNP O
modeling modeling 0 0 0 0 0 0 0 0 8 0 TO VB NN NNP NNP O
approaches. approaches. 0 0 0 0 0 0 0 0 11 0 VB NN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBZ PRP$ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 NNP VBZ PRP$ NN WDT O
hypothesis hypothesis 0 0 0 0 0 0 0 0 10 0 VBZ PRP$ NN WDT JJ O
that that 0 0 0 0 0 0 0 0 4 0 PRP$ NN WDT JJ -NONE- O
rapid rapid 0 0 0 0 0 0 0 0 5 0 NN WDT JJ -NONE- VBG O
Monte-Carlo Monte-Carlo 1 0 1 0 0 0 0 0 11 0 WDT JJ -NONE- VBG IN O
sampling sampling 0 0 0 0 0 0 0 0 8 0 JJ -NONE- VBG IN NN O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- VBG IN NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 VBG IN NN NN CC O
backbone backbone 0 0 0 0 0 0 0 0 8 0 IN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ JJ O
side-chain side-chain 0 0 1 0 0 0 0 0 10 0 NN CC JJ JJ NN O
conformational conformational 0 0 0 0 0 0 0 0 14 0 CC JJ JJ NN IN O
space space 0 0 0 0 0 0 0 0 5 0 JJ JJ NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NNP MD O
Rosetta Rosetta 1 0 0 0 0 0 0 0 7 0 NN IN NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 IN NNP MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB VBN TO O
leveraged leveraged 0 0 0 0 0 0 0 0 9 0 MD VB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO VB DT O
meet meet 0 0 0 0 0 0 0 0 4 0 VBN TO VB DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 TO VB DT NNP NNP O
challenge. challenge. 0 0 0 0 0 0 0 0 10 0 VB DT NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 DT NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ VBN O
performs performs 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ VBN JJ O
unbiased unbiased 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN JJ NN O
comparative comparative 0 0 0 0 0 0 0 0 11 0 VBZ VBN JJ NN CC O
modeling modeling 0 0 0 0 0 0 0 0 8 0 VBN JJ NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBG NNS O
docking docking 0 0 0 0 0 0 0 0 7 0 NN CC VBG NNS VBG O
methodologies methodologies 0 0 0 0 0 0 0 0 13 0 CC VBG NNS VBG CD O
using using 0 0 0 0 0 0 0 0 5 0 VBG NNS VBG CD NN O
14 14 0 0 0 0 0 0 1 1 2 0 NNS VBG CD NN NN O
distinct distinct 0 0 0 0 0 0 0 0 8 0 VBG CD NN NN NNS O
high-resolution high-resolution 0 0 1 0 0 0 0 0 15 0 CD NN NN NNS CC O
GPCRs GPCRs 1 0 0 0 0 0 0 0 5 0 NN NN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNS JJ O
proposes proposes 0 0 0 0 0 0 0 0 8 0 NNS CC NNS JJ NN O
knowledge-based knowledge-based 0 0 1 0 0 0 0 0 15 0 CC NNS JJ NN NNS O
filtering filtering 0 0 0 0 0 0 0 0 9 0 NNS JJ NN NNS IN O
methods methods 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN NN IN O
improvement improvement 0 0 0 0 0 0 0 0 11 0 NNS IN NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN VBG NN O
sampling sampling 0 0 0 0 0 0 0 0 8 0 NN IN VBG NN CC O
performance performance 0 0 0 0 0 0 0 0 11 0 IN VBG NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBG NN CC NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
correct correct 0 0 0 0 0 0 0 0 7 0 NN IN NN NN NNP O
ligand-receptor ligand-receptor 0 0 1 0 0 0 0 0 15 0 IN NN NN NNP NNP O
interactions. interactions. 0 0 0 0 0 0 0 0 13 0 NN NN NNP NNP NNP O
On On 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP JJ O
average, average, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP JJ VBD O
top top 0 0 0 0 0 0 0 0 3 0 NNP NNP JJ VBD NN O
ranked ranked 0 0 0 0 0 0 0 0 6 0 NNP JJ VBD NN NNS O
receptor receptor 0 0 0 0 0 0 0 0 8 0 JJ VBD NN NNS VBN O
models models 0 0 0 0 0 0 0 0 6 0 VBD NN NNS VBN IN O
built built 0 0 0 0 0 0 0 0 5 0 NN NNS VBN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NNS VBN IN JJ NNS O
template template 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NNS IN O
structures structures 0 0 0 0 0 0 0 0 10 0 IN JJ NNS IN CD O
over over 0 0 0 0 0 0 0 0 4 0 JJ NNS IN CD NN O
50% 50% 0 0 0 0 0 0 0 1 3 0 NNS IN CD NN NN O
sequence sequence 0 0 0 0 0 0 0 0 8 0 IN CD NN NN VBP O
identity identity 0 0 0 0 0 0 0 0 8 0 CD NN NN VBP IN O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP IN CD O
within within 0 0 0 0 0 0 0 0 6 0 NN VBP IN CD CD O
2.9 2.9 0 0 0 0 0 0 0 1 3 0 VBP IN CD CD IN O
Å Å 1 1 0 0 0 0 0 0 1 0 IN CD CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 IN DT JJ NN IN O
structure, structure, 0 0 0 0 1 0 0 0 10 0 DT JJ NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NN O
average average 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
root root 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN NN O
mean mean 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
square square 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
deviation deviation 0 0 0 0 0 0 0 0 9 0 NN NN NN NN IN O
(RMSD) (RMSD) 0 1 0 0 0 0 0 0 6 0 NN NN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN CD CD O
2.2 2.2 0 0 0 0 0 0 0 1 3 0 NN IN CD CD IN O
Å Å 1 1 0 0 0 0 0 0 1 0 IN CD CD IN DT O
for for 0 0 0 0 0 0 0 0 3 0 CD CD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NN NN O
transmembrane transmembrane 0 0 0 0 0 0 0 0 13 0 IN DT NN NN CC O
region region 0 0 0 0 0 0 0 0 6 0 DT NN NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC CD CD O
5 5 0 0 0 0 0 0 1 1 1 0 NN CC CD CD IN O
Å Å 1 1 0 0 0 0 0 0 1 0 CC CD CD IN DT O
for for 0 0 0 0 0 0 0 0 3 0 CD CD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT JJ NN O
second second 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN NNP O
extracellular extracellular 0 0 0 0 0 0 0 0 13 0 DT JJ NN NNP NNP O
loop. loop. 0 0 0 0 0 0 0 0 5 0 JJ NN NNP NNP DT O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 NN NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
models models 0 0 0 0 0 0 0 0 6 0 NNP DT NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP RB VBN O
consistently consistently 0 0 0 0 0 0 0 0 12 0 NNS VBP RB VBN IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 VBP RB VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN JJ NNP O
low low 0 0 0 0 0 0 0 0 3 0 VBN IN JJ NNP NN O
Rosetta Rosetta 1 0 0 0 0 0 0 0 7 0 IN JJ NNP NN NNP O
energy energy 0 0 0 0 0 0 0 0 6 0 JJ NNP NN NNP TO O
score. score. 0 0 0 0 0 0 0 0 6 0 NNP NN NNP TO VB O
To To 1 0 0 0 0 0 0 0 2 0 NN NNP TO VB PRP$ O
predict predict 0 0 0 0 0 0 0 0 7 0 NNP TO VB PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 TO VB PRP$ NN -NONE- O
binding binding 0 0 0 0 0 0 0 0 7 0 VB PRP$ NN -NONE- NN O
modes, modes, 0 0 0 0 1 0 0 0 6 0 PRP$ NN -NONE- NN NNS O
ligand ligand 0 0 0 0 0 0 0 0 6 0 NN -NONE- NN NNS IN O
conformers conformers 0 0 0 0 0 0 0 0 10 0 -NONE- NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT CD NNS O
14 14 0 0 0 0 0 0 1 1 2 0 IN DT CD NNS JJ O
ligands ligands 0 0 0 0 0 0 0 0 7 0 DT CD NNS JJ IN O
co-crystalized co-crystalized 0 0 1 0 0 0 0 0 14 0 CD NNS JJ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNS JJ IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NNP VBD O
GPCRs GPCRs 1 0 0 0 0 0 0 0 5 0 IN DT NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNP VBD VBN IN O
docked docked 0 0 0 0 0 0 0 0 6 0 NNP VBD VBN IN DT O
against against 0 0 0 0 0 0 0 0 7 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ JJ O
top top 0 0 0 0 0 0 0 0 3 0 IN DT JJ JJ JJ O
ranked ranked 0 0 0 0 0 0 0 0 6 0 DT JJ JJ JJ NNP O
comparative comparative 0 0 0 0 0 0 0 0 11 0 JJ JJ JJ NNP NNP O
models. models. 0 0 0 0 0 0 0 0 7 0 JJ JJ NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN TO O
contrast contrast 0 0 0 0 0 0 0 0 8 0 NNP NNP NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT JJ NNS O
comparative comparative 0 0 0 0 0 0 0 0 11 0 TO DT JJ NNS -NONE- O
models models 0 0 0 0 0 0 0 0 6 0 DT JJ NNS -NONE- -NONE- O
themselves, themselves, 0 0 0 0 1 0 0 0 11 0 JJ NNS -NONE- -NONE- PRP O
however, however, 0 0 0 0 1 0 0 0 8 0 NNS -NONE- -NONE- PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 -NONE- -NONE- PRP VBZ JJ O
remains remains 0 0 0 0 0 0 0 0 7 0 -NONE- PRP VBZ JJ TO O
difficult difficult 0 0 0 0 0 0 0 0 9 0 PRP VBZ JJ TO RB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO RB VB O
unambiguously unambiguously 0 0 0 0 0 0 0 0 13 0 JJ TO RB VB JJ O
identify identify 0 0 0 0 0 0 0 0 8 0 TO RB VB JJ NN O
correct correct 0 0 0 0 0 0 0 0 7 0 RB VB JJ NN VBZ O
binding binding 0 0 0 0 0 0 0 0 7 0 VB JJ NN VBZ IN O
modes modes 0 0 0 0 0 0 0 0 5 0 JJ NN VBZ IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBZ IN NN NNP O
score score 0 0 0 0 0 0 0 0 5 0 VBZ IN NN NNP NNP O
alone. alone. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNP O
On On 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NN O
average, average, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP NN NN O
sampling sampling 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NN VBD O
performance performance 0 0 0 0 0 0 0 0 11 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
improved improved 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN CD O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD NN O
10(3) 10(3) 0 0 0 0 0 0 0 1 5 0 VBN IN CD NN IN O
fold fold 0 0 0 0 0 0 0 0 4 0 IN CD NN IN NN O
over over 0 0 0 0 0 0 0 0 4 0 CD NN IN NN VBG O
random random 0 0 0 0 0 0 0 0 6 0 NN IN NN VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 IN NN VBG JJ CC O
knowledge-based knowledge-based 0 0 1 0 0 0 0 0 15 0 NN VBG JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBG JJ CC JJ NNP O
energy-based energy-based 0 0 1 0 0 0 0 0 12 0 JJ CC JJ NNP NNP O
filters. filters. 0 0 0 0 0 0 0 0 8 0 CC JJ NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN DT O
assessing assessing 0 0 0 0 0 0 0 0 9 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN IN O
applicability applicability 0 0 0 0 0 0 0 0 13 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 NN IN JJ NN PRP O
constraints, constraints, 0 0 0 0 1 0 0 0 12 0 IN JJ NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 JJ NN PRP VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NN PRP VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBD IN NN NN O
sampling sampling 0 0 0 0 0 0 0 0 8 0 VBD IN NN NN VBZ O
performance performance 0 0 0 0 0 0 0 0 11 0 IN NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN IN CD O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 VBN IN CD NN IN O
order order 0 0 0 0 0 0 0 0 5 0 IN CD NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN NN IN O
magnitude magnitude 0 0 0 0 0 0 0 0 9 0 NN IN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN DT CD O
every every 0 0 0 0 0 0 0 0 5 0 NN IN DT CD NNS O
10 10 0 0 0 0 0 0 1 1 2 0 IN DT CD NNS VBN O
residues residues 0 0 0 0 0 0 0 0 8 0 DT CD NNS VBN TO O
known known 0 0 0 0 0 0 0 0 5 0 CD NNS VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO VB DT O
contact contact 0 0 0 0 0 0 0 0 7 0 VBN TO VB DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNP NNP O
ligand. ligand. 0 0 0 0 0 0 0 0 7 0 VB DT NNP NNP IN O
Additionally, Additionally, 1 0 0 0 1 0 0 0 13 0 DT NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
case case 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
DOR, DOR, 1 1 0 0 1 0 0 0 4 0 NN IN NNP NN IN O
knowledge knowledge 0 0 0 0 0 0 0 0 9 0 IN NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ JJ O
single single 0 0 0 0 0 0 0 0 6 0 IN DT JJ JJ JJ O
specific specific 0 0 0 0 0 0 0 0 8 0 DT JJ JJ JJ NN O
ligand-protein ligand-protein 0 0 1 0 0 0 0 0 14 0 JJ JJ JJ NN VBN O
contact contact 0 0 0 0 0 0 0 0 7 0 JJ JJ NN VBN VBG O
improved improved 0 0 0 0 0 0 0 0 8 0 JJ NN VBN VBG NN O
sampling sampling 0 0 0 0 0 0 0 0 8 0 NN VBN VBG NN CD O
efficiency efficiency 0 0 0 0 0 0 0 0 10 0 VBN VBG NN CD NNP O
7 7 0 0 0 0 0 0 1 1 1 0 VBG NN CD NNP NNP O
fold. fold. 0 0 0 0 0 0 0 0 5 0 NN CD NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 CD NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP JJ O
offer offer 0 0 0 0 0 0 0 0 5 0 NNP NNS VBP JJ NNS O
specific specific 0 0 0 0 0 0 0 0 8 0 NNS VBP JJ NNS WDT O
guidelines guidelines 0 0 0 0 0 0 0 0 10 0 VBP JJ NNS WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 JJ NNS WDT MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNS WDT MD VB TO O
lead lead 0 0 0 0 0 0 0 0 4 0 WDT MD VB TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 VB TO VBN NN IN O
success success 0 0 0 0 0 0 0 0 7 0 TO VBN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN NN O
determining determining 0 0 0 0 0 0 0 0 11 0 NN IN NN NN NNP O
receptor-ligand receptor-ligand 0 0 1 0 0 0 0 0 15 0 IN NN NN NNP NNP O
complexes. complexes. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
23844000 23844000 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : IN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ : IN JJ NN O
process] process] 0 0 0 0 0 0 0 0 8 0 : IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NNP O
PMC3699586 PMC3699586 1 1 0 0 0 0 0 1 10 0 JJ NN NNP NNP NNP O
Free Free 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
PMC PMC 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NONE O
Article Article 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NONE NONE O
A A 1 1 0 0 0 0 0 0 1 0 NONE NONE DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 NONE DT NN NN VBD O
flavonoid flavonoid 0 0 0 0 0 0 0 0 9 0 DT NN NN VBD IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP NNS O
Sophora Sophora 1 0 0 0 0 0 0 0 7 0 VBD IN NNP NNS VBD O
flavescens flavescens 0 0 0 0 0 0 0 0 10 0 IN NNP NNS VBD NN O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD NN NN O
anti-angiogenesis anti-angiogenesis 0 0 1 0 0 0 0 0 17 0 NNS VBD NN NN VBD O
activity, activity, 0 0 0 0 1 0 0 0 9 0 VBD NN NN VBD NNP O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NN NN VBD NNP NN O
VEGF VEGF 1 1 0 0 0 0 0 0 4 0 NN VBD NNP NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD NNP NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VBD -NONE- O
caused caused 0 0 0 0 0 0 0 0 6 0 NN CC VBD -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 CC VBD -NONE- NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 VBD -NONE- NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest -NONE- NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
XL, XL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cao Cao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
MA, MA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Pu Pu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
LP, LP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
SS, SS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Gao Gao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
QX, QX, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yuan Yuan 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
CS, CS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
CM. CM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Life Life 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Lanzhou Lanzhou 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Lanzhou, Lanzhou, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP DT O
Kushen, Kushen, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
dried dried 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN IN O
root root 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNS O
Sophora Sophora 1 0 0 0 0 0 0 0 7 0 NN IN NNP NNS -NONE- O
flavescens flavescens 0 0 0 0 0 0 0 0 10 0 IN NNP NNS -NONE- VBZ O
Ait, Ait, 1 0 0 0 1 0 0 0 4 0 NNP NNS -NONE- VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNS -NONE- VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- VBZ DT JJ JJ O
traditional traditional 0 0 0 0 0 0 0 0 11 0 VBZ DT JJ JJ JJ O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 DT JJ JJ JJ NNP O
herbal herbal 0 0 0 0 0 0 0 0 6 0 JJ JJ JJ NNP NNP O
medicine. medicine. 0 0 0 0 0 0 0 0 9 0 JJ JJ NNP NNP NNS O
Kushen Kushen 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNS VBP O
alkaloids alkaloids 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN VBN IN O
developed developed 0 0 0 0 0 0 0 0 9 0 VBP VBN VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NNP IN O
China China 1 0 0 0 0 0 0 0 5 0 VBN IN NNP IN NN O
as as 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
anticancer anticancer 0 0 0 0 0 0 0 0 10 0 NNP IN NN NN CC O
drugs, drugs, 0 0 0 0 1 0 0 0 6 0 IN NN NN CC JJR O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJR NN O
more more 0 0 0 0 0 0 0 0 4 0 NN CC JJR NN NN O
potent potent 0 0 0 0 0 0 0 0 6 0 CC JJR NN NN NNS O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 JJR NN NN NNS VBP O
activities activities 0 0 0 0 0 0 0 0 10 0 NN NN NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN VBN IN O
identified identified 0 0 0 0 0 0 0 0 10 0 VBP VBN VBN IN WRB O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN WRB NNS O
kushen kushen 0 0 0 0 0 0 0 0 6 0 VBN IN WRB NNS IN O
flavonoids flavonoids 0 0 0 0 0 0 0 0 10 0 IN WRB NNS IN IN O
than than 0 0 0 0 0 0 0 0 4 0 WRB NNS IN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS IN IN NN NNP O
kushen kushen 0 0 0 0 0 0 0 0 6 0 IN IN NN NNP NNP O
alkaloids. alkaloids. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN DT O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 DT NN DT JJ NNS O
anti-angiogenic anti-angiogenic 0 0 1 0 0 0 0 0 15 0 NN DT JJ NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
(2S)-7,2',4'-triihydroxy-5-methoxy-8-dimethylallyl (2S)-7,2',4'-triihydroxy-5-methoxy-8-dimethylallyl 0 0 1 0 1 1 0 1 50 0 NNS IN JJ NN NN O
flavanone flavanone 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN CD O
(Compound (Compound 0 0 0 0 0 0 0 0 9 0 JJ NN NN CD DT O
1, 1, 0 0 0 0 1 0 0 1 2 0 NN NN CD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN CD DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 CD DT NN NN VBD O
flavonoid flavonoid 0 0 0 0 0 0 0 0 9 0 DT NN NN VBD IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP VBD O
Kushen), Kushen), 1 0 0 0 1 0 0 0 8 0 VBD IN NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 IN NNP VBD VBN VBG O
examined examined 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VBD VBN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN VBG DT NN JJ O
human human 0 0 0 0 0 0 0 0 5 0 VBG DT NN JJ NN O
umbilical umbilical 0 0 0 0 0 0 0 0 9 0 DT NN JJ NN JJ O
vein vein 0 0 0 0 0 0 0 0 4 0 NN JJ NN JJ NN O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 JJ NN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN JJ NN NN NN O
line line 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN IN O
(ECV304) (ECV304) 0 1 0 0 0 0 0 1 8 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN CD O
compound compound 0 0 0 0 0 0 0 0 8 0 VBD IN NN CD NNS O
1 1 0 0 0 0 0 0 1 1 1 0 IN NN CD NNS -NONE- O
shows shows 0 0 0 0 0 0 0 0 5 0 NN CD NNS -NONE- NN O
anti-angiogenesis anti-angiogenesis 0 0 1 0 0 0 0 0 17 0 CD NNS -NONE- NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NNS -NONE- NN IN NN O
via via 0 0 0 0 0 0 0 0 3 0 -NONE- NN IN NN NNS O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 IN NN NNS IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 IN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
migration, migration, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN CC O
adhesion, adhesion, 0 0 0 0 1 0 0 0 9 0 NN NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB NNP O
tube tube 0 0 0 0 0 0 0 0 4 0 NN CC VB NNP NNP O
formation. formation. 0 0 0 0 0 0 0 0 10 0 CC VB NNP NNP NNS O
Further Further 1 0 0 0 0 0 0 0 7 0 VB NNP NNP NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN CD O
compound compound 0 0 0 0 0 0 0 0 8 0 VBD IN NN CD NNS O
1 1 0 0 0 0 0 0 1 1 1 0 IN NN CD NNS VBP O
blocks blocks 0 0 0 0 0 0 0 0 6 0 NN CD NNS VBP NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 CD NNS VBP NNS IN O
cycles cycles 0 0 0 0 0 0 0 0 6 0 NNS VBP NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN DT NN NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NN O
without without 0 0 0 0 0 0 0 0 7 0 NN NN IN NN -NONE- O
inducing inducing 0 0 0 0 0 0 0 0 8 0 NN IN NN -NONE- CC O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 IN NN -NONE- CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC RB VBZ O
down down 0 0 0 0 0 0 0 0 4 0 -NONE- CC RB VBZ JJ O
regulates regulates 0 0 0 0 0 0 0 0 9 0 CC RB VBZ JJ JJ O
vascular vascular 0 0 0 0 0 0 0 0 8 0 RB VBZ JJ JJ NN O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 VBZ JJ JJ NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NNP O
(VEGF) (VEGF) 0 1 0 0 0 0 0 0 6 0 NN NN NN NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ JJ O
free free 0 0 0 0 0 0 0 0 4 0 NNP NNP JJ JJ NN O
radical radical 0 0 0 0 0 0 0 0 7 0 NNP JJ JJ NN NN O
scavenging scavenging 0 0 0 0 0 0 0 0 10 0 JJ JJ NN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN CD O
compound compound 0 0 0 0 0 0 0 0 8 0 NN IN NN CD VBD O
1 1 0 0 0 0 0 0 1 1 1 0 IN NN CD VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN CD VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 CD VBD VBN IN CD O
through through 0 0 0 0 0 0 0 0 7 0 VBD VBN IN CD NN O
2',7'-dichlorofluorescin 2',7'-dichlorofluorescin 0 0 1 0 1 1 0 1 24 0 VBN IN CD NN -NONE- O
diacetate diacetate 0 0 0 0 0 0 0 0 9 0 IN CD NN -NONE- NN O
(DCFH-DA) (DCFH-DA) 0 1 1 0 0 0 0 0 9 0 CD NN -NONE- NN NN O
incubation incubation 0 0 0 0 0 0 0 0 10 0 NN -NONE- NN NN IN O
assay assay 0 0 0 0 0 0 0 0 5 0 -NONE- NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN IN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP VBZ O
anti-angiogenic anti-angiogenic 0 0 1 0 0 0 0 0 15 0 NNP NNP NNP VBZ IN O
properties properties 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN NN CD O
compound compound 0 0 0 0 0 0 0 0 8 0 VBZ IN NN CD CC O
1 1 0 0 0 0 0 0 1 1 1 0 IN NN CD CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN CD CC PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 CD CC PRP$ JJ NN O
antiproliferative antiproliferative 0 0 0 0 0 0 0 0 17 0 CC PRP$ JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 PRP$ JJ NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
endothelial endothelial 0 0 0 0 0 0 0 0 11 0 NN IN JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN VBG O
without without 0 0 0 0 0 0 0 0 7 0 JJ NNS IN VBG NN O
causing causing 0 0 0 0 0 0 0 0 7 0 NNS IN VBG NN NN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 IN VBG NN NN PRP O
make make 0 0 0 0 0 0 0 0 4 0 VBG NN NN PRP DT O
it it 0 0 0 0 0 0 0 0 2 0 NN NN PRP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN PRP DT JJ NN O
good good 0 0 0 0 0 0 0 0 4 0 PRP DT JJ NN IN O
candidate candidate 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NN IN NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
agent agent 0 0 0 0 0 0 0 0 5 0 IN DT NN IN NN O
against against 0 0 0 0 0 0 0 0 7 0 DT NN IN NN IN O
development development 0 0 0 0 0 0 0 0 11 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NONE O
tumors. tumors. 0 0 0 0 0 0 0 0 7 0 NN IN NNP NONE NONE O
Houttuynia Houttuynia 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP NN NNP O
cordata cordata 0 0 0 0 0 0 0 0 7 0 NONE NNP NN NNP NN O
Thunb Thunb 1 0 0 0 0 0 0 0 5 0 NNP NN NNP NN VBZ O
extract extract 0 0 0 0 0 0 0 0 7 0 NN NNP NN VBZ -NONE- O
modulates modulates 0 0 0 0 0 0 0 0 9 0 NNP NN VBZ -NONE- JJS O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 arrest NN VBZ -NONE- JJS CC B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBZ -NONE- JJS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- JJS CC JJ NN O
Fas/CD95-mediated Fas/CD95-mediated 1 0 1 1 0 0 0 1 17 0 JJS CC JJ NN NN O
death death 0 0 0 0 0 0 0 0 5 0 CC JJ NN NN JJ O
receptor receptor 0 0 0 0 0 0 0 0 8 0 JJ NN NN JJ NN O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 NN NN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN JJ NN NN IN O
death death 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NNP NNP O
A549 A549 1 1 0 0 0 0 0 1 4 0 NN NN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YF, YF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
JS, JS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chang Chang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
WS, WS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Tsai Tsai 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
SC, SC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Peng Peng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
SF, SF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YR. YR. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmacology, Pharmacology, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP IN O
College College 1 0 0 0 0 0 0 0 7 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
China China 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP CD O
No No 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP CD JJ O
91, 91, 0 0 0 0 1 0 0 1 3 0 NNP NNP CD JJ NN O
Hsueh-Shih Hsueh-Shih 1 0 1 0 0 0 0 0 10 0 NNP CD JJ NN NNP O
Road, Road, 1 0 0 0 1 0 0 0 5 0 CD JJ NN NNP CD O
Taichung Taichung 1 0 0 0 0 0 0 0 8 0 JJ NN NNP CD NNP O
40402, 40402, 0 0 0 0 1 0 0 1 6 0 NN NNP CD NNP NNP O
Taiwan. Taiwan. 1 0 0 0 0 0 0 0 7 0 NNP CD NNP NNP NNP O
yfchen@mail.cmu.edu.tw yfchen@mail.cmu.edu.tw 0 0 0 0 0 0 0 0 22 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NN O
Houttuynia Houttuynia 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NN NNP O
cordata cordata 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNP NNP O
Thunb Thunb 1 0 0 0 0 0 0 0 5 0 NNP NN NNP NNP VBZ O
(HCT) (HCT) 0 1 0 0 0 0 0 0 5 0 NN NNP NNP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ RB VBN O
commonly commonly 0 0 0 0 0 0 0 0 8 0 NNP VBZ RB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 VBZ RB VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNP CC O
Taiwan Taiwan 1 0 0 0 0 0 0 0 6 0 VBN IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 NNP CC JJ JJ NNS O
Asian Asian 1 0 0 0 0 0 0 0 5 0 CC JJ JJ NNS IN O
countries countries 0 0 0 0 0 0 0 0 9 0 JJ JJ NNS IN DT O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNS IN DT NN NN O
anti-inflammatory, anti-inflammatory, 0 0 1 0 1 0 0 0 18 0 IN DT NN NN CC O
antibacterial antibacterial 0 0 0 0 0 0 0 0 13 0 DT NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
antiviral antiviral 0 0 0 0 0 0 0 0 9 0 NN CC JJ NN NNP O
herbal herbal 0 0 0 0 0 0 0 0 6 0 CC JJ NN NNP NNP O
medicine. medicine. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 NNP DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN PRP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT JJ NN O
anti-human anti-human 0 0 1 0 0 0 0 0 10 0 VBD DT JJ NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN CC O
activity activity 0 0 0 0 0 0 0 0 8 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN CC NN NN NNS O
inhibition inhibition 0 0 0 0 0 0 0 0 10 0 CC NN NN NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 NN NN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP IN O
HCT HCT 1 1 0 0 0 0 0 0 3 0 NNS IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NNP IN NN NN NN O
lung lung 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN NN NN NNP NNP O
A549 A549 1 1 0 0 0 0 0 1 4 0 NN NN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN TO O
order order 0 0 0 0 0 0 0 0 5 0 NNP NNP NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO VB NNS O
investigate investigate 0 0 0 0 0 0 0 0 11 0 NN TO VB NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 TO VB NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VB NNS IN NNP IN O
HCT HCT 1 1 0 0 0 0 0 0 3 0 NNS IN NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
A549 A549 1 1 0 0 0 0 0 1 4 0 NNP IN NNP NNP NNP O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NN O
MTT MTT 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
assay assay 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB NN O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBN TO VB NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 TO VB NN NNP NNP O
viability. viability. 0 0 0 0 0 0 0 0 10 0 VB NN NNP NNP NN O
Flow Flow 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN VBD O
cytometry cytometry 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
employed employed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN NNP O
analysis, analysis, 0 0 0 0 1 0 0 0 9 0 NN NN NN NNP NNP O
DAPI DAPI 1 1 0 0 0 0 0 0 4 0 NN NN NNP NNP CC O
staining, staining, 0 0 0 0 1 0 0 0 9 0 NN NNP NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NNP NN O
Comet Comet 1 0 0 0 0 0 0 0 5 0 CC DT NNP NN VBD O
assay assay 0 0 0 0 0 0 0 0 5 0 DT NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NN CC O
fragmentation fragmentation 0 0 0 0 0 0 0 0 13 0 IN NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN CC NNP NNP NNP O
condensation. condensation. 0 0 0 0 0 0 0 0 13 0 CC NNP NNP NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN NN O
blot blot 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB NN O
analyze analyze 0 0 0 0 0 0 0 0 7 0 VBN TO VB NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 TO VB NN NN CC O
cycle cycle 0 0 0 0 0 0 0 0 5 0 VB NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ JJ O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 NN CC JJ JJ NN O
related related 0 0 0 0 0 0 0 0 7 0 CC JJ JJ NN NNP O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ JJ NN NNP NNP O
levels. levels. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP VBD O
HCT HCT 1 1 0 0 0 0 0 0 3 0 NN NNP NNP VBD JJ O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD JJ NNS O
morphological morphological 0 0 0 0 0 0 0 0 13 0 NNP VBD JJ NNS VBG O
changes changes 0 0 0 0 0 0 0 0 7 0 VBD JJ NNS VBG NN O
including including 0 0 0 0 0 0 0 0 9 0 JJ NNS VBG NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS VBG NN NN CC O
shrinkage shrinkage 0 0 0 0 0 0 0 0 9 0 VBG NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
rounding. rounding. 0 0 0 0 0 0 0 0 9 0 NN CC NNP NNP VBD O
HCT HCT 1 1 0 0 0 0 0 0 3 0 CC NNP NNP VBD DT O
increased increased 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN CC O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 VBD DT NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC -NONE- NN O
Sub-G1 Sub-G1 1 0 1 0 0 0 0 1 6 0 NN CC -NONE- NN -NONE- O
cell cell 0 0 0 0 0 0 0 0 4 0 CC -NONE- NN -NONE- NNS O
(apoptosis) (apoptosis) 0 0 0 0 0 0 0 0 11 0 -NONE- NN -NONE- NNS CC O
populations populations 0 0 0 0 0 0 0 0 11 0 NN -NONE- NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNS CC NNP VBD O
HCT HCT 1 1 0 0 0 0 0 0 3 0 NNS CC NNP VBD NNP O
increased increased 0 0 0 0 0 0 0 0 9 0 CC NNP VBD NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP VBD NNP NN CC O
fragmentation fragmentation 0 0 0 0 0 0 0 0 13 0 VBD NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN CC NNP NN IN O
condensation condensation 0 0 0 0 0 0 0 0 12 0 CC NNP NN IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NNP NN IN VBN IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN IN VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN NNP NN O
DAPI DAPI 1 1 0 0 0 0 0 0 4 0 VBN IN NNP NN CC O
staining staining 0 0 0 0 0 0 0 0 8 0 IN NNP NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NNP NNP O
Comet Comet 1 0 0 0 0 0 0 0 5 0 CC DT NNP NNP NNP O
assay. assay. 0 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP VBD O
HCT HCT 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 NNP VBD NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN -NONE- CC O
caspase-8 caspase-8 0 0 1 0 0 0 0 1 9 0 NN IN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN -NONE- CC NNP NNP O
caspase-3. caspase-3. 0 0 1 0 0 0 0 1 10 0 -NONE- CC NNP NNP NN O
Fas/CD95 Fas/CD95 1 0 0 1 0 0 0 1 8 0 CC NNP NNP NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNS VBD O
levels levels 0 0 0 0 0 0 0 0 6 0 NNP NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NNP O
HCT-treated HCT-treated 1 0 1 0 0 0 0 0 11 0 VBN IN JJ NNP NNP O
A549 A549 1 1 0 0 0 0 0 1 4 0 IN JJ NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase NNP NNP NNP NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NNP NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ JJ O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 NN CC JJ JJ NN O
related related 0 0 0 0 0 0 0 0 7 0 CC JJ JJ NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ JJ NN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 JJ NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNS IN NN NN NN O
D1, D1, 1 1 0 0 1 0 0 1 3 0 IN NN NN NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NN NN NN NNP CD O
CDK CDK 1 1 0 0 0 0 0 0 3 0 NN NN NNP CD CC O
4 4 0 0 0 0 0 0 1 1 1 0 NN NNP CD CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC NNP CD O
CDK CDK 1 1 0 0 0 0 0 0 3 0 CD CC NNP CD VBD O
2 2 0 0 0 0 0 0 1 1 1 0 CC NNP CD VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 NNP CD VBD JJ CC O
decreased, decreased, 0 0 0 0 1 0 0 0 10 0 CD VBD JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC JJ NN O
p27, p27, 0 0 0 0 1 0 0 1 4 0 JJ CC JJ NN CC O
caspase-8 caspase-8 0 0 1 0 0 0 0 1 9 0 CC JJ NN CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC -NONE- VBD O
caspase-3 caspase-3 0 0 1 0 0 0 0 1 9 0 NN CC -NONE- VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC -NONE- VBD VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 -NONE- VBD VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNS O
A549 A549 1 1 0 0 0 0 0 1 4 0 VBN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NNP NNS IN NNP NNP O
HCT HCT 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NNP NNP O
treatment. treatment. 0 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NNP NNS VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN JJ -NONE- O
HCT-induced HCT-induced 1 0 1 0 0 0 0 0 11 0 VBD IN JJ -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase IN JJ -NONE- NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 arrest JJ -NONE- NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 -NONE- NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ JJ O
Fas/CD95-dependent Fas/CD95-dependent 1 0 1 1 0 0 0 1 18 0 NN CC JJ JJ NN O
apoptotic apoptotic 0 0 0 0 0 0 0 0 9 0 CC JJ JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN IN O
death death 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
A549 A549 1 1 0 0 0 0 0 1 4 0 NN IN NNP NNP NONE O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NONE NONE O
Novel Novel 1 0 0 0 0 0 0 0 5 0 NONE NONE NNP NNS -NONE- O
mutations mutations 0 0 0 0 0 0 0 0 9 0 NONE NNP NNS -NONE- CC O
m.3959G>A m.3959G>A 0 0 0 0 0 0 0 1 9 0 NNP NNS -NONE- CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC JJ IN O
m.3995A>G m.3995A>G 0 0 0 0 0 0 0 1 9 0 -NONE- CC JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC JJ IN JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 JJ IN JJ NN -NONE- O
gene gene 0 0 0 0 0 0 0 0 4 0 IN JJ NN -NONE- VBN O
MT-ND1 MT-ND1 1 1 1 0 0 0 0 1 6 0 JJ NN -NONE- VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN -NONE- VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 -NONE- VBN IN NNP NNP O
MELAS. MELAS. 1 1 0 0 0 0 0 0 6 0 VBN IN NNP NNP NNP O
Lin Lin 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhao Zhao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
CB, CB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lu Lu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
JH, JH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
HJ, HJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zhu Zhu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
WH, WH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Xi Xi 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
JY, JY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lu Lu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Luo Luo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
SS, SS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ma Ma 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xiao Xiao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
BG, BG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lu Lu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
CZ. CZ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Neurology, Neurology, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
Huashan Huashan 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP . O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP . NNP O
. . 0 0 0 0 0 0 0 0 1 0 NNP NNP . NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP . NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 . NNP NNP NNP NNP O
Mitochondrial Mitochondrial 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP JJ O
encephalopathy, encephalopathy, 0 0 0 0 1 0 0 0 15 0 NNP NNP NNP JJ NN O
lactic lactic 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN CC O
acidosis acidosis 0 0 0 0 0 0 0 0 8 0 NNP JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NNS O
stroke-like stroke-like 0 0 1 0 0 0 0 0 11 0 NN CC JJ NNS -NONE- O
episodes episodes 0 0 0 0 0 0 0 0 8 0 CC JJ NNS -NONE- VBP O
(MELAS) (MELAS) 0 1 0 0 0 0 0 0 7 0 JJ NNS -NONE- VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNS -NONE- VBP JJ JJ O
progressive progressive 0 0 0 0 0 0 0 0 11 0 -NONE- VBP JJ JJ NN O
neurodegenerative neurodegenerative 0 0 0 0 0 0 0 0 17 0 VBP JJ JJ NN VBN O
disorder disorder 0 0 0 0 0 0 0 0 8 0 JJ JJ NN VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 JJ NN VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN VBN IN JJ RB O
polygenetic, polygenetic, 0 0 0 0 1 0 0 0 12 0 VBN IN JJ RB VBN O
maternally maternally 0 0 0 0 0 0 0 0 10 0 IN JJ RB VBN NNS O
inherited inherited 0 0 0 0 0 0 0 0 9 0 JJ RB VBN NNS IN O
mutations mutations 0 0 0 0 0 0 0 0 9 0 RB VBN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBN NNS IN JJ NNP O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 NNS IN JJ NNP NNP O
DNA. DNA. 1 1 0 0 0 0 0 0 4 0 IN JJ NNP NNP CD O
Approximately Approximately 1 0 0 0 0 0 0 0 13 0 JJ NNP NNP CD IN O
80% 80% 0 0 0 0 0 0 0 1 3 0 NNP NNP CD IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP CD IN NNP NNS O
MELAS MELAS 1 1 0 0 0 0 0 0 5 0 CD IN NNP NNS VBP O
cases cases 0 0 0 0 0 0 0 0 5 0 IN NNP NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 NNS VBP VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
mutation mutation 0 0 0 0 0 0 0 0 8 0 IN DT NN NN IN O
m.3243A>G m.3243A>G 0 0 0 0 0 0 0 1 9 0 DT NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 IN DT JJ NNP NNP O
tRNALeu tRNALeu 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NN O
(UUR) (UUR) 0 1 0 0 0 0 0 0 5 0 JJ NNP NNP NN NNP O
gene gene 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNP NNP O
(MT-TL1). (MT-TL1). 0 1 1 0 0 0 0 1 9 0 NNP NN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD CD O
reported reported 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NNP VBD CD NNS IN O
probands probands 0 0 0 0 0 0 0 0 8 0 VBD CD NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN NNP NNP O
MELAS MELAS 1 1 0 0 0 0 0 0 5 0 NNS IN NNP NNP NNP O
features. features. 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NN O
Muscle Muscle 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN VBD O
biopsy biopsy 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBD JJ O
identified identified 0 0 0 0 0 0 0 0 10 0 NNP NN VBD JJ NNS O
ragged-red ragged-red 0 0 1 0 0 0 0 0 10 0 NN VBD JJ NNS -NONE- O
fibers fibers 0 0 0 0 0 0 0 0 6 0 VBD JJ NNS -NONE- IN O
(RRF) (RRF) 0 1 0 0 0 0 0 0 5 0 JJ NNS -NONE- IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN NNP NNP O
Gomori Gomori 1 0 0 0 0 0 0 0 6 0 -NONE- IN NNP NNP NNP O
Trichrome Trichrome 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
staining. staining. 0 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN NN O
respiratory respiratory 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NN NN O
chain chain 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN NN O
function function 0 0 0 0 0 0 0 0 8 0 NN NN NN NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NN NN NN VBD VBN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NN VBD VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NN VBD VBN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 VBD VBN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN JJ NN O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NN O
respiratory respiratory 0 0 0 0 0 0 0 0 11 0 IN JJ NN NN NN O
chain chain 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN PRP O
complex complex 0 0 0 0 0 0 0 0 7 0 NN NN NN PRP IN O
I I 1 1 0 0 0 0 0 0 1 0 NN NN PRP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN PRP IN DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 PRP IN DT NNP NNP O
probands. probands. 0 0 0 0 0 0 0 0 9 0 IN DT NNP NNP IN O
Sequencing Sequencing 1 0 0 0 0 0 0 0 10 0 DT NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NNP O
mitochondrial mitochondrial 0 0 0 0 0 0 0 0 13 0 IN DT JJ NNP VBD O
DNA DNA 1 1 0 0 0 0 0 0 3 0 DT JJ NNP VBD CD O
revealed revealed 0 0 0 0 0 0 0 0 8 0 JJ NNP VBD CD NN O
two two 0 0 0 0 0 0 0 0 3 0 NNP VBD CD NN -NONE- O
novel novel 0 0 0 0 0 0 0 0 5 0 VBD CD NN -NONE- NN O
MT-ND1 MT-ND1 1 1 1 0 0 0 0 1 6 0 CD NN -NONE- NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 NN -NONE- NN NN NN O
missense missense 0 0 0 0 0 0 0 0 8 0 -NONE- NN NN NN NN O
mutations, mutations, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN CC O
m.3959G>A m.3959G>A 0 0 0 0 0 0 0 1 9 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP WDT O
m.3995A>G, m.3995A>G, 0 0 0 0 1 0 0 1 10 0 NN CC NNP WDT VBP O
which which 0 0 0 0 0 0 0 0 5 0 CC NNP WDT VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NNP WDT VBP RB VBN O
highly highly 0 0 0 0 0 0 0 0 6 0 WDT VBP RB VBN IN O
conserved conserved 0 0 0 0 0 0 0 0 9 0 VBP RB VBN IN NNP O
among among 0 0 0 0 0 0 0 0 5 0 RB VBN IN NNP NNP O
species. species. 0 0 0 0 0 0 0 0 8 0 VBN IN NNP NNP JJ O
Protein Protein 1 0 0 0 0 0 0 0 7 0 IN NNP NNP JJ NN O
secondary secondary 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN NNS O
structure structure 0 0 0 0 0 0 0 0 9 0 NNP JJ NN NNS VBD O
predictions predictions 0 0 0 0 0 0 0 0 11 0 JJ NN NNS VBD IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NN NNS VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 VBD IN DT NNS MD O
mutations mutations 0 0 0 0 0 0 0 0 9 0 IN DT NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 DT NNS MD VB DT O
alter alter 0 0 0 0 0 0 0 0 5 0 NNS MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN NN O
peptide peptide 0 0 0 0 0 0 0 0 7 0 VB DT NN NN CC O
structure structure 0 0 0 0 0 0 0 0 9 0 DT NN NN CC MD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN CC MD VB TO O
lead lead 0 0 0 0 0 0 0 0 4 0 CC MD VB TO VBN O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO VBN NNP O
decreased decreased 0 0 0 0 0 0 0 0 9 0 VB TO VBN NNP NN O
ND1 ND1 1 1 0 0 0 0 0 1 3 0 TO VBN NNP NN NNP O
gene gene 0 0 0 0 0 0 0 0 4 0 VBN NNP NN NNP NNP O
stability. stability. 0 0 0 0 0 0 0 0 10 0 NNP NN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT CD O
these these 0 0 0 0 0 0 0 0 5 0 VBP IN DT CD NN O
two two 0 0 0 0 0 0 0 0 3 0 IN DT CD NN NNS O
novel novel 0 0 0 0 0 0 0 0 5 0 DT CD NN NNS MD O
mutations mutations 0 0 0 0 0 0 0 0 9 0 CD NN NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB TO O
contribute contribute 0 0 0 0 0 0 0 0 10 0 NNS MD VB TO DT O
to to 0 0 0 0 0 0 0 0 2 0 MD VB TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VB TO DT NNP VBZ O
MELAS MELAS 1 1 0 0 0 0 0 0 5 0 TO DT NNP VBZ IN O
phenotypes phenotypes 0 0 0 0 0 0 0 0 10 0 DT NNP VBZ IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 IN DT NNS IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 DT NNS IN PRP$ NNP O
our our 0 0 0 0 0 0 0 0 3 0 NNS IN PRP$ NNP NNP O
study. study. 0 0 0 0 0 0 0 0 6 0 IN PRP$ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 PRP$ NNP NNP CD JJ O
23834081 23834081 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : IN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 JJ : IN JJ IN O
supplied supplied 0 0 0 0 0 0 0 0 8 0 : IN JJ IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN JJ IN JJ NONE O
publisher] publisher] 0 0 0 0 0 0 0 0 10 0 JJ IN JJ NONE NONE O
Influenza Influenza 1 0 0 0 0 0 0 0 9 0 NONE NONE NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NONE NNP DT NN NNP O
virus virus 0 0 0 0 0 0 0 0 5 0 NNP DT NN NNP NNS O
NS1 NS1 1 1 0 0 0 0 0 1 3 0 DT NN NNP NNS -NONE- O
induces induces 0 0 0 0 0 0 0 0 7 0 NN NNP NNS -NONE- VBP O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NNP NNS -NONE- VBP NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 NNS -NONE- VBP NN JJS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest -NONE- VBP NN JJS IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBP NN JJS IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN JJS IN NN DT O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 JJS IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 NN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
RhoA RhoA 1 0 0 0 0 0 0 0 4 0 NN IN NNP NNP NNP O
protein. protein. 0 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Jiang Jiang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gao Gao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Song Song 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
W. W. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Microbiology, Microbiology, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP NNP O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Beijing, Beijing, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Influenza Influenza 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN VBZ O
virus virus 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN VBZ DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN VBZ O
pathogenic pathogenic 0 0 0 0 0 0 0 0 10 0 DT JJ NN VBZ VBN O
virus virus 0 0 0 0 0 0 0 0 5 0 JJ NN VBZ VBN TO O
known known 0 0 0 0 0 0 0 0 5 0 NN VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB NN O
induce induce 0 0 0 0 0 0 0 0 6 0 VBN TO VB NN NN O
host host 0 0 0 0 0 0 0 0 4 0 TO VB NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VB NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NN NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
G(0)/G(1) G(0)/G(1) 1 1 0 1 0 0 0 1 9 phase NN IN NNP NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC VB JJ O
create create 0 0 0 0 0 0 0 0 6 0 NN CC VB JJ NNS O
beneficial beneficial 0 0 0 0 0 0 0 0 10 0 CC VB JJ NNS IN O
conditions conditions 0 0 0 0 0 0 0 0 10 0 VB JJ NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN JJ NNP O
viral viral 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNP NNP O
replication. replication. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP WRB O
However, However, 1 0 0 0 1 0 0 0 8 0 JJ NNP NNP WRB DT O
how how 0 0 0 0 0 0 0 0 3 0 NNP NNP WRB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP WRB DT NN VBZ O
virus virus 0 0 0 0 0 0 0 0 5 0 WRB DT NN VBZ NN O
achieves achieves 0 0 0 0 0 0 0 0 8 arrest DT NN VBZ NN VBZ O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN VBZ NN VBZ NNP O
remains remains 0 0 0 0 0 0 0 0 7 0 VBZ NN VBZ NNP NNP O
unclear. unclear. 0 0 0 0 0 0 0 0 8 0 NN VBZ NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 VBZ NNP NNP VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NNS VBG O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 VBD DT NNS VBG DT O
underlying underlying 0 0 0 0 0 0 0 0 10 0 DT NNS VBG DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNS VBG DT NN CC O
process process 0 0 0 0 0 0 0 0 7 0 VBG DT NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 NN CC VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 CC VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ NN O
nonstructural nonstructural 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN CD O
protein protein 0 0 0 0 0 0 0 0 7 0 DT JJ NN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 JJ NN CD NN VBZ O
(NS1) (NS1) 0 1 0 0 0 0 0 1 5 0 NN CD NN VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 CD NN VBZ NNP NNP O
required. required. 0 0 0 0 0 0 0 0 9 0 NN VBZ NNP NNP IN O
Based Based 1 0 0 0 0 0 0 0 5 0 VBZ NNP NNP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN PRP O
finding, finding, 0 0 0 0 1 0 0 0 8 0 IN DT NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBD DT O
generated generated 0 0 0 0 0 0 0 0 9 0 NN PRP VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 PRP VBD DT JJ NN O
viable viable 0 0 0 0 0 0 0 0 6 0 VBD DT JJ NN DT O
influenza influenza 0 0 0 0 0 0 0 0 9 0 DT JJ NN DT NN O
A A 1 1 0 0 0 0 0 0 1 0 JJ NN DT NN NN O
virus virus 0 0 0 0 0 0 0 0 5 0 NN DT NN NN VBG O
(H1N1) (H1N1) 0 1 0 0 0 0 0 1 6 0 DT NN NN VBG DT O
lacking lacking 0 0 0 0 0 0 0 0 7 0 NN NN VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT JJ NNP O
entire entire 0 0 0 0 0 0 0 0 6 0 VBG DT JJ NNP NN O
NS1 NS1 1 1 0 0 0 0 0 1 3 0 DT JJ NNP NN TO O
gene gene 0 0 0 0 0 0 0 0 4 0 JJ NNP NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO NN DT O
study study 0 0 0 0 0 0 0 0 5 0 NN TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN IN O
function function 0 0 0 0 0 0 0 0 8 0 NN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN IN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NNP NNP O
regulation. regulation. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN TO O
addition addition 0 0 0 0 0 0 0 0 8 0 NNP NNP NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO DT NN O
some some 0 0 0 0 0 0 0 0 4 0 NN TO DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 TO DT NN NN NNS O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN NNS WDT O
regulators regulators 0 0 0 0 0 0 0 0 10 0 NN NN NNS WDT VBD O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT VBD -NONE- O
were were 0 0 0 0 0 0 0 0 4 0 NNS WDT VBD -NONE- DT O
changed, changed, 0 0 0 0 1 0 0 0 8 0 WDT VBD -NONE- DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD -NONE- DT NN CC O
concentration concentration 0 0 0 0 0 0 0 0 13 0 -NONE- DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NNP O
RhoA RhoA 1 0 0 0 0 0 0 0 4 0 NN IN NNP NNP WDT O
protein, protein, 0 0 0 0 1 0 0 0 8 0 IN NNP NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP WDT VBZ VBN TO O
thought thought 0 0 0 0 0 0 0 0 7 0 WDT VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB JJ IN O
pivotal pivotal 0 0 0 0 0 0 0 0 7 0 TO VB JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VB JJ IN JJ NN O
G(1)/S G(1)/S 1 1 0 1 0 0 0 1 6 phase JJ IN JJ NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN VBD O
transition, transition, 0 0 0 0 1 0 0 0 11 0 JJ NN NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB VBN IN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 VBD RB VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN NN NNP O
overexpressing overexpressing 0 0 0 0 0 0 0 0 14 0 VBN IN NN NNP CC O
NS1. NS1. 1 1 0 0 0 0 0 1 4 0 IN NN NNP CC IN O
And And 1 0 0 0 0 0 0 0 3 0 NN NNP CC IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP CC IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT NN DT O
meantime, meantime, 0 0 0 0 1 0 0 0 9 0 IN DT NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 DT NN DT NN NN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NN DT NN NN IN O
level level 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN NN O
regulator regulator 0 0 0 0 0 0 0 0 9 0 NN NN NN NN NN O
pRb, pRb, 0 0 0 0 1 0 0 0 4 0 NN NN NN NN IN O
downstream downstream 0 0 0 0 0 0 0 0 10 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
RhoA RhoA 1 0 0 0 0 0 0 0 4 0 NN IN NNP NNP VBD O
kinase, kinase, 0 0 0 0 1 0 0 0 7 0 IN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 VBN IN DT JJ NNP O
NS1-dependent NS1-dependent 1 0 1 0 0 0 0 1 13 0 IN DT JJ NNP NNP O
manner. manner. 0 0 0 0 0 0 0 0 7 0 DT JJ NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NNP NN O
NS1 NS1 1 1 0 0 0 0 0 1 3 0 IN DT NNP NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 DT NNP NN NNS -NONE- O
induces induces 0 0 0 0 0 0 0 0 7 0 NNP NN NNS -NONE- VBP O
G(0)/G(1) G(0)/G(1) 1 1 0 1 0 0 0 1 9 0 NN NNS -NONE- VBP NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 NNS -NONE- VBP NN JJS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest -NONE- VBP NN JJS RB O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBP NN JJS RB IN O
mainly mainly 0 0 0 0 0 0 0 0 6 0 NN JJS RB IN VBG O
through through 0 0 0 0 0 0 0 0 7 0 JJS RB IN VBG IN O
interfering interfering 0 0 0 0 0 0 0 0 11 0 RB IN VBG IN DT O
with with 0 0 0 0 0 0 0 0 4 0 IN VBG IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT JJ NN O
RhoA/pRb RhoA/pRb 1 0 0 1 0 0 0 0 8 0 IN DT JJ NN NN O
signaling signaling 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN RB O
cascade, cascade, 0 0 0 0 1 0 0 0 8 0 JJ NN NN RB VBG O
thus thus 0 0 0 0 0 0 0 0 4 0 NN NN RB VBG JJ O
providing providing 0 0 0 0 0 0 0 0 9 0 NN RB VBG JJ NNS O
favorable favorable 0 0 0 0 0 0 0 0 9 0 RB VBG JJ NNS IN O
conditions conditions 0 0 0 0 0 0 0 0 10 0 VBG JJ NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN JJ NN O
viral viral 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN CC O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
replication. replication. 0 0 0 0 0 0 0 0 12 0 NN CC NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 CC NNP NNP RB VBD O
further further 0 0 0 0 0 0 0 0 7 0 NNP NNP RB VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP RB VBD DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NNP NN O
NS1 NS1 1 1 0 0 0 0 0 1 3 0 VBD DT NNP NN IN O
protein protein 0 0 0 0 0 0 0 0 7 0 DT NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
avian avian 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN VBZ O
influenza influenza 0 0 0 0 0 0 0 0 9 0 IN JJ NN VBZ JJ O
virus virus 0 0 0 0 0 0 0 0 5 0 JJ NN VBZ JJ CC O
(H5N1) (H5N1) 0 1 0 0 0 0 0 1 6 0 NN VBZ JJ CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 VBZ JJ CC VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 JJ CC VBN IN PRP O
that that 0 0 0 0 0 0 0 0 4 0 CC VBN IN PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 VBN IN PRP MD RB O
can can 0 0 0 0 0 0 0 0 3 0 IN PRP MD RB VB O
also also 0 0 0 0 0 0 0 0 4 0 PRP MD RB VB DT O
decrease decrease 0 0 0 0 0 0 0 0 8 0 MD RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 VB DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
RhoA, RhoA, 1 0 0 0 1 0 0 0 5 0 NN IN JJ NN WDT O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 IN JJ NN WDT DT O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN WDT DT NNP VBZ O
H5N1 H5N1 1 1 0 0 0 0 0 1 4 0 WDT DT NNP VBZ MD O
virus virus 0 0 0 0 0 0 0 0 5 0 DT NNP VBZ MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP VBZ MD VB DT O
affect affect 0 0 0 0 0 0 0 0 6 0 VBZ MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VB DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
through through 0 0 0 0 0 0 0 0 7 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
same same 0 0 0 0 0 0 0 0 4 0 IN DT JJ NNP NNP O
mechanism. mechanism. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP NNP O
NS1/RhoA/pRb NS1/RhoA/pRb 1 0 0 1 0 0 0 1 12 0 NNP NNP NNP NNP WDT O
cascade, cascade, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP WDT MD VB DT O
induce induce 0 0 0 0 0 0 0 0 6 0 WDT MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN NN O
G(0)/G(1) G(0)/G(1) 1 1 0 1 0 0 0 1 9 0 VB DT NN NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 DT NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NN NN NN NN VBD O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN VBD JJ O
identified identified 0 0 0 0 0 0 0 0 10 0 NN NN VBD JJ NNS O
here, here, 0 0 0 0 1 0 0 0 5 0 NN VBD JJ NNS DT O
provides provides 0 0 0 0 0 0 0 0 8 0 VBD JJ NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 JJ NNS DT JJ NN O
unified unified 0 0 0 0 0 0 0 0 7 0 NNS DT JJ NN IN O
explanation explanation 0 0 0 0 0 0 0 0 11 0 DT JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT RB O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT RB JJ O
seemingly seemingly 0 0 0 0 0 0 0 0 9 0 IN DT RB JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 DT RB JJ NNP NNS O
NS1 NS1 1 1 0 0 0 0 0 1 3 0 RB JJ NNP NNS VBD O
functions functions 0 0 0 0 0 0 0 0 9 0 JJ NNP NNS VBD IN O
involved involved 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN JJ NN O
viral viral 0 0 0 0 0 0 0 0 5 0 VBD IN JJ NN NNP O
replication replication 0 0 0 0 0 0 0 0 11 0 IN JJ NN NNP NNP O
events. events. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBD O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBD JJ O
shed shed 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD JJ IN O
light light 0 0 0 0 0 0 0 0 5 0 NNS VBD JJ IN DT O
on on 0 0 0 0 0 0 0 0 2 0 VBD JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBZ O
influenza influenza 0 0 0 0 0 0 0 0 9 0 NN IN NN VBZ NN O
virus virus 0 0 0 0 0 0 0 0 5 0 IN NN VBZ NN CC O
replication replication 0 0 0 0 0 0 0 0 11 0 NN VBZ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBZ NN CC JJ JJ O
open open 0 0 0 0 0 0 0 0 4 0 NN CC JJ JJ NNS O
new new 0 0 0 0 0 0 0 0 3 0 CC JJ JJ NNS IN O
avenues avenues 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN NN DT O
understanding understanding 0 0 0 0 0 0 0 0 13 0 NNS IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN IN O
interaction interaction 0 0 0 0 0 0 0 0 11 0 NN DT NN IN NNS O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN NNS CC O
pathogens pathogens 0 0 0 0 0 0 0 0 9 0 NN IN NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC NNP NONE O
hosts. hosts. 0 0 0 0 0 0 0 0 6 0 NNS CC NNP NONE NONE O
Ethyl Ethyl 1 0 0 0 0 0 0 0 5 0 NONE NONE NNP VBP NN O
acetate acetate 0 0 0 0 0 0 0 0 7 0 NONE NNP VBP NN IN O
extraction extraction 0 0 0 0 0 0 0 0 10 0 NNP VBP NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 VBP NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
herbal herbal 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN NNP O
formula, formula, 0 0 0 0 1 0 0 0 8 0 JJ NN NN NNP NNP O
Jiedu Jiedu 1 0 0 0 0 0 0 0 5 0 NN NN NNP NNP NNP O
Xiaozheng Xiaozheng 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP VBZ O
Yin, Yin, 1 0 0 0 1 0 0 0 4 0 NNP NNP NNP VBZ DT O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
hepatocellular hepatocellular 0 0 0 0 0 0 0 0 14 0 NN IN JJ NN NNS O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN NN O
via via 0 0 0 0 0 0 0 0 3 0 NN NNS IN NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 NNS IN NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 phase NN IN -NONE- NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 arrest IN -NONE- NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 -NONE- NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN CC O
vivo vivo 0 0 0 0 0 0 0 0 4 0 NN IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 CC IN NNP NNP NNP O
Cao Cao 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lin Lin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhao Zhao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zheng Zheng 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ye Ye 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liao Liao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Du Du 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Fujian Fujian 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Integrative Integrative 1 0 0 0 0 0 0 0 11 0 NNP IN NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Fujian Fujian 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Traditional Traditional 1 0 0 0 0 0 0 0 11 0 NNP IN NNP NNP NNP O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Fuzhou, Fuzhou, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
People's People's 1 0 0 0 0 1 0 0 8 0 NNP NNP NNP NNP IN O
Republic Republic 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
Jiedu Jiedu 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Xiaozheng Xiaozheng 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Yin Yin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP DT O
(JXY), (JXY), 0 1 0 0 1 0 0 0 6 0 NNP NNP NNP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT JJ NN O
polyherbal polyherbal 0 0 0 0 0 0 0 0 10 0 NNP DT JJ NN IN O
formula formula 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ JJ O
traditional traditional 0 0 0 0 0 0 0 0 11 0 NN IN JJ JJ NN O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 IN JJ JJ NN NN O
medicine medicine 0 0 0 0 0 0 0 0 8 0 JJ JJ NN NN VBZ O
(TCM), (TCM), 0 1 0 0 1 0 0 0 6 0 JJ NN NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 VBZ VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB JJ O
treat treat 0 0 0 0 0 0 0 0 5 0 VBN TO VB JJ NNS O
various various 0 0 0 0 0 0 0 0 7 0 TO VB JJ NNS IN O
kinds kinds 0 0 0 0 0 0 0 0 5 0 VB JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNS IN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NN IN NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 NNP DT NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN NN O
anticancer anticancer 0 0 0 0 0 0 0 0 10 0 IN PRP$ NN NN VBZ O
activity activity 0 0 0 0 0 0 0 0 8 0 PRP$ NN NN VBZ RB O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ RB TO O
yet yet 0 0 0 0 0 0 0 0 3 0 NN VBZ RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ RB TO VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 RB TO VB NNP JJ O
elucidated. elucidated. 0 0 0 0 0 0 0 0 11 0 TO VB NNP JJ NNS O
Air-dried Air-dried 1 0 1 0 0 0 0 0 9 0 VB NNP JJ NNS VBD O
herbs herbs 0 0 0 0 0 0 0 0 5 0 NNP JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN IN O
extracted extracted 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNS IN O
reagents reagents 0 0 0 0 0 0 0 0 8 0 VBN IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNP NNP O
polarity. polarity. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP VBZ O
HepG2 HepG2 1 0 0 0 0 0 0 1 5 0 JJ NNP NNP VBZ VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 VBZ VBD VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 VBN IN JJ NNS IN O
doses doses 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
ethyl ethyl 0 0 0 0 0 0 0 0 5 0 NNS IN NN NN NN O
acetate acetate 0 0 0 0 0 0 0 0 7 0 IN NN NN NN NN O
extract extract 0 0 0 0 0 0 0 0 7 0 NN NN NN NN CC O
(EE-JXY) (EE-JXY) 0 1 1 0 0 0 0 0 8 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
chloroform chloroform 0 0 0 0 0 0 0 0 10 0 NN CC NN NN NN O
extract extract 0 0 0 0 0 0 0 0 7 0 CC NN NN NN IN O
(CE-JXY) (CE-JXY) 0 1 1 0 0 0 0 0 8 0 NN NN NN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN CD NNP O
24 24 0 0 0 0 0 0 1 1 2 0 NN IN CD NNP NNP O
h. h. 0 0 0 0 0 0 0 0 2 0 IN CD NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NN VBD O
viability viability 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
MTT MTT 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NNP NNP O
assay. assay. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NN O
Colony Colony 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN NN O
formation formation 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN VBD O
ability ability 0 0 0 0 0 0 0 0 7 0 NNP NN NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD RB NNP O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB NNP NNP O
evaluated. evaluated. 0 0 0 0 0 0 0 0 10 0 VBD RB NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 RB NNP NNP NN VBD O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
FACS. FACS. 1 1 0 0 0 0 0 0 5 0 VBN IN NNP NNP VBG O
Tumor Tumor 1 0 0 0 0 0 0 0 5 0 IN NNP NNP VBG JJ O
bearing bearing 0 0 0 0 0 0 0 0 7 0 NNP NNP VBG JJ NN O
BALB/c BALB/c 1 0 0 1 0 0 0 0 6 0 NNP VBG JJ NN NN O
nude nude 0 0 0 0 0 0 0 0 4 0 VBG JJ NN NN VBD O
mice mice 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
treated treated 0 0 0 0 0 0 0 0 7 0 NN VBD VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ NN O
EE-JXY EE-JXY 1 1 1 0 0 0 0 0 6 0 VBN IN JJ NN NN O
(0.06 (0.06 0 0 0 0 0 0 0 1 5 0 IN JJ NN NN IN O
g/kg) g/kg) 0 0 0 1 0 0 0 0 5 0 JJ NN NN IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN CD NNP O
20 20 0 0 0 0 0 0 1 1 2 0 NN IN CD NNP NNP O
days. days. 0 0 0 0 0 0 0 0 5 0 IN CD NNP NNP NN O
Tumor Tumor 1 0 0 0 0 0 0 0 5 0 CD NNP NNP NN CC O
volume volume 0 0 0 0 0 0 0 0 6 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN VBD O
weight weight 0 0 0 0 0 0 0 0 6 0 NN CC NN VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 CC NN VBD NNP NNP O
monitored. monitored. 0 0 0 0 0 0 0 0 10 0 NN VBD NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NN IN O
percentage percentage 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
PCNA-positive PCNA-positive 1 0 1 0 0 0 0 0 13 0 NN IN JJ NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 IN JJ NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NN IN O
level level 0 0 0 0 0 0 0 0 5 0 CC DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase NN IN NNP NN NNS B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NNP NN NNS JJ O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNP NN NNS JJ NNP O
[cyclin-dependent [cyclin-dependent 0 0 1 0 0 0 0 0 17 0 NN NNS JJ NNP NNP O
kinase2 kinase2 0 0 0 0 0 0 0 1 7 0 NNS JJ NNP NNP NNP O
(CDK2), (CDK2), 0 1 0 0 1 0 0 1 7 0 JJ NNP NNP NNP NNP O
cyclin‑dependent cyclin‑dependent 0 0 0 0 0 0 0 0 16 0 NNP NNP NNP NNP NNP O
kinase4 kinase4 0 0 0 0 0 0 0 1 7 0 NNP NNP NNP NNP NN O
(CDK4), (CDK4), 0 1 0 0 1 0 0 1 7 0 NNP NNP NNP NN NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNP CC O
D D 1 1 0 0 0 0 0 0 1 0 NNP NN NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC VB NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP CC VB NNP CC O
E E 1 1 0 0 0 0 0 0 1 0 CC VB NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VB NNP CC NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase NNP CC NNP NN NNS B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 CC NNP NN NNS JJ O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNP NN NNS JJ NNP O
[cyclin-dependent [cyclin-dependent 0 0 1 0 0 0 0 0 17 0 NN NNS JJ NNP NNP O
kinase1 kinase1 0 0 0 0 0 0 0 1 7 0 NNS JJ NNP NNP NN O
(CDK1), (CDK1), 0 1 0 0 1 0 0 1 7 0 JJ NNP NNP NN DT O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP NNP NN DT CC O
A A 1 1 0 0 0 0 0 0 1 0 NNP NN DT CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN DT CC NN NN O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 DT CC NN NN VBD O
B] B] 1 1 0 0 0 0 0 0 2 0 CC NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN CC O
immunohistochemistry immunohistochemistry 0 0 0 0 0 0 0 0 20 0 VBN IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NNP O
western western 0 0 0 0 0 0 0 0 7 0 NN CC JJ NNP NNP O
blotting. blotting. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP NNP CC O
EE-JXY EE-JXY 1 1 1 0 0 0 0 0 6 0 JJ NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ JJ O
CE-JXY CE-JXY 1 1 1 0 0 0 0 0 6 0 NNP CC JJ JJ JJ O
dose-dependently dose-dependently 0 0 1 0 0 0 0 0 16 0 CC JJ JJ JJ DT O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 JJ JJ JJ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ JJ DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 JJ DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
HepG2 HepG2 1 0 0 0 0 0 0 1 5 0 NN IN NNP NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS -NONE- IN O
(P<0.01 (P<0.01 0 1 0 0 0 0 0 1 7 0 NNP NNS -NONE- IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNS -NONE- IN NNP NNP O
both). both). 0 0 0 0 0 0 0 0 6 0 -NONE- IN NNP NNP NNP O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP VBD O
EE-JXY EE-JXY 1 1 1 0 0 0 0 0 6 0 NNP NNP NNP VBD DT O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 VBD DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NNS CC O
colonies colonies 0 0 0 0 0 0 0 0 8 0 IN NN NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC VBD DT O
blocked blocked 0 0 0 0 0 0 0 0 7 0 NNS CC VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VBD DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD DT NN NN TO O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 phase NN TO NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 TO NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
dose-dependent dose-dependent 0 0 1 0 0 0 0 0 14 0 IN DT JJ NN -NONE- O
manner manner 0 0 0 0 0 0 0 0 6 0 DT JJ NN -NONE- IN O
(P<0.01 (P<0.01 0 1 0 0 0 0 0 1 7 0 JJ NN -NONE- IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN -NONE- IN NNP NNP O
all). all). 0 0 0 0 0 0 0 0 5 0 -NONE- IN NNP NNP VBD O
EE-JXY EE-JXY 1 1 1 0 0 0 0 0 6 0 IN NNP NNP VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNP VBD DT RB O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBD DT RB NN O
obviously obviously 0 0 0 0 0 0 0 0 9 0 VBD DT RB NN NN O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 DT RB NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 RB NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
vivo vivo 0 0 0 0 0 0 0 0 4 0 NN IN NN NNP NNP O
(P<0.05). (P<0.05). 0 1 0 0 0 0 0 1 9 0 IN NN NNP NNP NN O
Further Further 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NN VBD O
investigation investigation 0 0 0 0 0 0 0 0 13 0 NNP NNP NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN JJ VBN O
EE-JXY EE-JXY 1 1 1 0 0 0 0 0 6 0 VBD IN JJ VBN DT O
decreased decreased 0 0 0 0 0 0 0 0 9 0 IN JJ VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ VBN DT NN NN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBN DT NN NN IN O
index index 0 0 0 0 0 0 0 0 5 0 DT NN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS -NONE- O
tumors tumors 0 0 0 0 0 0 0 0 6 0 NN IN NNS -NONE- IN O
(P<0.01) (P<0.01) 0 1 0 0 0 0 0 1 8 0 IN NNS -NONE- IN VBG O
through through 0 0 0 0 0 0 0 0 7 0 NNS -NONE- IN VBG DT O
increasing increasing 0 0 0 0 0 0 0 0 10 0 -NONE- IN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBG DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
G1-related G1-related 1 0 1 0 0 0 0 1 10 0 NN IN JJ NNS JJ O
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN JJ NNS JJ NNP O
(cyclin (cyclin 0 0 0 0 0 0 0 0 7 0 JJ NNS JJ NNP CC O
D D 1 1 0 0 0 0 0 0 1 0 NNS JJ NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC VB JJ O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP CC VB JJ -NONE- O
E, E, 1 1 0 0 1 0 0 0 2 0 CC VB JJ -NONE- CC O
P<0.05 P<0.05 1 1 0 0 0 0 0 1 6 0 VB JJ -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ -NONE- CC NNP NNP O
P<0.01). P<0.01). 1 1 0 0 0 0 0 1 8 0 -NONE- CC NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP NNS O
JXY JXY 1 1 0 0 0 0 0 0 3 0 VBD IN NNP NNS DT O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 IN NNP NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNS DT NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NNS DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
HepG2 HepG2 1 0 0 0 0 0 0 1 5 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN JJS O
at at 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJS IN O
least least 0 0 0 0 0 0 0 0 5 0 NNS IN JJS IN NN O
via via 0 0 0 0 0 0 0 0 3 0 IN JJS IN NN DT O
arresting arresting 0 0 0 0 0 0 0 0 9 0 JJS IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN DT NN NN IN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 IN DT NNP NNP NONE B_TIMEXCCP
phase. phase. 0 0 0 0 0 0 0 0 6 0 DT NNP NNP NONE NONE O
MicroRNA-23b MicroRNA-23b 1 0 1 0 0 0 0 1 12 0 NONE NONE NN NNS IN O
Functions Functions 1 0 0 0 0 0 0 0 9 0 NONE NN NNS IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NNP NNP O
Tumor Tumor 1 0 0 0 0 0 0 0 5 0 IN DT NNP NNP IN O
Suppressor Suppressor 1 0 0 0 0 0 0 0 10 0 DT NNP NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Regulating Regulating 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP IN O
Zeb1 Zeb1 1 0 0 0 0 0 0 1 4 0 IN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Bladder Bladder 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Cancer. Cancer. 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Majid Majid 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dar Dar 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
AA, AA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Saini Saini 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Deng Deng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Chang Chang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
I, I, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Greene Greene 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tanaka Tanaka 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Dahiya Dahiya 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yamamura Yamamura 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Urology, Urology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
VA VA 1 1 0 0 0 0 0 0 2 0 IN NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP CC O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
UCSF, UCSF, 1 1 0 0 1 0 0 0 5 0 NNP CC NNP NNP NNP O
San San 1 0 0 0 0 0 0 0 3 0 CC NNP NNP NNP NNP O
Francisco, Francisco, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
California, California, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
MicroRNAs MicroRNAs 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP VBP O
(miRNAs) (miRNAs) 0 0 0 0 0 0 0 0 8 0 NNP NNP NNP VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP JJ JJ O
small, small, 0 0 0 0 1 0 0 0 6 0 NNP VBP JJ JJ NNP O
non-coding non-coding 0 0 1 0 0 0 0 0 10 0 VBP JJ JJ NNP IN O
RNAs RNAs 1 0 0 0 0 0 0 0 4 0 JJ JJ NNP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNP IN JJ NN O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NNP IN JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN VBN NN O
targeted targeted 0 0 0 0 0 0 0 0 8 0 NN IN VBN NN IN O
repression repression 0 0 0 0 0 0 0 0 10 0 IN VBN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN CC O
transcription transcription 0 0 0 0 0 0 0 0 13 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP NNP O
translation. translation. 0 0 0 0 0 0 0 0 12 0 NN CC NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN PRP O
study study 0 0 0 0 0 0 0 0 5 0 NNP DT NN PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NN PRP VBP IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN -NONE- -NONE- O
miRNA-23b miRNA-23b 0 0 1 0 0 0 0 1 9 0 VBP IN -NONE- -NONE- VBZ O
(miR-23b) (miR-23b) 0 0 1 0 0 0 0 1 9 0 IN -NONE- -NONE- VBZ IN O
acts acts 0 0 0 0 0 0 0 0 4 0 -NONE- -NONE- VBZ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 IN DT NN NN IN O
suppressor suppressor 0 0 0 0 0 0 0 0 10 0 DT NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NN IN NN NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNP O
Quantitative Quantitative 1 0 0 0 0 0 0 0 12 0 NN NNP NNP NNP NNP O
real-time real-time 0 0 1 0 0 0 0 0 9 0 NNP NNP NNP NNP NN O
PCR PCR 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN JJ VBZ O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 VBD IN JJ VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 IN JJ VBZ RB JJ O
significantly significantly 0 0 0 0 0 0 0 0 13 0 JJ VBZ RB JJ IN O
down-regulated down-regulated 0 0 1 0 0 0 0 0 14 0 VBZ RB JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 JJ IN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NNS CC O
lines lines 0 0 0 0 0 0 0 0 5 0 NN NN NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NN NNS O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NNS CC NN NNS VBN O
tissues tissues 0 0 0 0 0 0 0 0 7 0 CC NN NNS VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 NN NNS VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO JJ NNS O
non-malignant non-malignant 0 0 1 0 0 0 0 0 13 0 VBN TO JJ NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 TO JJ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC JJ NN O
normal normal 0 0 0 0 0 0 0 0 6 0 NNS CC JJ NN NNP O
tissue tissue 0 0 0 0 0 0 0 0 6 0 CC JJ NN NNP NNP O
samples. samples. 0 0 0 0 0 0 0 0 8 0 JJ NN NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP RB VBP O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP RB VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 RB VBP IN JJ NN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 VBP IN JJ NN VBZ O
expression expression 0 0 0 0 0 0 0 0 10 0 IN JJ NN VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ TO O
potential potential 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT JJ TO VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 JJ TO VB JJ CC O
diagnostic diagnostic 0 0 0 0 0 0 0 0 10 0 TO VB JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VB JJ CC JJ NN O
prognostic prognostic 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NN IN O
biomarker biomarker 0 0 0 0 0 0 0 0 9 0 CC JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NN IN NN NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNP O
High High 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NNP NNP NNP NN VBZ O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB VBN O
positively positively 0 0 0 0 0 0 0 0 10 0 NN VBZ RB VBN IN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 VBZ RB VBN IN JJR O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN JJR JJ O
higher higher 0 0 0 0 0 0 0 0 6 0 VBN IN JJR JJ NN O
overall overall 0 0 0 0 0 0 0 0 7 0 IN JJR JJ NN IN O
survival survival 0 0 0 0 0 0 0 0 8 0 JJR JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NN IN NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 NN NN NNS IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBN IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NNS IN VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN VBN IN JJ NNP O
Kaplan-Meier Kaplan-Meier 1 0 1 0 0 0 0 0 12 0 VBN IN JJ NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP NN O
ROC ROC 1 1 0 0 0 0 0 0 3 0 JJ NNP NNP NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NN VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN JJ NN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 VBD IN JJ NN MD O
expression expression 0 0 0 0 0 0 0 0 10 0 IN JJ NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 JJ NN MD VB IN O
distinguish distinguish 0 0 0 0 0 0 0 0 11 0 NN MD VB IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 MD VB IN JJ CC O
normal normal 0 0 0 0 0 0 0 0 6 0 VB IN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 JJ CC NN NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 CC NN NN NNP NNP O
tissues. tissues. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP PRP O
Further Further 1 0 0 0 0 0 0 0 7 0 NN NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
elucidated elucidated 0 0 0 0 0 0 0 0 10 0 NNP PRP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT JJ NN O
biological biological 0 0 0 0 0 0 0 0 10 0 VBD DT JJ NN IN O
significance significance 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NN IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NNP O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NNP IN NN NNP NN O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NN IN O
Over-expression Over-expression 1 0 1 0 0 0 0 0 15 0 NN NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP IN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NN IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NNP IN NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBD NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NN NNS VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS VBD NN NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBD NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD NN O
impaired impaired 0 0 0 0 0 0 0 0 8 0 NN CC VBD NN NNP O
colony colony 0 0 0 0 0 0 0 0 6 0 CC VBD NN NNP NNP O
formation. formation. 0 0 0 0 0 0 0 0 10 0 VBD NN NNP NNP VBD O
Fluorescence Fluorescence 1 0 0 0 0 0 0 0 12 0 NN NNP NNP VBD NN O
activated activated 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NN NN O
sorting sorting 0 0 0 0 0 0 0 0 7 0 VBD NN NN NN NN O
(FACS) (FACS) 0 1 0 0 0 0 0 0 6 0 NN NN NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NN NN NN VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN NN IN O
re-expression re-expression 0 0 1 0 0 0 0 0 13 0 VBD IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP IN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NN IN NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 NNP IN NN NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBD -NONE- O
induced induced 0 0 0 0 0 0 0 0 7 0 NN NNS VBD -NONE- NN O
G0/G1 G0/G1 1 1 0 1 0 0 0 1 5 0 NNS VBD -NONE- NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 VBD -NONE- NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest -NONE- NN NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN CC NN IN VBG O
while while 0 0 0 0 0 0 0 0 5 0 CC NN IN VBG NN O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 NN IN VBG NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN VBG NN NN CC O
migration migration 0 0 0 0 0 0 0 0 9 0 VBG NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
invasion. invasion. 0 0 0 0 0 0 0 0 9 0 NN CC NNP NNP NN O
Luciferase Luciferase 1 0 0 0 0 0 0 0 10 0 CC NNP NNP NN VBZ O
reporter reporter 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBZ VBN O
assays assays 0 0 0 0 0 0 0 0 6 0 NNP NN VBZ VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NN VBZ VBN IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN -NONE- DT O
Zeb1, Zeb1, 1 0 0 0 1 0 0 1 5 0 VBN IN -NONE- DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN -NONE- DT JJ NN O
crucial crucial 0 0 0 0 0 0 0 0 7 0 -NONE- DT JJ NN IN O
regulator regulator 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
epithelial-to-mesenchymal epithelial-to-mesenchymal 0 0 1 0 0 0 0 0 25 0 NN IN JJ NN NN O
transition transition 0 0 0 0 0 0 0 0 10 0 IN JJ NN NN VBZ O
(EMT), (EMT), 0 1 0 0 1 0 0 0 6 0 JJ NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 VBZ DT JJ NN IN O
target target 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ IN O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NN IN JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN NNP O
bladder bladder 0 0 0 0 0 0 0 0 7 0 JJ IN NN NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 VBP IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNS O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NN IN NNP NNS DT O
confers confers 0 0 0 0 0 0 0 0 7 0 IN NNP NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNS DT JJ NN O
proliferative proliferative 0 0 0 0 0 0 0 0 13 0 NNS DT JJ NN CC O
advantage advantage 0 0 0 0 0 0 0 0 9 0 DT JJ NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBZ NN O
promotes promotes 0 0 0 0 0 0 0 0 8 0 NN CC VBZ NN NN O
bladder bladder 0 0 0 0 0 0 0 0 7 0 CC VBZ NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 VBZ NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN CC O
migration migration 0 0 0 0 0 0 0 0 9 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
invasion. invasion. 0 0 0 0 0 0 0 0 9 0 NN CC NNP NNP NNP O
Furthermore, Furthermore, 1 0 0 0 1 0 0 0 12 0 CC NNP NNP NNP IN O
re-expression re-expression 0 0 1 0 0 0 0 0 13 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP MD O
miR-23b miR-23b 0 0 1 0 0 0 0 1 7 0 NNP IN NNP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NNP MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ JJ O
beneficial beneficial 0 0 0 0 0 0 0 0 10 0 VB DT JJ JJ NN O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT JJ JJ NN IN O
strategy strategy 0 0 0 0 0 0 0 0 8 0 JJ JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NNP O
bladder bladder 0 0 0 0 0 0 0 0 7 0 IN NN NN NNP NONE O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NONE NONE O
Evaluation Evaluation 1 0 0 0 0 0 0 0 10 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NNP O
Conjunctival Conjunctival 1 0 0 0 0 0 0 0 12 0 NN IN NNP NNP NNP O
Bleb Bleb 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Detection Detection 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
After After 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP IN O
Vitrectomy Vitrectomy 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Ultrasound Ultrasound 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Biomicroscopy, Biomicroscopy, 1 0 0 0 1 0 0 0 14 0 IN NNP NNP NNP NNP O
Optical Optical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Coherence Coherence 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CC O
Tomography Tomography 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Direct Direct 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNP NNP O
Visualization. Visualization. 1 0 0 0 0 0 0 0 14 0 CC NNP NNP NNP NNP O
Benitez-Herreros Benitez-Herreros 1 0 1 0 0 0 0 0 16 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lopez-Guajardo Lopez-Guajardo 1 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Camara-Gonzalez Camara-Gonzalez 1 0 1 0 0 0 0 0 15 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Perez-Crespo Perez-Crespo 1 0 1 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Silva-Mato Silva-Mato 1 0 1 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Alvaro-Meca Alvaro-Meca 1 0 1 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Teus Teus 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
MA. MA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Ophthalmology, Ophthalmology, 1 0 0 0 1 0 0 0 14 0 NNP IN NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Principe Principe 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Asturias, Asturias, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP IN O
Alcalá Alcalá 1 0 0 0 0 0 0 0 6 0 IN NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP , O
Henares Henares 1 0 0 0 0 0 0 0 7 0 NNP IN NNP , NNP O
, , 0 0 0 0 1 0 0 0 1 0 IN NNP , NNP , O
Madrid Madrid 1 0 0 0 0 0 0 0 6 0 NNP , NNP , NNP O
, , 0 0 0 0 1 0 0 0 1 0 , NNP , NNP . O
Spain Spain 1 0 0 0 0 0 0 0 5 0 NNP , NNP . NNP O
. . 0 0 0 0 0 0 0 0 1 0 , NNP . NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP . NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 . NNP NNP NNP NNP O
Purpose: Purpose: 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB NN O
compare compare 0 0 0 0 0 0 0 0 7 0 NNP NNP VB NN NN O
ultrasound ultrasound 0 0 0 0 0 0 0 0 10 0 NNP VB NN NN NN O
biomicroscopy biomicroscopy 0 0 0 0 0 0 0 0 13 0 VB NN NN NN NN O
(UBM), (UBM), 0 1 0 0 1 0 0 0 6 0 NN NN NN NN JJ O
anterior-segment anterior-segment 0 0 1 0 0 0 0 0 16 0 NN NN NN JJ NN O
optical optical 0 0 0 0 0 0 0 0 7 0 NN NN JJ NN NN O
coherence coherence 0 0 0 0 0 0 0 0 9 0 NN JJ NN NN NN O
tomography tomography 0 0 0 0 0 0 0 0 10 0 JJ NN NN NN CC O
(AS-OCT), (AS-OCT), 0 1 1 0 1 0 0 0 9 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 NN CC JJ NN IN O
visualization visualization 0 0 0 0 0 0 0 0 13 0 CC JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
detecting detecting 0 0 0 0 0 0 0 0 9 0 NN IN NN NN NNS O
conjunctival conjunctival 0 0 0 0 0 0 0 0 12 0 IN NN NN NNS IN O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NN NN NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NNS O
sutureless sutureless 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNS IN O
sclerotomies sclerotomies 0 0 0 0 0 0 0 0 12 0 IN NN NNS IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NN NNS IN NNP NNP O
vitrectomy. vitrectomy. 0 0 0 0 0 0 0 0 11 0 NNS IN NNP NNP VBZ O
Conjunctival Conjunctival 1 0 0 0 0 0 0 0 12 0 IN NNP NNP VBZ VBP O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP VBN IN O
formed formed 0 0 0 0 0 0 0 0 6 0 VBZ VBP VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN NN NN O
sclerotomy sclerotomy 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN JJ O
leakage leakage 0 0 0 0 0 0 0 0 7 0 IN NN NN JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 NN NN JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO NN NNP O
incompetent incompetent 0 0 0 0 0 0 0 0 11 0 JJ TO NN NNP NNP O
closure. closure. 0 0 0 0 0 0 0 0 8 0 TO NN NNP NNP NNP O
Methods: Methods: 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
Experimental, Experimental, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP CC O
randomized, randomized, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
observer-masked observer-masked 0 0 1 0 0 0 0 0 15 0 NNP CC JJ NN IN O
study study 0 0 0 0 0 0 0 0 5 0 CC JJ NN IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT JJ NNS O
23-gauge 23-gauge 0 0 1 0 0 0 0 1 8 0 IN WDT JJ NNS VBD O
vitrectomies vitrectomies 0 0 0 0 0 0 0 0 12 0 WDT JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
cadaveric cadaveric 0 0 0 0 0 0 0 0 9 0 VBN IN JJ NN NNP O
pig pig 0 0 0 0 0 0 0 0 3 0 IN JJ NN NNP NNP O
eyes. eyes. 0 0 0 0 0 0 0 0 5 0 JJ NN NNP NNP NN O
Postoperative Postoperative 1 0 0 0 0 0 0 0 13 0 NN NNP NNP NN NNS O
conjunctival conjunctival 0 0 0 0 0 0 0 0 12 0 NNP NNP NN NNS VBD O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
UBM, UBM, 1 1 0 0 1 0 0 0 4 0 VBN IN NNP NNP CC O
AS-OCT, AS-OCT, 1 1 1 0 1 0 0 0 7 0 IN NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NNP O
direct direct 0 0 0 0 0 0 0 0 6 0 NNP CC JJ NNP NNP O
visualization. visualization. 0 0 0 0 0 0 0 0 14 0 CC JJ NNP NNP NN O
No No 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN VBZ O
conjunctival conjunctival 0 0 0 0 0 0 0 0 12 0 NNP NNP NN VBZ VBD O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NNP NN VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN VBZ VBD VBN IN O
classified classified 0 0 0 0 0 0 0 0 10 0 VBZ VBD VBN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP -NONE- O
Grade Grade 1 0 0 0 0 0 0 0 5 0 VBN IN NNP -NONE- NNP O
0 0 0 0 0 0 0 0 1 1 1 0 IN NNP -NONE- NNP NN O
(G0), (G0), 0 1 0 0 1 0 0 1 5 0 NNP -NONE- NNP NN NNS O
thin thin 0 0 0 0 0 0 0 0 4 0 -NONE- NNP NN NNS JJ O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NNP NN NNS JJ IN O
(less (less 0 0 0 0 0 0 0 0 5 0 NN NNS JJ IN CC O
than than 0 0 0 0 0 0 0 0 4 0 NNS JJ IN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 JJ IN CC JJ TO O
equal equal 0 0 0 0 0 0 0 0 5 0 IN CC JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 CC JJ TO JJ IN O
one-half one-half 0 0 1 0 0 0 0 0 8 0 JJ TO JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 TO JJ IN JJ NN O
scleral scleral 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN IN O
thickness) thickness) 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CD O
Grade Grade 1 0 0 0 0 0 0 0 5 0 NN IN NNP CD NNP O
1 1 0 0 0 0 0 0 1 1 1 0 IN NNP CD NNP CC O
(G1) (G1) 0 1 0 0 0 0 0 1 4 0 NNP CD NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 CD NNP CC VB NNS O
thick thick 0 0 0 0 0 0 0 0 5 0 NNP CC VB NNS JJ O
blebs blebs 0 0 0 0 0 0 0 0 5 0 CC VB NNS JJ IN O
(greater (greater 0 0 0 0 0 0 0 0 8 0 VB NNS JJ IN JJ O
than than 0 0 0 0 0 0 0 0 4 0 NNS JJ IN JJ IN O
one-half one-half 0 0 1 0 0 0 0 0 8 0 JJ IN JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN JJ IN JJ NN O
scleral scleral 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN IN O
thickness) thickness) 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP CD O
Grade Grade 1 0 0 0 0 0 0 0 5 0 NN IN NNP CD NNP O
2 2 0 0 0 0 0 0 1 1 1 0 IN NNP CD NNP NNP O
(G2). (G2). 0 1 0 0 0 0 0 1 5 0 NNP CD NNP NNP NNP O
Results: Results: 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
Fifty Fifty 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NN VBZ O
pig pig 0 0 0 0 0 0 0 0 3 0 NNP NNP NN VBZ VBD O
eyes eyes 0 0 0 0 0 0 0 0 4 0 NNP NN VBZ VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 NN VBZ VBD NNP NNP O
included. included. 0 0 0 0 0 0 0 0 9 0 VBZ VBD NNP NNP VBZ O
Conjunctival Conjunctival 1 0 0 0 0 0 0 0 12 0 VBD NNP NNP VBZ VBD O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 VBZ VBD VBN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD NN O
13.3% 13.3% 0 0 0 0 0 0 0 1 5 0 VBN IN CD NN -NONE- O
(8% (8% 0 0 0 0 0 0 0 1 3 0 IN CD NN -NONE- CD O
G1, G1, 1 1 0 0 1 0 0 1 3 0 CD NN -NONE- CD -NONE- O
5.3% 5.3% 0 0 0 0 0 0 0 1 4 0 NN -NONE- CD -NONE- IN O
G2) G2) 1 1 0 0 0 0 0 1 3 0 -NONE- CD -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD -NONE- IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NNS VBD O
incisions incisions 0 0 0 0 0 0 0 0 9 0 IN DT NNS VBD IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 DT NNS VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NN IN O
UBM, UBM, 1 1 0 0 1 0 0 0 4 0 VBD IN NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN CD NN O
20% 20% 0 0 0 0 0 0 0 1 3 0 NN IN CD NN -NONE- O
(14.7% (14.7% 0 0 0 0 0 0 0 1 6 0 IN CD NN -NONE- CD O
G1, G1, 1 1 0 0 1 0 0 1 3 0 CD NN -NONE- CD -NONE- O
5.3% 5.3% 0 0 0 0 0 0 0 1 4 0 NN -NONE- CD -NONE- IN O
G2) G2) 1 1 0 0 0 0 0 1 3 0 -NONE- CD -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD -NONE- IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NNS VBD O
sclerotomies sclerotomies 0 0 0 0 0 0 0 0 12 0 IN DT NNS VBD IN O
studied studied 0 0 0 0 0 0 0 0 7 0 DT NNS VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN NN CC O
AS-OCT, AS-OCT, 1 1 1 0 1 0 0 0 7 0 VBD IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN CD NN O
7.3% 7.3% 0 0 0 0 0 0 0 1 4 0 CC IN CD NN -NONE- O
(2% (2% 0 0 0 0 0 0 0 1 3 0 IN CD NN -NONE- CD O
G1, G1, 1 1 0 0 1 0 0 1 3 0 CD NN -NONE- CD -NONE- O
5.3% 5.3% 0 0 0 0 0 0 0 1 4 0 NN -NONE- CD -NONE- IN O
G2) G2) 1 1 0 0 0 0 0 1 3 0 -NONE- CD -NONE- IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CD -NONE- IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- IN DT NNS VBD O
wounds wounds 0 0 0 0 0 0 0 0 6 0 IN DT NNS VBD IN O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 DT NNS VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN JJ NNP O
direct direct 0 0 0 0 0 0 0 0 6 0 VBD IN JJ NNP JJ O
visualization. visualization. 0 0 0 0 0 0 0 0 14 0 IN JJ NNP JJ VBD O
AS-OCT AS-OCT 1 1 1 0 0 0 0 0 6 0 JJ NNP JJ VBD DT O
was was 0 0 0 0 0 0 0 0 3 0 NNP JJ VBD DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 JJ VBD DT JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBD DT JJS JJ NN O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 DT JJS JJ NN IN O
method method 0 0 0 0 0 0 0 0 6 0 JJS JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
identifying identifying 0 0 0 0 0 0 0 0 11 0 NN IN NN NN NNS O
conjunctival conjunctival 0 0 0 0 0 0 0 0 12 0 IN NN NN NNS WRB O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NN NN NNS WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 NN NNS WRB VBN IN O
compared compared 0 0 0 0 0 0 0 0 8 0 NNS WRB VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 WRB VBN IN NNP CC O
UBM UBM 1 1 0 0 0 0 0 0 3 0 VBN IN NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 NNP CC JJ NN NN O
visualization visualization 0 0 0 0 0 0 0 0 13 0 CC JJ NN NN : O
(p (p 0 0 0 0 0 0 0 0 2 0 JJ NN NN : CD O
< < 0 0 0 0 0 0 0 0 1 0 NN NN : CD IN O
0.001). 0.001). 0 0 0 0 0 0 0 1 7 0 NN : CD IN JJ O
In In 1 0 0 0 0 0 0 0 2 0 : CD IN JJ NNP O
turn, turn, 0 0 0 0 1 0 0 0 5 0 CD IN JJ NNP VBD O
UBM UBM 1 1 0 0 0 0 0 0 3 0 IN JJ NNP VBD JJR O
was was 0 0 0 0 0 0 0 0 3 0 JJ NNP VBD JJR IN O
better better 0 0 0 0 0 0 0 0 6 0 NNP VBD JJR IN JJ O
than than 0 0 0 0 0 0 0 0 4 0 VBD JJR IN JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 JJR IN JJ NN IN O
visualization visualization 0 0 0 0 0 0 0 0 13 0 IN JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
observing observing 0 0 0 0 0 0 0 0 9 0 NN IN NN NN NNS O
sclerotomy sclerotomy 0 0 0 0 0 0 0 0 10 0 IN NN NN NNS -NONE- O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NN NN NNS -NONE- : O
(p (p 0 0 0 0 0 0 0 0 2 0 NN NNS -NONE- : CD O
= = 0 0 0 0 0 0 0 0 1 0 NNS -NONE- : CD NN O
0.004). 0.004). 0 0 0 0 0 0 0 1 7 0 -NONE- : CD NN JJ O
Conclusions: Conclusions: 1 0 0 0 0 0 0 0 12 0 : CD NN JJ VBZ O
AS-OCT AS-OCT 1 1 1 0 0 0 0 0 6 0 CD NN JJ VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN JJ VBZ DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 JJ VBZ DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBZ DT RBS JJ NN O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 DT RBS JJ NN IN O
technique technique 0 0 0 0 0 0 0 0 9 0 RBS JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN JJ O
detecting detecting 0 0 0 0 0 0 0 0 9 0 NN IN NN JJ NNS O
subclinical subclinical 0 0 0 0 0 0 0 0 11 0 IN NN JJ NNS -NONE- O
blebs blebs 0 0 0 0 0 0 0 0 5 0 NN JJ NNS -NONE- CC O
(G1) (G1) 0 1 0 0 0 0 0 1 4 0 JJ NNS -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC NNP PRP O
thus, thus, 0 0 0 0 1 0 0 0 5 0 -NONE- CC NNP PRP MD O
it it 0 0 0 0 0 0 0 0 2 0 CC NNP PRP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP PRP MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 PRP MD VB JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 MD VB JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VB JJ IN NN IN O
research research 0 0 0 0 0 0 0 0 8 0 JJ IN NN IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN VBG DT O
studying studying 0 0 0 0 0 0 0 0 8 0 NN IN VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 VBG DT NN IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ NNS O
surgical surgical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NNS CC O
factors factors 0 0 0 0 0 0 0 0 7 0 IN JJ NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNS MD O
maneuvers maneuvers 0 0 0 0 0 0 0 0 9 0 NNS CC NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 CC NNS MD VB IN O
exert exert 0 0 0 0 0 0 0 0 5 0 NNS MD VB IN NN O
on on 0 0 0 0 0 0 0 0 2 0 MD VB IN NN NN O
sclerotomy sclerotomy 0 0 0 0 0 0 0 0 10 0 VB IN NN NN NN O
closure closure 0 0 0 0 0 0 0 0 7 0 IN NN NN NN IN O
capacity capacity 0 0 0 0 0 0 0 0 8 0 NN NN NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NN NN IN NNP NNP O
vitrectomy. vitrectomy. 0 0 0 0 0 0 0 0 11 0 NN IN NNP NNP NNP O
Direct Direct 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP IN O
visualization, visualization, 0 0 0 0 1 0 0 0 14 0 NNP NNP NNP IN VBZ O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNP IN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP IN VBZ VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 IN VBZ VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN NN JJ O
routine routine 0 0 0 0 0 0 0 0 7 0 VBN IN NN JJ NN O
clinical clinical 0 0 0 0 0 0 0 0 8 0 IN NN JJ NN TO O
practice practice 0 0 0 0 0 0 0 0 8 0 NN JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB WDT O
determine determine 0 0 0 0 0 0 0 0 9 0 NN TO VB WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 TO VB WDT NNS MD O
sclerotomies sclerotomies 0 0 0 0 0 0 0 0 12 0 VB WDT NNS MD VB O
should should 0 0 0 0 0 0 0 0 6 0 WDT NNS MD VB -NONE- O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB -NONE- VBZ O
sutured, sutured, 0 0 0 0 1 0 0 0 8 0 MD VB -NONE- VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 VB -NONE- VBZ JJ RB O
useful useful 0 0 0 0 0 0 0 0 6 0 -NONE- VBZ JJ RB TO O
only only 0 0 0 0 0 0 0 0 4 0 VBZ JJ RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ RB TO VB NN O
identify identify 0 0 0 0 0 0 0 0 8 0 RB TO VB NN NNS O
thick thick 0 0 0 0 0 0 0 0 5 0 TO VB NN NNS -NONE- O
blebs blebs 0 0 0 0 0 0 0 0 5 0 VB NN NNS -NONE- IN O
(G2) (G2) 0 1 0 0 0 0 0 1 4 0 NN NNS -NONE- IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NNS -NONE- IN NNP NONE O
vitrectomy. vitrectomy. 0 0 0 0 0 0 0 0 11 0 -NONE- IN NNP NONE NONE O
Linac Linac 1 0 0 0 0 0 0 0 5 0 NONE NONE NNP VBD NNP O
based based 0 0 0 0 0 0 0 0 5 0 NONE NNP VBD NNP IN O
SBRT SBRT 1 1 0 0 0 0 0 0 4 0 NNP VBD NNP IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBD NNP IN NN NN O
prostate prostate 0 0 0 0 0 0 0 0 8 0 NNP IN NN NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN CD NNS O
5 5 0 0 0 0 0 0 1 1 1 0 NN IN CD NNS IN O
fractions fractions 0 0 0 0 0 0 0 0 9 0 IN CD NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN NNP CC O
VMAT VMAT 1 1 0 0 0 0 0 0 4 0 NNS IN NNP CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC VBG NN O
flattening flattening 0 0 0 0 0 0 0 0 10 0 NNP CC VBG NN JJ O
filter filter 0 0 0 0 0 0 0 0 6 0 CC VBG NN JJ NN O
free free 0 0 0 0 0 0 0 0 4 0 VBG NN JJ NN JJ O
beams: beams: 0 0 0 0 0 0 0 0 6 0 NN JJ NN JJ NN O
preliminary preliminary 0 0 0 0 0 0 0 0 11 0 JJ NN JJ NN IN O
report report 0 0 0 0 0 0 0 0 6 0 NN JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 phase NN IN DT NN NNP O
phase phase 0 0 0 0 0 0 0 0 5 0 IN DT NN NNP NNP O
II II 1 1 0 0 0 0 0 0 2 0 DT NN NNP NNP NNP O
study. study. 0 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
Alongi Alongi 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cozzi Cozzi 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Arcangeli Arcangeli 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Iftode Iftode 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Comito Comito 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Villa Villa 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lobefalo Lobefalo 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Navarria Navarria 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Reggiori Reggiori 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mancosu Mancosu 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Clerici Clerici 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Fogliata Fogliata 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tomatis Tomatis 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Taverna Taverna 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Graziotti Graziotti 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Scorsetti Scorsetti 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 NNP NNP VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VB DT NN CC O
feasibility feasibility 0 0 0 0 0 0 0 0 11 0 VB DT NN CC RB O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC RB NN O
early early 0 0 0 0 0 0 0 0 5 0 NN CC RB NN NNS O
side side 0 0 0 0 0 0 0 0 4 0 CC RB NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 RB NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NN O
short short 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN JJ O
course course 0 0 0 0 0 0 0 0 6 0 DT JJ NN JJ NN O
hypo-fractionated hypo-fractionated 0 0 1 0 0 0 0 0 17 0 JJ NN JJ NN NN O
SBRT SBRT 1 1 0 0 0 0 0 0 4 0 NN JJ NN NN IN O
programme programme 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN NNP NNP O
Volumetric Volumetric 1 0 0 0 0 0 0 0 10 0 NN IN NNP NNP NNP O
Modulated Modulated 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Arc Arc 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Therapy Therapy 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP CC O
(VMAT) (VMAT) 0 1 0 0 0 0 0 0 6 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Flattening Flattening 1 0 0 0 0 0 0 0 10 0 NNP CC NNP NNP NNP O
Filter Filter 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
Free Free 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
(FFF) (FFF) 0 1 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
beams. beams. 0 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP JJ NN O
prospective prospective 0 0 0 0 0 0 0 0 11 phase NNP NNP JJ NN NN O
phase phase 0 0 0 0 0 0 0 0 5 0 NNP JJ NN NN NN O
I-II I-II 1 1 1 0 0 0 0 0 4 0 JJ NN NN NN VBD O
study, study, 0 0 0 0 1 0 0 0 6 0 NN NN NN VBD IN O
started started 0 0 0 0 0 0 0 0 7 0 NN NN VBD IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP NNP O
February February 1 0 0 0 0 0 0 0 8 0 VBD IN NNP NNP NNP O
2012. 2012. 0 0 0 0 0 0 0 1 5 0 IN NNP NNP NNP NN O
Inclusion Inclusion 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NN -NONE- O
criteria criteria 0 0 0 0 0 0 0 0 8 0 NNP NNP NN -NONE- NN O
were: were: 0 0 0 0 0 0 0 0 5 0 NNP NN -NONE- NN : O
age age 0 0 0 0 0 0 0 0 3 0 NN -NONE- NN : CD O
<= <= 0 0 0 0 0 0 0 0 2 0 -NONE- NN : CD -NONE- O
80 80 0 0 0 0 0 0 1 1 2 0 NN : CD -NONE- JJ O
years, years, 0 0 0 0 1 0 0 0 6 0 : CD -NONE- JJ NN O
WHO-PS WHO-PS 1 1 1 0 0 0 0 0 6 0 CD -NONE- JJ NN CD O
<= <= 0 0 0 0 0 0 0 0 2 0 -NONE- JJ NN CD NNP O
2, 2, 0 0 0 0 1 0 0 1 2 0 JJ NN CD NNP NNP O
PSA PSA 1 1 0 0 0 0 0 0 3 0 NN CD NNP NNP CD O
<= <= 0 0 0 0 0 0 0 0 2 0 CD NNP NNP CD -NONE- O
20 20 0 0 0 0 0 0 1 1 2 0 NNP NNP CD -NONE- RB O
ng/ml, ng/ml, 0 0 0 1 1 0 0 0 6 0 NNP CD -NONE- RB VBN O
histologically histologically 0 0 0 0 0 0 0 0 14 0 CD -NONE- RB VBN NN O
proven proven 0 0 0 0 0 0 0 0 6 0 -NONE- RB VBN NN -NONE- O
prostate prostate 0 0 0 0 0 0 0 0 8 0 RB VBN NN -NONE- -NONE- O
adenocarcinoma, adenocarcinoma, 0 0 0 0 1 0 0 0 15 0 VBN NN -NONE- -NONE- -NONE- O
T1-T2 T1-T2 1 1 1 0 0 0 0 1 5 0 NN -NONE- -NONE- -NONE- DT O
stage, stage, 0 0 0 0 1 0 0 0 6 0 -NONE- -NONE- -NONE- DT JJ O
no no 0 0 0 0 0 0 0 0 2 0 -NONE- -NONE- DT JJ NN O
distant distant 0 0 0 0 0 0 0 0 7 0 -NONE- DT JJ NN DT O
metastases, metastases, 0 0 0 0 1 0 0 0 11 0 DT JJ NN DT JJ O
no no 0 0 0 0 0 0 0 0 2 0 JJ NN DT JJ NN O
previous previous 0 0 0 0 0 0 0 0 8 0 NN DT JJ NN JJ O
surgery surgery 0 0 0 0 0 0 0 0 7 0 DT JJ NN JJ IN O
other other 0 0 0 0 0 0 0 0 5 0 JJ NN JJ IN JJ O
than than 0 0 0 0 0 0 0 0 4 0 NN JJ IN JJ DT O
TURP, TURP, 1 1 0 0 1 0 0 0 5 0 JJ IN JJ DT NN O
no no 0 0 0 0 0 0 0 0 2 0 IN JJ DT NN NNS O
malignant malignant 0 0 0 0 0 0 0 0 9 0 JJ DT NN NNS IN O
tumours tumours 0 0 0 0 0 0 0 0 7 0 DT NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ CD O
previous previous 0 0 0 0 0 0 0 0 8 0 IN DT JJ CD NN O
5 5 0 0 0 0 0 0 1 1 1 0 DT JJ CD NN NNP O
years, years, 0 0 0 0 1 0 0 0 6 0 JJ CD NN NNP CD O
IPSS IPSS 1 1 0 0 0 0 0 0 4 0 CD NN NNP CD NNP O
0--7. 0--7. 0 0 1 0 0 0 0 1 5 0 NN NNP CD NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP CD NNP NN VBD O
schedule schedule 0 0 0 0 0 0 0 0 8 0 CD NNP NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD JJ IN O
35Gy 35Gy 0 0 0 0 0 0 0 1 4 0 NN VBD JJ IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD JJ IN CD NN O
5 5 0 0 0 0 0 0 1 1 1 0 JJ IN CD NN NNP O
alternative alternative 0 0 0 0 0 0 0 0 11 0 IN CD NN NNP NNP O
days. days. 0 0 0 0 0 0 0 0 5 0 CD NN NNP NNP VBD O
SBRT SBRT 1 1 0 0 0 0 0 0 4 0 NN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
delivered delivered 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NNP O
RapidArc RapidArc 1 0 0 0 0 0 0 0 8 0 VBN IN NNP NNP IN O
VMAT, VMAT, 1 1 0 0 1 0 0 0 5 0 IN NNP NNP IN CD O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN CD NNP O
10MV 10MV 0 1 0 0 0 0 0 1 4 0 NNP IN CD NNP NNP O
FFF FFF 1 1 0 0 0 0 0 0 3 0 IN CD NNP NNP NNP O
photons. photons. 0 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
Toxicity Toxicity 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN VBD O
assessment assessment 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN VBG O
performed performed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN VBG TO O
according according 0 0 0 0 0 0 0 0 9 0 VBD VBN VBG TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBG TO NNP NNP O
CTCAE CTCAE 1 1 0 0 0 0 0 0 5 0 VBG TO NNP NNP NNP O
v4.0 v4.0 0 0 0 0 0 0 0 1 4 0 TO NNP NNP NNP NNP O
scale. scale. 0 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP VBZ O
EPIC EPIC 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP VBZ VBN O
questionnaires questionnaires 0 0 0 0 0 0 0 0 14 0 NNP NNP VBZ VBN NNP O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NNP VBZ VBN NNP JJ O
Quality-of-Life.. Quality-of-Life.. 1 0 1 0 0 0 0 0 17 0 VBZ VBN NNP JJ JJ O
Neo-adjuvant/concomitant Neo-adjuvant/concomitant 1 0 1 1 0 0 0 0 24 0 VBN NNP JJ JJ VBD O
hormonal-therapy hormonal-therapy 0 0 1 0 0 0 0 0 16 0 NNP JJ JJ VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ JJ VBD VBN VBG O
prescribed prescribed 0 0 0 0 0 0 0 0 10 0 JJ VBD VBN VBG TO O
according according 0 0 0 0 0 0 0 0 9 0 VBD VBN VBG TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBG TO VB NNP O
risk risk 0 0 0 0 0 0 0 0 4 0 VBG TO VB NNP NNP O
classification. classification. 0 0 0 0 0 0 0 0 15 0 TO VB NNP NNP NN O
SpaceOARTM SpaceOARTM 1 0 0 0 0 0 0 0 10 0 VB NNP NNP NN VBD O
gel gel 0 0 0 0 0 0 0 0 3 0 NNP NNP NN VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD RB VBN O
optionally optionally 0 0 0 0 0 0 0 0 10 0 NN VBD RB VBN TO O
implanted implanted 0 0 0 0 0 0 0 0 9 0 VBD RB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO VB DT O
increase increase 0 0 0 0 0 0 0 0 8 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
separation separation 0 0 0 0 0 0 0 0 10 0 VB DT NN NN IN O
space space 0 0 0 0 0 0 0 0 5 0 DT NN NN IN DT O
between between 0 0 0 0 0 0 0 0 7 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CC O
prostate prostate 0 0 0 0 0 0 0 0 8 0 IN DT NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT JJ NNP O
rectal rectal 0 0 0 0 0 0 0 0 6 0 CC DT JJ NNP NNP O
wall. wall. 0 0 0 0 0 0 0 0 5 0 DT JJ NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NNP O
Median Median 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP VBD O
follow-up follow-up 0 0 1 0 0 0 0 0 9 0 NNP NNP NNP VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD CD NNS O
11 11 0 0 0 0 0 0 1 1 2 0 NNP VBD CD NNS -NONE- O
months months 0 0 0 0 0 0 0 0 6 0 VBD CD NNS -NONE- CD O
(range: (range: 0 0 0 0 0 0 0 0 7 0 CD NNS -NONE- CD CD O
5--16); 5--16); 0 0 1 0 0 0 0 1 7 0 NNS -NONE- CD CD NNS O
40 40 0 0 0 0 0 0 1 1 2 0 -NONE- CD CD NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 CD CD NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD VBN IN O
recruited recruited 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN CC O
protocol protocol 0 0 0 0 0 0 0 0 8 0 IN DT NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NNP NNP O
treated.. treated.. 0 0 0 0 0 0 0 0 9 0 NN CC NNP NNP TO O
According According 1 0 0 0 0 0 0 0 9 0 CC NNP NNP TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNP TO NNP NNP O
NCCN NCCN 1 1 0 0 0 0 0 0 4 0 NNP TO NNP NNP CD O
criteria, criteria, 0 0 0 0 1 0 0 0 9 0 TO NNP NNP CD NNS O
26/40 26/40 0 0 0 1 0 0 0 1 5 0 NNP NNP CD NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP CD NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD JJ CC O
low-risk low-risk 0 0 1 0 0 0 0 0 8 0 NNS VBD JJ CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBD JJ CC CD VBD O
14/40 14/40 0 0 0 1 0 0 0 1 5 0 JJ CC CD VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 CC CD VBD JJ NNP O
intermediate intermediate 0 0 0 0 0 0 0 0 12 0 CD VBD JJ NNP NNP O
risk. risk. 0 0 0 0 0 0 0 0 5 0 VBD JJ NNP NNP NN O
Median Median 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NN VBD O
age age 0 0 0 0 0 0 0 0 3 0 NNP NNP NN VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD CD NNS O
70 70 0 0 0 0 0 0 1 1 2 0 NN VBD CD NNS -NONE- O
years years 0 0 0 0 0 0 0 0 5 0 VBD CD NNS -NONE- JJ O
(56--80), (56--80), 0 0 1 0 1 0 0 1 9 0 CD NNS -NONE- JJ JJ O
median median 0 0 0 0 0 0 0 0 6 0 NNS -NONE- JJ JJ NNP O
initial initial 0 0 0 0 0 0 0 0 7 0 -NONE- JJ JJ NNP VBD O
PSA PSA 1 1 0 0 0 0 0 0 3 0 JJ JJ NNP VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 JJ NNP VBD CD JJ O
6.25 6.25 0 0 0 0 0 0 0 1 4 0 NNP VBD CD JJ -NONE- O
ng/ml ng/ml 0 0 0 1 0 0 0 0 5 0 VBD CD JJ -NONE- NNP O
(0.50-13.43 (0.50-13.43 0 0 1 0 0 0 0 1 11 0 CD JJ -NONE- NNP NNP O
ng/ml). ng/ml). 0 0 0 1 0 0 0 0 7 0 JJ -NONE- NNP NNP NNP O
Median Median 1 0 0 0 0 0 0 0 6 0 -NONE- NNP NNP NNP NN O
Gleason Gleason 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NN VBD O
score score 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD CD NNP O
6 6 0 0 0 0 0 0 1 1 1 0 NN VBD CD NNP NNP O
(6--7). (6--7). 0 0 1 0 0 0 0 1 7 0 VBD CD NNP NNP NNS O
All All 1 0 0 0 0 0 0 0 3 0 CD NNP NNP NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBD DT O
completed completed 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBD DT NN IN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 VBD DT NN IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 DT NN IN VBN JJ O
programmed programmed 0 0 0 0 0 0 0 0 10 0 NN IN VBN JJ CD O
(median (median 0 0 0 0 0 0 0 0 7 0 IN VBN JJ CD NNS O
11.8 11.8 0 0 0 0 0 0 0 1 4 0 VBN JJ CD NNS NNP O
days days 0 0 0 0 0 0 0 0 4 0 JJ CD NNS NNP NNP O
(9--22). (9--22). 0 0 1 0 0 0 0 1 8 0 CD NNS NNP NNP NNPS O
Acute Acute 1 0 0 0 0 0 0 0 5 0 NNS NNP NNP NNPS VBD O
Toxicities Toxicities 1 0 0 0 0 0 0 0 10 0 NNP NNP NNPS VBD IN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNPS VBD IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NNPS VBD IN JJ NNP O
follow: follow: 0 0 0 0 0 0 0 0 7 0 VBD IN JJ NNP NNP O
Rectum Rectum 1 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP CD O
G0: G0: 1 1 0 0 0 0 0 1 3 0 JJ NNP NNP CD NNS O
30/40 30/40 0 0 0 1 0 0 0 1 5 0 NNP NNP CD NNS -NONE- O
cases cases 0 0 0 0 0 0 0 0 5 0 NNP CD NNS -NONE- -NONE- O
(75%); (75%); 0 0 0 0 0 0 0 1 6 0 CD NNS -NONE- -NONE- CD O
G1: G1: 1 1 0 0 0 0 0 1 3 0 NNS -NONE- -NONE- CD -NONE- O
6/40 6/40 0 0 0 1 0 0 0 1 4 0 -NONE- -NONE- CD -NONE- JJ O
(15%); (15%); 0 0 0 0 0 0 0 1 6 0 -NONE- CD -NONE- JJ CD O
G2: G2: 1 1 0 0 0 0 0 1 3 0 CD -NONE- JJ CD NNP O
4/40 4/40 0 0 0 1 0 0 0 1 4 0 -NONE- JJ CD NNP NNP O
(10%). (10%). 0 0 0 0 0 0 0 1 6 0 JJ CD NNP NNP NNP O
Genito-urinary: Genito-urinary: 1 0 1 0 0 0 0 0 15 0 CD NNP NNP NNP CD O
G0: G0: 1 1 0 0 0 0 0 1 3 0 NNP NNP NNP CD -NONE- O
16/40 16/40 0 0 0 1 0 0 0 1 5 0 NNP NNP CD -NONE- JJ O
(40%); (40%); 0 0 0 0 0 0 0 1 6 0 NNP CD -NONE- JJ CD O
G1: G1: 1 1 0 0 0 0 0 1 3 0 CD -NONE- JJ CD NN O
8/40 8/40 0 0 0 1 0 0 0 1 4 0 -NONE- JJ CD NN -NONE- O
(20%); (20%); 0 0 0 0 0 0 0 1 6 0 JJ CD NN -NONE- CD O
G2: G2: 1 1 0 0 0 0 0 1 3 0 CD NN -NONE- CD NNP O
16/34 16/34 0 0 0 1 0 0 0 1 5 0 NN -NONE- CD NNP NNP O
(40%). (40%). 0 0 0 0 0 0 0 1 6 0 -NONE- CD NNP NNP CD O
In In 1 0 0 0 0 0 0 0 2 0 CD NNP NNP CD NNP O
two two 0 0 0 0 0 0 0 0 3 0 NNP NNP CD NNP JJ O
G2 G2 1 1 0 0 0 0 0 1 2 0 NNP CD NNP JJ NN O
urinary urinary 0 0 0 0 0 0 0 0 7 0 CD NNP JJ NN NN O
retention retention 0 0 0 0 0 0 0 0 9 0 NNP JJ NN NN NN O
cases, cases, 0 0 0 0 1 0 0 0 6 0 JJ NN NN NN NN O
intermittent intermittent 0 0 0 0 0 0 0 0 12 0 NN NN NN NN VBD O
catheter catheter 0 0 0 0 0 0 0 0 8 0 NN NN NN VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD NNP NNP O
needed. needed. 0 0 0 0 0 0 0 0 7 0 NN VBD NNP NNP NN O
No No 1 0 0 0 0 0 0 0 2 0 VBD NNP NNP NN NNP O
acute acute 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NNP CC O
G3 G3 1 1 0 0 0 0 0 1 2 0 NNP NN NNP CC JJR O
or or 0 0 0 0 0 0 0 0 2 0 NN NNP CC JJR NN O
greater greater 0 0 0 0 0 0 0 0 7 0 NNP CC JJR NN VBD O
toxicity toxicity 0 0 0 0 0 0 0 0 8 0 CC JJR NN VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 JJR NN VBD NNP NNP O
found. found. 0 0 0 0 0 0 0 0 6 0 NN VBD NNP NNP NN O
Median Median 1 0 0 0 0 0 0 0 6 0 VBD NNP NNP NN NN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN VBD O
time time 0 0 0 0 0 0 0 0 4 0 NNP NN NN VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD CD NN O
126 126 0 0 0 0 0 0 1 1 3 0 NN VBD CD NN NNP O
sec sec 0 0 0 0 0 0 0 0 3 0 VBD CD NN NNP NNP O
(120--136). (120--136). 0 0 1 0 0 0 0 1 11 0 CD NN NNP NNP VBD O
SpaceOARTM SpaceOARTM 1 0 0 0 0 0 0 0 10 0 NN NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
implanted implanted 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD NNP O
8 8 0 0 0 0 0 0 1 1 1 0 VBN IN CD NNP NNP O
patients. patients. 0 0 0 0 0 0 0 0 9 0 IN CD NNP NNP NN O
PSA PSA 1 1 0 0 0 0 0 0 3 0 CD NNP NNP NN IN O
reduction reduction 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
pre-treatment pre-treatment 0 0 1 0 0 0 0 0 13 0 IN DT JJ NN IN O
value value 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBD O
marker marker 0 0 0 0 0 0 0 0 6 0 IN DT NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD VBN IN O
documented documented 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNP O
all all 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
patients. patients. 0 0 0 0 0 0 0 0 9 0 IN DT NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 DT NNP NNP NNP NNS O
Early Early 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NNP IN O
SBRT SBRT 1 1 0 0 0 0 0 0 4 0 VBP IN NNP IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN NNP CC O
RapidArc RapidArc 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNS O
FFF FFF 1 1 0 0 0 0 0 0 3 0 NNP CC NNP NNS IN O
beams beams 0 0 0 0 0 0 0 0 5 0 CC NNP NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNS IN JJ NN O
prostate prostate 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD NNS O
5 5 0 0 0 0 0 0 1 1 1 0 NN IN CD NNS VBZ O
fractions fractions 0 0 0 0 0 0 0 0 9 0 IN CD NNS VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 CD NNS VBZ JJ CC O
feasible feasible 0 0 0 0 0 0 0 0 8 0 NNS VBZ JJ CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 VBZ JJ CC VBD IN O
tolerated tolerated 0 0 0 0 0 0 0 0 9 0 JJ CC VBD IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC VBD IN NN NNP O
acute acute 0 0 0 0 0 0 0 0 5 0 VBD IN NN NNP NNP O
setting. setting. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP NNP O
Longer Longer 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP VBZ O
follow-up follow-up 0 0 1 0 0 0 0 0 9 0 NNP NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN IN O
needed needed 0 0 0 0 0 0 0 0 6 0 NNP VBZ VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ VBN IN NN IN O
assessment assessment 0 0 0 0 0 0 0 0 10 0 VBN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
late late 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN CC O
toxicity toxicity 0 0 0 0 0 0 0 0 8 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NONE O
outcome. outcome. 0 0 0 0 0 0 0 0 8 0 NN CC NNP NONE NONE O
TGF-β-Neutralizing TGF-β-Neutralizing 1 0 1 0 0 0 0 0 18 0 NONE NONE JJ NNP CD O
Antibody Antibody 1 0 0 0 0 0 0 0 8 0 NONE JJ NNP CD NNS O
1D11 1D11 0 1 0 0 0 0 0 1 4 0 JJ NNP CD NNS JJ O
Enhances Enhances 1 0 0 0 0 0 0 0 8 0 NNP CD NNS JJ NNP O
Cytarabine-Induced Cytarabine-Induced 1 0 1 0 0 0 0 0 18 0 CD NNS JJ NNP IN O
Apoptosis Apoptosis 1 0 0 0 0 0 0 0 9 0 NNS JJ NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNP IN NNP NNP O
AML AML 1 1 0 0 0 0 0 0 3 0 NNP IN NNP NNP IN O
Cells Cells 1 0 0 0 0 0 0 0 5 0 IN NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
Bone Bone 1 0 0 0 0 0 0 0 4 0 IN DT NNP NNP NNP O
Marrow Marrow 1 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP NNP O
Microenvironment. Microenvironment. 1 0 0 0 0 0 0 0 17 0 NNP NNP NNP NNP NNP O
Tabe Tabe 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shi Shi 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
YX, YX, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zeng Zeng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jin Jin 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shikami Shikami 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hatanaka Hatanaka 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Miida Miida 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hsu Hsu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
FJ, FJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Andreeff Andreeff 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Konopleva Konopleva 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Leukemia, Leukemia, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Texas Texas 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
MD MD 1 1 0 0 0 0 0 0 2 0 IN NNP NNP NNP NNP O
Anderson Anderson 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Houston, Houston, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Texas, Texas, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP : O
America America 1 0 0 0 0 0 0 0 7 0 NNPS IN NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 IN NNP : NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP : NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN NNP NNP O
Clinical Clinical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Juntendo Juntendo 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Tokyo, Tokyo, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CC O
Hypoxia Hypoxia 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNS IN O
interactions interactions 0 0 0 0 0 0 0 0 12 0 NNP CC NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 CC NNS IN NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
marrow marrow 0 0 0 0 0 0 0 0 6 0 IN NN NN NN NN O
(BM) (BM) 0 1 0 0 0 0 0 0 4 0 NN NN NN NN NNS O
stromal stromal 0 0 0 0 0 0 0 0 7 0 NN NN NN NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP VBN IN O
emerged emerged 0 0 0 0 0 0 0 0 7 0 NNS VBP VBN IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 VBP VBN IN JJ NNS O
essential essential 0 0 0 0 0 0 0 0 9 0 VBN IN JJ NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 IN JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
leukemic leukemic 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNP NN O
BM BM 1 1 0 0 0 0 0 0 2 0 DT JJ NNP NN IN O
microenvironment microenvironment 0 0 0 0 0 0 0 0 16 0 JJ NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
promoting promoting 0 0 0 0 0 0 0 0 9 0 NN IN NN NN NN O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 IN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN CC O
survival survival 0 0 0 0 0 0 0 0 8 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
chemoresistance. chemoresistance. 0 0 0 0 0 0 0 0 16 0 NN CC NNP NNP NNS O
High High 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN VBG NN O
transforming transforming 0 0 0 0 0 0 0 0 12 0 NNS IN VBG NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 IN VBG NN NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 VBG NN NN NN CD O
beta beta 0 0 0 0 0 0 0 0 4 0 NN NN NN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NN NN CD NN VBN O
(TGFβ1) (TGFβ1) 0 0 0 0 0 0 0 1 7 0 NN CD NN VBN IN O
produced produced 0 0 0 0 0 0 0 0 8 0 CD NN VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBN IN NNP JJ O
BM BM 1 1 0 0 0 0 0 0 2 0 VBN IN NNP JJ NNS O
stromal stromal 0 0 0 0 0 0 0 0 7 0 IN NNP JJ NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
BM BM 1 1 0 0 0 0 0 0 2 0 IN DT NNP NN NN O
niche niche 0 0 0 0 0 0 0 0 5 0 DT NNP NN NN NN O
regulate regulate 0 0 0 0 0 0 0 0 8 0 NNP NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 NN NN NN NN CC O
survival, survival, 0 0 0 0 1 0 0 0 9 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NN O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 NN CC NNP NN IN O
depending depending 0 0 0 0 0 0 0 0 9 0 CC NNP NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
cellular cellular 0 0 0 0 0 0 0 0 8 0 IN DT JJ NNP NNP O
context. context. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP NNP O
Exogenous Exogenous 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP VBD O
TGFβ1 TGFβ1 1 0 0 0 0 0 0 1 5 0 NNP NNP NNP VBD NN O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NNP VBD NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN NN VBD O
acute acute 0 0 0 0 0 0 0 0 5 0 NN IN NN VBD NN O
myeloid myeloid 0 0 0 0 0 0 0 0 7 0 IN NN VBD NN -NONE- O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 NN VBD NN -NONE- VBZ O
(AML) (AML) 0 1 0 0 0 0 0 0 5 0 VBD NN -NONE- VBZ IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN -NONE- VBZ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ IN DT NN NNP O
quiescent quiescent 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 DT NN NNP NNP WDT O
state, state, 0 0 0 0 1 0 0 0 6 0 NN NNP NNP WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 NNP WDT VBD RB VBN O
further further 0 0 0 0 0 0 0 0 7 0 WDT VBD RB VBN IN O
facilitated facilitated 0 0 0 0 0 0 0 0 11 0 VBD RB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ IN O
co-culture co-culture 0 0 1 0 0 0 0 0 10 0 IN DT JJ IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 DT JJ IN JJ JJ O
BM-derived BM-derived 1 0 1 0 0 0 0 0 10 0 JJ IN JJ JJ NN O
mesenchymal mesenchymal 0 0 0 0 0 0 0 0 11 0 IN JJ JJ NN NNS O
stem stem 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NNS NNP O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS NNP NNP O
(MSCs). (MSCs). 0 0 0 0 0 0 0 0 7 0 NN NNS NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNS NNP NNP NNP NNP O
turn, turn, 0 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NN O
TGFβ-neutralizing TGFβ-neutralizing 1 0 1 0 0 0 0 0 17 0 NNP NNP NNP NN CD O
antibody antibody 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CD VBN O
1D11 1D11 0 1 0 0 0 0 0 1 4 0 NNP NN CD VBN -NONE- O
abrogated abrogated 0 0 0 0 0 0 0 0 9 0 NN CD VBN -NONE- VBN O
rhTGFβ1 rhTGFβ1 0 0 0 0 0 0 0 1 7 0 CD VBN -NONE- VBN NN O
induced induced 0 0 0 0 0 0 0 0 7 0 VBN -NONE- VBN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 -NONE- VBN NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 VBN NN NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NNP O
Blocking Blocking 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP IN O
TGFβ TGFβ 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP IN CD O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN CD JJ O
1D11 1D11 0 1 0 0 0 0 0 1 4 0 NNP IN CD JJ VBN O
further further 0 0 0 0 0 0 0 0 7 0 IN CD JJ VBN NN O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 CD JJ VBN NN JJ O
cytarabine cytarabine 0 0 0 0 0 0 0 0 10 0 JJ VBN NN JJ NN O
(Ara-C)-induced (Ara-C)-induced 0 0 1 0 0 0 0 0 15 0 VBN NN JJ NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 NN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNS O
AML AML 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ CC O
hypoxic hypoxic 0 0 0 0 0 0 0 0 7 0 NNS IN JJ CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ CC IN JJ NNP O
normoxic normoxic 0 0 0 0 0 0 0 0 8 0 CC IN JJ NNP NNP O
conditions. conditions. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP NNS O
Additional Additional 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP NNS IN O
constituents constituents 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NNP NNP O
BM BM 1 1 0 0 0 0 0 0 2 0 NNS IN NNP NNP DT O
niche, niche, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
stroma-secreted stroma-secreted 0 0 1 0 0 0 0 0 15 0 NNP DT JJ NN NNP O
chemokine chemokine 0 0 0 0 0 0 0 0 9 0 DT JJ NN NNP CC O
CXCL12 CXCL12 1 1 0 0 0 0 0 1 6 0 JJ NN NNP CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NNP CC PRP$ NN NNP O
receptor receptor 0 0 0 0 0 0 0 0 8 0 CC PRP$ NN NNP NN O
CXCR4 CXCR4 1 1 0 0 0 0 0 1 5 0 PRP$ NN NNP NN JJ O
play play 0 0 0 0 0 0 0 0 4 0 NN NNP NN JJ NNS O
crucial crucial 0 0 0 0 0 0 0 0 7 0 NNP NN JJ NNS IN O
roles roles 0 0 0 0 0 0 0 0 5 0 NN JJ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN CC O
migration migration 0 0 0 0 0 0 0 0 9 0 IN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NN O
stroma/leukemia stroma/leukemia 0 0 0 1 0 0 0 0 15 0 NN CC NNP NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 CC NNP NN NNP NNP O
interactions. interactions. 0 0 0 0 0 0 0 0 13 0 NNP NN NNP NNP IN O
Treatment Treatment 1 0 0 0 0 0 0 0 9 0 NN NNP NNP IN CD O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN CD VBN O
1D11 1D11 0 1 0 0 0 0 0 1 4 0 NNP IN CD VBN IN O
combined combined 0 0 0 0 0 0 0 0 8 0 IN CD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 CD VBN IN NNP NN O
CXCR4 CXCR4 1 1 0 0 0 0 0 1 5 0 VBN IN NNP NN IN O
antagonist antagonist 0 0 0 0 0 0 0 0 10 0 IN NNP NN IN CC O
plerixafor plerixafor 0 0 0 0 0 0 0 0 10 0 NNP NN IN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN IN CC JJ VBN O
Ara-C Ara-C 1 0 1 0 0 0 0 0 5 0 IN CC JJ VBN NN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 CC JJ VBN NN NN O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 JJ VBN NN NN CC O
burden burden 0 0 0 0 0 0 0 0 6 0 VBN NN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBD NN O
prolonged prolonged 0 0 0 0 0 0 0 0 9 0 NN CC VBD NN IN O
survival survival 0 0 0 0 0 0 0 0 8 0 CC VBD NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD NN IN DT IN O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN DT IN NN NN O
vivo vivo 0 0 0 0 0 0 0 0 4 0 DT IN NN NN NNP O
leukemia leukemia 0 0 0 0 0 0 0 0 8 0 IN NN NN NNP NNP O
model. model. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN NN IN O
blockade blockade 0 0 0 0 0 0 0 0 8 0 VBP IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP IN O
TGFβ TGFβ 1 0 0 0 0 0 0 0 4 0 NN IN NNP IN CD O
by by 0 0 0 0 0 0 0 0 2 0 IN NNP IN CD CC O
1D11 1D11 0 1 0 0 0 0 0 1 4 0 NNP IN CD CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC NN IN O
abrogation abrogation 0 0 0 0 0 0 0 0 10 0 CD CC NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN -NONE- VBG O
CXCL12/CXCR4 CXCL12/CXCR4 1 1 0 1 0 0 0 1 12 0 NN IN -NONE- VBG MD O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN -NONE- VBG MD VB O
may may 0 0 0 0 0 0 0 0 3 0 -NONE- VBG MD VB DT O
enhance enhance 0 0 0 0 0 0 0 0 7 0 VBG MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN IN O
efficacy efficacy 0 0 0 0 0 0 0 0 8 0 VB DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
chemotherapy chemotherapy 0 0 0 0 0 0 0 0 12 0 NN IN NN IN NNP O
against against 0 0 0 0 0 0 0 0 7 0 IN NN IN NNP NNS O
AML AML 1 1 0 0 0 0 0 0 3 0 NN IN NNP NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NNP NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNP O
hypoxic hypoxic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP O
BM BM 1 1 0 0 0 0 0 0 2 0 DT JJ NNP NNP NONE O
microenvironment. microenvironment. 0 0 0 0 0 0 0 0 17 0 JJ NNP NNP NONE NONE O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NONE NONE NNP NN NNS O
resection resection 0 0 0 0 0 0 0 0 9 0 NONE NNP NN NNS NNP O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNP NN NNS NNP CC O
Sgs1 Sgs1 1 0 0 0 0 0 0 1 4 0 NN NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP VBP O
Exo1 Exo1 1 0 0 0 0 0 0 1 4 0 NNP CC NNP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 CC NNP VBP VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 NNP VBP VBN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 VBP VBN IN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 VBN IN NNP NN NN G1
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 IN NNP NN NN IN G1
activation activation 0 0 0 0 0 0 0 0 10 0 NNP NN NN IN VBG O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN VBG NNP O
budding budding 0 0 0 0 0 0 0 0 7 0 NN IN VBG NNP NNP O
yeast. yeast. 0 0 0 0 0 0 0 0 6 0 IN VBG NNP NNP NNP O
Balogun Balogun 1 0 0 0 0 0 0 0 7 0 VBG NNP NNP NNP NNP O
FO, FO, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Truman Truman 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
AW, AW, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kron Kron 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
SJ. SJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Committee Committee 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP IN NNP NNP CC O
Pathogenesis Pathogenesis 1 0 0 0 0 0 0 0 12 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Chicago, Chicago, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Chicago, Chicago, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP CD O
IL IL 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD -NONE- O
60637, 60637, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD -NONE- NNP O
USA; USA; 1 1 0 0 0 0 0 0 4 0 NNP CD -NONE- NNP NNP O
Ludwig Ludwig 1 0 0 0 0 0 0 0 6 0 CD -NONE- NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 -NONE- NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Metastasis Metastasis 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Research, Research, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Chicago, Chicago, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Chicago, Chicago, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP CD O
IL IL 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
60637, 60637, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP VBZ O
Double-strand Double-strand 1 0 1 0 0 0 0 0 13 0 NNP NNP NNP VBZ JJ O
breaks breaks 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ JJ IN O
(DSBs) (DSBs) 0 0 0 0 0 0 0 0 6 0 NNP VBZ JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN NN NN O
budding budding 0 0 0 0 0 0 0 0 7 0 JJ IN NN NN NN O
yeast yeast 0 0 0 0 0 0 0 0 5 0 IN NN NN NN NN O
trigger trigger 0 0 0 0 0 0 0 0 7 0 NN NN NN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP NN -NONE- O
damage damage 0 0 0 0 0 0 0 0 6 0 IN NNP NN -NONE- VBG O
checkpoints, checkpoints, 0 0 0 0 1 0 0 0 12 0 NNP NN -NONE- VBG NN O
allowing allowing 0 0 0 0 0 0 0 0 8 0 NN -NONE- VBG NN TO O
repair repair 0 0 0 0 0 0 0 0 6 0 -NONE- VBG NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBG NN TO NNP NNP O
occur. occur. 0 0 0 0 0 0 0 0 6 0 NN TO NNP NNP NN O
Although Although 1 0 0 0 0 0 0 0 8 0 TO NNP NNP NN VBZ O
resection resection 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ JJ IN O
necessary necessary 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN NN JJ O
initiating initiating 0 0 0 0 0 0 0 0 10 0 JJ IN NN JJ NN O
damage-induced damage-induced 0 0 1 0 0 0 0 0 14 0 IN NN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN JJ NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest JJ NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP DT O
G2, G2, 1 1 0 0 1 0 0 1 3 0 NN IN NNP DT NN B_TIMEXCCP
no no 0 0 0 0 0 0 0 0 2 0 IN NNP DT NN VBZ O
role role 0 0 0 0 0 0 0 0 4 0 NNP DT NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 DT NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN TO O
assigned assigned 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN TO PRP O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO PRP IN O
it it 0 0 0 0 0 0 0 0 2 0 VBN TO PRP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 TO PRP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP IN DT NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN IN NNP NNP NNP G1
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP PRP G1
Here Here 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP PRP VBP IN DT O
for for 0 0 0 0 0 0 0 0 3 0 PRP VBP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN WDT O
time time 0 0 0 0 0 0 0 0 4 0 DT JJ NN WDT DT O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN WDT DT NN NNS O
resection resection 0 0 0 0 0 0 0 0 9 0 WDT DT NN NNS NNP O
proteins proteins 0 0 0 0 0 0 0 0 8 0 DT NN NNS NNP CC O
Sgs1 Sgs1 1 0 0 0 0 0 0 1 4 0 NN NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP VBP O
Exo1 Exo1 1 0 0 0 0 0 0 1 4 0 NNP CC NNP VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 CC NNP VBP VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 NNP VBP VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBP VBN IN JJ NNP O
efficient efficient 0 0 0 0 0 0 0 0 9 0 VBN IN JJ NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN JJ NNP NN NNP G1
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 JJ NNP NN NNP NNP G1
activation. activation. 0 0 0 0 0 0 0 0 11 0 NNP NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP IN O
find find 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBP IN NNP VBD O
G1 G1 1 1 0 0 0 0 0 1 2 0 VBP IN NNP VBD NNS B_TIMEXCCP
arrested arrested 0 0 0 0 0 0 0 0 8 0 IN NNP VBD NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP VBD NNS IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBD NNS IN NN NNP O
histone histone 0 0 0 0 0 0 0 0 7 0 NNS IN NN NNP NN O
H2A H2A 1 1 0 0 0 0 0 1 3 0 IN NN NNP NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NN NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NN IN NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NN NN O
ionizing ionizing 0 0 0 0 0 0 0 0 8 0 NN TO NN NN VBZ O
radiation radiation 0 0 0 0 0 0 0 0 9 0 TO NN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ IN O
independent independent 0 0 0 0 0 0 0 0 11 0 NN VBZ JJ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN NNP CC O
Sgs1 Sgs1 1 0 0 0 0 0 0 1 4 0 JJ IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Exo1. Exo1. 1 0 0 0 0 0 0 1 5 0 NNP CC NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 CC NNP NNP NNP DT O
contrast, contrast, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NNP DT NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 NNS VBP VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBP VBN IN JJ NN O
damage-induced damage-induced 0 0 1 0 0 0 0 0 14 0 VBN IN JJ NN IN O
recruitment recruitment 0 0 0 0 0 0 0 0 11 0 IN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP TO O
Rfa1 Rfa1 1 0 0 0 0 0 0 1 4 0 NN IN NNP TO DT O
to to 0 0 0 0 0 0 0 0 2 0 IN NNP TO DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP TO DT NNP NNP O
DSB DSB 1 1 0 0 0 0 0 0 3 0 TO DT NNP NNP NN O
sites, sites, 0 0 0 0 1 0 0 0 6 0 DT NNP NNP NN IN O
phosphorylation phosphorylation 0 0 0 0 0 0 0 0 15 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
Rad53 Rad53 1 0 0 0 0 0 0 1 5 0 IN DT NNP NN -NONE- O
effector effector 0 0 0 0 0 0 0 0 8 0 DT NNP NN -NONE- NN O
kinase, kinase, 0 0 0 0 1 0 0 0 7 0 NNP NN -NONE- NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN -NONE- NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest -NONE- NN NN NN CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
RNR3 RNR3 1 1 0 0 0 0 0 1 4 0 NN CC NNP NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 CC NNP NNP NNP NN O
Checkpoint Checkpoint 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NN IN B_TIMEXCCP
activation activation 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP VBZ O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN IN NNP VBZ DT B_TIMEXCCP
requires requires 0 0 0 0 0 0 0 0 8 0 IN NNP VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT JJ NN O
catalytic catalytic 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
Sgs1, Sgs1, 1 0 0 0 1 0 0 1 5 0 NN IN JJ NN WDT O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 IN JJ NN WDT PRP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN WDT PRP VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 WDT PRP VBZ NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 PRP VBZ NNP NN VBD O
resection resection 0 0 0 0 0 0 0 0 9 0 VBZ NNP NN VBD IN O
mediated mediated 0 0 0 0 0 0 0 0 8 0 NNP NN VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP IN O
Sgs1 Sgs1 1 0 0 0 0 0 0 1 4 0 VBD IN NNP IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 IN NNP IN NNS DT O
stimulates stimulates 0 0 0 0 0 0 0 0 10 0 NNP IN NNS DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NNS DT NN NN O
damage damage 0 0 0 0 0 0 0 0 6 0 NNS DT NN NN NN O
response response 0 0 0 0 0 0 0 0 8 0 DT NN NN NN RB O
pathway pathway 0 0 0 0 0 0 0 0 7 0 NN NN NN RB IN O
rather rather 0 0 0 0 0 0 0 0 6 0 NN NN RB IN JJ O
than than 0 0 0 0 0 0 0 0 4 0 NN RB IN JJ NNS O
protein-protein protein-protein 0 0 1 0 0 0 0 0 15 0 RB IN JJ NNS IN O
interactions interactions 0 0 0 0 0 0 0 0 12 0 IN JJ NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NNS IN JJ NNP O
other other 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNP NNP O
DDR DDR 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NNP NNP O
proteins. proteins. 0 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP DT O
Together, Together, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP DT NNS VBP NNP O
implicate implicate 0 0 0 0 0 0 0 0 9 0 DT NNS VBP NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNS VBP NNP NNP WDT O
resection, resection, 0 0 0 0 1 0 0 0 10 0 VBP NNP NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NNP NNP WDT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP WDT VBZ VBN TO O
thought thought 0 0 0 0 0 0 0 0 7 0 WDT VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB JJ IN O
minimal minimal 0 0 0 0 0 0 0 0 7 0 TO VB JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VB JJ IN JJ IN O
G1, G1, 1 1 0 0 1 0 0 1 3 0 JJ IN JJ IN JJ B_TIMEXCCP
as as 0 0 0 0 0 0 0 0 2 0 IN JJ IN JJ IN O
necessary necessary 0 0 0 0 0 0 0 0 9 0 JJ IN JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 IN JJ IN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 JJ IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN DT NNP NNP NONE G1
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 DT NNP NNP NONE NONE G1
Sulforaphane Sulforaphane 1 0 0 0 0 0 0 0 12 0 NONE NONE NNP VBZ JJ O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NONE NNP VBZ JJ NN O
PDGF-induced PDGF-induced 1 0 1 0 0 0 0 0 12 0 NNP VBZ JJ NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBZ JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN JJ O
rat rat 0 0 0 0 0 0 0 0 3 0 NN IN NN JJ NN O
aortic aortic 0 0 0 0 0 0 0 0 6 0 IN NN JJ NN NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 NN JJ NN NN NN O
smooth smooth 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
muscle muscle 0 0 0 0 0 0 0 0 6 0 NN NN NN NN IN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
up-regulation up-regulation 0 0 1 0 0 0 0 0 13 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP VBG O
p53 p53 0 0 0 0 0 0 0 1 3 0 NN IN NNP VBG TO O
leading leading 0 0 0 0 0 0 0 0 7 0 IN NNP VBG TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBG TO NNS VBP O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 VBG TO NNS VBP NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 TO NNS VBP NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNS VBP NN NNP NNP O
arrest. arrest. 0 0 0 0 0 0 0 0 7 0 VBP NN NNP NNP NNP O
Yoo Yoo 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NNP O
SH, SH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lim Lim 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kim Kim 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
SJ, SJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yoo Yoo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
KD, KD, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yoo Yoo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
HS, HS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hong Hong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
JT, JT, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Lee Lee 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
MY, MY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yun Yun 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
YP. YP. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
College College 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pharmacy, Pharmacy, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP CC O
Bioresource Bioresource 1 0 0 0 0 0 0 0 11 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Health, Health, 1 0 0 0 1 0 0 0 7 0 NNP CC NNP NNP NNP O
Chungbuk Chungbuk 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Cheongju, Cheongju, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP IN O
Republic Republic 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Korea. Korea. 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP VBZ O
Vascular Vascular 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP VBZ JJ O
diseases diseases 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 NNP VBZ JJ IN NN O
as as 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN NN CC O
atherosclerosis atherosclerosis 0 0 0 0 0 0 0 0 15 0 JJ IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN NN O
restenosis restenosis 0 0 0 0 0 0 0 0 10 0 NN CC NN NN NN O
artery artery 0 0 0 0 0 0 0 0 6 0 CC NN NN NN VBP O
angioplasty angioplasty 0 0 0 0 0 0 0 0 11 0 NN NN NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN VBP VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBP VBN IN JJ NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NN NN O
smooth smooth 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN NN O
muscle muscle 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
(VSMC) (VSMC) 0 1 0 0 0 0 0 0 6 0 NN NN NN NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
intimal intimal 0 0 0 0 0 0 0 0 7 0 NN CC JJ NN JJ O
thickening thickening 0 0 0 0 0 0 0 0 10 0 CC JJ NN JJ NNP O
arterial arterial 0 0 0 0 0 0 0 0 8 0 JJ NN JJ NNP NNP O
walls. walls. 0 0 0 0 0 0 0 0 6 0 NN JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 DT NN NN PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN NNS O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 VBD DT NN NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 DT NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ DT O
sulforaphane, sulforaphane, 0 0 0 0 1 0 0 0 13 0 NNS IN JJ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 IN JJ DT JJ VBN O
isothiocyanate isothiocyanate 0 0 0 0 0 0 0 0 14 0 JJ DT JJ VBN IN O
produced produced 0 0 0 0 0 0 0 0 8 0 DT JJ VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ VBN IN JJ NN O
cruciferous cruciferous 0 0 0 0 0 0 0 0 11 0 VBN IN JJ NN IN O
vegetables, vegetables, 0 0 0 0 1 0 0 0 11 0 IN JJ NN IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
VSMC VSMC 1 1 0 0 0 0 0 0 4 0 NN IN NNP NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NN O
neointimal neointimal 0 0 0 0 0 0 0 0 10 0 NN CC JJ NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 CC JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
rat rat 0 0 0 0 0 0 0 0 3 0 IN DT NN NN NN O
carotid carotid 0 0 0 0 0 0 0 0 7 0 DT NN NN NN NN O
artery artery 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NNP O
injury injury 0 0 0 0 0 0 0 0 6 0 NN NN NN NNP NNP O
model. model. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP IN O
Sulforaphane Sulforaphane 1 0 0 0 0 0 0 0 12 0 NN NNP NNP IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNS IN O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 IN DT NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN CD CD O
0.5, 0.5, 0 0 0 0 1 0 0 1 4 0 NNS IN CD CD CC O
1.0, 1.0, 0 0 0 0 1 0 0 1 4 0 IN CD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC CD RB O
2.0μM 2.0μM 0 0 0 0 0 0 0 1 5 0 CD CC CD RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 CC CD RB VBN JJ O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 CD RB VBN JJ NN O
platelet-derived platelet-derived 0 0 1 0 0 0 0 0 16 0 RB VBN JJ NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBN JJ NN NN JJ O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ NN NN JJ NNP O
(PDGF)-BB-induced (PDGF)-BB-induced 0 0 1 0 0 0 0 0 17 0 NN NN JJ NNP NN O
VSMC VSMC 1 1 0 0 0 0 0 0 4 0 NN JJ NNP NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 JJ NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
concentration-dependent concentration-dependent 0 0 1 0 0 0 0 0 23 0 IN DT JJ NN VBD O
manner, manner, 0 0 0 0 1 0 0 0 7 0 DT JJ NN VBD IN O
determined determined 0 0 0 0 0 0 0 0 10 0 JJ NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 VBD IN NN NNP NNP O
count. count. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NN O
IC50 IC50 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP NN IN O
value value 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNP O
sulforaphane-inhibited sulforaphane-inhibited 0 0 1 0 0 0 0 0 22 0 NN IN JJ NNP NN O
VSMC VSMC 1 1 0 0 0 0 0 0 4 0 IN JJ NNP NN VBD O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 JJ NNP NN VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD CD NNP O
0.8μM. 0.8μM. 0 0 0 0 0 0 0 1 6 0 NN VBD CD NNP VBD O
Sulforaphane Sulforaphane 1 0 0 0 0 0 0 0 12 0 VBD CD NNP VBD DT O
increased increased 0 0 0 0 0 0 0 0 9 0 CD NNP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT JJ NN O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 VBD DT JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN NNP O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNP CC O
p21 p21 0 0 0 0 0 0 0 1 3 0 NN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
p53 p53 0 0 0 0 0 0 0 1 3 0 NNP CC NNP NNP IN O
levels, levels, 0 0 0 0 1 0 0 0 7 0 CC NNP NNP IN PRP O
while while 0 0 0 0 0 0 0 0 5 0 NNP NNP IN PRP VBD O
it it 0 0 0 0 0 0 0 0 2 0 NNP IN PRP VBD NNP O
decreased decreased 0 0 0 0 0 0 0 0 9 0 IN PRP VBD NNP CC O
CDK2 CDK2 1 1 0 0 0 0 0 1 4 0 PRP VBD NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 VBD NNP CC VB NNP O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 NNP CC VB NNP NNP O
E E 1 1 0 0 0 0 0 0 1 0 CC VB NNP NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 VB NNP NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NN IN O
sulforaphane sulforaphane 0 0 0 0 0 0 0 0 12 0 NNS IN NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NN O
vascular vascular 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN VBD O
thickening thickening 0 0 0 0 0 0 0 0 10 0 IN JJ NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD VBN CD O
determined determined 0 0 0 0 0 0 0 0 10 0 NN VBD VBN CD IN O
14days 14days 0 0 0 0 0 0 0 1 6 0 VBD VBN CD IN DT O
after after 0 0 0 0 0 0 0 0 5 0 VBN CD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NN TO O
injury injury 0 0 0 0 0 0 0 0 6 0 IN DT NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN VBD O
rat rat 0 0 0 0 0 0 0 0 3 0 TO DT NN VBD NNP O
carotid carotid 0 0 0 0 0 0 0 0 7 0 DT NN VBD NNP NNP O
artery. artery. 0 0 0 0 0 0 0 0 7 0 NN VBD NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP JJ NN O
angiographic angiographic 0 0 0 0 0 0 0 0 12 0 NNP NNP JJ NN NN O
mean mean 0 0 0 0 0 0 0 0 4 0 NNP JJ NN NN NNS O
luminary luminary 0 0 0 0 0 0 0 0 8 0 JJ NN NN NNS IN O
diameters diameters 0 0 0 0 0 0 0 0 9 0 NN NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN VBD O
group group 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD IN O
treated treated 0 0 0 0 0 0 0 0 7 0 DT NN VBD IN CD O
with with 0 0 0 0 0 0 0 0 4 0 NN VBD IN CD CC O
2 2 0 0 0 0 0 0 1 1 1 0 VBD IN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 IN CD CC CD NN O
4μM 4μM 0 0 0 0 0 0 0 1 3 0 CD CC CD NN VBD O
sulforaphane sulforaphane 0 0 0 0 0 0 0 0 12 0 CC CD NN VBD CD O
were were 0 0 0 0 0 0 0 0 4 0 CD NN VBD CD CC O
0.25±0.1 0.25±0.1 0 0 0 0 0 0 0 1 8 0 NN VBD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 VBD CD CC CD NN O
0.09±0.1mm(2), 0.09±0.1mm(2), 0 0 0 0 1 0 0 1 14 0 CD CC CD NN IN O
respectively, respectively, 0 0 0 0 1 0 0 0 13 0 CC CD NN IN DT O
while while 0 0 0 0 0 0 0 0 5 0 CD NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
value value 0 0 0 0 0 0 0 0 5 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
control control 0 0 0 0 0 0 0 0 7 0 IN DT NN NNS VBD O
groups groups 0 0 0 0 0 0 0 0 6 0 DT NN NNS VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 NN NNS VBD CD VBG O
0.40±0.1mm(2), 0.40±0.1mm(2), 0 0 0 0 1 0 0 1 14 0 NNS VBD CD VBG IN O
indicating indicating 0 0 0 0 0 0 0 0 10 0 VBD CD VBG IN NN O
that that 0 0 0 0 0 0 0 0 4 0 CD VBG IN NN MD O
sulforaphane sulforaphane 0 0 0 0 0 0 0 0 12 0 VBG IN NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN NN MD VB JJ O
inhibit inhibit 0 0 0 0 0 0 0 0 7 0 NN MD VB JJ NNP O
neointimal neointimal 0 0 0 0 0 0 0 0 10 0 MD VB JJ NNP NNP O
formation. formation. 0 0 0 0 0 0 0 0 10 0 VB JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
PCNA, PCNA, 1 1 0 0 1 0 0 0 5 0 NN IN NNP NN IN O
maker maker 0 0 0 0 0 0 0 0 5 0 IN NNP NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNP NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN VBD O
arrest, arrest, 0 0 0 0 1 0 0 0 7 0 NN NN NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD JJ IN O
decreased, decreased, 0 0 0 0 1 0 0 0 10 0 NN VBD JJ IN DT O
while while 0 0 0 0 0 0 0 0 5 0 VBD JJ IN DT IN O
that that 0 0 0 0 0 0 0 0 4 0 JJ IN DT IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN NNP CC O
p53 p53 0 0 0 0 0 0 0 1 3 0 DT IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBD O
p21 p21 0 0 0 0 0 0 0 1 3 0 NNP CC NNP VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 CC NNP VBD JJ WDT O
increased, increased, 0 0 0 0 1 0 0 0 10 0 NNP VBD JJ WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 VBD JJ WDT VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 JJ WDT VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 WDT VBD DT JJ NN O
same same 0 0 0 0 0 0 0 0 4 0 VBD DT JJ NN IN O
pattern pattern 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN CD O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD IN O
one one 0 0 0 0 0 0 0 0 3 0 NN IN CD IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN CD IN NNP NNP O
in-vitro in-vitro 0 0 1 0 0 0 0 0 8 0 CD IN NNP NNP NNP O
study. study. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN JJ NNP O
sulforaphane-inhibited sulforaphane-inhibited 0 0 1 0 0 0 0 0 22 0 VBP IN JJ NNP NN O
VSMC VSMC 1 1 0 0 0 0 0 0 4 0 IN JJ NNP NN MD O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 JJ NNP NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NN MD VB IN O
occur occur 0 0 0 0 0 0 0 0 5 0 NN MD VB IN DT O
through through 0 0 0 0 0 0 0 0 7 0 MD VB IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT NNS VBP O
G1/S G1/S 1 1 0 1 0 0 0 1 4 0 IN DT NNS VBP NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 DT NNS VBP NN JJS O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NNS VBP NN JJS IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBP NN JJS IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN JJS IN NN IN O
up-regulation up-regulation 0 0 1 0 0 0 0 0 13 0 JJS IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NN O
p53 p53 0 0 0 0 0 0 0 1 3 0 NN IN NNP NN -NONE- O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN NNP NN -NONE- CC O
pathway, pathway, 0 0 0 0 1 0 0 0 8 0 NNP NN -NONE- CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC RB VB O
then then 0 0 0 0 0 0 0 0 4 0 -NONE- CC RB VB TO O
lead lead 0 0 0 0 0 0 0 0 4 0 CC RB VB TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB VB TO DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 VB TO DT VBN JJ O
decreased decreased 0 0 0 0 0 0 0 0 9 0 TO DT VBN JJ NN O
neointimal neointimal 0 0 0 0 0 0 0 0 10 0 DT VBN JJ NN NNP O
hyperplasia hyperplasia 0 0 0 0 0 0 0 0 11 0 VBN JJ NN NNP NNP O
thickening. thickening. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP NNP NN O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 NN NNP NNP NN MD O
sulforaphane sulforaphane 0 0 0 0 0 0 0 0 12 0 NNP NNP NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NN MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT NN NN O
promising promising 0 0 0 0 0 0 0 0 9 0 VB DT NN NN IN O
candidate candidate 0 0 0 0 0 0 0 0 9 0 DT NN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
therapy therapy 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
atherosclerosis atherosclerosis 0 0 0 0 0 0 0 0 15 0 NN IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NNP O
post-angiography post-angiography 0 0 1 0 0 0 0 0 16 0 NN CC JJ NNP NONE O
restenosis. restenosis. 0 0 0 0 0 0 0 0 11 0 CC JJ NNP NONE NONE O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NONE NONE JJ NN IN O
Characterization Characterization 1 0 0 0 0 0 0 0 16 0 NONE JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
Echinococcus Echinococcus 1 0 0 0 0 0 0 0 12 0 NN IN NNP NN NNS O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 IN NNP NN NNS IN O
Cysts Cysts 1 0 0 0 0 0 0 0 5 0 NNP NN NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 NNS IN NNP NNP NNP O
Indian Indian 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Patients: Patients: 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP IN O
Identification Identification 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
G1, G1, 1 1 0 0 1 0 0 1 3 0 NNP IN NNP NNP NNP O
G3, G3, 1 1 0 0 1 0 0 1 3 0 IN NNP NNP NNP CC O
G5 G5 1 1 0 0 0 0 0 1 2 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
G6 G6 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNP NNP O
Genotypes. Genotypes. 1 0 0 0 0 0 0 0 10 0 CC NNP NNP NNP NNP O
Sharma Sharma 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sehgal Sehgal 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Fomda Fomda 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
BA, BA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Malhotra Malhotra 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Malla Malla 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
N. N. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Parasitology, Parasitology, 1 0 0 0 1 0 0 0 13 0 NNP IN NNP NNP NNP O
Postgraduate Postgraduate 1 0 0 0 0 0 0 0 12 0 IN NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP CC O
Education Education 1 0 0 0 0 0 0 0 9 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Research, Research, 1 0 0 0 1 0 0 0 9 0 NNP CC NNP NNP NNP O
Chandigarh, Chandigarh, 1 0 0 0 1 0 0 0 11 0 CC NNP NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NN O
Cystic Cystic 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN -NONE- O
echinococcosis echinococcosis 0 0 0 0 0 0 0 0 14 0 NNP NNP NN -NONE- VBN O
(CE) (CE) 0 1 0 0 0 0 0 0 4 0 NNP NN -NONE- VBN IN O
caused caused 0 0 0 0 0 0 0 0 6 0 NN -NONE- VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 -NONE- VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
Echinococcus Echinococcus 1 0 0 0 0 0 0 0 12 0 IN DT NNP NNP VBZ O
granulosus, granulosus, 0 0 0 0 1 0 0 0 11 0 DT NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ JJ O
major major 0 0 0 0 0 0 0 0 5 0 VBZ DT JJ JJ NN O
public public 0 0 0 0 0 0 0 0 6 0 DT JJ JJ NN NN O
health health 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NN O
problem problem 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN VBG O
worldwide, worldwide, 0 0 0 0 1 0 0 0 10 0 NN NN NN VBG NNP O
including including 0 0 0 0 0 0 0 0 9 0 NN NN VBG NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NN VBG NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 VBG NNP NNP JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NNS IN O
genotypes genotypes 0 0 0 0 0 0 0 0 9 0 NNP JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 NNS IN NNP NN JJ O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 IN NNP NN JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 NNP NN JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN JJ IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 JJ IN JJ NN VBP O
hydatidosis hydatidosis 0 0 0 0 0 0 0 0 11 0 IN JJ NN VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NN VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBP VBN VBN IN O
reported reported 0 0 0 0 0 0 0 0 8 0 VBP VBN VBN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 VBN VBN IN JJ NNS O
endemic endemic 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NNS IN O
areas areas 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN DT O
throughout throughout 0 0 0 0 0 0 0 0 10 0 JJ NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NNP O
world. world. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 DT NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
genetic genetic 0 0 0 0 0 0 0 0 7 0 NNP DT JJ NN IN O
characterization characterization 0 0 0 0 0 0 0 0 16 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NN VBG O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 IN NNP NN VBG DT O
infecting infecting 0 0 0 0 0 0 0 0 9 0 NNP NN VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 VBG DT JJ NN IN O
population population 0 0 0 0 0 0 0 0 10 0 DT JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP VBZ O
India India 1 0 0 0 0 0 0 0 5 0 NN IN NNP VBZ NNP O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ NNP DT O
lacking. lacking. 0 0 0 0 0 0 0 0 8 0 NNP VBZ NNP DT NN O
The The 1 0 0 0 0 0 0 0 3 0 VBZ NNP DT NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NN IN NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
ascertain ascertain 0 0 0 0 0 0 0 0 9 0 VBD TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
genotype(s) genotype(s) 0 0 0 0 0 0 0 0 11 0 VB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ JJ O
parasite parasite 0 0 0 0 0 0 0 0 8 0 IN DT JJ JJ IN O
responsible responsible 0 0 0 0 0 0 0 0 11 0 DT JJ JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ JJ IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 JJ IN JJ NN IN O
hydatidosis hydatidosis 0 0 0 0 0 0 0 0 11 0 IN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
METHODOLOGY/PRINCIPAL METHODOLOGY/PRINCIPAL 1 1 0 1 0 0 0 0 21 0 NNP NNP NNP NNP NNP O
FINDINGS: FINDINGS: 1 1 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NN O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN DT O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN VBZ O
transmission transmission 0 0 0 0 0 0 0 0 12 0 NN DT NN VBZ IN O
patterns patterns 0 0 0 0 0 0 0 0 8 0 DT NN VBZ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN VBZ IN NNP NNP O
E. E. 1 1 0 0 0 0 0 0 2 0 VBZ IN NNP NNP JJ O
granulosus, granulosus, 0 0 0 0 1 0 0 0 11 0 IN NNP NNP JJ NN O
genotypic genotypic 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NNS O
hydatid hydatid 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NNS VBD O
cysts cysts 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBD IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 JJ NNS VBD IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN CD JJ O
32 32 0 0 0 0 0 0 1 1 2 0 VBD IN CD JJ NN O
cystic cystic 0 0 0 0 0 0 0 0 6 0 IN CD JJ NN NN O
echinococcosis echinococcosis 0 0 0 0 0 0 0 0 14 0 CD JJ NN NN NNS O
(CE) (CE) 0 1 0 0 0 0 0 0 4 0 JJ NN NN NNS VBG O
patients patients 0 0 0 0 0 0 0 0 8 0 NN NN NNS VBG IN O
residing residing 0 0 0 0 0 0 0 0 8 0 NN NNS VBG IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBG IN CD JJ O
7 7 0 0 0 0 0 0 1 1 1 0 VBG IN CD JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 IN CD JJ NNS IN O
states states 0 0 0 0 0 0 0 0 6 0 CD JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NNP O
North North 1 0 0 0 0 0 0 0 5 0 NNS IN NNP NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NN O
Mitochondrial Mitochondrial 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NN NN O
cytochrome cytochrome 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN NN O
c c 0 0 0 0 0 0 0 0 1 0 NNP NN NN NN NNP O
oxidase oxidase 0 0 0 0 0 0 0 0 7 0 NN NN NN NNP NNP O
subunit1 subunit1 0 0 0 0 0 0 0 1 8 0 NN NN NNP NNP NN O
(cox1) (cox1) 0 0 0 0 0 0 0 1 6 0 NN NNP NNP NN VBD O
sequencing sequencing 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
done done 0 0 0 0 0 0 0 0 4 0 NN VBD VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VBN IN JJ NN IN O
identification identification 0 0 0 0 0 0 0 0 14 0 IN JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
isolates. isolates. 0 0 0 0 0 0 0 0 9 0 IN DT NNP NNP IN O
Most Most 1 0 0 0 0 0 0 0 4 0 DT NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNS O
CE CE 1 1 0 0 0 0 0 0 2 0 IN DT NNP NNS -NONE- O
patients patients 0 0 0 0 0 0 0 0 8 0 DT NNP NNS -NONE- VBD O
(30/32) (30/32) 0 0 0 1 0 0 0 1 7 0 NNP NNS -NONE- VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS -NONE- VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 -NONE- VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB VBN IN O
infected infected 0 0 0 0 0 0 0 0 8 0 TO VB VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VB VBN IN JJ NN O
hydatid hydatid 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NN IN O
cyst cyst 0 0 0 0 0 0 0 0 4 0 IN JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
either either 0 0 0 0 0 0 0 0 6 0 NN IN DT NNP NNP O
G3 G3 1 1 0 0 0 0 0 1 2 0 IN DT NNP NNP CC O
(53.1%) (53.1%) 0 0 0 0 0 0 0 1 7 0 DT NNP NNP CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NNP NNP CC NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNP NN O
(40.62%) (40.62%) 0 0 0 0 0 0 0 1 8 0 CC NNP NNP NN CC O
genotype genotype 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC CD DT O
one one 0 0 0 0 0 0 0 0 3 0 NN CC CD DT IN O
each each 0 0 0 0 0 0 0 0 4 0 CC CD DT IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD DT IN NNP JJ O
G5 G5 1 1 0 0 0 0 0 1 2 0 DT IN NNP JJ NN O
(cattle (cattle 0 0 0 0 0 0 0 0 7 0 IN NNP JJ NN CC O
strain) strain) 0 0 0 0 0 0 0 0 7 0 NNP JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
G6 G6 1 1 0 0 0 0 0 1 2 0 NN CC NNP NNP NNP O
(camel (camel 0 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
strain) strain) 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
genotype. genotype. 0 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
CONCLUSIONS/SIGNIFICANCE: CONCLUSIONS/SIGNIFICANCE: 1 1 0 1 0 0 0 0 25 0 NNP NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP DT O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNP NNS VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT JJ NN O
zoonotic zoonotic 0 0 0 0 0 0 0 0 8 0 VBP DT JJ NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN IN NNP NNP NNP O
(sheep (sheep 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP CC O
strain) strain) 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
G3 G3 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNP NNP O
(buffalo (buffalo 0 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP VBZ O
strain) strain) 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP VBZ IN O
genotypes genotypes 0 0 0 0 0 0 0 0 9 0 NNP NNP VBZ IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 VBZ IN NNP NN IN O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 IN NNP NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT JJ IN O
emerged emerged 0 0 0 0 0 0 0 0 7 0 IN DT JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 DT JJ IN JJ NNS O
predominant predominant 0 0 0 0 0 0 0 0 11 0 JJ IN JJ NNS VBG O
genotypes genotypes 0 0 0 0 0 0 0 0 9 0 IN JJ NNS VBG DT O
infecting infecting 0 0 0 0 0 0 0 0 9 0 JJ NNS VBG DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBG DT NNS IN O
humans humans 0 0 0 0 0 0 0 0 6 0 VBG DT NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 DT NNS IN NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNS IN NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NN TO O
addition addition 0 0 0 0 0 0 0 0 8 0 NNP NNP NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO NNP DT O
this, this, 0 0 0 0 1 0 0 0 5 0 NN TO NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NNP DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN NNS O
study study 0 0 0 0 0 0 0 0 5 0 DT NN NN NNS DT O
reports reports 0 0 0 0 0 0 0 0 7 0 NN NN NNS DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN NNS DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 NNS DT JJ NN NNP O
human human 0 0 0 0 0 0 0 0 5 0 DT JJ NN NNP NN O
CE CE 1 1 0 0 0 0 0 0 2 0 JJ NN NNP NN VBD O
case case 0 0 0 0 0 0 0 0 4 0 NN NNP NN VBD IN O
infected infected 0 0 0 0 0 0 0 0 8 0 NNP NN VBD IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP NN O
G5 G5 1 1 0 0 0 0 0 1 2 0 VBD IN NNP NN JJ O
genotype genotype 0 0 0 0 0 0 0 0 8 0 IN NNP NN JJ NN O
(cattle (cattle 0 0 0 0 0 0 0 0 7 0 NNP NN JJ NN IN O
strain) strain) 0 0 0 0 0 0 0 0 7 0 NN JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NN O
Asian Asian 1 0 0 0 0 0 0 0 5 0 IN DT JJ NN CC O
country country 0 0 0 0 0 0 0 0 7 0 DT JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NN O
G6 G6 1 1 0 0 0 0 0 1 2 0 NN IN NNP NN NNP O
genotype genotype 0 0 0 0 0 0 0 0 8 0 IN NNP NN NNP NNP O
(camel (camel 0 0 0 0 0 0 0 0 6 0 NNP NN NNP NNP IN O
strain) strain) 0 0 0 0 0 0 0 0 7 0 NN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
India. India. 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNS MD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NNS MD VB JJ O
have have 0 0 0 0 0 0 0 0 4 0 NNS MD VB JJ NNS O
important important 0 0 0 0 0 0 0 0 9 0 MD VB JJ NNS IN O
implications implications 0 0 0 0 0 0 0 0 12 0 VB JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
planning planning 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
control control 0 0 0 0 0 0 0 0 7 0 NN IN NN NNS IN O
strategies strategies 0 0 0 0 0 0 0 0 10 0 IN NN NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNP NONE O
hydatidosis. hydatidosis. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NONE NONE O
ERα, ERα, 1 0 0 0 1 0 0 0 4 0 NONE NONE NN NNP CC O
SKP2 SKP2 1 1 0 0 0 0 0 1 4 0 NONE NN NNP CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC -NONE- NN O
E2F-1 E2F-1 1 1 1 0 0 0 0 1 5 0 NNP CC -NONE- NN DT O
form form 0 0 0 0 0 0 0 0 4 0 CC -NONE- NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- NN DT NN NN O
feed feed 0 0 0 0 0 0 0 0 4 0 NN DT NN NN NN O
forward forward 0 0 0 0 0 0 0 0 7 0 DT NN NN NN VBG O
loop loop 0 0 0 0 0 0 0 0 4 0 NN NN NN VBG JJ O
driving driving 0 0 0 0 0 0 0 0 7 0 NN NN VBG JJ NN O
late late 0 0 0 0 0 0 0 0 4 0 NN VBG JJ NN NNS O
ERα ERα 1 0 0 0 0 0 0 0 3 0 VBG JJ NN NNS CC O
targets targets 0 0 0 0 0 0 0 0 7 0 JJ NN NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 NNS CC NNP NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 CC NNP NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP NN NN NNP NNP O
progression. progression. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Srinivasan Srinivasan 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Nawaz Nawaz 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Slingerland Slingerland 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
JM. JM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP CD O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP CD NNP O
1] 1] 0 0 0 0 0 0 0 1 2 0 NNP NNP CD NNP NNP O
Braman Braman 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Family Family 1 0 0 0 0 0 0 0 6 0 CD NNP NNP NNP NNP O
Breast Breast 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Miami Miami 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Sylvester Sylvester 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Comprehensive Comprehensive 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Miami, Miami, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
FL, FL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
USA USA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
[2] [2] 0 0 0 0 0 0 0 1 3 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Biochemistry Biochemistry 1 0 0 0 0 0 0 0 12 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Miami Miami 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Miller Miller 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Miami, Miami, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NNP O
FL, FL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNS O
Estrogen Estrogen 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNS NN O
triggers triggers 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS NN VBD O
transactivation transactivation 0 0 0 0 0 0 0 0 15 0 NNP NNS NN VBD VBN O
coupled coupled 0 0 0 0 0 0 0 0 7 0 NNS NN VBD VBN NN O
estrogen estrogen 0 0 0 0 0 0 0 0 8 0 NN VBD VBN NN : O
receptor receptor 0 0 0 0 0 0 0 0 8 0 VBD VBN NN : JJ O
α α 0 0 0 0 0 0 0 0 1 0 VBN NN : JJ NN O
(ERα) (ERα) 0 0 0 0 0 0 0 0 5 0 NN : JJ NN CC O
proteolysis, proteolysis, 0 0 0 0 1 0 0 0 12 0 : JJ NN CC NNS O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNS IN O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 NN CC NNS IN NN O
thereof thereof 0 0 0 0 0 0 0 0 7 0 CC NNS IN NN NNP O
remain remain 0 0 0 0 0 0 0 0 6 0 NNS IN NN NNP NNP O
obscure. obscure. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP NNS O
Present Present 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBP JJ O
link link 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP JJ NN O
estrogen:ERα-driven estrogen:ERα-driven 0 0 1 0 0 0 0 0 19 0 NNS VBP JJ NN IN O
transcription transcription 0 0 0 0 0 0 0 0 13 0 VBP JJ NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NNP NNP O
progression. progression. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP VBD O
Although Although 1 0 0 0 0 0 0 0 8 0 NN NNP NNP VBD NNP O
liganded liganded 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NNP NNS O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NNP VBD NNP NNS JJ O
induces induces 0 0 0 0 0 0 0 0 7 0 VBD NNP NNS JJ NNS O
many many 0 0 0 0 0 0 0 0 4 0 NNP NNS JJ NNS IN O
genes genes 0 0 0 0 0 0 0 0 5 0 NNS JJ NNS IN CD O
within within 0 0 0 0 0 0 0 0 6 0 JJ NNS IN CD JJ O
1-4 1-4 0 0 1 0 0 0 0 1 3 0 NNS IN CD JJ NN O
h, h, 0 0 0 0 1 0 0 0 2 0 IN CD JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 CD JJ NN NN IN O
activation activation 0 0 0 0 0 0 0 0 10 0 JJ NN NN IN CD O
after after 0 0 0 0 0 0 0 0 5 0 NN NN IN CD NN O
6 6 0 0 0 0 0 0 1 1 1 0 NN IN CD NN VBZ O
h h 0 0 0 0 0 0 0 0 1 0 IN CD NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 CD NN VBZ VBN TO O
thought thought 0 0 0 0 0 0 0 0 7 0 NN VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB NNP NNP O
indirect. indirect. 0 0 0 0 0 0 0 0 9 0 TO VB NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 VB NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP NNP O
identify identify 0 0 0 0 0 0 0 0 8 0 NNP PRP VBP NNP IN O
SKP2 SKP2 1 1 0 0 0 0 0 1 4 0 PRP VBP NNP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBP NNP IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT JJ NN O
late-acting late-acting 0 0 1 0 0 0 0 0 11 0 IN DT JJ NN WDT O
coactivator coactivator 0 0 0 0 0 0 0 0 11 0 DT JJ NN WDT VBZ O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT VBZ -NONE- O
drives drives 0 0 0 0 0 0 0 0 6 0 NN WDT VBZ -NONE- NNS O
ERα ERα 1 0 0 0 0 0 0 0 3 0 WDT VBZ -NONE- NNS TO O
targets targets 0 0 0 0 0 0 0 0 7 0 VBZ -NONE- NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- NNS TO VB JJ O
promote promote 0 0 0 0 0 0 0 0 7 0 NNS TO VB JJ NNP O
G1-to-S G1-to-S 1 0 1 0 0 0 0 1 7 0 TO VB JJ NNP NNP B_TIMEXCCP
progression. progression. 0 0 0 0 0 0 0 0 12 0 VB JJ NNP NNP NN O
Data Data 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN DT O
support support 0 0 0 0 0 0 0 0 7 0 NNP NNP NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NN DT NN IN O
model model 0 0 0 0 0 0 0 0 5 0 NN DT NN IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT JJ NN O
estrogen-activated estrogen-activated 0 0 1 0 0 0 0 0 18 0 IN WDT JJ NN -NONE- O
cyclin cyclin 0 0 0 0 0 0 0 0 6 0 WDT JJ NN -NONE- VBZ O
E-CDK2 E-CDK2 1 1 1 0 0 0 0 1 6 0 JJ NN -NONE- VBZ CC O
binds binds 0 0 0 0 0 0 0 0 5 0 NN -NONE- VBZ CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- VBZ CC NNS -NONE- O
phosphorylates phosphorylates 0 0 0 0 0 0 0 0 14 0 VBZ CC NNS -NONE- TO O
ERαS341, ERαS341, 1 0 0 0 1 0 0 1 8 0 CC NNS -NONE- TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS -NONE- TO VB -NONE- O
prime prime 0 0 0 0 0 0 0 0 5 0 -NONE- TO VB -NONE- VBG O
ERα-SCFSKP2 ERα-SCFSKP2 1 0 1 0 0 0 0 1 11 0 TO VB -NONE- VBG IN O
binding binding 0 0 0 0 0 0 0 0 7 0 VB -NONE- VBG IN -NONE- O
via via 0 0 0 0 0 0 0 0 3 0 -NONE- VBG IN -NONE- IN O
SKP2-L248QTLL252 SKP2-L248QTLL252 1 1 1 0 0 0 0 1 16 0 VBG IN -NONE- IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN -NONE- IN JJ NNP O
late late 0 0 0 0 0 0 0 0 4 0 -NONE- IN JJ NNP NNP G1
G1. G1. 1 1 0 0 0 0 0 1 3 0 IN JJ NNP NNP VBZ G1
SKP2 SKP2 1 1 0 0 0 0 0 1 4 0 JJ NNP NNP VBZ JJ O
activates activates 0 0 0 0 0 0 0 0 9 0 NNP NNP VBZ JJ NN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NNP VBZ JJ NN CC O
ubiquitylation ubiquitylation 0 0 0 0 0 0 0 0 14 0 VBZ JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
proteolysis. proteolysis. 0 0 0 0 0 0 0 0 12 0 NN CC NNP NNP RB O
Putative Putative 1 0 0 0 0 0 0 0 8 0 CC NNP NNP RB JJ O
late late 0 0 0 0 0 0 0 0 4 0 NNP NNP RB JJ NNS O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NNP RB JJ NNS VBD O
targets targets 0 0 0 0 0 0 0 0 7 0 RB JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN IN O
identified identified 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NNP O
expression expression 0 0 0 0 0 0 0 0 10 0 VBN IN NN NNP NNP O
profiling. profiling. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NN O
SKP2 SKP2 1 1 0 0 0 0 0 1 4 0 NN NNP NNP NN VBD O
knockdown knockdown 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD -NONE- O
attenuated attenuated 0 0 0 0 0 0 0 0 10 0 NNP NN VBD -NONE- CC O
E2F-1 E2F-1 1 1 1 0 0 0 0 1 5 0 NN VBD -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBD -NONE- CC NNP NNP O
BLM BLM 1 1 0 0 0 0 0 0 3 0 -NONE- CC NNP NNP NNP O
induction. induction. 0 0 0 0 0 0 0 0 10 0 CC NNP NNP NNP NNP O
SKP2 SKP2 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP NNP CC O
overexpression, overexpression, 0 0 0 0 1 0 0 0 15 0 NNP NNP NNP CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NNP NNP CC RB NN O
not not 0 0 0 0 0 0 0 0 3 0 NNP CC RB NN IN O
coactivator coactivator 0 0 0 0 0 0 0 0 11 0 CC RB NN IN JJ O
motif motif 0 0 0 0 0 0 0 0 5 0 RB NN IN JJ NN O
mutant mutant 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN VBD O
SKP2-L248QTAA252, SKP2-L248QTAA252, 1 1 1 0 1 0 0 1 17 0 IN JJ NN VBD JJ O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 JJ NN VBD JJ -NONE- O
estrogen-induced estrogen-induced 0 0 1 0 0 0 0 0 16 0 NN VBD JJ -NONE- CC O
E2F-1 E2F-1 1 1 1 0 0 0 0 1 5 0 VBD JJ -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ -NONE- CC NNP NNP O
BLM BLM 1 1 0 0 0 0 0 0 3 0 -NONE- CC NNP NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 CC NNP NNP NNP NN O
SKP2 SKP2 1 1 0 0 0 0 0 1 4 0 NNP NNP NNP NN VBD O
knockdown knockdown 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD JJ O
impaired impaired 0 0 0 0 0 0 0 0 8 0 NNP NN VBD JJ NN O
estrogen-stimulated estrogen-stimulated 0 0 1 0 0 0 0 0 19 0 NN VBD JJ NN NN O
ERα, ERα, 1 0 0 0 1 0 0 0 4 0 VBD JJ NN NN NNP O
SKP2, SKP2, 1 1 0 0 1 0 0 1 5 0 JJ NN NN NNP CC O
SRC3 SRC3 1 1 0 0 0 0 0 1 4 0 NN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NN O
RNA RNA 1 1 0 0 0 0 0 0 3 0 NNP CC NNP NN NNP O
polymerase polymerase 0 0 0 0 0 0 0 0 10 0 CC NNP NN NNP NN O
II II 1 1 0 0 0 0 0 0 2 0 NNP NN NNP NN TO O
recruitment recruitment 0 0 0 0 0 0 0 0 11 0 NN NNP NN TO -NONE- O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO -NONE- CC O
E2F-1 E2F-1 1 1 1 0 0 0 0 1 5 0 NN TO -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 TO -NONE- CC NNP NNP O
BLM BLM 1 1 0 0 0 0 0 0 3 0 -NONE- CC NNP NNP NNP O
promoters. promoters. 0 0 0 0 0 0 0 0 10 0 CC NNP NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN RB O
work work 0 0 0 0 0 0 0 0 4 0 NNP NNP NN RB RB O
not not 0 0 0 0 0 0 0 0 3 0 NNP NN RB RB VBZ O
only only 0 0 0 0 0 0 0 0 4 0 NN RB RB VBZ DT O
identifies identifies 0 0 0 0 0 0 0 0 10 0 RB RB VBZ DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 RB VBZ DT JJ NNS O
late-activated late-activated 0 0 1 0 0 0 0 0 14 0 VBZ DT JJ NNS IN O
genes genes 0 0 0 0 0 0 0 0 5 0 DT JJ NNS IN NN O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
bona bona 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN NN O
fide fide 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NNS O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN NN NN NNS CC O
targets targets 0 0 0 0 0 0 0 0 7 0 NN NN NNS CC VBZ O
but but 0 0 0 0 0 0 0 0 3 0 NN NNS CC VBZ DT O
describes describes 0 0 0 0 0 0 0 0 9 0 NNS CC VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC VBZ DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 VBZ DT NN NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT NN NN IN PRP$ O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 NN IN PRP$ JJ NNP O
periodic periodic 0 0 0 0 0 0 0 0 8 0 IN PRP$ JJ NNP NNP O
activation. activation. 0 0 0 0 0 0 0 0 11 0 PRP$ JJ NNP NNP VBZ O
SKP2 SKP2 1 1 0 0 0 0 0 1 4 0 JJ NNP NNP VBZ IN O
serves serves 0 0 0 0 0 0 0 0 6 0 NNP NNP VBZ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN JJ NN O
dual dual 0 0 0 0 0 0 0 0 4 0 VBZ IN JJ NN NNP O
ERα ERα 1 0 0 0 0 0 0 0 3 0 IN JJ NN NNP NNP O
E3 E3 1 1 0 0 0 0 0 1 2 0 JJ NN NNP NNP IN O
ligase/coactivator ligase/coactivator 0 0 0 1 0 0 0 0 18 0 NN NNP NNP IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN JJ NN O
late-activated late-activated 0 0 1 0 0 0 0 0 14 0 NNP IN JJ NN NN O
target target 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN VBG O
genes, genes, 0 0 0 0 1 0 0 0 6 0 JJ NN NN VBG DT O
revealing revealing 0 0 0 0 0 0 0 0 9 0 NN NN VBG DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBG DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 VBG DT NN NN NN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 DT NN NN NN -NONE- O
whereby whereby 0 0 0 0 0 0 0 0 7 0 NN NN NN -NONE- NN O
ERα/SCFSKP2 ERα/SCFSKP2 1 0 0 1 0 0 0 1 11 0 NN NN -NONE- NN IN O
transactivation transactivation 0 0 0 0 0 0 0 0 15 0 NN -NONE- NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- NN IN -NONE- VBZ O
E2F-1 E2F-1 1 1 1 0 0 0 0 1 5 0 NN IN -NONE- VBZ RB O
feeds feeds 0 0 0 0 0 0 0 0 5 0 IN -NONE- VBZ RB TO O
forward forward 0 0 0 0 0 0 0 0 7 0 -NONE- VBZ RB TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ RB TO VB JJ O
drive drive 0 0 0 0 0 0 0 0 5 0 RB TO VB JJ NN O
G1-to-S.Oncogene G1-to-S.Oncogene 1 0 1 0 0 0 0 1 16 0 TO VB JJ NN NN B_TIMEXCCP
advance advance 0 0 0 0 0 0 0 0 7 0 VB JJ NN NN NN O
online online 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN CD O
publication, publication, 0 0 0 0 1 0 0 0 12 0 NN NN NN CD NNP O
17 17 0 0 0 0 0 0 1 1 2 0 NN NN CD NNP CD O
June June 1 0 0 0 0 0 0 0 4 0 NN CD NNP CD NNP O
2013; 2013; 0 0 0 0 0 0 0 1 5 0 CD NNP CD NNP NONE O
doi:10.1038/onc.2013.197. doi:10.1038/onc.2013.197. 0 0 0 1 0 0 0 1 25 0 NNP CD NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN IN O
use use 0 0 0 0 0 0 0 0 3 0 NONE DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
granulocyte granulocyte 0 0 0 0 0 0 0 0 11 0 NN IN NN NN VBG O
colony colony 0 0 0 0 0 0 0 0 6 0 IN NN NN VBG NNP O
stimulating stimulating 0 0 0 0 0 0 0 0 11 0 NN NN VBG NNP NNP O
factoR factoR 0 0 0 0 0 0 0 0 6 0 NN VBG NNP NNP NNP O
(G-CSF) (G-CSF) 0 1 1 0 0 0 0 0 7 0 VBG NNP NNP NNP RB O
(filgrastim) (filgrastim) 0 0 0 0 0 0 0 0 12 0 NNP NNP NNP RB IN O
alone alone 0 0 0 0 0 0 0 0 5 0 NNP NNP RB IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN IN O
mobilization mobilization 0 0 0 0 0 0 0 0 12 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
stem stem 0 0 0 0 0 0 0 0 4 0 NN IN NN NN IN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
autologous autologous 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN NN O
stem stem 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNP NNP O
transplantation. transplantation. 0 0 0 0 0 0 0 0 16 0 NN NN NNP NNP NNP O
Talhi Talhi 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Osmani Osmani 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Brahimi Brahimi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yafour Yafour 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bouhass Bouhass 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Arabi Arabi 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Bekadja Bekadja 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
MA. MA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Hematology Hematology 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP CC NNP NNP NNP O
Therapy, Therapy, 1 0 0 0 1 0 0 0 8 0 CC NNP NNP NNP NNP O
Etablissement Etablissement 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NN O
Hospitalier Hospitalier 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NN NNP O
et et 0 0 0 0 0 0 0 0 2 0 NNP NNP NN NNP NNP O
Universitaire Universitaire 1 0 0 0 0 0 0 0 13 0 NNP NN NNP NNP CD O
(EHU) (EHU) 0 1 0 0 0 0 0 0 5 0 NN NNP NNP CD NNP O
1st 1st 0 0 0 0 0 0 0 1 3 0 NNP NNP CD NNP NNP O
November, November, 1 0 0 0 1 0 0 0 9 0 NNP CD NNP NNP NNP O
Oran, Oran, 1 0 0 0 1 0 0 0 5 0 CD NNP NNP NNP NNP O
Algeria. Algeria. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
23830594 23830594 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : IN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 JJ : IN JJ IN O
supplied supplied 0 0 0 0 0 0 0 0 8 0 : IN JJ IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN JJ IN JJ NONE O
publisher] publisher] 0 0 0 0 0 0 0 0 10 0 JJ IN JJ NONE NONE O
Henryin, Henryin, 1 0 0 0 1 0 0 0 8 0 NONE NONE NN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NONE NN DT JJ NN O
ent-kaurane ent-kaurane 0 0 1 0 0 0 0 0 11 0 NN DT JJ NN NNS O
Diterpenoid, Diterpenoid, 1 0 0 0 1 0 0 0 12 0 DT JJ NN NNS NNP O
Inhibits Inhibits 1 0 0 0 0 0 0 0 8 0 JJ NN NNS NNP NNP O
Wnt Wnt 1 0 0 0 0 0 0 0 3 0 NN NNS NNP NNP IN O
Signaling Signaling 1 0 0 0 0 0 0 0 9 0 NNS NNP NNP IN NNP O
through through 0 0 0 0 0 0 0 0 7 0 NNP NNP IN NNP IN O
Interference Interference 1 0 0 0 0 0 0 0 12 0 NNP IN NNP IN -NONE- O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN -NONE- NNP O
β-Catenin/TCF4 β-Catenin/TCF4 0 0 1 1 0 0 0 1 14 0 NNP IN -NONE- NNP IN O
Interaction Interaction 1 0 0 0 0 0 0 0 11 0 IN -NONE- NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 -NONE- NNP IN NNP NNP O
Colorectal Colorectal 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
Cells. Cells. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Pu Pu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jiang Jiang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Su Su 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kong Kong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Mao Mao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sun Sun 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Y. Y. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
State State 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Key Key 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Laboratory Laboratory 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Phytochemistry Phytochemistry 1 0 0 0 0 0 0 0 14 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNPS O
Plant Plant 1 0 0 0 0 0 0 0 5 0 NNP CC NNP NNPS IN O
Resources Resources 1 0 0 0 0 0 0 0 9 0 CC NNP NNPS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
West West 1 0 0 0 0 0 0 0 4 0 NNPS IN NNP NNP NNP O
China, China, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP NNP O
Kunming Kunming 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Botany, Botany, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP NNP O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Kunming, Kunming, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP : O
China China 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 NNP NNP : NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP : NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 IN DT NNP NNP IN O
Academy Academy 1 0 0 0 0 0 0 0 7 0 DT NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Beijing, Beijing, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Aberrant Aberrant 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBG O
Wnt/β-catenin Wnt/β-catenin 1 0 1 1 0 0 0 0 13 0 NNP NNP NNP VBG VBZ O
signaling signaling 0 0 0 0 0 0 0 0 9 0 NNP NNP VBG VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP VBG VBZ VBN RB O
been been 0 0 0 0 0 0 0 0 4 0 VBG VBZ VBN RB VBN O
strongly strongly 0 0 0 0 0 0 0 0 8 0 VBZ VBN RB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBN RB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
tumorigenesis tumorigenesis 0 0 0 0 0 0 0 0 13 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NNP O
colorectal colorectal 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 JJ JJ NNP NNP IN O
Inhibitors Inhibitors 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN MD O
pathway pathway 0 0 0 0 0 0 0 0 7 0 IN DT NN MD RB O
may may 0 0 0 0 0 0 0 0 3 0 DT NN MD RB VB O
then then 0 0 0 0 0 0 0 0 4 0 NN MD RB VB JJ O
offer offer 0 0 0 0 0 0 0 0 5 0 MD RB VB JJ NNS O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 RB VB JJ NNS IN O
strategies strategies 0 0 0 0 0 0 0 0 10 0 VB JJ NNS IN RB O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNS IN RB IN NN O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN NN IN O
chemoprevention chemoprevention 0 0 0 0 0 0 0 0 15 0 RB IN NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 IN NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN NNP O
malignant malignant 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP NNP O
disease. disease. 0 0 0 0 0 0 0 0 8 0 DT NN NNP NNP VBZ O
Henryin Henryin 1 0 0 0 0 0 0 0 7 0 NN NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT JJ NN O
ent-kaurane ent-kaurane 0 0 1 0 0 0 0 0 11 0 VBZ DT JJ NN VBD O
diterpenoid diterpenoid 0 0 0 0 0 0 0 0 11 0 DT JJ NN VBD IN O
isolated isolated 0 0 0 0 0 0 0 0 8 0 JJ NN VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNP NNP O
Isodonrubescens Isodonrubescens 1 0 0 0 0 0 0 0 15 0 VBD IN NNP NNP NNP O
var. var. 0 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP DT O
lushanensis, lushanensis, 0 0 0 0 1 0 0 0 12 0 NNP NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN RB O
plant plant 0 0 0 0 0 0 0 0 5 0 NNP DT NN RB VBN O
long long 0 0 0 0 0 0 0 0 4 0 DT NN RB VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN RB VBN VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 RB VBN VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NN NN O
folk folk 0 0 0 0 0 0 0 0 4 0 VBN IN NN NN TO O
medicine medicine 0 0 0 0 0 0 0 0 8 0 IN NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB NN O
prevent prevent 0 0 0 0 0 0 0 0 7 0 NN TO VB NN CC O
inflammation inflammation 0 0 0 0 0 0 0 0 12 0 TO VB NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VB NN CC JJ NNP O
gastrointestinal gastrointestinal 0 0 0 0 0 0 0 0 16 0 NN CC JJ NNP NNP O
disease. disease. 0 0 0 0 0 0 0 0 8 0 CC JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 DT NN NN PRP NN O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP NN WDT O
report report 0 0 0 0 0 0 0 0 6 0 NN PRP NN WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 PRP NN WDT NN RB O
henryin henryin 0 0 0 0 0 0 0 0 7 0 NN WDT NN RB VBZ O
selectively selectively 0 0 0 0 0 0 0 0 11 0 WDT NN RB VBZ DT O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 NN RB VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBZ DT NN IN O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBZ DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NN O
colorectal colorectal 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NNP NN O
GI50 GI50 1 1 0 0 0 0 0 1 4 0 IN DT NNP NN IN O
value value 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NNP O
nano-molar nano-molar 0 0 1 0 0 0 0 0 10 0 IN DT JJ NNP NNP O
range. range. 0 0 0 0 0 0 0 0 6 0 DT JJ NNP NNP NN O
Microarray Microarray 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP NN CC O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NNS O
reporter reporter 0 0 0 0 0 0 0 0 8 0 NN CC NN NNS VBD O
assays assays 0 0 0 0 0 0 0 0 6 0 CC NN NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NNS VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN VBD O
henryin henryin 0 0 0 0 0 0 0 0 7 0 VBD IN NN VBD IN O
worked worked 0 0 0 0 0 0 0 0 6 0 IN NN VBD IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN NN IN O
antagonist antagonist 0 0 0 0 0 0 0 0 10 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NN O
Wnt Wnt 1 0 0 0 0 0 0 0 3 0 NN IN NNP NN NNP O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN NNP NN NNP NNP O
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP VBD O
Henryin Henryin 1 0 0 0 0 0 0 0 7 0 NN NNP NNP VBD DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 NN IN NNP NNP CC O
D1 D1 1 1 0 0 0 0 0 1 2 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP CC O
C-myc, C-myc, 1 0 1 0 1 0 0 0 6 0 NNP CC NNP CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC VBD NNS O
induced induced 0 0 0 0 0 0 0 0 7 0 NNP CC VBD NNS NN O
G1/S G1/S 1 1 0 1 0 0 0 1 4 phase CC VBD NNS NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 arrest VBD NNS NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNS NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
HCT116 HCT116 1 1 0 0 0 0 0 1 6 0 NN IN NNP NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NN O
Concurrently, Concurrently, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NN VBD O
henryin henryin 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NNP NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VB DT O
affect affect 0 0 0 0 0 0 0 0 6 0 VBD RB VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT JJ NN O
cytosol-nuclear cytosol-nuclear 0 0 1 0 0 0 0 0 15 0 VB DT JJ NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
soluble soluble 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN CC O
β-catenin, β-catenin, 0 0 1 0 1 0 0 0 10 0 IN JJ NN CC VBD O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD DT O
impaired impaired 0 0 0 0 0 0 0 0 8 0 NN CC VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VBD DT NN IN O
association association 0 0 0 0 0 0 0 0 11 0 VBD DT NN IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN -NONE- JJ O
β-catenin/TCF4 β-catenin/TCF4 0 0 1 1 0 0 0 1 14 0 NN IN -NONE- JJ NN O
transcriptional transcriptional 0 0 0 0 0 0 0 0 15 0 IN -NONE- JJ NN JJ O
complex complex 0 0 0 0 0 0 0 0 7 0 -NONE- JJ NN JJ IN O
likely likely 0 0 0 0 0 0 0 0 6 0 JJ NN JJ IN RB O
through through 0 0 0 0 0 0 0 0 7 0 NN JJ IN RB VBG O
directly directly 0 0 0 0 0 0 0 0 8 0 JJ IN RB VBG DT O
blocking blocking 0 0 0 0 0 0 0 0 8 0 IN RB VBG DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 RB VBG DT VBG IN O
binding binding 0 0 0 0 0 0 0 0 7 0 VBG DT VBG IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT VBG IN JJ TO O
β-catenin β-catenin 0 0 1 0 0 0 0 0 9 0 VBG IN JJ TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 IN JJ TO NNP NNP O
TCF4. TCF4. 1 1 0 0 0 0 0 1 5 0 JJ TO NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 TO NNP NNP RB RB O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNP RB RB VBN O
then then 0 0 0 0 0 0 0 0 4 0 NNP RB RB VBN DT O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 RB RB VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT NN NN O
structure-activity structure-activity 0 0 1 0 0 0 0 0 18 0 VBN DT NN NN IN O
relationship relationship 0 0 0 0 0 0 0 0 12 0 DT NN NN IN DT O
among among 0 0 0 0 0 0 0 0 5 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
ent-kaurane ent-kaurane 0 0 1 0 0 0 0 0 11 0 IN DT JJ NN NNP O
type type 0 0 0 0 0 0 0 0 4 0 DT JJ NN NNP NNP O
diterpenoids. diterpenoids. 0 0 0 0 0 0 0 0 13 0 JJ NN NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBZ O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBZ IN O
suggests suggests 0 0 0 0 0 0 0 0 8 0 NNP NNS VBZ IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBZ IN JJ IN O
henryin, henryin, 0 0 0 0 1 0 0 0 8 0 VBZ IN JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN JJ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 IN DT NN NN IN O
inhibitor inhibitor 0 0 0 0 0 0 0 0 9 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
Wnt Wnt 1 0 0 0 0 0 0 0 3 0 NN IN NNP NNP MD O
signaling, signaling, 0 0 0 0 1 0 0 0 10 0 IN NNP NNP MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NNP MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NNP MD VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 VB DT JJ NN IN O
candidate candidate 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ JJ O
further further 0 0 0 0 0 0 0 0 7 0 NN IN JJ JJ NN O
preclinical preclinical 0 0 0 0 0 0 0 0 11 0 IN JJ JJ NN IN O
evaluation evaluation 0 0 0 0 0 0 0 0 10 0 JJ JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NN O
colon colon 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN NN NN NN CC O
treatment, treatment, 0 0 0 0 1 0 0 0 10 0 NN NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 NN CC IN JJ NNS O
such such 0 0 0 0 0 0 0 0 4 0 CC IN JJ NNS RBR O
warrants warrants 0 0 0 0 0 0 0 0 8 0 IN JJ NNS RBR NNP O
further further 0 0 0 0 0 0 0 0 7 0 JJ NNS RBR NNP NONE O
exploration. exploration. 0 0 0 0 0 0 0 0 12 0 NNS RBR NNP NONE NONE O
Overexpression Overexpression 1 0 0 0 0 0 0 0 14 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NNS O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN IN NNP NNS NN O
inhibits inhibits 0 0 0 0 0 0 0 0 8 0 IN NNP NNS NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 NNP NNS NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNS NN CC NN IN O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP JJ O
MKN28 MKN28 1 1 0 0 0 0 0 1 5 0 NN IN NNP JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 IN NNP JJ NN NNS O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBG NNP O
suppressing suppressing 0 0 0 0 0 0 0 0 11 0 NNS IN VBG NNP NNP O
β-catenin. β-catenin. 0 0 1 0 0 0 0 0 10 0 IN VBG NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 VBG NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Teng Teng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
R, R, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Guo Guo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xu Xu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xie Xie 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shen Shen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
L. L. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Surgical Surgical 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Oncology, Oncology, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Sir Sir 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Run Run 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Run Run 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Shaw Shaw 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Zhejiang Zhejiang 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Hangzhou, Hangzhou, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP CD O
Zhejiang Zhejiang 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CD NNP O
310016, 310016, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
P.R. P.R. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
relationship relationship 0 0 0 0 0 0 0 0 12 0 NNP NNP NN IN NN O
between between 0 0 0 0 0 0 0 0 7 0 NNP NN IN NN NN O
estrogen estrogen 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NN O
receptor receptor 0 0 0 0 0 0 0 0 8 0 IN NN NN NN CC O
(ER)α (ER)α 0 0 0 0 0 0 0 0 5 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
patient patient 0 0 0 0 0 0 0 0 7 0 NN CC NN NN VBZ O
prognosis prognosis 0 0 0 0 0 0 0 0 9 0 CC NN NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
identified identified 0 0 0 0 0 0 0 0 10 0 VBZ VBN VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NN NN O
cancer; cancer; 0 0 0 0 0 0 0 0 7 0 IN JJ NN NN DT O
however, however, 0 0 0 0 1 0 0 0 8 0 JJ NN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NN NN O
definite definite 0 0 0 0 0 0 0 0 8 0 NN DT NN NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NNP IN JJ NN VBZ O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN VBZ TO O
remains remains 0 0 0 0 0 0 0 0 7 0 JJ NN VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO VB RB O
be be 0 0 0 0 0 0 0 0 2 0 VBZ TO VB RB NNP O
fully fully 0 0 0 0 0 0 0 0 5 0 TO VB RB NNP NNP O
elucidated. elucidated. 0 0 0 0 0 0 0 0 11 0 VB RB NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 RB NNP NNP NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
present present 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
vitro vitro 0 0 0 0 0 0 0 0 5 0 NN IN NN NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN NN NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBD TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
impact impact 0 0 0 0 0 0 0 0 6 0 VB DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ IN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN IN JJ IN NN O
on on 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ IN NN NN NN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 IN NN NN NN CC O
migration migration 0 0 0 0 0 0 0 0 9 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN CC NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NNP NNP O
lines. lines. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT JJ NN O
biological biological 0 0 0 0 0 0 0 0 10 0 VBD DT JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN IN NNP NN IN O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 IN NNP NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNP O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
An An 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP JJ O
MKN28 MKN28 1 1 0 0 0 0 0 1 5 0 NNP NNP NNP JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN RB O
line line 0 0 0 0 0 0 0 0 4 0 NN NN NN RB VBG O
stably stably 0 0 0 0 0 0 0 0 6 0 NN NN RB VBG NN O
overexpressing overexpressing 0 0 0 0 0 0 0 0 14 0 NN RB VBG NN VBD O
ERα ERα 1 0 0 0 0 0 0 0 3 0 RB VBG NN VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 VBG NN VBD NNP NNP O
established. established. 0 0 0 0 0 0 0 0 12 0 NN VBD NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN IN NNP NN IN O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 IN NNP NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN VBD O
growth growth 0 0 0 0 0 0 0 0 6 0 IN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NN O
evaluating evaluating 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN NN NN NN NN O
survival, survival, 0 0 0 0 1 0 0 0 9 0 NN NN NN NN NN O
colony colony 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
formation, formation, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NN CC O
migration migration 0 0 0 0 0 0 0 0 9 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN VBD O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN CC NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC NN VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
Transwell Transwell 1 0 0 0 0 0 0 0 9 0 VBN IN NNP NNP NNP O
migration/invasion migration/invasion 0 0 0 1 0 0 0 0 18 0 IN NNP NNP NNP NNP O
assays. assays. 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 NNP NN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ RB O
several several 0 0 0 0 0 0 0 0 7 0 NNS IN JJ RB VBN O
potentially potentially 0 0 0 0 0 0 0 0 11 0 IN JJ RB VBN NNS O
involved involved 0 0 0 0 0 0 0 0 8 0 JJ RB VBN NNS VBD O
genes genes 0 0 0 0 0 0 0 0 5 0 RB VBN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 VBN NNS VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
western western 0 0 0 0 0 0 0 0 7 0 VBN IN JJ NN TO O
blotting blotting 0 0 0 0 0 0 0 0 8 0 IN JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB DT O
elucidate elucidate 0 0 0 0 0 0 0 0 9 0 NN TO VB DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT VBG JJ O
underlying underlying 0 0 0 0 0 0 0 0 10 0 VB DT VBG JJ NNP O
molecular molecular 0 0 0 0 0 0 0 0 9 0 DT VBG JJ NNP NNP O
mechanisms. mechanisms. 0 0 0 0 0 0 0 0 11 0 VBG JJ NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP NNP O
Student's Student's 1 0 0 0 0 1 0 0 9 0 NNP NNP NNP NNP VBD O
t-test t-test 0 0 1 0 0 0 0 0 6 0 NNP NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NNP VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
determine determine 0 0 0 0 0 0 0 0 9 0 VBN TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NNS O
statistical statistical 0 0 0 0 0 0 0 0 11 0 VB DT JJ NNS IN O
differences differences 0 0 0 0 0 0 0 0 11 0 DT JJ NNS IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN JJ NN O
various various 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NN CC O
experimental experimental 0 0 0 0 0 0 0 0 12 0 IN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
control control 0 0 0 0 0 0 0 0 7 0 NN CC NN NN CC O
groups, groups, 0 0 0 0 1 0 0 0 7 0 CC NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
one-way one-way 0 0 1 0 0 0 0 0 7 0 NN CC JJ NNP NN O
ANOVA ANOVA 1 1 0 0 0 0 0 0 5 0 CC JJ NNP NN VBD O
test test 0 0 0 0 0 0 0 0 4 0 JJ NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
determine determine 0 0 0 0 0 0 0 0 9 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
difference difference 0 0 0 0 0 0 0 0 10 0 VB DT NN IN CD O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN CD CC O
three three 0 0 0 0 0 0 0 0 5 0 NN IN CD CC JJR O
or or 0 0 0 0 0 0 0 0 2 0 IN CD CC JJR NNP O
more more 0 0 0 0 0 0 0 0 4 0 CD CC JJR NNP NNP O
groups. groups. 0 0 0 0 0 0 0 0 7 0 CC JJR NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 JJR NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNS VBD IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN -NONE- NN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 VBD IN -NONE- NN RB O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 IN -NONE- NN RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 -NONE- NN RB VBN NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NN RB VBN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 RB VBN NN NN CC O
growth growth 0 0 0 0 0 0 0 0 6 0 VBN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP VBD O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 NN CC NNP VBD NN O
blocked blocked 0 0 0 0 0 0 0 0 7 0 CC NNP VBD NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NN IN O
entry entry 0 0 0 0 0 0 0 0 5 0 VBD NN NN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
G1/G0 G1/G0 1 1 0 1 0 0 0 1 5 phase IN DT JJ NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT JJ NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC VBD NN O
promoted promoted 0 0 0 0 0 0 0 0 8 0 NN CC VBD NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 CC VBD NN NNP NNP O
apoptosis. apoptosis. 0 0 0 0 0 0 0 0 10 0 VBD NN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NNP NNP O
addition, addition, 0 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP VBD O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP VBD DT O
reduced reduced 0 0 0 0 0 0 0 0 7 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN CC O
motility motility 0 0 0 0 0 0 0 0 8 0 VBD DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNS MD O
phenotypes phenotypes 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS MD RB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NNS MD RB VB O
partly partly 0 0 0 0 0 0 0 0 6 0 NNS MD RB VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 MD RB VB VBN IN O
explained explained 0 0 0 0 0 0 0 0 9 0 RB VB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
β-catenin β-catenin 0 0 1 0 0 0 0 0 9 0 NN IN JJ NN VBD O
expression expression 0 0 0 0 0 0 0 0 10 0 IN JJ NN VBD IN O
caused caused 0 0 0 0 0 0 0 0 6 0 JJ NN VBD IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NN NNP O
ERα ERα 1 0 0 0 0 0 0 0 3 0 VBD IN NN NNP NNP O
overexpression. overexpression. 0 0 0 0 0 0 0 0 15 0 IN NN NNP NNP NN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN RB O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 NNP NNP NN RB VBN O
effectively effectively 0 0 0 0 0 0 0 0 11 0 NNP NN RB VBN NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NN RB VBN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 RB VBN NN NN CC O
growth growth 0 0 0 0 0 0 0 0 6 0 VBN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN CC NN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 CC NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN JJ O
suppressing suppressing 0 0 0 0 0 0 0 0 11 0 NN IN NN JJ IN O
β-catenin β-catenin 0 0 1 0 0 0 0 0 9 0 IN NN JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN JJ IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN VBG O
cancer, cancer, 0 0 0 0 1 0 0 0 7 0 IN JJ NN VBG NN O
identifying identifying 0 0 0 0 0 0 0 0 11 0 JJ NN VBG NN IN O
ERα ERα 1 0 0 0 0 0 0 0 3 0 NN VBG NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBG NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NN O
promising promising 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN O
target target 0 0 0 0 0 0 0 0 6 0 DT NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ JJ O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 NN IN JJ JJ IN O
potential potential 0 0 0 0 0 0 0 0 9 0 IN JJ JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ JJ IN NN IN O
development development 0 0 0 0 0 0 0 0 11 0 JJ IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
new new 0 0 0 0 0 0 0 0 3 0 NN IN JJ NNS TO O
approaches approaches 0 0 0 0 0 0 0 0 10 0 IN JJ NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NNS TO VB JJ O
treat treat 0 0 0 0 0 0 0 0 5 0 NNS TO VB JJ NNP O
gastric gastric 0 0 0 0 0 0 0 0 7 0 TO VB JJ NNP NONE O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 VB JJ NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NN O
optimum optimum 0 0 0 0 0 0 0 0 7 0 NONE DT NN NN NN O
cut-off cut-off 0 0 1 0 0 0 0 0 7 0 DT NN NN NN TO O
value value 0 0 0 0 0 0 0 0 5 0 NN NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB NNP O
differentiate differentiate 0 0 0 0 0 0 0 0 13 0 NN TO VB NNP NN O
Echinococcus Echinococcus 1 0 0 0 0 0 0 0 12 0 TO VB NNP NN NN O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 VB NNP NN NN NN O
sensu sensu 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN IN O
stricto stricto 0 0 0 0 0 0 0 0 7 0 NN NN NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNS IN O
species species 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 NNS IN NNP NN NN O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 IN NNP NN NN NN O
sensu sensu 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN VBG O
lato lato 0 0 0 0 0 0 0 0 4 0 NN NN NN VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 NN NN VBG NN NN O
larval larval 0 0 0 0 0 0 0 0 6 0 NN VBG NN NN NN O
rostellar rostellar 0 0 0 0 0 0 0 0 9 0 VBG NN NN NN NNP O
hook hook 0 0 0 0 0 0 0 0 4 0 NN NN NN NNP NNP O
morphometry. morphometry. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP NNP O
Soriano Soriano 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
SV, SV, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Pierangeli Pierangeli 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
NB, NB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Pianciola Pianciola 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
LA, LA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Mazzeo Mazzeo 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lazzarini Lazzarini 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
LE, LE, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Debiaggi Debiaggi 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
MF, MF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Bergagna Bergagna 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
HF, HF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Basualdo Basualdo 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
JA. JA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CC O
Microbiology Microbiology 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Parasitology Parasitology 1 0 0 0 0 0 0 0 12 0 NNP CC NNP NNP NNP O
Department, Department, 1 0 0 0 1 0 0 0 11 0 CC NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Comahue Comahue 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Buenos Buenos 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CD O
Aires Aires 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD -NONE- O
1400, 1400, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD -NONE- JJ O
(8300) (8300) 0 0 0 0 0 0 0 1 6 0 NNP CD -NONE- JJ NNP O
Neuquén, Neuquén, 1 0 0 0 1 0 0 0 8 0 CD -NONE- JJ NNP NNP O
Argentina. Argentina. 1 0 0 0 0 0 0 0 10 0 -NONE- JJ NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NN O
Cystic Cystic 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NN VBD O
echinococcosis echinococcosis 0 0 0 0 0 0 0 0 14 0 NNP NNP NN VBD IN O
caused caused 0 0 0 0 0 0 0 0 6 0 NNP NN VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP CC O
Echinococcus Echinococcus 1 0 0 0 0 0 0 0 12 0 VBD IN NNP CC NN O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 IN NNP CC NN IN O
sensu sensu 0 0 0 0 0 0 0 0 5 0 NNP CC NN IN VBZ O
lato lato 0 0 0 0 0 0 0 0 4 0 CC NN IN VBZ CD O
is is 0 0 0 0 0 0 0 0 2 0 NN IN VBZ CD IN O
one one 0 0 0 0 0 0 0 0 3 0 IN VBZ CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBZ CD IN DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 IN DT RBS JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 DT RBS JJ NN NNS O
helminth helminth 0 0 0 0 0 0 0 0 8 0 RBS JJ NN NNS IN O
zoonoses zoonoses 0 0 0 0 0 0 0 0 8 0 JJ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN PRP O
world; world; 0 0 0 0 0 0 0 0 6 0 IN DT NN PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 DT NN PRP VBZ DT O
affects affects 0 0 0 0 0 0 0 0 7 0 NN PRP VBZ DT NNS O
both both 0 0 0 0 0 0 0 0 4 0 PRP VBZ DT NNS CC O
humans humans 0 0 0 0 0 0 0 0 6 0 VBZ DT NNS CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC NNP NNP O
livestock. livestock. 0 0 0 0 0 0 0 0 10 0 NNS CC NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 CC NNP NNP NN VBZ O
disease disease 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ JJ IN O
endemic endemic 0 0 0 0 0 0 0 0 7 0 NN VBZ JJ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN NNP CC O
Argentina Argentina 1 0 0 0 0 0 0 0 9 0 JJ IN NNP CC RB O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC RB JJ O
highly highly 0 0 0 0 0 0 0 0 6 0 NNP CC RB JJ IN O
endemic endemic 0 0 0 0 0 0 0 0 7 0 CC RB JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
province province 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
Neuquén. Neuquén. 1 0 0 0 0 0 0 0 8 0 NN IN NNP NNP JJ O
Considerable Considerable 1 0 0 0 0 0 0 0 12 0 IN NNP NNP JJ CC O
genetic genetic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP JJ CC JJ NN O
phenotypic phenotypic 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NN VBZ O
variation variation 0 0 0 0 0 0 0 0 9 0 CC JJ NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 VBZ VBN VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NNP NNP O
E. E. 1 1 0 0 0 0 0 0 2 0 VBN IN NNP NNP CC O
granulosus, granulosus, 0 0 0 0 1 0 0 0 11 0 IN NNP NNP CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC CD JJ O
ten ten 0 0 0 0 0 0 0 0 3 0 NNP CC CD JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 CC CD JJ NNS -NONE- O
genotypes genotypes 0 0 0 0 0 0 0 0 9 0 CD JJ NNS -NONE- VBP O
(G1-G10) (G1-G10) 0 1 1 0 0 0 0 1 8 0 JJ NNS -NONE- VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNS -NONE- VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 -NONE- VBP VBN VBN VBG O
identified identified 0 0 0 0 0 0 0 0 10 0 VBP VBN VBN VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 VBN VBN VBG JJ NNP O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VBN VBG JJ NNP NNP O
tools. tools. 0 0 0 0 0 0 0 0 6 0 VBG JJ NNP NNP VBZ O
Echinococcus Echinococcus 1 0 0 0 0 0 0 0 12 0 JJ NNP NNP VBZ NN O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ NN IN O
sensu sensu 0 0 0 0 0 0 0 0 5 0 NNP VBZ NN IN MD O
lato lato 0 0 0 0 0 0 0 0 4 0 VBZ NN IN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN IN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 IN MD VB VBN DT O
considered considered 0 0 0 0 0 0 0 0 10 0 MD VB VBN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VB VBN DT NN NN O
species species 0 0 0 0 0 0 0 0 7 0 VBN DT NN NN VBD O
complex, complex, 0 0 0 0 1 0 0 0 8 0 DT NN NN VBD IN O
comprised comprised 0 0 0 0 0 0 0 0 9 0 NN NN VBD IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 VBD IN NNP NN NN O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 IN NNP NN NN NN O
sensu sensu 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN NN O
stricto stricto 0 0 0 0 0 0 0 0 7 0 NN NN NN NN NNP O
(G1-G3), (G1-G3), 0 1 1 0 1 0 0 1 8 0 NN NN NN NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 NN NN NNP NN -NONE- O
equinus equinus 0 0 0 0 0 0 0 0 7 0 NN NNP NN -NONE- NNP O
(G4), (G4), 0 1 0 0 1 0 0 1 5 0 NNP NN -NONE- NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 NN -NONE- NNP NN -NONE- O
ortleppi ortleppi 0 0 0 0 0 0 0 0 8 0 -NONE- NNP NN -NONE- CC O
(G5) (G5) 0 1 0 0 0 0 0 1 4 0 NNP NN -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 -NONE- CC NNP NN NNP O
canadensis canadensis 0 0 0 0 0 0 0 0 10 0 CC NNP NN NNP NNP O
(G6-G10). (G6-G10). 0 1 1 0 0 0 0 1 9 0 NNP NN NNP NNP JJ O
In In 1 0 0 0 0 0 0 0 2 0 NN NNP NNP JJ NN O
endemic endemic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN DT O
areas, areas, 0 0 0 0 1 0 0 0 6 0 NNP JJ NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NN IN O
characterization characterization 0 0 0 0 0 0 0 0 16 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
cystic cystic 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NN O
echinococcosis echinococcosis 0 0 0 0 0 0 0 0 14 0 IN JJ NN NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN VBZ O
epidemiology epidemiology 0 0 0 0 0 0 0 0 12 0 NN NN NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ JJ IN O
important important 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN NN TO O
order order 0 0 0 0 0 0 0 0 5 0 JJ IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB JJ O
apply apply 0 0 0 0 0 0 0 0 5 0 NN TO VB JJ NN O
adequate adequate 0 0 0 0 0 0 0 0 8 0 TO VB JJ NN NNP O
control control 0 0 0 0 0 0 0 0 7 0 VB JJ NN NNP DT O
strategies. strategies. 0 0 0 0 0 0 0 0 11 0 JJ NN NNP DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT JJ NN O
cut-off cut-off 0 0 1 0 0 0 0 0 7 0 NNP DT JJ NN IN O
value value 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN JJ O
larval larval 0 0 0 0 0 0 0 0 6 0 NN IN NN JJ NN O
large large 0 0 0 0 0 0 0 0 5 0 IN NN JJ NN NN O
hook hook 0 0 0 0 0 0 0 0 4 0 NN JJ NN NN NN O
total total 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN TO O
length length 0 0 0 0 0 0 0 0 6 0 NN NN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VB NNP O
distinguish distinguish 0 0 0 0 0 0 0 0 11 0 NN TO VB NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 TO VB NNP NN NN O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 VB NNP NN NN NN O
sensu sensu 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN VBZ O
stricto stricto 0 0 0 0 0 0 0 0 7 0 NN NN NN VBZ IN O
isolates isolates 0 0 0 0 0 0 0 0 8 0 NN NN VBZ IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN VBZ IN DT VBN O
those those 0 0 0 0 0 0 0 0 5 0 VBZ IN DT VBN IN O
produced produced 0 0 0 0 0 0 0 0 8 0 IN DT VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 DT VBN IN JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NNS IN O
species species 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ VBD O
complex complex 0 0 0 0 0 0 0 0 7 0 IN DT JJ VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 DT JJ VBD VBN IN O
defined defined 0 0 0 0 0 0 0 0 7 0 JJ VBD VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NNP NNP O
time. time. 0 0 0 0 0 0 0 0 5 0 DT JJ NNP NNP CD O
Overall, Overall, 1 0 0 0 1 0 0 0 8 0 JJ NNP NNP CD NN O
1780 1780 0 0 0 0 0 0 1 1 4 0 NNP NNP CD NN NNS O
larval larval 0 0 0 0 0 0 0 0 6 0 NNP CD NN NNS IN O
hooks hooks 0 0 0 0 0 0 0 0 5 0 CD NN NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN CD NNS O
36 36 0 0 0 0 0 0 1 1 2 0 NNS IN CD NNS VBD O
isolates isolates 0 0 0 0 0 0 0 0 8 0 IN CD NNS VBD IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 CD NNS VBD IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN NN O
sheep sheep 0 0 0 0 0 0 0 0 5 0 VBD IN NN NN CD O
(n= (n= 0 0 0 0 0 0 0 0 3 0 IN NN NN CD NN O
11, 11, 0 0 0 0 1 0 0 1 3 0 NN NN CD NN NNS O
G1), G1), 1 1 0 0 1 0 0 1 4 0 NN CD NN NNS -NONE- O
goats goats 0 0 0 0 0 0 0 0 5 0 CD NN NNS -NONE- CD O
(n= (n= 0 0 0 0 0 0 0 0 3 0 NN NNS -NONE- CD -NONE- O
10, 10, 0 0 0 0 1 0 0 1 3 0 NNS -NONE- CD -NONE- JJ O
G6), G6), 1 1 0 0 1 0 0 1 4 0 -NONE- CD -NONE- JJ NN O
cattle cattle 0 0 0 0 0 0 0 0 6 0 CD -NONE- JJ NN CD O
(n= (n= 0 0 0 0 0 0 0 0 3 0 -NONE- JJ NN CD NN O
5, 5, 0 0 0 0 1 0 0 1 2 0 JJ NN CD NN CC O
G6) G6) 1 1 0 0 0 0 0 1 3 0 NN CD NN CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC NNS -NONE- O
pigs pigs 0 0 0 0 0 0 0 0 4 0 NN CC NNS -NONE- CD O
(n= (n= 0 0 0 0 0 0 0 0 3 0 CC NNS -NONE- CD -NONE- O
10, 10, 0 0 0 0 1 0 0 1 3 0 NNS -NONE- CD -NONE- VBD O
G7) G7) 1 1 0 0 0 0 0 1 3 0 -NONE- CD -NONE- VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 CD -NONE- VBD NNP NNP O
analysed. analysed. 0 0 0 0 0 0 0 0 9 0 -NONE- VBD NNP NNP IN O
Validation Validation 1 0 0 0 0 0 0 0 10 0 VBD NNP NNP IN JJ O
against against 0 0 0 0 0 0 0 0 7 0 NNP NNP IN JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNP IN JJ NN IN O
genotyping genotyping 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN NN O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
gold gold 0 0 0 0 0 0 0 0 4 0 NN IN NN NN VBD O
standard standard 0 0 0 0 0 0 0 0 8 0 IN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN RP O
carried carried 0 0 0 0 0 0 0 0 7 0 NN VBD VBN RP VBG O
out out 0 0 0 0 0 0 0 0 3 0 VBD VBN RP VBG DT O
using using 0 0 0 0 0 0 0 0 5 0 VBN RP VBG DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RP VBG DT NN NN O
receiver receiver 0 0 0 0 0 0 0 0 8 0 VBG DT NN NN JJ O
operating operating 0 0 0 0 0 0 0 0 9 0 DT NN NN JJ NN O
characteristic characteristic 0 0 0 0 0 0 0 0 14 0 NN NN JJ NN NN O
(ROC) (ROC) 0 1 0 0 0 0 0 0 5 0 NN JJ NN NN NNP O
curve curve 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN -NONE- O
optimum optimum 0 0 0 0 0 0 0 0 7 0 NNP NNP NN -NONE- NN O
cut-off cut-off 0 0 1 0 0 0 0 0 7 0 NNP NN -NONE- NN VBD O
value value 0 0 0 0 0 0 0 0 5 0 NN -NONE- NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 -NONE- NN VBD VBN IN O
defined defined 0 0 0 0 0 0 0 0 7 0 NN VBD VBN IN CD O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN CD NNP O
26.5 26.5 0 0 0 0 0 0 0 1 4 0 VBN IN CD NNP NNP O
μm. μm. 0 0 0 0 0 0 0 0 3 0 IN CD NNP NNP VBD O
The The 1 0 0 0 0 0 0 0 3 0 CD NNP NNP VBD NN O
proposed proposed 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NN VBD O
method method 0 0 0 0 0 0 0 0 6 0 NNP VBD NN VBD JJ O
showed showed 0 0 0 0 0 0 0 0 6 0 VBD NN VBD JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NN VBD JJ NN NN O
sensitivity sensitivity 0 0 0 0 0 0 0 0 11 0 VBD JJ NN NN CC O
(97.8%) (97.8%) 0 0 0 0 0 0 0 1 7 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
specificity specificity 0 0 0 0 0 0 0 0 11 0 NN CC NN NNP NNP O
(91.1%). (91.1%). 0 0 0 0 0 0 0 1 8 0 CC NN NNP NNP IN O
Since Since 1 0 0 0 0 0 0 0 5 0 NN NNP NNP IN JJS O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 NNP IN JJS JJ NNS O
endemic endemic 0 0 0 0 0 0 0 0 7 0 IN JJS JJ NNS DT O
regions regions 0 0 0 0 0 0 0 0 7 0 JJS JJ NNS DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ NNS DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNS DT JJ NN IN O
epidemiology epidemiology 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN VBZ O
echinococcosis echinococcosis 0 0 0 0 0 0 0 0 14 0 NN IN NN VBZ DT O
includes includes 0 0 0 0 0 0 0 0 8 0 IN NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN IN O
coexistence coexistence 0 0 0 0 0 0 0 0 11 0 VBZ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT RB O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT RB VBN O
widely widely 0 0 0 0 0 0 0 0 6 0 IN DT RB VBN NNP O
distributed distributed 0 0 0 0 0 0 0 0 11 0 DT RB VBN NNP NN O
E. E. 1 1 0 0 0 0 0 0 2 0 RB VBN NNP NN NN O
granulosus granulosus 0 0 0 0 0 0 0 0 10 0 VBN NNP NN NN NN O
sensu sensu 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN NNP O
stricto stricto 0 0 0 0 0 0 0 0 7 0 NN NN NN NNP NN O
G1 G1 1 1 0 0 0 0 0 1 2 0 NN NN NNP NN CC O
strain strain 0 0 0 0 0 0 0 0 6 0 NN NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 NN CC JJ NNS IN O
species species 0 0 0 0 0 0 0 0 7 0 CC JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ DT O
complex, complex, 0 0 0 0 1 0 0 0 8 0 IN DT JJ DT NN O
this this 0 0 0 0 0 0 0 0 4 0 DT JJ DT NN MD O
technique technique 0 0 0 0 0 0 0 0 9 0 JJ DT NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 DT NN MD VB JJ O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 MD VB JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VB JJ IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT NN CC O
quick quick 0 0 0 0 0 0 0 0 5 0 IN DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NN O
economical economical 0 0 0 0 0 0 0 0 10 0 NN CC JJ NN IN O
tool tool 0 0 0 0 0 0 0 0 4 0 CC JJ NN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN JJ CC O
epidemiological epidemiological 0 0 0 0 0 0 0 0 15 0 NN IN JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN NN O
surveillance surveillance 0 0 0 0 0 0 0 0 12 0 JJ CC NN NN NN O
field field 0 0 0 0 0 0 0 0 5 0 CC NN NN NN WRB O
studies, studies, 0 0 0 0 1 0 0 0 8 0 NN NN NN WRB JJ O
when when 0 0 0 0 0 0 0 0 4 0 NN NN WRB JJ NNS O
fertile fertile 0 0 0 0 0 0 0 0 7 0 NN WRB JJ NNS VBP O
cysts cysts 0 0 0 0 0 0 0 0 5 0 WRB JJ NNS VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP NNP NONE O
present. present. 0 0 0 0 0 0 0 0 8 0 NNS VBP NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NNP NNP O
Functional Functional 1 0 0 0 0 0 0 0 10 0 NONE DT NNP NNP IN O
Significance Significance 1 0 0 0 0 0 0 0 12 0 DT NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
MicroRNA-29c MicroRNA-29c 1 0 1 0 0 0 0 1 12 0 NNP IN NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP IN O
Patients Patients 1 0 0 0 0 0 0 0 8 0 NNP IN NNP IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN NNP NNP O
Colorectal Colorectal 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Cancer: Cancer: 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NNP NNP O
Potential Potential 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Circulating Circulating 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP IN O
Biomarker Biomarker 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP NNP O
Predicting Predicting 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Early Early 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
Relapse. Relapse. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
IP, IP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Tsai Tsai 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
HL, HL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
CW, CW, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
MY, MY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hou Hou 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
MF, MF, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Juo Juo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
SH, SH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
JY. JY. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Genetics, Genetics, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
College College 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Kaohsiung Kaohsiung 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Kaohsiung, Kaohsiung, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP : O
Taiwan Taiwan 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 NNP NNP : NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP : NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN NNP NNP O
Nursing, Nursing, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Shu-Zen Shu-Zen 1 0 1 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Junior Junior 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
College College 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Medicine Medicine 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Management, Management, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Kaohsiung, Kaohsiung, 1 0 0 0 1 0 0 0 10 0 CC NNP NNP NNP NNP O
Taiwan. Taiwan. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
recurrence recurrence 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
colorectal colorectal 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN VBZ O
(CRC) (CRC) 0 1 0 0 0 0 0 0 5 0 JJ NN NN VBZ NN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ NN IN O
frequent frequent 0 0 0 0 0 0 0 0 8 0 NN VBZ NN IN DT O
within within 0 0 0 0 0 0 0 0 6 0 VBZ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
year year 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
curative curative 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NN O
resection resection 0 0 0 0 0 0 0 0 9 0 IN JJ NN NN CC O
surgery surgery 0 0 0 0 0 0 0 0 7 0 JJ NN NN CC MD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN CC MD VB NNP O
be be 0 0 0 0 0 0 0 0 2 0 CC MD VB NNP NNP O
unavoidable. unavoidable. 0 0 0 0 0 0 0 0 12 0 MD VB NNP NNP VBP O
microRNAs microRNAs 0 0 0 0 0 0 0 0 9 0 VB NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBP VBN VBN TO O
suggested suggested 0 0 0 0 0 0 0 0 9 0 VBP VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB NNS O
play play 0 0 0 0 0 0 0 0 4 0 VBN TO VB NNS IN O
roles roles 0 0 0 0 0 0 0 0 5 0 TO VB NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VB NNS IN NN CC O
carcinogenesis carcinogenesis 0 0 0 0 0 0 0 0 14 0 NNS IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NN CC NN NNP NNP O
recurrence. recurrence. 0 0 0 0 0 0 0 0 11 0 CC NN NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP RB VBD O
recently recently 0 0 0 0 0 0 0 0 8 0 NNP NNP RB VBD JJ O
identified identified 0 0 0 0 0 0 0 0 10 0 NNP RB VBD JJ NN O
microRNA-29c microRNA-29c 0 0 1 0 0 0 0 1 12 0 RB VBD JJ NN IN O
(miRNA-29c) (miRNA-29c) 0 0 1 0 0 0 0 1 11 0 VBD JJ NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
predictor predictor 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN IN O
recurrence recurrence 0 0 0 0 0 0 0 0 10 0 IN JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NNP O
CRC. CRC. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 NNP DT NN NN PRP O
study, study, 0 0 0 0 1 0 0 0 6 0 DT NN NN PRP RB O
we we 0 0 0 0 0 0 0 0 2 0 NN NN PRP RB VBD O
further further 0 0 0 0 0 0 0 0 7 0 NN PRP RB VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 PRP RB VBD DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 RB VBD DT NNS CC O
functions functions 0 0 0 0 0 0 0 0 9 0 VBD DT NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC NN NN O
serum serum 0 0 0 0 0 0 0 0 5 0 NNS CC NN NN IN O
level level 0 0 0 0 0 0 0 0 5 0 CC NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ IN O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 NN IN JJ IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN TO O
relation relation 0 0 0 0 0 0 0 0 8 0 JJ IN NN TO RB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO RB NN O
early early 0 0 0 0 0 0 0 0 5 0 NN TO RB NN IN O
recurrence recurrence 0 0 0 0 0 0 0 0 10 0 TO RB NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 RB NN IN NNP NNP O
CRC. CRC. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 IN NNP NNP NNP PRP O
First First 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP PRP RB O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP RB VBD O
further further 0 0 0 0 0 0 0 0 7 0 NNP PRP RB VBD NN O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 PRP RB VBD NN IN O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 RB VBD NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBD NN IN JJ IN O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 NN IN JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN JJ NN O
non-early non-early 0 0 1 0 0 0 0 0 9 0 JJ IN JJ NN NNP O
relapse relapse 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNP NN O
subjects. subjects. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NN IN O
Gain-of-function Gain-of-function 1 0 1 0 0 0 0 0 16 0 NN NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNS O
vitro vitro 0 0 0 0 0 0 0 0 5 0 NN IN NN NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 IN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NNS VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VB DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ IN O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 NN IN JJ IN NN O
on on 0 0 0 0 0 0 0 0 2 0 IN JJ IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ IN NN NN NN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 IN NN NN NN NN O
migration, migration, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN CC O
invasion, invasion, 0 0 0 0 1 0 0 0 9 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN CC NN NN NNP O
cycle cycle 0 0 0 0 0 0 0 0 5 0 CC NN NN NNP NNP O
progression. progression. 0 0 0 0 0 0 0 0 12 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NN O
colon colon 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 NNP NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NNP O
line line 0 0 0 0 0 0 0 0 4 0 NN NN NN NNP CC O
Caco2 Caco2 1 0 0 0 0 0 0 1 5 0 NN NN NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP CC DT NN NN O
stable stable 0 0 0 0 0 0 0 0 6 0 CC DT NN NN VBG O
clone clone 0 0 0 0 0 0 0 0 5 0 DT NN NN VBG JJ O
overexpressing overexpressing 0 0 0 0 0 0 0 0 14 0 NN NN VBG JJ VBD O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 NN VBG JJ VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 VBG JJ VBD VBN TO O
xenografted xenografted 0 0 0 0 0 0 0 0 11 0 JJ VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBN TO VB DT IN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VB DT IN NN NN O
vivo vivo 0 0 0 0 0 0 0 0 4 0 DT IN NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 IN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ IN O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 NN IN JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN JJ NNP O
null null 0 0 0 0 0 0 0 0 4 0 JJ IN JJ NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 IN JJ NNP NNP NN O
Finally, Finally, 1 0 0 0 1 0 0 0 8 0 JJ NNP NNP NN NN O
circulating circulating 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NN VBD O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NN VBD VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ NN O
potential potential 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
biomarker biomarker 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN RB O
identifying identifying 0 0 0 0 0 0 0 0 11 0 NN IN NN RB NNP O
early early 0 0 0 0 0 0 0 0 5 0 IN NN RB NNP NNP O
relapse. relapse. 0 0 0 0 0 0 0 0 8 0 NN RB NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 RB NNP NNP NNP NN O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 NNP NNP NNP NN RB O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP NN RB VBN IN O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NN RB VBN IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 RB VBN IN JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NN VBN O
relapse relapse 0 0 0 0 0 0 0 0 7 0 IN JJ NN VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 JJ NN VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN VBN TO JJ NN O
non-early non-early 0 0 1 0 0 0 0 0 9 0 VBN TO JJ NN IN O
relapse relapse 0 0 0 0 0 0 0 0 7 0 TO JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
UICC UICC 1 1 0 0 0 0 0 0 4 0 NN IN NNP NN NNP O
stage stage 0 0 0 0 0 0 0 0 5 0 IN NNP NN NNP CC O
II II 1 1 0 0 0 0 0 0 2 0 NNP NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
III III 1 1 0 0 0 0 0 0 3 0 NNP CC NNP NNP NNS O
CRC CRC 1 1 0 0 0 0 0 0 3 0 CC NNP NNP NNS -NONE- O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS -NONE- : O
(P (P 0 1 0 0 0 0 0 0 2 0 NNP NNS -NONE- : CD O
= = 0 0 0 0 0 0 0 0 1 0 NNS -NONE- : CD IN O
0.021). 0.021). 0 0 0 0 0 0 0 1 7 0 -NONE- : CD IN NN O
In In 1 0 0 0 0 0 0 0 2 0 : CD IN NN NNS O
vitro vitro 0 0 0 0 0 0 0 0 5 0 CD IN NN NNS VBD O
studies studies 0 0 0 0 0 0 0 0 7 0 IN NN NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NNS VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN IN O
overexpression overexpression 0 0 0 0 0 0 0 0 14 0 VBD IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ VBN O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 NN IN JJ VBN NN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 IN JJ VBN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ VBN NN NN CC O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 VBN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
migration. migration. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 CC NNP NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN NNS O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP NN NN NNS RB O
studies studies 0 0 0 0 0 0 0 0 7 0 NN NN NNS RB VBD O
also also 0 0 0 0 0 0 0 0 4 0 NN NNS RB VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NNS RB VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 RB VBD IN JJ VBN O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 VBD IN JJ VBN DT O
caused caused 0 0 0 0 0 0 0 0 6 0 IN JJ VBN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 JJ VBN DT NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 VBN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP NNP O
G2 G2 1 1 0 0 0 0 0 1 2 0 NNP CC NNP NNP NNP O
population. population. 0 0 0 0 0 0 0 0 11 0 CC NNP NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
vivo, vivo, 0 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP VBD O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 NNP NNP NNP VBD NN O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD NN NN O
tumor tumor 0 0 0 0 0 0 0 0 5 0 NNP VBD NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 VBD NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
null null 0 0 0 0 0 0 0 0 4 0 NN IN JJ NNP NNP O
mice. mice. 0 0 0 0 0 0 0 0 5 0 IN JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN -NONE- O
serum serum 0 0 0 0 0 0 0 0 5 0 NNP NNP NN -NONE- VBD O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 NNP NN -NONE- VBD RB O
increased increased 0 0 0 0 0 0 0 0 9 0 NN -NONE- VBD RB IN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 -NONE- VBD RB IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD RB IN JJ VBN O
early early 0 0 0 0 0 0 0 0 5 0 RB IN JJ VBN NNS O
relapsed relapsed 0 0 0 0 0 0 0 0 8 0 IN JJ VBN NNS VBN O
patients patients 0 0 0 0 0 0 0 0 8 0 JJ VBN NNS VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 VBN NNS VBN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO JJ VBN O
non-early non-early 0 0 1 0 0 0 0 0 9 0 VBN TO JJ VBN NNS O
elapsed elapsed 0 0 0 0 0 0 0 0 7 0 TO JJ VBN NNS -NONE- O
patients patients 0 0 0 0 0 0 0 0 8 0 JJ VBN NNS -NONE- : O
(P (P 0 1 0 0 0 0 0 0 2 0 VBN NNS -NONE- : CD O
= = 0 0 0 0 0 0 0 0 1 0 NNS -NONE- : CD NN O
0.012). 0.012). 0 0 0 0 0 0 0 1 7 0 -NONE- : CD NN JJ O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 : CD NN JJ NNS O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 CD NN JJ NNS NN O
shows shows 0 0 0 0 0 0 0 0 5 0 NN JJ NNS NN -NONE- O
anti-tumorigenesis anti-tumorigenesis 0 0 1 0 0 0 0 0 18 0 JJ NNS NN -NONE- CC O
activity, activity, 0 0 0 0 1 0 0 0 9 0 NNS NN -NONE- CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC JJ NN O
preoperative preoperative 0 0 0 0 0 0 0 0 12 0 -NONE- CC JJ NN NN O
circulating circulating 0 0 0 0 0 0 0 0 11 0 CC JJ NN NN NNS O
miRNA-29c miRNA-29c 0 0 1 0 0 0 0 1 9 0 JJ NN NN NNS MD O
levels levels 0 0 0 0 0 0 0 0 6 0 NN NN NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 MD VB VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO VB JJ O
predict predict 0 0 0 0 0 0 0 0 7 0 VBN TO VB JJ JJ O
postoperative postoperative 0 0 0 0 0 0 0 0 13 0 TO VB JJ JJ NN O
early early 0 0 0 0 0 0 0 0 5 0 VB JJ JJ NN IN O
relapse relapse 0 0 0 0 0 0 0 0 7 0 JJ JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NONE O
CRC. CRC. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NONE NONE O
Phase Phase 1 0 0 0 0 0 0 0 5 0 NONE NONE NN CD NN O
1 1 0 0 0 0 0 0 1 1 1 0 NONE NN CD NN IN O
study study 0 0 0 0 0 0 0 0 5 0 NN CD NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD NN IN JJ NN O
intravenous intravenous 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN NN O
rigosertib rigosertib 0 0 0 0 0 0 0 0 10 0 IN JJ NN NN CD O
(ON (ON 0 1 0 0 0 0 0 0 3 0 JJ NN NN CD DT O
01910.Na), 01910.Na), 0 0 0 0 1 0 0 1 10 0 NN NN CD DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN CD DT NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 CD DT NN NN NN O
benzyl benzyl 0 0 0 0 0 0 0 0 6 0 DT NN NN NN NN O
styryl styryl 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
sulfone sulfone 0 0 0 0 0 0 0 0 7 0 NN NN NN NN VBG O
structure structure 0 0 0 0 0 0 0 0 9 0 NN NN NN VBG JJ O
producing producing 0 0 0 0 0 0 0 0 9 0 NN NN VBG JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 arrest NN VBG JJ NN CC B_TIMEXCCP
arrest arrest 0 0 0 0 0 0 0 0 6 0 VBG JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP IN O
apoptosis, apoptosis, 0 0 0 0 1 0 0 0 10 0 NN CC NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN NN NNS O
adult adult 0 0 0 0 0 0 0 0 5 0 NNP IN NN NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ NNP O
advanced advanced 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NNP NNP O
cancer. cancer. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NNP O
Ohnuma Ohnuma 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Lehrer Lehrer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ren Ren 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cho Cho 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
SY, SY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Maniar Maniar 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Silverman Silverman 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sung Sung 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gretz Gretz 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP CD O
HF HF 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
3rd, 3rd, 0 0 0 0 1 0 0 1 4 0 NNP NNP CD NNP NNP O
Benisovich Benisovich 1 0 0 0 0 0 0 0 10 0 NNP CD NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 CD NNP NNP NNP NNP O
Navada Navada 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Akahoho Akahoho 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wilck Wilck 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Taft Taft 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
DR, DR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Roboz Roboz 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wilhelm Wilhelm 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
F, F, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Holland Holland 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
JF. JF. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Radiology Radiology 1 0 0 0 0 0 0 0 9 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Tisch Tisch 1 0 0 0 0 0 0 0 5 0 NNP CC NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Icahn Icahn 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
Medicine Medicine 1 0 0 0 0 0 0 0 8 0 NNP IN NNP IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
Mount Mount 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Sinai Sinai 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
York, York, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
NY, NY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Rigosertib Rigosertib 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP CD O
(ON (ON 0 1 0 0 0 0 0 0 3 0 NNP NNP NNP CD DT O
01910.Na), 01910.Na), 0 0 0 0 1 0 0 1 10 0 NNP NNP CD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP CD DT JJ NN O
synthetic synthetic 0 0 0 0 0 0 0 0 9 0 CD DT JJ NN NN O
novel novel 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN NN O
benzyl benzyl 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
styryl styryl 0 0 0 0 0 0 0 0 6 0 NN NN NN NN VBD O
sulfone, sulfone, 0 0 0 0 1 0 0 0 8 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN TO O
administered administered 0 0 0 0 0 0 0 0 12 0 NN VBD VBN TO CD O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO CD NNS O
28 28 0 0 0 0 0 0 1 1 2 0 VBN TO CD NNS IN O
patients patients 0 0 0 0 0 0 0 0 8 0 TO CD NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 CD NNS IN JJ NN O
advanced advanced 0 0 0 0 0 0 0 0 8 0 NNS IN JJ NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 IN JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NNP NNP O
Phase Phase 1 0 0 0 0 0 0 0 5 0 IN DT NNP NNP NN O
I I 1 1 0 0 0 0 0 0 1 0 DT NNP NNP NN IN O
trial trial 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN TO O
order order 0 0 0 0 0 0 0 0 5 0 NN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB PRP$ O
characterize characterize 0 0 0 0 0 0 0 0 12 0 NN TO VB PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 TO VB PRP$ JJ NN O
pharmacokinetic pharmacokinetic 0 0 0 0 0 0 0 0 15 0 VB PRP$ JJ NN NN O
profile, profile, 0 0 0 0 1 0 0 0 8 0 PRP$ JJ NN NN DT O
determine determine 0 0 0 0 0 0 0 0 9 0 JJ NN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT JJ NNS O
dose-limiting dose-limiting 0 0 1 0 0 0 0 0 13 0 NN DT JJ NNS -NONE- O
toxicities toxicities 0 0 0 0 0 0 0 0 10 0 DT JJ NNS -NONE- NN O
(DLT), (DLT), 0 1 0 0 1 0 0 0 6 0 JJ NNS -NONE- NN DT O
define define 0 0 0 0 0 0 0 0 6 0 NNS -NONE- NN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- NN DT VBN NN O
recommended recommended 0 0 0 0 0 0 0 0 11 phase NN DT VBN NN NNP O
phase phase 0 0 0 0 0 0 0 0 5 0 DT VBN NN NNP NN O
II II 1 1 0 0 0 0 0 0 2 0 VBN NN NNP NN -NONE- O
dose dose 0 0 0 0 0 0 0 0 4 0 NN NNP NN -NONE- CC O
(RPTD) (RPTD) 0 1 0 0 0 0 0 0 6 0 NNP NN -NONE- CC TO O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC TO VB O
to to 0 0 0 0 0 0 0 0 2 0 -NONE- CC TO VB DT O
document document 0 0 0 0 0 0 0 0 8 0 CC TO VB DT NN O
any any 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NNP O
antitumor antitumor 0 0 0 0 0 0 0 0 9 0 VB DT NN NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 DT NN NNP NNP IN O
Patients Patients 1 0 0 0 0 0 0 0 8 0 NN NNP NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN JJ NN O
advanced advanced 0 0 0 0 0 0 0 0 8 0 NNP IN JJ NN NNS O
malignant malignant 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNS NN O
neoplasms neoplasms 0 0 0 0 0 0 0 0 9 0 JJ NN NNS NN TO O
refractory refractory 0 0 0 0 0 0 0 0 10 0 NN NNS NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS NN TO VB NN O
standard standard 0 0 0 0 0 0 0 0 8 0 NN TO VB NN VBD O
therapy therapy 0 0 0 0 0 0 0 0 7 0 TO VB NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 VB NN VBD VBN VBG O
given given 0 0 0 0 0 0 0 0 5 0 NN VBD VBN VBG NNS O
escalating escalating 0 0 0 0 0 0 0 0 10 0 VBD VBN VBG NNS IN O
doses doses 0 0 0 0 0 0 0 0 5 0 VBN VBG NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBG NNS IN NN NN O
rigosertib rigosertib 0 0 0 0 0 0 0 0 10 0 NNS IN NN NN CD O
(50, (50, 0 0 0 0 1 0 0 1 4 0 IN NN NN CD CD O
100, 100, 0 0 0 0 1 0 0 1 4 0 NN NN CD CD CD O
150, 150, 0 0 0 0 1 0 0 1 4 0 NN CD CD CD CD O
250, 250, 0 0 0 0 1 0 0 1 4 0 CD CD CD CD CD O
325, 325, 0 0 0 0 1 0 0 1 4 0 CD CD CD CD CD O
400, 400, 0 0 0 0 1 0 0 1 4 0 CD CD CD CD CD O
650, 650, 0 0 0 0 1 0 0 1 4 0 CD CD CD CD CD O
850, 850, 0 0 0 0 1 0 0 1 4 0 CD CD CD CD CD O
1,050, 1,050, 0 0 0 0 1 0 0 1 6 0 CD CD CD CD CD O
1,375, 1,375, 0 0 0 0 1 0 0 1 6 0 CD CD CD CD JJ O
1,700 1,700 0 0 0 0 1 0 0 1 5 0 CD CD CD JJ IN O
mg/m(2)/24h) mg/m(2)/24h) 0 0 0 1 0 0 0 1 12 0 CD CD JJ IN DT O
as as 0 0 0 0 0 0 0 0 2 0 CD JJ IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 JJ IN DT JJ JJ O
3-day 3-day 0 0 1 0 0 0 0 1 5 0 IN DT JJ JJ NN O
continuous continuous 0 0 0 0 0 0 0 0 10 0 DT JJ JJ NN NN O
infusion infusion 0 0 0 0 0 0 0 0 8 0 JJ JJ NN NN DT O
(CI) (CI) 0 1 0 0 0 0 0 0 4 0 JJ NN NN DT CD O
every every 0 0 0 0 0 0 0 0 5 0 NN NN DT CD NNP O
2 2 0 0 0 0 0 0 1 1 1 0 NN DT CD NNP NNP O
weeks. weeks. 0 0 0 0 0 0 0 0 6 0 DT CD NNP NNP VBD O
An An 1 0 0 0 0 0 0 0 2 0 CD NNP NNP VBD NNP O
accelerated accelerated 0 0 0 0 0 0 0 0 11 0 NNP NNP VBD NNP NN O
Fibonacci Fibonacci 1 0 0 0 0 0 0 0 9 0 NNP VBD NNP NN NN O
titration titration 0 0 0 0 0 0 0 0 9 0 VBD NNP NN NN IN O
schedule schedule 0 0 0 0 0 0 0 0 8 0 NNP NN NN IN VBN O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN VBN NNS O
specified specified 0 0 0 0 0 0 0 0 9 0 NN IN VBN NNS IN O
decreases decreases 0 0 0 0 0 0 0 0 9 0 IN VBN NNS IN NNS O
for for 0 0 0 0 0 0 0 0 3 0 VBN NNS IN NNS VBD O
toxicities toxicities 0 0 0 0 0 0 0 0 10 0 NNS IN NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NNS VBD VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 NNS VBD VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NN IN O
escalation escalation 0 0 0 0 0 0 0 0 10 0 VBN IN NN IN NN O
until until 0 0 0 0 0 0 0 0 5 0 IN NN IN NN -NONE- O
grade grade 0 0 0 0 0 0 0 0 5 0 NN IN NN -NONE- NN O
≥2 ≥2 0 0 0 0 0 0 0 1 2 0 IN NN -NONE- NN NNP O
toxicity toxicity 0 0 0 0 0 0 0 0 8 0 NN -NONE- NN NNP NNP O
occurred. occurred. 0 0 0 0 0 0 0 0 9 0 -NONE- NN NNP NNP NN O
Intrapatient Intrapatient 1 0 0 0 0 0 0 0 12 0 NN NNP NNP NN NN O
dose dose 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBD O
escalation escalation 0 0 0 0 0 0 0 0 10 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
allowed allowed 0 0 0 0 0 0 0 0 7 0 NN VBD VBN IN NN O
if if 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN VBD O
toxicity toxicity 0 0 0 0 0 0 0 0 8 0 VBN IN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN NN VBD VBN -NONE- O
grade grade 0 0 0 0 0 0 0 0 5 0 NN VBD VBN -NONE- CC O
≤2 ≤2 0 0 0 0 0 0 0 1 2 0 VBD VBN -NONE- CC DT O
and and 0 0 0 0 0 0 0 0 3 0 VBN -NONE- CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- CC DT NN VBD O
disease disease 0 0 0 0 0 0 0 0 7 0 CC DT NN VBD NNP O
remained remained 0 0 0 0 0 0 0 0 8 0 DT NN VBD NNP NNP O
stable. stable. 0 0 0 0 0 0 0 0 7 0 NN VBD NNP NNP NNS O
Plasma Plasma 1 0 0 0 0 0 0 0 6 0 VBD NNP NNP NNS -NONE- O
pharmacokinetics pharmacokinetics 0 0 0 0 0 0 0 0 16 0 NNP NNP NNS -NONE- CC O
(PK) (PK) 0 1 0 0 0 0 0 0 4 0 NNP NNS -NONE- CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC JJ NNP O
urinary urinary 0 0 0 0 0 0 0 0 7 0 -NONE- CC JJ NNP NNS O
PK PK 1 1 0 0 0 0 0 0 2 0 CC JJ NNP NNS VBD O
assessments assessments 0 0 0 0 0 0 0 0 11 0 JJ NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
studied studied 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT CD O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT CD CC O
1st 1st 0 0 0 0 0 0 0 1 3 0 IN DT CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 DT CD CC CD NNP O
4th 4th 0 0 0 0 0 0 0 1 3 0 CD CC CD NNP NNP O
cycles. cycles. 0 0 0 0 0 0 0 0 7 0 CC CD NNP NNP NNS O
Twenty-nine Twenty-nine 1 0 1 0 0 0 0 0 11 0 CD NNP NNP NNS -NONE- O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS -NONE- NNS O
(12 (12 0 0 0 0 0 0 0 1 3 0 NNP NNS -NONE- NNS CC O
men men 0 0 0 0 0 0 0 0 3 0 NNS -NONE- NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNS CC CD NN O
17 17 0 0 0 0 0 0 1 1 2 0 NNS CC CD NN NN O
women; women; 0 0 0 0 0 0 0 0 6 0 CC CD NN NN CD O
age age 0 0 0 0 0 0 0 0 3 0 CD NN NN CD NN O
36-87 36-87 0 0 1 0 0 0 0 1 5 0 NN NN CD NN IN O
y y 0 0 0 0 0 0 0 0 1 0 NN CD NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 CD NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ IN O
median median 0 0 0 0 0 0 0 0 6 0 IN DT JJ IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN CD JJ O
63 63 0 0 0 0 0 0 1 1 2 0 JJ IN CD JJ VBD O
y) y) 0 0 0 0 0 0 0 0 2 0 IN CD JJ VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 CD JJ VBD JJ CC O
registered, registered, 0 0 0 0 1 0 0 0 11 0 JJ VBD JJ CC CD O
but but 0 0 0 0 0 0 0 0 3 0 VBD JJ CC CD VBD O
one one 0 0 0 0 0 0 0 0 3 0 JJ CC CD VBD IN O
died died 0 0 0 0 0 0 0 0 4 0 CC CD VBD IN NN O
before before 0 0 0 0 0 0 0 0 6 0 CD VBD IN NN NN O
study study 0 0 0 0 0 0 0 0 5 0 VBD IN NN NN VBD O
drug drug 0 0 0 0 0 0 0 0 4 0 IN NN NN VBD NNP O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD NNP JJ O
given. given. 0 0 0 0 0 0 0 0 6 0 NN VBD NNP JJ NNS O
Twenty-eight Twenty-eight 1 0 1 0 0 0 0 0 12 0 VBD NNP JJ NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP JJ NNS VBD DT O
received received 0 0 0 0 0 0 0 0 8 0 JJ NNS VBD DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBD DT JJ IN O
median median 0 0 0 0 0 0 0 0 6 0 VBD DT JJ IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN CD NNS O
3 3 0 0 0 0 0 0 1 1 1 0 JJ IN CD NNS IN O
cycles cycles 0 0 0 0 0 0 0 0 6 0 IN CD NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN NNP NNP O
therapy. therapy. 0 0 0 0 0 0 0 0 8 0 NNS IN NNP NNP JJ O
Most Most 1 0 0 0 0 0 0 0 4 0 IN NNP NNP JJ NN O
common common 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN -NONE- O
grade grade 0 0 0 0 0 0 0 0 5 0 NNP JJ NN -NONE- VBZ O
≥2 ≥2 0 0 0 0 0 0 0 1 2 0 JJ NN -NONE- VBZ JJ O
toxicities toxicities 0 0 0 0 0 0 0 0 10 0 NN -NONE- VBZ JJ TO O
attributable attributable 0 0 0 0 0 0 0 0 12 0 -NONE- VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB VBN O
rigosertib rigosertib 0 0 0 0 0 0 0 0 10 0 JJ TO VB VBN -NONE- O
included included 0 0 0 0 0 0 0 0 8 0 TO VB VBN -NONE- -NONE- O
fatigue, fatigue, 0 0 0 0 1 0 0 0 8 0 VB VBN -NONE- -NONE- VBG O
anorexia, anorexia, 0 0 0 0 1 0 0 0 9 0 VBN -NONE- -NONE- VBG CC O
vomiting vomiting 0 0 0 0 0 0 0 0 8 0 -NONE- -NONE- VBG CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- VBG CC NNP NNP O
constipation. constipation. 0 0 0 0 0 0 0 0 13 0 VBG CC NNP NNP VBD O
DLTs DLTs 1 0 0 0 0 0 0 0 4 0 CC NNP NNP VBD JJ O
included included 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD JJ NN O
muscular muscular 0 0 0 0 0 0 0 0 8 0 NNP VBD JJ NN NN O
weakness, weakness, 0 0 0 0 1 0 0 0 9 0 VBD JJ NN NN NN O
hyponatremia, hyponatremia, 0 0 0 0 1 0 0 0 13 0 JJ NN NN NN NN O
neutropenia, neutropenia, 0 0 0 0 1 0 0 0 12 0 NN NN NN NN CC O
delirium delirium 0 0 0 0 0 0 0 0 8 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
confusional confusional 0 0 0 0 0 0 0 0 11 0 NN CC JJ NNP NNP O
state. state. 0 0 0 0 0 0 0 0 6 0 CC JJ NNP NNP NNS O
Risk Risk 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNS IN JJ NNS O
severe severe 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NNS VBP O
toxicities toxicities 0 0 0 0 0 0 0 0 10 0 IN JJ NNS VBP JJ O
include include 0 0 0 0 0 0 0 0 7 0 JJ NNS VBP JJ JJ O
pre-existing pre-existing 0 0 1 0 0 0 0 0 12 0 NNS VBP JJ JJ NN O
neurological neurological 0 0 0 0 0 0 0 0 12 0 VBP JJ JJ NN CC O
dysfunction dysfunction 0 0 0 0 0 0 0 0 11 0 JJ JJ NN CC VBD O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC VBD JJ O
advanced advanced 0 0 0 0 0 0 0 0 8 0 NN CC VBD JJ NN O
gynecologic gynecologic 0 0 0 0 0 0 0 0 11 0 CC VBD JJ NN IN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 VBD JJ NN IN JJ O
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN JJ NNP O
pelvic pelvic 0 0 0 0 0 0 0 0 6 0 NN IN JJ NNP NNP O
surgery. surgery. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP NNS O
Rigosertib Rigosertib 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP NNS VBD O
pharmacokinetics pharmacokinetics 0 0 0 0 0 0 0 0 16 0 NNP NNP NNS VBD JJ O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNS VBD JJ NN O
rapid rapid 0 0 0 0 0 0 0 0 5 0 NNS VBD JJ NN NN O
plasma plasma 0 0 0 0 0 0 0 0 6 0 VBD JJ NN NN NNS O
distribution distribution 0 0 0 0 0 0 0 0 12 phases JJ NN NN NNS CC O
phases phases 0 0 0 0 0 0 0 0 6 0 NN NN NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC JJ NNP O
urinary urinary 0 0 0 0 0 0 0 0 7 0 NNS CC JJ NNP NNP O
excretion. excretion. 0 0 0 0 0 0 0 0 10 0 CC JJ NNP NNP IN O
Elevations Elevations 1 0 0 0 0 0 0 0 10 0 JJ NNP NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NNP O
plasma plasma 0 0 0 0 0 0 0 0 6 0 NNP IN NN NNP CC O
Cmax Cmax 1 0 0 0 0 0 0 0 4 0 IN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP JJ O
AUC AUC 1 1 0 0 0 0 0 0 3 0 NNP CC NNP JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 CC NNP JJ TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 NNP JJ TO NNS IN O
decreases decreases 0 0 0 0 0 0 0 0 9 0 JJ TO NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 TO NNS IN NN NN O
plasma plasma 0 0 0 0 0 0 0 0 6 0 NNS IN NN NN VBD O
clearance clearance 0 0 0 0 0 0 0 0 9 0 IN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN JJ NN O
acute acute 0 0 0 0 0 0 0 0 5 0 VBN IN JJ NN -NONE- O
grade grade 0 0 0 0 0 0 0 0 5 0 IN JJ NN -NONE- NNP O
≥3 ≥3 0 0 0 0 0 0 0 1 2 0 JJ NN -NONE- NNP NNP O
toxicities. toxicities. 0 0 0 0 0 0 0 0 11 0 NN -NONE- NNP NNP CD O
Of Of 1 0 0 0 0 0 0 0 2 0 -NONE- NNP NNP CD JJ O
22 22 0 0 0 0 0 0 1 1 2 0 NNP NNP CD JJ NN O
evaluable evaluable 0 0 0 0 0 0 0 0 9 0 NNP CD JJ NN CD O
patients, patients, 0 0 0 0 1 0 0 0 9 0 CD JJ NN CD NN O
9 9 0 0 0 0 0 0 1 1 1 0 JJ NN CD NN VBD O
(41%) (41%) 0 0 0 0 0 0 0 1 5 0 NN CD NN VBD DT O
achieved achieved 0 0 0 0 0 0 0 0 8 0 CD NN VBD DT JJS O
a a 0 0 0 0 0 0 0 0 1 0 NN VBD DT JJS JJ O
best best 0 0 0 0 0 0 0 0 4 0 VBD DT JJS JJ NN O
overall overall 0 0 0 0 0 0 0 0 7 0 DT JJS JJ NN IN O
response response 0 0 0 0 0 0 0 0 8 0 JJS JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
stable stable 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN DT O
disease; disease; 0 0 0 0 0 0 0 0 8 0 IN JJ NN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 JJ NN DT JJ NNS O
other other 0 0 0 0 0 0 0 0 5 0 NN DT JJ NNS -NONE- O
patients patients 0 0 0 0 0 0 0 0 8 0 DT JJ NNS -NONE- CD O
(n=13; (n=13; 0 0 0 0 0 0 0 1 6 0 JJ NNS -NONE- CD NNP O
59%) 59%) 0 0 0 0 0 0 0 1 4 0 NNS -NONE- CD NNP NNP O
progressed. progressed. 0 0 0 0 0 0 0 0 11 0 -NONE- CD NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 CD NNP NNP NN JJ O
median median 0 0 0 0 0 0 0 0 6 0 NNP NNP NN JJ NN O
progression-free progression-free 0 0 1 0 0 0 0 0 16 0 NNP NN JJ NN NN O
survival survival 0 0 0 0 0 0 0 0 8 0 NN JJ NN NN VBD O
time time 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD CD NNS O
50 50 0 0 0 0 0 0 1 1 2 0 NN VBD CD NNS -NONE- O
days days 0 0 0 0 0 0 0 0 4 0 VBD CD NNS -NONE- NN O
(95% (95% 0 0 0 0 0 0 0 1 4 0 CD NNS -NONE- NN NN O
confidence confidence 0 0 0 0 0 0 0 0 10 0 NNS -NONE- NN NN NN O
interval interval 0 0 0 0 0 0 0 0 8 0 -NONE- NN NN NN CD O
[CI]: [CI]: 0 1 0 0 0 0 0 0 5 0 NN NN NN CD NNP O
37-80 37-80 0 0 1 0 0 0 0 1 5 0 NN NN CD NNP NNP O
days). days). 0 0 0 0 0 0 0 0 6 0 NN CD NNP NNP NNP O
Nine Nine 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NNP NNS O
(41%) (41%) 0 0 0 0 0 0 0 1 5 0 NNP NNP NNP NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBD IN O
survived survived 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD IN IN O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBD IN IN CD O
over over 0 0 0 0 0 0 0 0 4 0 VBD IN IN CD NNP O
1 1 0 0 0 0 0 0 1 1 1 0 IN IN CD NNP NNP O
y. y. 0 0 0 0 0 0 0 0 2 0 IN CD NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 CD NNP NNP NNP VBD O
summary, summary, 0 0 0 0 1 0 0 0 8 0 NNP NNP NNP VBD NNP O
prolonged prolonged 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NNP NNS O
IV IV 1 1 0 0 0 0 0 0 2 0 NNP VBD NNP NNS IN O
infusions infusions 0 0 0 0 0 0 0 0 9 0 VBD NNP NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN NN VBD O
rigosertib rigosertib 0 0 0 0 0 0 0 0 10 0 NNS IN NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 IN NN VBD RB RB O
generally generally 0 0 0 0 0 0 0 0 9 0 NN VBD RB RB NNP O
well well 0 0 0 0 0 0 0 0 4 0 VBD RB RB NNP NNP O
tolerated. tolerated. 0 0 0 0 0 0 0 0 10 0 RB RB NNP NNP NNP O
Nine Nine 1 0 0 0 0 0 0 0 4 0 RB NNP NNP NNP NNS O
(41%) (41%) 0 0 0 0 0 0 0 1 5 0 NNP NNP NNP NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBD JJ O
achieved achieved 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD JJ NN O
stable stable 0 0 0 0 0 0 0 0 6 0 NNS VBD JJ NN CC O
disease disease 0 0 0 0 0 0 0 0 7 0 VBD JJ NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC CD NN O
9 9 0 0 0 0 0 0 1 1 1 0 NN CC CD NN NNS O
(41%) (41%) 0 0 0 0 0 0 0 1 5 0 CC CD NN NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 CD NN NNS VBD IN O
survived survived 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN IN O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBD IN IN CD O
over over 0 0 0 0 0 0 0 0 4 0 VBD IN IN CD NNP O
1 1 0 0 0 0 0 0 1 1 1 0 IN IN CD NNP NNP O
year. year. 0 0 0 0 0 0 0 0 5 0 IN CD NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 CD NNP NNP NNP VBZ O
RPTD RPTD 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP VBZ TO O
appears appears 0 0 0 0 0 0 0 0 7 0 NNP NNP VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBZ TO VB CD O
be be 0 0 0 0 0 0 0 0 2 0 VBZ TO VB CD JJ O
850 850 0 0 0 0 0 0 1 1 3 0 TO VB CD JJ NNP O
mg/m(2)/24hr mg/m(2)/24hr 0 0 0 1 0 0 0 1 12 0 VB CD JJ NNP NN O
CI CI 1 1 0 0 0 0 0 0 2 0 CD JJ NNP NN CD O
x x 0 0 0 0 0 0 0 0 1 0 JJ NNP NN CD NNP O
3 3 0 0 0 0 0 0 1 1 1 0 NNP NN CD NNP NNP O
days. days. 0 0 0 0 0 0 0 0 5 0 NN CD NNP NNP NNP O
(ClinicalTrials.gov (ClinicalTrials.gov 0 0 0 0 0 0 0 0 19 0 CD NNP NNP NNP NNP O
identifier: identifier: 0 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NONE O
NCT01538537). NCT01538537). 1 1 0 0 0 0 0 1 13 0 NNP NNP NNP NONE NONE O
Alcohol Alcohol 1 0 0 0 0 0 0 0 7 0 NONE NONE NN NN CC O
dehydrogenase dehydrogenase 0 0 0 0 0 0 0 0 13 0 NONE NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
cytochrome cytochrome 0 0 0 0 0 0 0 0 10 0 NN CC NN NNP CD O
P450 P450 1 1 0 0 0 0 0 1 4 0 CC NN NNP CD MD O
2E1 2E1 0 1 0 0 0 0 0 1 3 0 NN NNP CD MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP CD MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 CD MD VB VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 MD VB VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN JJ NN O
long-term long-term 0 0 1 0 0 0 0 0 9 0 VBN IN JJ NN TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 IN JJ NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO NN IN O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 NN TO NN IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 TO NN IN VBN NN O
cultured cultured 0 0 0 0 0 0 0 0 8 0 NN IN VBN NN -NONE- O
liver liver 0 0 0 0 0 0 0 0 5 0 IN VBN NN -NONE- NNP O
HEP-G2 HEP-G2 1 1 1 0 0 0 0 1 6 0 VBN NN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN -NONE- NNP NNP NNP O
Balusikova Balusikova 1 0 0 0 0 0 0 0 10 0 -NONE- NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kovar Kovar 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 CC NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP CC NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 CC NNP IN NNP IN O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP IN NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
Diabetes, Diabetes, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP CC O
Metabolism Metabolism 1 0 0 0 0 0 0 0 10 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Nutrition, Nutrition, 1 0 0 0 1 0 0 0 10 0 NNP CC NNP NNP NNP O
Third Third 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Charles Charles 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Prague, Prague, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP CD O
Ruska Ruska 1 0 0 0 0 0 0 0 5 0 IN NNP NNP CD CD O
87, 87, 0 0 0 0 1 0 0 1 3 0 NNP NNP CD CD CD O
100 100 0 0 0 0 0 0 1 1 3 0 NNP CD CD CD NNP O
00, 00, 0 0 0 0 1 0 0 1 3 0 CD CD CD NNP CD O
Prague Prague 1 0 0 0 0 0 0 0 6 0 CD CD NNP CD NNP O
10, 10, 0 0 0 0 1 0 0 1 3 0 CD NNP CD NNP NNP O
Czech Czech 1 0 0 0 0 0 0 0 5 0 NNP CD NNP NNP NNP O
Republic, Republic, 1 0 0 0 1 0 0 0 9 0 CD NNP NNP NNP NNP O
kamilabalusikova@seznam.cz. kamilabalusikova@seznam.cz. 0 0 0 0 0 0 0 0 27 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 VBZ VBN VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN JJ NNS O
previous previous 0 0 0 0 0 0 0 0 8 0 VBN IN JJ NNS WDT O
studies studies 0 0 0 0 0 0 0 0 7 0 IN JJ NNS WDT RB O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT RB -NONE- O
liver liver 0 0 0 0 0 0 0 0 5 0 NNS WDT RB -NONE- NNS O
HEP-G2 HEP-G2 1 1 1 0 0 0 0 1 6 0 WDT RB -NONE- NNS JJ O
cells cells 0 0 0 0 0 0 0 0 5 0 RB -NONE- NNS JJ NN O
(human (human 0 0 0 0 0 0 0 0 6 0 -NONE- NNS JJ NN NN O
hepatocellular hepatocellular 0 0 0 0 0 0 0 0 14 0 NNS JJ NN NN NN O
carcinoma) carcinoma) 0 0 0 0 0 0 0 0 10 0 JJ NN NN NN PRP$ O
lose lose 0 0 0 0 0 0 0 0 4 0 NN NN NN PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NN NN PRP$ NN TO O
ability ability 0 0 0 0 0 0 0 0 7 0 NN PRP$ NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 PRP$ NN TO NN JJ O
express express 0 0 0 0 0 0 0 0 7 0 NN TO NN JJ NN O
active active 0 0 0 0 0 0 0 0 6 0 TO NN JJ NN NN O
alcohol alcohol 0 0 0 0 0 0 0 0 7 0 NN JJ NN NN NN O
dehydrogenase dehydrogenase 0 0 0 0 0 0 0 0 13 0 JJ NN NN NN CC O
(ADH) (ADH) 0 1 0 0 0 0 0 0 5 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
cytochrome cytochrome 0 0 0 0 0 0 0 0 10 0 NN CC NN NNP CD O
P450 P450 1 1 0 0 0 0 0 1 4 0 CC NN NNP CD NNP O
2E1 2E1 0 1 0 0 0 0 0 1 3 0 NN NNP CD NNP NNP O
(CYP2E1). (CYP2E1). 0 1 0 0 0 0 0 1 9 0 NNP CD NNP NNP DT O
Although Although 1 0 0 0 0 0 0 0 8 0 CD NNP NNP DT VBP O
both both 0 0 0 0 0 0 0 0 4 0 NNP NNP DT VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP DT VBP JJ NN O
ethanol-inducible ethanol-inducible 0 0 1 0 0 0 0 0 17 0 DT VBP JJ NN JJ O
enzymes, enzymes, 0 0 0 0 1 0 0 0 8 0 VBP JJ NN JJ NN O
short-term short-term 0 0 1 0 0 0 0 0 10 0 JJ NN JJ NN TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 NN JJ NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO NN VBZ O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 NN TO NN VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 TO NN VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VB DT O
cause cause 0 0 0 0 0 0 0 0 5 0 VBZ RB VB DT NNS O
any any 0 0 0 0 0 0 0 0 3 0 RB VB DT NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 VB DT NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NNS IN NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 NNS IN NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 IN NN CC NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN CC NN IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN VBN -NONE- O
cultured cultured 0 0 0 0 0 0 0 0 8 0 NN IN VBN -NONE- NNP O
HEP-G2 HEP-G2 1 1 1 0 0 0 0 1 6 0 IN VBN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 VBN -NONE- NNP NNP PRP O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 -NONE- NNP NNP PRP VBD O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBD DT O
tested tested 0 0 0 0 0 0 0 0 6 0 NNP PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
long-term long-term 0 0 1 0 0 0 0 0 9 0 NN IN JJ NN TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 IN JJ NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO NN IN O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 NN TO NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 TO NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CC O
expression expression 0 0 0 0 0 0 0 0 10 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN CC NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NNP O
both both 0 0 0 0 0 0 0 0 4 0 NN IN DT NNP CC O
ADH ADH 1 1 0 0 0 0 0 0 3 0 IN DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP IN O
CYP2E1 CYP2E1 1 1 0 0 0 0 0 1 6 0 NNP CC NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CC NNP IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NNP IN DT NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP CC O
ADH ADH 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBD O
CYP2E1 CYP2E1 1 1 0 0 0 0 0 1 6 0 NNP CC NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 CC NNP VBD VBN IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NNP O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 IN DT NNP NNP NN O
and/or and/or 0 0 0 1 0 0 0 0 6 0 DT NNP NNP NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN VBG O
level level 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 NN NN VBG JJ NNP O
real-time real-time 0 0 1 0 0 0 0 0 9 0 NN VBG JJ NNP CC O
PCR PCR 1 1 0 0 0 0 0 0 3 0 VBG JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP NN O
Western Western 1 0 0 0 0 0 0 0 7 0 NNP CC NNP NN NNP O
blot blot 0 0 0 0 0 0 0 0 4 0 CC NNP NN NNP NNP O
analysis. analysis. 0 0 0 0 0 0 0 0 9 0 NNP NN NNP NNP JJ O
Specific Specific 1 0 0 0 0 0 0 0 8 0 NN NNP NNP JJ NNS O
colorimetric colorimetric 0 0 0 0 0 0 0 0 12 0 NNP NNP JJ NNS VBD O
assays assays 0 0 0 0 0 0 0 0 6 0 NNP JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 NNS VBD VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
measurement measurement 0 0 0 0 0 0 0 0 11 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP CC O
ADH ADH 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP JJ O
CYP2E1 CYP2E1 1 1 0 0 0 0 0 1 6 0 NNP CC NNP JJ NNP O
enzymatic enzymatic 0 0 0 0 0 0 0 0 9 0 CC NNP JJ NNP -NONE- O
activities. activities. 0 0 0 0 0 0 0 0 11 0 NNP JJ NNP -NONE- VBZ O
Caco-2 Caco-2 1 0 1 0 0 0 0 1 6 0 JJ NNP -NONE- VBZ JJ O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP -NONE- VBZ JJ NNP O
(active (active 0 0 0 0 0 0 0 0 7 0 -NONE- VBZ JJ NNP CC O
CYP2E1 CYP2E1 1 1 0 0 0 0 0 1 6 0 VBZ JJ NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC JJ NN O
inactive inactive 0 0 0 0 0 0 0 0 8 0 NNP CC JJ NN VBD O
ADH) ADH) 1 1 0 0 0 0 0 0 4 0 CC JJ NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN IN NN O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NNP O
control control 0 0 0 0 0 0 0 0 7 0 VBN IN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP VBD O
Significantly Significantly 1 0 0 0 0 0 0 0 13 0 NN NNP NNP VBD NN O
increased increased 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NN NN O
protein protein 0 0 0 0 0 0 0 0 7 0 NNP VBD NN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
ADH ADH 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN CD O
(about (about 0 0 0 0 0 0 0 0 6 0 IN NNP IN CD IN O
2.5-fold) 2.5-fold) 0 0 1 0 0 0 0 1 9 0 NNP IN CD IN RB O
as as 0 0 0 0 0 0 0 0 2 0 IN CD IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 CD IN RB IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN NNP NNP O
CYP2E1 CYP2E1 1 1 0 0 0 0 0 1 6 0 RB IN NNP NNP CD O
(about (about 0 0 0 0 0 0 0 0 6 0 IN NNP NNP CD VBD O
1.6-fold) 1.6-fold) 0 0 1 0 0 0 0 1 9 0 NNP NNP CD VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP CD VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 CD VBD VBN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN -NONE- NNS O
HEP-G2 HEP-G2 1 1 1 0 0 0 0 1 6 0 VBN IN -NONE- NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 IN -NONE- NNS IN JJ O
after after 0 0 0 0 0 0 0 0 5 0 -NONE- NNS IN JJ -NONE- O
long-term long-term 0 0 1 0 0 0 0 0 9 0 NNS IN JJ -NONE- JJ O
(12 (12 0 0 0 0 0 0 0 1 3 0 IN JJ -NONE- JJ NN O
mo) mo) 0 0 0 0 0 0 0 0 3 0 JJ -NONE- JJ NN TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 -NONE- JJ NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO NNP DT O
ethanol. ethanol. 0 0 0 0 0 0 0 0 8 0 NN TO NNP DT NN O
The The 1 0 0 0 0 0 0 0 3 0 TO NNP DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NNP DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP CC O
ADH ADH 1 1 0 0 0 0 0 0 3 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBD O
CYP2E1 CYP2E1 1 1 0 0 0 0 0 1 6 0 NNP CC NNP VBD RB O
was was 0 0 0 0 0 0 0 0 3 0 CC NNP VBD RB RB O
also also 0 0 0 0 0 0 0 0 4 0 NNP VBD RB RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 VBD RB RB VBN IN O
increased increased 0 0 0 0 0 0 0 0 9 0 RB RB VBN IN CD O
from from 0 0 0 0 0 0 0 0 4 0 RB VBN IN CD CD O
12 12 0 0 0 0 0 0 1 1 2 0 VBN IN CD CD CD O
± ± 0 0 0 0 0 0 0 0 1 0 IN CD CD CD CC O
3 3 0 0 0 0 0 0 1 1 1 0 CD CD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC CD CD O
6 6 0 0 0 0 0 0 1 1 1 0 CD CC CD CD CD O
± ± 0 0 0 0 0 0 0 0 1 0 CC CD CD CD JJ O
1 1 0 0 0 0 0 0 1 1 1 0 CD CD CD JJ IN O
nmol/h/mg nmol/h/mg 0 0 0 1 0 0 0 0 9 0 CD CD JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD JJ IN JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 JJ IN JJ NN TO O
protein protein 0 0 0 0 0 0 0 0 7 0 IN JJ NN TO CD O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO CD CD O
191 191 0 0 0 0 0 0 1 1 3 0 NN TO CD CD CD O
± ± 0 0 0 0 0 0 0 0 1 0 TO CD CD CD CC O
9 9 0 0 0 0 0 0 1 1 1 0 CD CD CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD CD CC CD CD O
57 57 0 0 0 0 0 0 1 1 2 0 CD CC CD CD CD O
± ± 0 0 0 0 0 0 0 0 1 0 CC CD CD CD JJ O
9 9 0 0 0 0 0 0 1 1 1 0 CD CD CD JJ IN O
nmol/h/mg nmol/h/mg 0 0 0 1 0 0 0 0 9 0 CD CD JJ IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CD JJ IN JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 JJ IN JJ NN NNP O
protein, protein, 0 0 0 0 1 0 0 0 8 0 IN JJ NN NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 JJ NN NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBP IN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNP VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNP VBP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNS O
ethanol-metabolizing ethanol-metabolizing 0 0 1 0 0 0 0 0 20 0 NN IN JJ NNS IN O
enzymes enzymes 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN VBN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN VBN -NONE- O
cultured cultured 0 0 0 0 0 0 0 0 8 0 NNS IN VBN -NONE- NNS O
HEP-G2 HEP-G2 1 1 1 0 0 0 0 1 6 0 IN VBN -NONE- NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 VBN -NONE- NNS VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- NNS VBZ JJ CC O
reversible reversible 0 0 0 0 0 0 0 0 10 0 NNS VBZ JJ CC MD O
and and 0 0 0 0 0 0 0 0 3 0 VBZ JJ CC MD VB O
can can 0 0 0 0 0 0 0 0 3 0 JJ CC MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 CC MD VB VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 MD VB VBN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN VBN NN O
prolonged prolonged 0 0 0 0 0 0 0 0 9 0 VBN IN VBN NN TO O
exposure exposure 0 0 0 0 0 0 0 0 8 0 IN VBN NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 VBN NN TO NNP NNP O
ethanol. ethanol. 0 0 0 0 0 0 0 0 8 0 NN TO NNP NNP VBP O
We We 1 0 0 0 0 0 0 0 2 0 TO NNP NNP VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP RB JJ O
therefore therefore 0 0 0 0 0 0 0 0 9 0 NNP VBP RB JJ TO O
able able 0 0 0 0 0 0 0 0 4 0 VBP RB JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO VB -NONE- O
reactivate reactivate 0 0 0 0 0 0 0 0 10 0 JJ TO VB -NONE- NNS O
HEP-G2 HEP-G2 1 1 1 0 0 0 0 1 6 0 TO VB -NONE- NNS JJ O
cells cells 0 0 0 0 0 0 0 0 5 0 VB -NONE- NNS JJ NNS O
metabolic metabolic 0 0 0 0 0 0 0 0 9 0 -NONE- NNS JJ NNS VBG O
functions functions 0 0 0 0 0 0 0 0 9 0 NNS JJ NNS VBG NN O
concerning concerning 0 0 0 0 0 0 0 0 10 0 JJ NNS VBG NN NN O
ethanol ethanol 0 0 0 0 0 0 0 0 7 0 NNS VBG NN NN RB O
oxidation oxidation 0 0 0 0 0 0 0 0 9 0 VBG NN NN RB IN O
just just 0 0 0 0 0 0 0 0 4 0 NN NN RB IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN RB IN NN IN O
modification modification 0 0 0 0 0 0 0 0 12 0 RB IN NN IN IN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN IN IN NN NN O
vitro vitro 0 0 0 0 0 0 0 0 5 0 IN IN NN NN NNS O
culture culture 0 0 0 0 0 0 0 0 7 0 IN NN NN NNS IN O
conditions conditions 0 0 0 0 0 0 0 0 10 0 NN NN NNS IN NN O
without without 0 0 0 0 0 0 0 0 7 0 NN NNS IN NN IN O
necessity necessity 0 0 0 0 0 0 0 0 9 0 NNS IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN IN O
transfection transfection 0 0 0 0 0 0 0 0 12 0 NN IN NN IN PRP$ O
with with 0 0 0 0 0 0 0 0 4 0 IN NN IN PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ NN NN O
side side 0 0 0 0 0 0 0 0 4 0 IN PRP$ NN NN : O
effect effect 0 0 0 0 0 0 0 0 6 0 PRP$ NN NN : NN O
- - 0 0 1 0 0 0 0 0 1 0 NN NN : NN NNP O
enzyme enzyme 0 0 0 0 0 0 0 0 6 0 NN : NN NNP NONE O
overexpression. overexpression. 0 0 0 0 0 0 0 0 15 0 : NN NNP NONE NONE O
Genistein-induced Genistein-induced 1 0 1 0 0 0 0 0 17 0 NONE NONE JJ NN NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 NONE JJ NN NN NN B_TIMEXCCP
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 arrest NN NN NN NN IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NN NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NN O
intestinal intestinal 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NN NN O
colon colon 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NN -NONE- O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ NN NN -NONE- VBZ O
Caco-2 Caco-2 1 0 1 0 0 0 0 1 6 0 NN NN -NONE- VBZ VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 NN -NONE- VBZ VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- VBZ VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBZ VBZ VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN NNP NNP O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 VBN IN NNP NNP CC O
B1 B1 1 1 0 0 0 0 0 1 2 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Chk2 Chk2 1 0 0 0 0 0 0 1 4 0 NNP CC NNP NNP NNP O
down-regulation. down-regulation. 0 0 1 0 0 0 0 0 16 0 CC NNP NNP NNP NNP O
Han Han 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kurita Kurita 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Isoda Isoda 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
H. H. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Graduate Graduate 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Life Life 1 0 0 0 0 0 0 0 4 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Environmental Environmental 1 0 0 0 0 0 0 0 13 0 NNP CC NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CD O
Tsukuba, Tsukuba, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP CD -NONE- O
1-1-1 1-1-1 0 0 1 0 0 0 0 1 5 0 IN NNP CD -NONE- JJ O
Tennodai, Tennodai, 1 0 0 0 1 0 0 0 9 0 NNP CD -NONE- JJ NN O
Tsukuba, Tsukuba, 1 0 0 0 1 0 0 0 8 0 CD -NONE- JJ NN CD O
Ibaraki, Ibaraki, 1 0 0 0 1 0 0 0 8 0 -NONE- JJ NN CD NN O
305-8572, 305-8572, 0 0 1 0 1 0 0 1 9 0 JJ NN CD NN NNP O
Japan, Japan, 1 0 0 0 1 0 0 0 6 0 NN CD NN NNP NNP O
han.junkyu.gn@u.tsukuba.ac.jp. han.junkyu.gn@u.tsukuba.ac.jp. 0 0 0 0 0 0 0 0 30 0 CD NN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP VBZ O
Genistein Genistein 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT JJ JJ O
isoflavonic isoflavonic 0 0 0 0 0 0 0 0 11 0 VBZ DT JJ JJ VBN O
phyto-oestrogen phyto-oestrogen 0 0 1 0 0 0 0 0 15 0 DT JJ JJ VBN IN O
contained contained 0 0 0 0 0 0 0 0 9 0 JJ JJ VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ VBN IN NN NNP O
soya soya 0 0 0 0 0 0 0 0 4 0 VBN IN NN NNP NNP O
beans. beans. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ VBN TO O
thought thought 0 0 0 0 0 0 0 0 7 0 NNP VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB JJ O
display display 0 0 0 0 0 0 0 0 7 0 VBN TO VB JJ NNP O
anti-cancer anti-cancer 0 0 1 0 0 0 0 0 11 0 TO VB JJ NNP NNP O
effects. effects. 0 0 0 0 0 0 0 0 8 0 VB JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
designed designed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB PRP$ O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBN TO VB PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 TO VB PRP$ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VB PRP$ NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NN O
intestinal intestinal 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NN NN O
colon colon 0 0 0 0 0 0 0 0 5 0 JJ JJ NN NN -NONE- O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ NN NN -NONE- NNP O
Caco-2 Caco-2 1 0 1 0 0 0 0 1 6 0 NN NN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN -NONE- NNP NNP NNP O
MTT MTT 1 1 0 0 0 0 0 0 3 0 -NONE- NNP NNP NNP NN O
assay, assay, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP NN JJ O
flow flow 0 0 0 0 0 0 0 0 4 0 NNP NNP NN JJ NN O
cytometric cytometric 0 0 0 0 0 0 0 0 10 0 NNP NN JJ NN CC O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
western western 0 0 0 0 0 0 0 0 7 0 NN CC JJ NN VBD O
blotting blotting 0 0 0 0 0 0 0 0 8 0 CC JJ NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD VBN TO O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VB DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
genistein genistein 0 0 0 0 0 0 0 0 9 0 NN IN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NN O
proliferation, proliferation, 0 0 0 0 1 0 0 0 14 0 IN NN NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNS O
protein protein 0 0 0 0 0 0 0 0 7 0 NN CC NN NNS IN O
alterations alterations 0 0 0 0 0 0 0 0 11 0 CC NN NNS IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBN NN O
selected selected 0 0 0 0 0 0 0 0 8 0 NNS IN VBN NN JJ O
cell cell 0 0 0 0 0 0 0 0 4 0 IN VBN NN JJ NNS O
cycle-related cycle-related 0 0 1 0 0 0 0 0 13 0 VBN NN JJ NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 NN JJ NNS IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN -NONE- NNP O
Caco-2 Caco-2 1 0 1 0 0 0 0 1 6 0 NNS IN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN -NONE- NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 -NONE- NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNS VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN CC O
genistein genistein 0 0 0 0 0 0 0 0 9 0 VBD IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN RB O
daidzein daidzein 0 0 0 0 0 0 0 0 8 0 NN CC NN RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 CC NN RB VBN NN O
suppressed suppressed 0 0 0 0 0 0 0 0 10 0 NN RB VBN NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 RB VBN NN NNP NNP O
proliferation. proliferation. 0 0 0 0 0 0 0 0 14 0 VBN NN NNP NNP NN O
Genistein Genistein 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NN VBD O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
demonstrated demonstrated 0 0 0 0 0 0 0 0 12 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB NN O
modulate modulate 0 0 0 0 0 0 0 0 8 0 VBN TO VB NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 TO VB NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 VB NN NN NN IN O
distribution distribution 0 0 0 0 0 0 0 0 12 0 NN NN NN IN NN O
through through 0 0 0 0 0 0 0 0 7 0 NN NN IN NN IN O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NN IN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NN O
G2/M G2/M 1 1 0 1 0 0 0 1 4 0 NNS IN JJ NN IN B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 IN JJ NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN NN O
decreasing decreasing 0 0 0 0 0 0 0 0 10 0 DT JJ NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 NN IN NNP NNP CC O
B1 B1 1 1 0 0 0 0 0 1 2 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NN O
Serine/threonine-protein Serine/threonine-protein 1 0 1 1 0 0 0 0 24 0 NNP CC NNP NN CD O
kinase kinase 0 0 0 0 0 0 0 0 6 0 CC NNP NN CD NN O
2 2 0 0 0 0 0 0 1 1 1 0 NNP NN CD NN NNS O
(Chk2) (Chk2) 0 0 0 0 0 0 0 1 6 0 NN CD NN NNS NNP O
proteins proteins 0 0 0 0 0 0 0 0 8 0 CD NN NNS NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 NN NNS NNP NNP NN O
However, However, 1 0 0 0 1 0 0 0 8 0 NNS NNP NNP NN VBD O
daidzein daidzein 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD RB O
did did 0 0 0 0 0 0 0 0 3 0 NNP NN VBD RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBD RB VB DT O
alter alter 0 0 0 0 0 0 0 0 5 0 VBD RB VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VB DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VB DT NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 DT NN NN NN IN O
progression progression 0 0 0 0 0 0 0 0 11 0 NN NN NN IN -NONE- O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN -NONE- NNP O
Caco-2 Caco-2 1 0 1 0 0 0 0 1 6 0 NN IN -NONE- NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN -NONE- NNP NNP DT O
All All 1 0 0 0 0 0 0 0 3 0 -NONE- NNP NNP DT NN O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NN RB O
observation observation 0 0 0 0 0 0 0 0 11 0 NNP DT NN RB VBP O
strongly strongly 0 0 0 0 0 0 0 0 8 0 DT NN RB VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NN RB VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 RB VBP IN NN VBZ O
genistein genistein 0 0 0 0 0 0 0 0 9 0 VBP IN NN VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 IN NN VBZ JJ NN O
anti-proliferative anti-proliferative 0 0 1 0 0 0 0 0 18 0 NN VBZ JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBZ JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN NN JJ NN O
intestinal intestinal 0 0 0 0 0 0 0 0 10 0 IN NN JJ NN NN O
colon colon 0 0 0 0 0 0 0 0 5 0 NN JJ NN NN -NONE- O
cancer cancer 0 0 0 0 0 0 0 0 6 0 JJ NN NN -NONE- VBZ O
Caco-2 Caco-2 1 0 1 0 0 0 0 1 6 0 NN NN -NONE- VBZ IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN -NONE- VBZ IN DT O
through through 0 0 0 0 0 0 0 0 7 0 -NONE- VBZ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT NN IN O
down-regulation down-regulation 0 0 1 0 0 0 0 0 15 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN NN O
cycle cycle 0 0 0 0 0 0 0 0 5 0 IN NN NN NN NN O
check check 0 0 0 0 0 0 0 0 5 0 NN NN NN NN -NONE- O
point point 0 0 0 0 0 0 0 0 5 0 NN NN NN -NONE- NNP O
proteins, proteins, 0 0 0 0 1 0 0 0 9 0 NN NN -NONE- NNP NNP O
Cyclin Cyclin 1 0 0 0 0 0 0 0 6 0 NN -NONE- NNP NNP CC O
B1 B1 1 1 0 0 0 0 0 1 2 0 -NONE- NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NONE O
Chk2. Chk2. 1 0 0 0 0 0 0 1 5 0 NNP CC NNP NONE NONE O
Integrin-linked Integrin-linked 1 0 1 0 0 0 0 0 15 0 NONE NONE JJ NN VBG O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NONE JJ NN VBG NNS O
silencing silencing 0 0 0 0 0 0 0 0 9 0 JJ NN VBG NNS DT O
induces induces 0 0 0 0 0 0 0 0 7 0 NN VBG NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBG NNS DT JJ NNS O
S/G2/M S/G2/M 1 1 0 1 0 0 0 1 6 phases NNS DT JJ NNS VBP B_TIMEXCCP
phases phases 0 0 0 0 0 0 0 0 6 0 DT JJ NNS VBP NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP NN VBG O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNS VBP NN VBG CC O
slowing slowing 0 0 0 0 0 0 0 0 7 0 VBP NN VBG CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN VBG CC NNS JJ O
modulates modulates 0 0 0 0 0 0 0 0 9 0 VBG CC NNS JJ NNS O
metastasis-related metastasis-related 0 0 1 0 0 0 0 0 18 0 CC NNS JJ NNS IN O
genes genes 0 0 0 0 0 0 0 0 5 0 NNS JJ NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP NN O
SGC7901 SGC7901 1 1 0 0 0 0 0 1 7 0 NNS IN NNP NN JJ O
human human 0 0 0 0 0 0 0 0 5 0 IN NNP NN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NNP NN JJ NN NNP O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 NN JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
Song Song 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhao Zhao 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jiang Jiang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Oncology, Oncology, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Provincial Provincial 1 0 0 0 0 0 0 0 10 0 IN NNP NNP NNP VBD O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP VBD TO O
affiliated affiliated 0 0 0 0 0 0 0 0 10 0 NNP NNP VBD TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNP VBD TO NNP NNP O
Shandong Shandong 1 0 0 0 0 0 0 0 8 0 VBD TO NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 TO NNP NNP NNP NNP O
Jinan, Jinan, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
songwei_sd@yahoo.com.cn songwei_sd@yahoo.com.cn 0 0 0 0 0 0 0 0 23 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND BACKGROUND 1 1 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
AND AND 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
AIM: AIM: 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NN O
Integrin-linked Integrin-linked 1 0 1 0 0 0 0 0 15 0 NNP NNP NNP NN VBZ O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
implicated implicated 0 0 0 0 0 0 0 0 10 0 VBZ VBN VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NN IN O
metastasis metastasis 0 0 0 0 0 0 0 0 10 0 VBN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ NNP O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNP NNP O
tumors. tumors. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NNS O
Recent Recent 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NNS VBP RB VBN IN O
shown shown 0 0 0 0 0 0 0 0 5 0 VBP RB VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
down-regulation down-regulation 0 0 1 0 0 0 0 0 15 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
integrin-linked integrin-linked 0 0 1 0 0 0 0 0 15 0 NN IN JJ NN VBZ O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN JJ NN VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 JJ NN VBZ JJ JJ O
anti-tumor anti-tumor 0 0 1 0 0 0 0 0 10 0 NN VBZ JJ JJ IN O
potential potential 0 0 0 0 0 0 0 0 9 0 VBZ JJ JJ IN NN O
by by 0 0 0 0 0 0 0 0 2 0 JJ JJ IN NN DT O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 JJ IN NN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT JJ NN O
metastatic metastatic 0 0 0 0 0 0 0 0 10 0 NN DT JJ NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
several several 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS IN O
types types 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN VBN JJ O
cultured cultured 0 0 0 0 0 0 0 0 8 0 NNS IN VBN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 IN VBN JJ NN NNP O
cancer cancer 0 0 0 0 0 0 0 0 6 0 VBN JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 NNP DT NN IN WDT O
by by 0 0 0 0 0 0 0 0 2 0 DT NN IN WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT JJ NN O
integrin-linked integrin-linked 0 0 1 0 0 0 0 0 15 0 IN WDT JJ NN NNS O
kinase kinase 0 0 0 0 0 0 0 0 6 0 WDT JJ NN NNS VBZ O
regulates regulates 0 0 0 0 0 0 0 0 9 0 JJ NN NNS VBZ IN O
metastasis metastasis 0 0 0 0 0 0 0 0 10 0 NN NNS VBZ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBZ IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 VBZ IN JJ JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN VBZ O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 JJ JJ NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ RB RB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB RB NNP O
fully fully 0 0 0 0 0 0 0 0 5 0 VBZ RB RB NNP NNP O
clear. clear. 0 0 0 0 0 0 0 0 6 0 RB RB NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 RB NNP NNP VBD DT O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBD DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
integrin-linked integrin-linked 0 0 1 0 0 0 0 0 15 0 NN IN JJ NN NN O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN IN O
deletion deletion 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNS O
metastasis-associated metastasis-associated 0 0 1 0 0 0 0 0 21 0 NN IN JJ NNS IN O
markers markers 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 NNS IN JJ JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN -NONE- O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 JJ JJ NN -NONE- NN O
SGC-7901 SGC-7901 1 1 1 0 0 0 0 1 8 0 JJ NN -NONE- NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 NN -NONE- NN NNP NNP O
lines. lines. 0 0 0 0 0 0 0 0 6 0 -NONE- NN NNP NNP NNP O
METHODS: METHODS: 1 1 0 0 0 0 0 0 8 0 NN NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD NN O
generated generated 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP VBD NN NNS VBN O
lines lines 0 0 0 0 0 0 0 0 5 0 VBD NN NNS VBN IN O
depleted depleted 0 0 0 0 0 0 0 0 8 0 NN NNS VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBN IN JJ NNP O
integrin-linked integrin-linked 0 0 1 0 0 0 0 0 15 0 VBN IN JJ NNP NNP O
kinase. kinase. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NN O
Cell Cell 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN CC O
adhesion adhesion 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN VBD O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN CC NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CC NN VBD VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NN O
MTS MTS 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN CC O
assay assay 0 0 0 0 0 0 0 0 5 0 DT NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NNP O
transwell transwell 0 0 0 0 0 0 0 0 9 0 NN CC NN NNP NNP O
assay. assay. 0 0 0 0 0 0 0 0 6 0 CC NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBD O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NNP O
flow flow 0 0 0 0 0 0 0 0 4 0 VBN IN NN NNP NNP O
cytometry. cytometry. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP IN O
Expression Expression 1 0 0 0 0 0 0 0 10 0 NN NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNS O
metastasis-related metastasis-related 0 0 1 0 0 0 0 0 18 0 NNP IN JJ NNS VBD O
genes genes 0 0 0 0 0 0 0 0 5 0 IN JJ NNS VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NNS VBD VBN IN O
assessed assessed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN -NONE- O
reporter reporter 0 0 0 0 0 0 0 0 8 0 VBN IN NN -NONE- JJ O
assay, assay, 0 0 0 0 1 0 0 0 6 0 IN NN -NONE- JJ JJ O
quantitative quantitative 0 0 0 0 0 0 0 0 12 0 NN -NONE- JJ JJ CC O
RT-PCR RT-PCR 1 1 1 0 0 0 0 0 6 0 -NONE- JJ JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ JJ CC JJ NNP O
western western 0 0 0 0 0 0 0 0 7 0 JJ CC JJ NNP NNP O
blotting. blotting. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS VBD O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBD DT O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNS VBD DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNS VBD DT NN NN O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 VBD DT NN NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 DT NN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN CC O
adhesion adhesion 0 0 0 0 0 0 0 0 8 0 IN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
invasion invasion 0 0 0 0 0 0 0 0 8 0 NN CC NN IN VBG O
after after 0 0 0 0 0 0 0 0 5 0 CC NN IN VBG IN O
silencing silencing 0 0 0 0 0 0 0 0 9 0 NN IN VBG IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN VBG IN JJ NNP O
integrin-linked integrin-linked 0 0 1 0 0 0 0 0 15 0 VBG IN JJ NNP NNP O
kinase. kinase. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBD O
cycle cycle 0 0 0 0 0 0 0 0 5 0 NNP NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
slowed slowed 0 0 0 0 0 0 0 0 6 0 NN VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NNP O
S/G2/M S/G2/M 1 1 0 1 0 0 0 1 6 0 VBN IN JJ NNP JJ B_TIMEXCCP
phases. phases. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP JJ NNS O
Metastasis-related Metastasis-related 1 0 1 0 0 0 0 0 18 0 JJ NNP JJ NNS -NONE- O
genes genes 0 0 0 0 0 0 0 0 5 0 NNP JJ NNS -NONE- -NONE- O
E-cadherin, E-cadherin, 1 0 1 0 1 0 0 0 11 0 JJ NNS -NONE- -NONE- CC O
MMP-2/9 MMP-2/9 1 1 1 1 0 0 0 1 7 0 NNS -NONE- -NONE- CC VB O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC VB JJ O
cystatin cystatin 0 0 0 0 0 0 0 0 8 0 -NONE- CC VB JJ IN O
B, B, 1 1 0 0 1 0 0 0 2 0 CC VB JJ IN RB O
as as 0 0 0 0 0 0 0 0 2 0 VB JJ IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 JJ IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN NNS O
signaling signaling 0 0 0 0 0 0 0 0 9 0 IN DT NN NNS -NONE- O
molecules molecules 0 0 0 0 0 0 0 0 9 0 DT NN NNS -NONE- -NONE- O
p-Akt, p-Akt, 0 0 1 0 1 0 0 0 6 0 NN NNS -NONE- -NONE- CC O
NF-κB, NF-κB, 1 0 1 0 1 0 0 0 6 0 NNS -NONE- -NONE- CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC -NONE- JJ O
AP-1 AP-1 1 1 1 0 0 0 0 1 4 0 -NONE- CC -NONE- JJ VBD O
activation, activation, 0 0 0 0 1 0 0 0 11 0 CC -NONE- JJ VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 -NONE- JJ VBD RB NNP O
also also 0 0 0 0 0 0 0 0 4 0 JJ VBD RB NNP NNP O
modulated. modulated. 0 0 0 0 0 0 0 0 10 0 VBD RB NNP NNP NNS O
Our Our 1 0 0 0 0 0 0 0 3 0 RB NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN JJ NN O
integrin-linked integrin-linked 0 0 1 0 0 0 0 0 15 0 VBP IN JJ NN NNS O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN JJ NN NNS DT O
plays plays 0 0 0 0 0 0 0 0 5 0 JJ NN NNS DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN NNS DT JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 NNS DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
metastasis metastasis 0 0 0 0 0 0 0 0 10 0 NN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ JJ O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NN NNP O
carcinoma carcinoma 0 0 0 0 0 0 0 0 9 0 JJ JJ NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 JJ NN NNP NNP NNP O
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 NN NNP NNP NNP IN O
Down-regulation Down-regulation 1 0 1 0 0 0 0 0 15 0 NNP NNP NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NN O
integrin-linked integrin-linked 0 0 1 0 0 0 0 0 15 0 NNP IN JJ NN VBD O
kinase kinase 0 0 0 0 0 0 0 0 6 0 IN JJ NN VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 JJ NN VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN VBD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NN IN O
impairment impairment 0 0 0 0 0 0 0 0 10 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
metastatic metastatic 0 0 0 0 0 0 0 0 10 0 IN DT JJ NN IN O
potential potential 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
gastric gastric 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NNS O
tumor tumor 0 0 0 0 0 0 0 0 5 0 IN JJ NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN VBG O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN VBG JJ O
regulating regulating 0 0 0 0 0 0 0 0 10 0 NNS IN VBG JJ NN O
metastasis-related metastasis-related 0 0 1 0 0 0 0 0 18 0 IN VBG JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 VBG JJ NN NN IN O
expression, expression, 0 0 0 0 1 0 0 0 11 0 JJ NN NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NN DT O
inhibiting inhibiting 0 0 0 0 0 0 0 0 10 0 NN IN NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NNP NN O
Akt Akt 1 0 0 0 0 0 0 0 3 0 NN DT NNP NN IN O
pathway pathway 0 0 0 0 0 0 0 0 7 0 DT NNP NN IN RB O
as as 0 0 0 0 0 0 0 0 2 0 NNP NN IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NN IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NN IN O
activity activity 0 0 0 0 0 0 0 0 8 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
transcription transcription 0 0 0 0 0 0 0 0 13 0 NN IN NN NNP NNP O
factors. factors. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP NN O
Integrin-linked Integrin-linked 1 0 1 0 0 0 0 0 15 0 NN NNP NNP NN MD O
kinase kinase 0 0 0 0 0 0 0 0 6 0 NNP NNP NN MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 MD VB VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJ JJ O
potential potential 0 0 0 0 0 0 0 0 9 0 IN DT JJ JJ NNP O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 DT JJ JJ NNP NONE O
target. target. 0 0 0 0 0 0 0 0 7 0 JJ JJ NNP NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NNP CC O
Design Design 1 0 0 0 0 0 0 0 6 0 NONE DT NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 DT NNP CC NNP IN O
Implementation Implementation 1 0 0 0 0 0 0 0 14 0 NNP CC NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP NNP O
Adsorptive Adsorptive 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP IN O
Removal Removal 1 0 0 0 0 0 0 0 7 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
Cu(II) Cu(II) 1 0 0 0 0 0 0 0 6 0 NNP IN NNP IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 IN NNP IN NNP NNP O
Leachate Leachate 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Using Using 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP NNP O
ANFIS. ANFIS. 1 1 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Turan Turan 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
NG, NG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ozgonenel Ozgonenel 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
O. O. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Environmental Environmental 1 0 0 0 0 0 0 0 13 0 NNP IN NNP NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 IN NNP NNP NNP NNP O
Engineering Engineering 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Faculty, Faculty, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP NNP O
Ondokuz Ondokuz 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Mayıs Mayıs 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Samsun, Samsun, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP CD O
Kurupelit Kurupelit 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP CD NNP O
55139, 55139, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
Turkey. Turkey. 1 0 0 0 0 0 0 0 7 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP VBD O
Clinoptilolite Clinoptilolite 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
investigated investigated 0 0 0 0 0 0 0 0 12 0 NNP VBD VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
removal removal 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
Cu(II) Cu(II) 1 0 0 0 0 0 0 0 6 0 NN IN NNP NNS IN O
ions ions 0 0 0 0 0 0 0 0 4 0 IN NNP NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNS IN JJ NNP O
industrial industrial 0 0 0 0 0 0 0 0 10 0 NNS IN JJ NNP NNP O
leachate. leachate. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP JJ O
Adaptive Adaptive 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP JJ NN O
neural neural 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN NN O
fuzzy fuzzy 0 0 0 0 0 0 0 0 5 0 NNP JJ NN NN NN O
interface interface 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN NN O
system system 0 0 0 0 0 0 0 0 6 0 NN NN NN NN VBD O
(ANFIS) (ANFIS) 0 1 0 0 0 0 0 0 7 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 NN VBD VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NN DT O
modeling modeling 0 0 0 0 0 0 0 0 8 0 VBN IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN NN O
batch batch 0 0 0 0 0 0 0 0 5 0 NN DT NN NN NN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 DT NN NN NN CC O
system system 0 0 0 0 0 0 0 0 6 0 NN NN NN CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBG DT O
predicting predicting 0 0 0 0 0 0 0 0 10 0 NN CC VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC VBG DT JJ NN O
optimal optimal 0 0 0 0 0 0 0 0 7 0 VBG DT JJ NN NN O
input input 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN WDT O
values, values, 0 0 0 0 1 0 0 0 7 0 JJ NN NN WDT -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT -NONE- JJ O
is, is, 0 0 0 0 1 0 0 0 3 0 NN WDT -NONE- JJ NN O
initial initial 0 0 0 0 0 0 0 0 7 0 WDT -NONE- JJ NN NN O
pH, pH, 0 0 0 0 1 0 0 0 3 0 -NONE- JJ NN NN NN O
adsorbent adsorbent 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN CC O
dosage, dosage, 0 0 0 0 1 0 0 0 7 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
contact contact 0 0 0 0 0 0 0 0 7 0 NN CC NN NNP NNP O
time. time. 0 0 0 0 0 0 0 0 5 0 CC NN NNP NNP VBD O
Experiments Experiments 1 0 0 0 0 0 0 0 11 0 NN NNP NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD VBN IN O
studied studied 0 0 0 0 0 0 0 0 7 0 NNP VBD VBN IN NN O
under under 0 0 0 0 0 0 0 0 5 0 VBD VBN IN NN NN O
laboratory laboratory 0 0 0 0 0 0 0 0 10 0 VBN IN NN NN CC O
batch batch 0 0 0 0 0 0 0 0 5 0 IN NN NN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VBN VBN O
fixed fixed 0 0 0 0 0 0 0 0 5 0 NN CC VBN VBN NNP O
bed bed 0 0 0 0 0 0 0 0 3 0 CC VBN VBN NNP NNP O
conditions. conditions. 0 0 0 0 0 0 0 0 11 0 VBN VBN NNP NNP VBZ O
The The 1 0 0 0 0 0 0 0 3 0 VBN NNP NNP VBZ IN O
outcomes outcomes 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 NNP VBZ IN VBN NNP O
suggested suggested 0 0 0 0 0 0 0 0 9 0 VBZ IN VBN NNP NN O
ANFIS ANFIS 1 1 0 0 0 0 0 0 5 0 IN VBN NNP NN VBD O
modeling modeling 0 0 0 0 0 0 0 0 8 0 VBN NNP NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NN VBD RB VBN O
then then 0 0 0 0 0 0 0 0 4 0 NN VBD RB VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 VBD RB VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBN TO DT JJ JJ O
full full 0 0 0 0 0 0 0 0 4 0 TO DT JJ JJ NN O
factorial factorial 0 0 0 0 0 0 0 0 9 0 DT JJ JJ NN NN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 JJ JJ NN NN NN O
design design 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN WDT O
(2(3)), (2(3)), 0 0 0 0 1 0 0 1 7 0 NN NN NN WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN WDT VBD VBN TO O
utilized utilized 0 0 0 0 0 0 0 0 8 0 WDT VBD VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO NN DT O
assess assess 0 0 0 0 0 0 0 0 6 0 VBN TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NNS O
three three 0 0 0 0 0 0 0 0 5 0 NN IN CD NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 IN CD NNS IN DT O
on on 0 0 0 0 0 0 0 0 2 0 CD NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
adsorption adsorption 0 0 0 0 0 0 0 0 10 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNS O
Cu(II) Cu(II) 1 0 0 0 0 0 0 0 6 0 NN IN NNP NNS IN O
ions ions 0 0 0 0 0 0 0 0 4 0 IN NNP NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ NN O
aqueous aqueous 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NN IN O
leachate leachate 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNP O
industrial industrial 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNP NNP O
waste. waste. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP VBD O
It It 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NNP VBD VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNS O
optimized optimized 0 0 0 0 0 0 0 0 9 0 IN DT JJ NNS VBP O
parameters parameters 0 0 0 0 0 0 0 0 10 0 DT JJ NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP RB JJ O
almost almost 0 0 0 0 0 0 0 0 6 0 NNS VBP RB JJ TO O
close close 0 0 0 0 0 0 0 0 5 0 VBP RB JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 RB JJ TO DT NNP O
each each 0 0 0 0 0 0 0 0 4 0 JJ TO DT NNP NNP O
other. other. 0 0 0 0 0 0 0 0 6 0 TO DT NNP NNP JJS O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP JJS NN O
highest highest 0 0 0 0 0 0 0 0 7 0 NNP NNP JJS NN NN O
removal removal 0 0 0 0 0 0 0 0 7 0 NNP JJS NN NN VBD O
efficiency efficiency 0 0 0 0 0 0 0 0 10 0 JJS NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NN VBD VBN IN IN O
as as 0 0 0 0 0 0 0 0 2 0 VBD VBN IN IN CD O
about about 0 0 0 0 0 0 0 0 5 0 VBN IN IN CD IN O
93.65% 93.65% 0 0 0 0 0 0 0 1 6 0 IN IN CD IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 IN CD IN NNP CD O
pH pH 0 0 0 0 0 0 0 0 2 0 CD IN NNP CD NN O
6, 6, 0 0 0 0 1 0 0 1 2 0 IN NNP CD NN NN O
adsorbent adsorbent 0 0 0 0 0 0 0 0 9 0 NNP CD NN NN CD O
dosage dosage 0 0 0 0 0 0 0 0 6 0 CD NN NN CD NN O
11.4 11.4 0 0 0 0 0 0 0 1 4 0 NN NN CD NN CC O
g/L, g/L, 0 0 0 1 1 0 0 0 4 0 NN CD NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC NN NN O
contact contact 0 0 0 0 0 0 0 0 7 0 NN CC NN NN CD O
time time 0 0 0 0 0 0 0 0 4 0 CC NN NN CD NN O
33 33 0 0 0 0 0 0 1 1 2 0 NN NN CD NN IN O
min min 0 0 0 0 0 0 0 0 3 0 NN CD NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 CD NN IN NN NNS O
batch batch 0 0 0 0 0 0 0 0 5 0 NN IN NN NNS IN O
conditions conditions 0 0 0 0 0 0 0 0 10 0 IN NN NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN CD JJ O
2(3) 2(3) 0 0 0 0 0 0 0 1 4 0 NNS IN CD JJ NN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 IN CD JJ NN CC O
design design 0 0 0 0 0 0 0 0 6 0 CD JJ NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC IN CD O
about about 0 0 0 0 0 0 0 0 5 0 NN CC IN CD IN O
90.43% 90.43% 0 0 0 0 0 0 0 1 6 0 CC IN CD IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 IN CD IN NNP CD O
pH pH 0 0 0 0 0 0 0 0 2 0 CD IN NNP CD NN O
5, 5, 0 0 0 0 1 0 0 1 2 0 IN NNP CD NN NN O
adsorbent adsorbent 0 0 0 0 0 0 0 0 9 0 NNP CD NN NN CD O
dosage dosage 0 0 0 0 0 0 0 0 6 0 CD NN NN CD JJ O
15 15 0 0 0 0 0 0 1 1 2 0 NN NN CD JJ CC O
g/L g/L 0 0 0 1 0 0 0 0 3 0 NN CD JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 CD JJ CC NN NN O
contact contact 0 0 0 0 0 0 0 0 7 0 JJ CC NN NN CD O
time time 0 0 0 0 0 0 0 0 4 0 CC NN NN CD NN O
35 35 0 0 0 0 0 0 1 1 2 0 NN NN CD NN IN O
min min 0 0 0 0 0 0 0 0 3 0 NN CD NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 CD NN IN NN NNS O
batch batch 0 0 0 0 0 0 0 0 5 0 NN IN NN NNS IN O
conditions conditions 0 0 0 0 0 0 0 0 10 0 IN NN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NNP O
ANFIS. ANFIS. 1 1 0 0 0 0 0 0 6 0 NNS IN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNS VBP O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP NNS VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN JJ VBZ O
clinoptilolite clinoptilolite 0 0 0 0 0 0 0 0 14 0 VBP IN JJ VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 IN JJ VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 JJ VBZ DT JJ NN O
efficient efficient 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN CC O
sorbent sorbent 0 0 0 0 0 0 0 0 7 0 DT JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP WDT O
ANFIS, ANFIS, 1 1 0 0 1 0 0 0 6 0 NN CC NNP WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 CC NNP WDT VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP WDT VBZ JJ TO O
easy easy 0 0 0 0 0 0 0 0 4 0 WDT VBZ JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO NN CC O
implement implement 0 0 0 0 0 0 0 0 9 0 JJ TO NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 TO NN CC VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NN CC VBZ JJ TO O
able able 0 0 0 0 0 0 0 0 4 0 CC VBZ JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO NN DT O
model model 0 0 0 0 0 0 0 0 5 0 JJ TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN NN O
batch batch 0 0 0 0 0 0 0 0 5 0 NN DT NN NN NNP O
experimental experimental 0 0 0 0 0 0 0 0 12 0 DT NN NN NNP NONE O
system. system. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NONE NONE O
Prevalence Prevalence 1 0 0 0 0 0 0 0 10 0 NONE NONE NN NN CC O
rate rate 0 0 0 0 0 0 0 0 4 0 NONE NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB NNS O
risk risk 0 0 0 0 0 0 0 0 4 0 NN CC VB NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 CC VB NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VB NNS IN NN IN O
depression depression 0 0 0 0 0 0 0 0 10 0 NNS IN NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNS IN O
outpatients outpatients 0 0 0 0 0 0 0 0 11 0 NN IN NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NN NNP O
premature premature 0 0 0 0 0 0 0 0 9 0 NNS IN NN NNP NNP O
ejaculation. ejaculation. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gao Gao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Xia Xia 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
L, L, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hao Hao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhou Zhou 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Liang Liang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
C. C. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Urology, Urology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
First First 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Affiliated Affiliated 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Anhui Anhui 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Hefei, Hefei, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP CD O
Anhui Anhui 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD NNP O
230032, 230032, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
purpose purpose 0 0 0 0 0 0 0 0 7 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBZ TO O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBZ TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN NN O
prevalence prevalence 0 0 0 0 0 0 0 0 10 0 VB DT NN NN CC O
rate rate 0 0 0 0 0 0 0 0 4 0 DT NN NN CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC VB NNS O
risk risk 0 0 0 0 0 0 0 0 4 0 NN CC VB NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 CC VB NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VB NNS IN NN IN O
depression depression 0 0 0 0 0 0 0 0 10 0 NNS IN NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNS WP O
outpatients outpatients 0 0 0 0 0 0 0 0 11 0 NN IN NNS WP VBD O
who who 0 0 0 0 0 0 0 0 3 0 IN NNS WP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS WP VBD VBN IN O
diagnosed diagnosed 0 0 0 0 0 0 0 0 9 0 WP VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NNP O
PE. PE. 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NNP IN O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 IN NNP NNP IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 NNP NNP IN NNP CD O
September September 1 0 0 0 0 0 0 0 9 0 NNP IN NNP CD CC O
2009 2009 0 0 0 0 0 0 1 1 4 0 IN NNP CD CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC NNP CD O
September September 1 0 0 0 0 0 0 0 9 0 CD CC NNP CD CD O
2011, 2011, 0 0 0 0 1 0 0 1 5 0 CC NNP CD CD NNS O
1801 1801 0 0 0 0 0 0 1 1 4 0 NNP CD CD NNS IN O
outpatients outpatients 0 0 0 0 0 0 0 0 11 0 CD CD NNS IN NN O
at at 0 0 0 0 0 0 0 0 2 0 CD NNS IN NN NNS O
andrology andrology 0 0 0 0 0 0 0 0 9 0 NNS IN NN NNS VBD O
clinics clinics 0 0 0 0 0 0 0 0 7 0 IN NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN CC O
enrolled enrolled 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBN CC VBD TO O
consented consented 0 0 0 0 0 0 0 0 9 0 VBN CC VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CC VBD TO VB IN O
participate participate 0 0 0 0 0 0 0 0 11 0 VBD TO VB IN PRP$ O
in in 0 0 0 0 0 0 0 0 2 0 TO VB IN PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 VB IN PRP$ NN IN O
survey survey 0 0 0 0 0 0 0 0 6 0 IN PRP$ NN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN VBN DT O
completed completed 0 0 0 0 0 0 0 0 9 0 NN IN VBN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN VBN DT JJ NNP O
verbal verbal 0 0 0 0 0 0 0 0 6 0 VBN DT JJ NNP NNP O
questionnaire. questionnaire. 0 0 0 0 0 0 0 0 14 0 DT JJ NNP NNP VBD O
It It 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBD DT O
included included 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN NN O
following: following: 0 0 0 0 0 0 0 0 10 0 VBD DT NN NN JJ O
(1) (1) 0 0 0 0 0 0 0 1 3 0 DT NN NN JJ NNS O
demographic demographic 0 0 0 0 0 0 0 0 11 0 NN NN JJ NNS -NONE- O
data data 0 0 0 0 0 0 0 0 4 0 NN JJ NNS -NONE- -NONE- O
(e.g., (e.g., 0 0 0 0 1 0 0 0 6 0 JJ NNS -NONE- -NONE- NN O
age, age, 0 0 0 0 1 0 0 0 4 0 NNS -NONE- -NONE- NN NN O
body body 0 0 0 0 0 0 0 0 4 0 -NONE- -NONE- NN NN NN O
mass mass 0 0 0 0 0 0 0 0 4 0 -NONE- NN NN NN NN O
index), index), 0 0 0 0 1 0 0 0 7 0 NN NN NN NN NNP O
(2) (2) 0 0 0 0 0 0 0 1 3 0 NN NN NN NNP NNP O
PE PE 1 1 0 0 0 0 0 0 2 0 NN NN NNP NNP JJ O
duration, duration, 0 0 0 0 1 0 0 0 9 0 NN NNP NNP JJ NN O
medical medical 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN CC O
history, history, 0 0 0 0 1 0 0 0 8 0 NNP JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
sexual sexual 0 0 0 0 0 0 0 0 6 0 NN CC JJ NN NN O
history, history, 0 0 0 0 1 0 0 0 8 0 CC JJ NN NN JJ O
(3) (3) 0 0 0 0 0 0 0 1 3 0 JJ NN NN JJ JJ O
self-estimated self-estimated 0 0 1 0 0 0 0 0 14 0 NN NN JJ JJ NN O
intravaginal intravaginal 0 0 0 0 0 0 0 0 12 0 NN JJ JJ NN NN O
ejaculatory ejaculatory 0 0 0 0 0 0 0 0 11 0 JJ JJ NN NN NN O
latency latency 0 0 0 0 0 0 0 0 7 0 JJ NN NN NN NN O
times, times, 0 0 0 0 1 0 0 0 6 0 NN NN NN NN DT O
(4) (4) 0 0 0 0 0 0 0 1 3 0 NN NN NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NNP NNP O
Zung Zung 1 0 0 0 0 0 0 0 4 0 NN DT NNP NNP NNP O
Self-rating Self-rating 1 0 1 0 0 0 0 0 11 0 DT NNP NNP NNP NNP O
Depression Depression 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Scale Scale 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP CC O
(SDS), (SDS), 0 1 0 0 1 0 0 0 6 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP DT O
(5) (5) 0 0 0 0 0 0 0 1 3 0 NNP CC NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CC NNP DT NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP DT NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 DT NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Health Health 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Chronic Chronic 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Prostatitis Prostatitis 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Symptom Symptom 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Index Index 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP CC O
(NIH-CPSI) (NIH-CPSI) 0 1 1 0 0 0 0 0 10 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP DT O
(6) (6) 0 0 0 0 0 0 0 1 3 0 NNP CC NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 CC NNP DT NNP NNP O
International International 1 0 0 0 0 0 0 0 13 0 NNP DT NNP NNP IN O
Index Index 1 0 0 0 0 0 0 0 5 0 DT NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Erectile Erectile 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Function Function 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
(IIEF-5). (IIEF-5). 0 1 1 0 0 0 0 1 9 0 NNP NNP NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNP NNS VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT JJ IN O
total total 0 0 0 0 0 0 0 0 5 0 IN DT JJ IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN CD NNS O
1,206 1,206 0 0 0 0 1 0 0 1 5 0 JJ IN CD NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 IN CD NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD VBN IN O
diagnosed diagnosed 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NNP O
PE. PE. 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NN NN O
prevalence prevalence 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 NNP NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN IN O
depression depression 0 0 0 0 0 0 0 0 10 0 NN IN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNP NNS O
PE PE 1 1 0 0 0 0 0 0 2 0 IN DT NNP NNS VBD O
patients patients 0 0 0 0 0 0 0 0 8 0 DT NNP NNS VBD CD O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNS VBD CD NNP O
26.78%. 26.78%. 0 0 0 0 0 0 0 1 7 0 NNS VBD CD NNP VBD O
Depression Depression 1 0 0 0 0 0 0 0 10 0 VBD CD NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 CD NNP VBD VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NNP VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NNP O
PE PE 1 1 0 0 0 0 0 0 2 0 VBN IN NNP NNP NNP O
duration, duration, 0 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
NIH-CPSI NIH-CPSI 1 1 1 0 0 0 0 0 8 0 NNP NNP NNP NNP CC O
score, score, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
IIEF-5 IIEF-5 1 1 1 0 0 0 0 1 6 0 NNP CC NNP NNP NNP O
score. score. 0 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNS O
Risk Risk 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNS IN NN RB O
depression depression 0 0 0 0 0 0 0 0 10 0 NNS IN NN RB VBD O
specifically specifically 0 0 0 0 0 0 0 0 12 0 IN NN RB VBD NNP O
included included 0 0 0 0 0 0 0 0 8 0 NN RB VBD NNP NNS O
PE PE 1 1 0 0 0 0 0 0 2 0 RB VBD NNP NNS IN O
durations durations 0 0 0 0 0 0 0 0 9 0 VBD NNP NNS IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNS IN CD CD O
13-24, 13-24, 0 0 1 0 1 0 0 1 6 0 NNS IN CD CD CC O
25-60, 25-60, 0 0 1 0 1 0 0 1 6 0 IN CD CD CC -NONE- O
or or 0 0 0 0 0 0 0 0 2 0 CD CD CC -NONE- JJ O
≥61 ≥61 0 0 0 0 0 0 0 1 3 0 CD CC -NONE- JJ NNP O
months, months, 0 0 0 0 1 0 0 0 7 0 CC -NONE- JJ NNP NNS O
CPSI CPSI 1 1 0 0 0 0 0 0 4 0 -NONE- JJ NNP NNS IN O
scores scores 0 0 0 0 0 0 0 0 6 0 JJ NNP NNS IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN CD CC O
15-30 15-30 0 0 1 0 0 0 0 1 5 0 NNS IN CD CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 IN CD CC JJ CC O
≥31, ≥31, 0 0 0 0 1 0 0 1 4 0 CD CC JJ CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 CC JJ CC -NONE- NNS O
IIEF-5 IIEF-5 1 1 1 0 0 0 0 1 6 0 JJ CC -NONE- NNS NNP O
scores scores 0 0 0 0 0 0 0 0 6 0 CC -NONE- NNS NNP NNP O
<22. <22. 0 0 0 0 0 0 0 1 4 0 -NONE- NNS NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNS NNP NNP NNS VBD O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBD IN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN JJ VBN O
several several 0 0 0 0 0 0 0 0 7 0 VBD IN JJ VBN NNS O
associated associated 0 0 0 0 0 0 0 0 10 0 IN JJ VBN NNS -NONE- O
factors factors 0 0 0 0 0 0 0 0 7 0 JJ VBN NNS -NONE- -NONE- O
(PE (PE 0 1 0 0 0 0 0 0 3 0 VBN NNS -NONE- -NONE- NNP O
duration, duration, 0 0 0 0 1 0 0 0 9 0 NNS -NONE- -NONE- NNP NNP O
CPSI CPSI 1 1 0 0 0 0 0 0 4 0 -NONE- -NONE- NNP NNP CC O
scores, scores, 0 0 0 0 1 0 0 0 7 0 -NONE- NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
IIEF-5 IIEF-5 1 1 1 0 0 0 0 1 6 0 NNP CC NNP NNP VBD O
scores) scores) 0 0 0 0 0 0 0 0 7 0 CC NNP NNP VBD DT O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT NN NNS O
risk risk 0 0 0 0 0 0 0 0 4 0 VBD DT NN NNS IN O
factors factors 0 0 0 0 0 0 0 0 7 0 DT NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN IN O
depression depression 0 0 0 0 0 0 0 0 10 0 NNS IN NN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NNS IN O
men men 0 0 0 0 0 0 0 0 3 0 NN IN NNS IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NNP NONE O
PE. PE. 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NONE NONE O
A A 1 1 0 0 0 0 0 0 1 0 NONE NONE DT JJ JJ O
PRISMA-driven PRISMA-driven 1 0 1 0 0 0 0 0 13 0 NONE DT JJ JJ NN O
systematic systematic 0 0 0 0 0 0 0 0 10 0 DT JJ JJ NN IN O
review review 0 0 0 0 0 0 0 0 6 0 JJ JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
predictive predictive 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS IN O
equations equations 0 0 0 0 0 0 0 0 9 0 IN JJ NNS IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN VBG JJ O
assessing assessing 0 0 0 0 0 0 0 0 9 0 NNS IN VBG JJ CC O
fat fat 0 0 0 0 0 0 0 0 3 0 IN VBG JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBG JJ CC JJ NN O
fat-free fat-free 0 0 1 0 0 0 0 0 8 0 JJ CC JJ NN IN O
mass mass 0 0 0 0 0 0 0 0 4 0 CC JJ NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
healthy healthy 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS CC O
children children 0 0 0 0 0 0 0 0 8 0 IN JJ NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NNS VBG O
adolescents adolescents 0 0 0 0 0 0 0 0 11 0 NNS CC NNS VBG NN O
using using 0 0 0 0 0 0 0 0 5 0 CC NNS VBG NN NN O
multicomponent multicomponent 0 0 0 0 0 0 0 0 14 0 NNS VBG NN NN NNS O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VBG NN NN NNS IN O
models models 0 0 0 0 0 0 0 0 6 0 NN NN NNS IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
reference reference 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP NNP O
method. method. 0 0 0 0 0 0 0 0 7 0 DT NN NNP NNP NNP O
Silva Silva 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
AM, AM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Fields Fields 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
DA, DA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Sardinha Sardinha 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
LB. LB. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CC O
Exercise Exercise 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Health Health 1 0 0 0 0 0 0 0 6 0 NNP CC NNP NNP NNP O
Laboratory, Laboratory, 1 0 0 0 1 0 0 0 11 0 CC NNP NNP NNP NNP O
CIPER, CIPER, 1 1 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Fac Fac 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Motricidade Motricidade 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Humana, Humana, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Univ Univ 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Tecn Tecn 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP CD O
Lisboa, Lisboa, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP CD NNP O
1499-002 1499-002 0 0 1 0 0 0 0 1 8 0 NNP NNP CD NNP NNP O
Cruz Cruz 1 0 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Quebrada, Quebrada, 1 0 0 0 1 0 0 0 9 0 CD NNP NNP NNP NNP O
Portugal. Portugal. 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
analiza@fmh.utl.pt analiza@fmh.utl.pt 0 0 0 0 0 0 0 0 18 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNS O
Simple Simple 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNS TO O
methods methods 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNP NNS TO NN DT O
assess assess 0 0 0 0 0 0 0 0 6 0 NNS TO NN DT JJ O
both both 0 0 0 0 0 0 0 0 4 0 TO NN DT JJ NN O
fat fat 0 0 0 0 0 0 0 0 3 0 NN DT JJ NN CC O
(FM) (FM) 0 1 0 0 0 0 0 0 4 0 DT JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
fat-free fat-free 0 0 1 0 0 0 0 0 8 0 NN CC JJ NN NN O
mass mass 0 0 0 0 0 0 0 0 4 0 CC JJ NN NN VBP O
(FFM) (FFM) 0 1 0 0 0 0 0 0 5 0 JJ NN NN VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP VBN IN O
required required 0 0 0 0 0 0 0 0 8 0 NN VBP VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBP VBN IN JJ NNP O
paediatric paediatric 0 0 0 0 0 0 0 0 10 0 VBN IN JJ NNP NNP O
populations. populations. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP JJ O
Several Several 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP JJ NN O
bioelectrical bioelectrical 0 0 0 0 0 0 0 0 13 0 NNP NNP JJ NN NNS O
impedance impedance 0 0 0 0 0 0 0 0 9 0 NNP JJ NN NNS -NONE- O
instruments instruments 0 0 0 0 0 0 0 0 11 0 JJ NN NNS -NONE- CC O
(BIAs) (BIAs) 0 0 0 0 0 0 0 0 6 0 NN NNS -NONE- CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC JJ NNS O
anthropometric anthropometric 0 0 0 0 0 0 0 0 14 0 -NONE- CC JJ NNS VBP O
equations equations 0 0 0 0 0 0 0 0 9 0 CC JJ NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBP VBN VBN VBG O
developed developed 0 0 0 0 0 0 0 0 9 0 VBP VBN VBN VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 VBN VBN VBG JJ NN O
different different 0 0 0 0 0 0 0 0 9 0 VBN VBG JJ NN NNS O
criterion criterion 0 0 0 0 0 0 0 0 9 0 VBG JJ NN NNS JJ O
methods methods 0 0 0 0 0 0 0 0 7 0 JJ NN NNS JJ NN O
(multicomponent (multicomponent 0 0 0 0 0 0 0 0 15 0 NN NNS JJ NN IN O
models) models) 0 0 0 0 0 0 0 0 7 0 NNS JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN NNP O
assessing assessing 0 0 0 0 0 0 0 0 9 0 NN IN NN NNP CC O
FM FM 1 1 0 0 0 0 0 0 2 0 IN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
FFM. FFM. 1 1 0 0 0 0 0 0 4 0 NNP CC NNP NNP NNP O
Through Through 1 0 0 0 0 0 0 0 7 0 CC NNP NNP NNP NNP O
childhood, childhood, 0 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NN O
FFM FFM 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN NNS O
density density 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNS IN O
increases increases 0 0 0 0 0 0 0 0 9 0 NNP NN NNS IN NNP O
while while 0 0 0 0 0 0 0 0 5 0 NN NNS IN NNP NN O
FFM FFM 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NN NNS O
hydration hydration 0 0 0 0 0 0 0 0 9 0 IN NNP NN NNS IN O
decreases decreases 0 0 0 0 0 0 0 0 9 0 NNP NN NNS IN VBG O
until until 0 0 0 0 0 0 0 0 5 0 NN NNS IN VBG NN O
reaching reaching 0 0 0 0 0 0 0 0 8 0 NNS IN VBG NN NNP O
adult adult 0 0 0 0 0 0 0 0 5 0 IN VBG NN NNP NNP O
values. values. 0 0 0 0 0 0 0 0 7 0 VBG NN NNP NNP NN O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 NN NNP NNP NN NNS O
multicomponent multicomponent 0 0 0 0 0 0 0 0 14 0 NNP NNP NN NNS MD O
models models 0 0 0 0 0 0 0 0 6 0 NNP NN NNS MD VB O
should should 0 0 0 0 0 0 0 0 6 0 NN NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 MD VB VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
gold gold 0 0 0 0 0 0 0 0 4 0 IN DT NN NN NN O
standard standard 0 0 0 0 0 0 0 0 8 0 DT NN NN NN IN O
method method 0 0 0 0 0 0 0 0 6 0 NN NN NN IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN VBG NN O
developing developing 0 0 0 0 0 0 0 0 10 0 NN IN VBG NN NNS O
simple simple 0 0 0 0 0 0 0 0 6 0 IN VBG NN NNS IN O
techniques techniques 0 0 0 0 0 0 0 0 10 0 VBG NN NNS IN JJ O
because because 0 0 0 0 0 0 0 0 7 0 NN NNS IN JJ NNS O
two-compartment two-compartment 0 0 1 0 0 0 0 0 15 0 NNS IN JJ NNS JJ O
models models 0 0 0 0 0 0 0 0 6 0 IN JJ NNS JJ NN O
(2C (2C 0 1 0 0 0 0 0 1 3 0 JJ NNS JJ NN RB O
model) model) 0 0 0 0 0 0 0 0 6 0 NNS JJ NN RB IN O
rely rely 0 0 0 0 0 0 0 0 4 0 JJ NN RB IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN RB IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT VBN NN O
assumed assumed 0 0 0 0 0 0 0 0 7 0 IN DT VBN NN NNS O
adult adult 0 0 0 0 0 0 0 0 5 0 DT VBN NN NNS IN O
values values 0 0 0 0 0 0 0 0 6 0 VBN NN NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNP NN O
FFM FFM 1 1 0 0 0 0 0 0 3 0 NNS IN NNP NN CC O
density density 0 0 0 0 0 0 0 0 7 0 IN NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN -NONE- O
hydration hydration 0 0 0 0 0 0 0 0 9 0 NN CC NN -NONE- -NONE- O
(1.1 (1.1 0 0 0 0 0 0 0 1 4 0 CC NN -NONE- -NONE- CC O
g/cm(3) g/cm(3) 0 0 0 1 0 0 0 1 7 0 NN -NONE- -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC CD NNP O
73.2%, 73.2%, 0 0 0 0 1 0 0 1 6 0 -NONE- CC CD NNP NNP O
respectively). respectively). 0 0 0 0 0 0 0 0 14 0 CC CD NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 CD NNP NNP NN MD O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN MD VB O
will will 0 0 0 0 0 0 0 0 4 0 NNP NN MD VB NNP O
review review 0 0 0 0 0 0 0 0 6 0 NN MD VB NNP NNP O
BIA BIA 1 1 0 0 0 0 0 0 3 0 MD VB NNP NNP JJ O
and/or and/or 0 0 0 1 0 0 0 0 6 0 VB NNP NNP JJ NNS O
anthropometric-based anthropometric-based 0 0 1 0 0 0 0 0 20 0 NNP NNP JJ NNS IN O
equations equations 0 0 0 0 0 0 0 0 9 0 NNP JJ NNS IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN VBG NN O
assessing assessing 0 0 0 0 0 0 0 0 9 0 NNS IN VBG NN NN O
body body 0 0 0 0 0 0 0 0 4 0 IN VBG NN NN IN O
composition composition 0 0 0 0 0 0 0 0 11 0 VBG NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NNP O
paediatric paediatric 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNP NNP O
populations. populations. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBD NNP O
reviewed reviewed 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD NNP NN O
English English 1 0 0 0 0 0 0 0 7 0 NNP VBD NNP NN NNS O
language language 0 0 0 0 0 0 0 0 8 0 VBD NNP NN NNS IN O
articles articles 0 0 0 0 0 0 0 0 8 0 NNP NN NNS IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN NNP NNP O
MEDLINE MEDLINE 1 1 0 0 0 0 0 0 7 0 NNS IN NNP NNP IN O
(1985-2012) (1985-2012) 0 0 1 0 0 0 0 1 11 0 IN NNP NNP IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
selection selection 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
predictive predictive 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNS VBD O
equations equations 0 0 0 0 0 0 0 0 9 0 IN JJ NNS VBD IN O
developed developed 0 0 0 0 0 0 0 0 9 0 JJ NNS VBD IN NN O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBD IN NN NNP O
assessing assessing 0 0 0 0 0 0 0 0 9 0 VBD IN NN NNP CC O
FM FM 1 1 0 0 0 0 0 0 2 0 IN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NN O
FFM FFM 1 1 0 0 0 0 0 0 3 0 NNP CC NNP NN NN O
using using 0 0 0 0 0 0 0 0 5 0 CC NNP NN NN NN O
three-compartment three-compartment 0 0 1 0 0 0 0 0 17 0 NNP NN NN NN CC O
(3C) (3C) 0 1 0 0 0 0 0 1 4 0 NN NN NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC CD NNS O
4C 4C 0 1 0 0 0 0 0 1 2 0 NN CC CD NNS IN O
models models 0 0 0 0 0 0 0 0 6 0 CC CD NNS IN NNP O
as as 0 0 0 0 0 0 0 0 2 0 CD NNS IN NNP NNP O
criterion. criterion. 0 0 0 0 0 0 0 0 10 0 NNS IN NNP NNP NNS O
Search Search 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNS VBD O
terms terms 0 0 0 0 0 0 0 0 5 0 NNP NNP NNS VBD JJ O
included included 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD JJ NN O
children, children, 0 0 0 0 1 0 0 0 9 0 NNS VBD JJ NN NN O
adolescent, adolescent, 0 0 0 0 1 0 0 0 11 0 VBD JJ NN NN NN O
childhood, childhood, 0 0 0 0 1 0 0 0 10 0 JJ NN NN NN CD O
adolescence, adolescence, 0 0 0 0 1 0 0 0 12 0 NN NN NN CD NN O
4C 4C 0 1 0 0 0 0 0 1 2 0 NN NN CD NN CD O
model, model, 0 0 0 0 1 0 0 0 6 0 NN CD NN CD NN O
3C 3C 0 1 0 0 0 0 0 1 2 0 CD NN CD NN NN O
model, model, 0 0 0 0 1 0 0 0 6 0 NN CD NN NN NN O
multicomponent multicomponent 0 0 0 0 0 0 0 0 14 0 CD NN NN NN NN O
model, model, 0 0 0 0 1 0 0 0 6 0 NN NN NN NN NN O
equation, equation, 0 0 0 0 1 0 0 0 9 0 NN NN NN NN NN O
prediction, prediction, 0 0 0 0 1 0 0 0 11 0 NN NN NN NN NN O
DXA, DXA, 1 1 0 0 1 0 0 0 4 0 NN NN NN NN NN O
BIA, BIA, 1 1 0 0 1 0 0 0 4 0 NN NN NN NN NN O
resistance, resistance, 0 0 0 0 1 0 0 0 11 0 NN NN NN NN NN O
anthropometry, anthropometry, 0 0 0 0 1 0 0 0 14 0 NN NN NN NN NN O
skinfold, skinfold, 0 0 0 0 1 0 0 0 9 0 NN NN NN NN CC O
FM, FM, 1 1 0 0 1 0 0 0 3 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP DT O
FFM. FFM. 1 1 0 0 0 0 0 0 4 0 NN CC NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 CC NNP DT NN IN O
total total 0 0 0 0 0 0 0 0 5 0 NNP DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NNS O
14 14 0 0 0 0 0 0 1 1 2 0 NN IN CD NNS -NONE- O
studies studies 0 0 0 0 0 0 0 0 7 0 IN CD NNS -NONE- -NONE- O
(33 (33 0 0 0 0 0 0 0 1 3 0 CD NNS -NONE- -NONE- VBD O
equations) equations) 0 0 0 0 0 0 0 0 10 0 NNS -NONE- -NONE- VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 -NONE- -NONE- VBD VBN IN O
selected selected 0 0 0 0 0 0 0 0 8 0 -NONE- VBD VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN VBD O
majority majority 0 0 0 0 0 0 0 0 8 0 IN DT NN VBD VBG O
developed developed 0 0 0 0 0 0 0 0 9 0 DT NN VBD VBG NNP O
using using 0 0 0 0 0 0 0 0 5 0 NN VBD VBG NNP IN O
DXA DXA 1 1 0 0 0 0 0 0 3 0 VBD VBG NNP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 VBG NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NN O
criterion criterion 0 0 0 0 0 0 0 0 9 0 IN DT NN NN IN O
method method 0 0 0 0 0 0 0 0 6 0 DT NN NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN DT VBN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT VBN NN O
limited limited 0 0 0 0 0 0 0 0 7 0 IN DT VBN NN IN O
number number 0 0 0 0 0 0 0 0 6 0 DT VBN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNS VBG O
studies studies 0 0 0 0 0 0 0 0 7 0 NN IN NNS VBG NN O
providing providing 0 0 0 0 0 0 0 0 9 0 IN NNS VBG NN NNP O
cross-validation cross-validation 0 0 1 0 0 0 0 0 16 0 NNS VBG NN NNP NNP O
results. results. 0 0 0 0 0 0 0 0 8 0 VBG NN NNP NNP DT O
Overall, Overall, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT VBN NNS O
selected selected 0 0 0 0 0 0 0 0 8 0 NNP DT VBN NNS VBP O
equations equations 0 0 0 0 0 0 0 0 9 0 DT VBN NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 VBN NNS VBP JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 NNS VBP JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBP JJ IN JJ NN O
epidemiological epidemiological 0 0 0 0 0 0 0 0 15 0 JJ IN JJ NN CC O
studies, studies, 0 0 0 0 1 0 0 0 8 0 IN JJ NN CC DT O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NNS O
some some 0 0 0 0 0 0 0 0 4 0 NN CC DT NNS RB O
concerns concerns 0 0 0 0 0 0 0 0 8 0 CC DT NNS RB VBP O
still still 0 0 0 0 0 0 0 0 5 0 DT NNS RB VBP IN O
arise arise 0 0 0 0 0 0 0 0 5 0 NNS RB VBP IN DT O
on on 0 0 0 0 0 0 0 0 2 0 RB VBP IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 VBP IN DT NN NNP O
individual individual 0 0 0 0 0 0 0 0 10 0 IN DT NN NNP NONE O
basis. basis. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NONE NONE O
Pre-Weaning Pre-Weaning 1 0 1 0 0 0 0 0 11 0 NONE NONE JJ NN NNP O
Growth Growth 1 0 0 0 0 0 0 0 6 0 NONE JJ NN NNP NNP O
Hormone Hormone 1 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNP O
Treatment Treatment 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
Ameliorates Ameliorates 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNP O
Bone Bone 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
Marrow Marrow 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Macrophage Macrophage 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
Inflammation Inflammation 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Adult Adult 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Male Male 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Rat Rat 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP VBG O
Offspring Offspring 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP VBG NNP O
following following 0 0 0 0 0 0 0 0 9 0 NNP NNP VBG NNP NNP O
Maternal Maternal 1 0 0 0 0 0 0 0 8 0 NNP VBG NNP NNP NNP O
Undernutrition. Undernutrition. 1 0 0 0 0 0 0 0 15 0 VBG NNP NNP NNP NNP O
Reynolds Reynolds 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
CM, CM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gray Gray 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
C, C, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Vickers Vickers 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
MH. MH. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Liggins Liggins 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP CC O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Gravida, Gravida, 1 0 0 0 1 0 0 0 8 0 NNP CC NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Centre Centre 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN NNP CC O
Growth Growth 1 0 0 0 0 0 0 0 6 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Development, Development, 1 0 0 0 1 0 0 0 12 0 NNP CC NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Auckland, Auckland, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Auckland, Auckland, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
New New 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Zealand. Zealand. 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Maternal Maternal 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN -NONE- O
undernutrition undernutrition 0 0 0 0 0 0 0 0 14 0 NNP NNP NN -NONE- VBZ O
(UN) (UN) 0 1 0 0 0 0 0 0 4 0 NNP NN -NONE- VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN -NONE- VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 -NONE- VBZ VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
development development 0 0 0 0 0 0 0 0 11 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
obesity obesity 0 0 0 0 0 0 0 0 7 0 NN IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NNS O
metabolic metabolic 0 0 0 0 0 0 0 0 9 0 NN CC JJ NNS IN O
complications complications 0 0 0 0 0 0 0 0 13 0 CC JJ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNP O
adult adult 0 0 0 0 0 0 0 0 5 0 NNS IN NN NNP NNP O
offspring. offspring. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP DT O
While While 1 0 0 0 0 0 0 0 5 0 NN NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 NNP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
inflammation inflammation 0 0 0 0 0 0 0 0 12 0 NN IN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN CC O
obesity obesity 0 0 0 0 0 0 0 0 7 0 NN IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NNS O
related related 0 0 0 0 0 0 0 0 7 0 NN CC JJ NNS VBZ O
comorbidities comorbidities 0 0 0 0 0 0 0 0 13 0 CC JJ NNS VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 JJ NNS VBZ VBN RB O
been been 0 0 0 0 0 0 0 0 4 0 NNS VBZ VBN RB -NONE- O
well well 0 0 0 0 0 0 0 0 4 0 VBZ VBN RB -NONE- EX O
established, established, 0 0 0 0 1 0 0 0 12 0 VBN RB -NONE- EX VBZ O
there there 0 0 0 0 0 0 0 0 5 0 RB -NONE- EX VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- EX VBZ JJ NN O
little little 0 0 0 0 0 0 0 0 6 0 EX VBZ JJ NN VBG O
evidence evidence 0 0 0 0 0 0 0 0 8 0 VBZ JJ NN VBG DT O
regarding regarding 0 0 0 0 0 0 0 0 9 0 JJ NN VBG DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBG DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ JJ O
maternal maternal 0 0 0 0 0 0 0 0 8 0 NNS IN JJ JJ NN O
UN-induced UN-induced 1 0 1 0 0 0 0 0 10 0 IN JJ JJ NN IN O
programming programming 0 0 0 0 0 0 0 0 11 0 JJ JJ NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
immune immune 0 0 0 0 0 0 0 0 6 0 NN IN NN NN IN O
function function 0 0 0 0 0 0 0 0 8 0 IN NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
male male 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN NNP O
adult adult 0 0 0 0 0 0 0 0 5 0 IN JJ NN NNP NNP O
offspring. offspring. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ DT O
examines examines 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NNS NN O
effects effects 0 0 0 0 0 0 0 0 7 0 VBZ DT NNS NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 DT NNS NN NN NN O
hormone hormone 0 0 0 0 0 0 0 0 7 0 NNS NN NN NN WDT O
(GH), (GH), 0 1 0 0 1 0 0 0 5 0 NN NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN WDT VBZ VBN TO O
known known 0 0 0 0 0 0 0 0 5 0 WDT VBZ VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ VBN TO VB JJ O
induce induce 0 0 0 0 0 0 0 0 6 0 VBN TO VB JJ NN O
anti-inflammatory anti-inflammatory 0 0 1 0 0 0 0 0 17 0 TO VB JJ NN IN O
effects, effects, 0 0 0 0 1 0 0 0 8 0 VB JJ NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ JJ O
maternal maternal 0 0 0 0 0 0 0 0 8 0 NN IN JJ JJ NN O
UN-induced UN-induced 1 0 1 0 0 0 0 0 10 0 IN JJ JJ NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN NN O
marrow marrow 0 0 0 0 0 0 0 0 6 0 JJ NN NN NN NN O
macrophage macrophage 0 0 0 0 0 0 0 0 10 0 NN NN NN NN NN O
(BMM) (BMM) 0 1 0 0 0 0 0 0 5 0 NN NN NN NN IN O
function function 0 0 0 0 0 0 0 0 8 0 NN NN NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NN O
adult adult 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NNP O
male male 0 0 0 0 0 0 0 0 4 0 IN NN NN NNP NNP O
offspring. offspring. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP NNS O
Sprague-Dawley Sprague-Dawley 1 0 1 0 0 0 0 0 14 0 NN NNP NNP NNS VBD O
rats rats 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN TO O
assigned assigned 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB JJ O
chow chow 0 0 0 0 0 0 0 0 4 0 VBN TO VB JJ CC O
(C) (C) 0 1 0 0 0 0 0 0 3 0 TO VB JJ CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 VB JJ CC NNP NNP O
UN UN 1 1 0 0 0 0 0 0 2 0 JJ CC NNP NNP NN O
(50% (50% 0 0 0 0 0 0 0 1 4 0 CC NNP NNP NN -NONE- O
ad ad 0 0 0 0 0 0 0 0 2 0 NNP NNP NN -NONE- JJ O
libitum; libitum; 0 0 0 0 0 0 0 0 8 0 NNP NN -NONE- JJ NN O
UN) UN) 1 1 0 0 0 0 0 0 3 0 NN -NONE- JJ NN IN O
diet diet 0 0 0 0 0 0 0 0 4 0 -NONE- JJ NN IN NNP O
throughout throughout 0 0 0 0 0 0 0 0 10 0 JJ NN IN NNP NNP O
gestation. gestation. 0 0 0 0 0 0 0 0 10 0 NN IN NNP NNP NNP O
Male Male 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP CC O
C C 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNS O
UN UN 1 1 0 0 0 0 0 0 2 0 NNP CC NNP NNS VBD O
pups pups 0 0 0 0 0 0 0 0 4 0 CC NNP NNS VBD NN O
received received 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD NN -NONE- O
saline saline 0 0 0 0 0 0 0 0 6 0 NNS VBD NN -NONE- CC O
(CS/UNS) (CS/UNS) 0 1 0 1 0 0 0 0 8 0 VBD NN -NONE- CC NNP O
or or 0 0 0 0 0 0 0 0 2 0 NN -NONE- CC NNP NNP O
GH GH 1 1 0 0 0 0 0 0 2 0 -NONE- CC NNP NNP NNP O
(2.5 (2.5 0 0 0 0 0 0 0 1 4 0 CC NNP NNP NNP NNP O
µg/g/d; µg/g/d; 0 0 0 1 0 0 0 0 7 0 NNP NNP NNP NNP IN O
CGH/UNGH) CGH/UNGH) 1 1 0 1 0 0 0 0 9 0 NNP NNP NNP IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NN CD O
day day 0 0 0 0 0 0 0 0 3 0 NNP IN NN CD NNP O
3-21. 3-21. 0 0 1 0 0 0 0 1 5 0 IN NN CD NNP NN O
Bone Bone 1 0 0 0 0 0 0 0 4 0 NN CD NNP NN JJ O
marrow marrow 0 0 0 0 0 0 0 0 6 0 CD NNP NN JJ NNS O
hematopoietic hematopoietic 0 0 0 0 0 0 0 0 13 0 NNP NN JJ NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN TO O
differentiated differentiated 0 0 0 0 0 0 0 0 14 0 NNS VBD VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN TO DT NN NN O
macrophage macrophage 0 0 0 0 0 0 0 0 10 0 TO DT NN NN IN O
phenotype phenotype 0 0 0 0 0 0 0 0 9 0 DT NN NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ -NONE- O
M-CSF M-CSF 1 1 1 0 0 0 0 0 5 0 NN IN JJ -NONE- NNP O
(50 (50 0 0 0 0 0 0 0 1 3 0 IN JJ -NONE- NNP NNP O
ng/ml). ng/ml). 0 0 0 1 0 0 0 0 7 0 JJ -NONE- NNP NNP NN O
Differentiated Differentiated 1 0 0 0 0 0 0 0 14 0 -NONE- NNP NNP NN NN O
bone bone 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN NNS O
marrow marrow 0 0 0 0 0 0 0 0 6 0 NNP NN NN NNS -NONE- O
macrophages macrophages 0 0 0 0 0 0 0 0 11 0 NN NN NNS -NONE- VBD O
(BMM) (BMM) 0 1 0 0 0 0 0 0 5 0 NN NNS -NONE- VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS -NONE- VBD VBN IN O
stimulated stimulated 0 0 0 0 0 0 0 0 10 0 -NONE- VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NNP O
LPS LPS 1 1 0 0 0 0 0 0 3 0 VBN IN NNP NNP NNP O
(100 (100 0 0 0 0 0 0 0 1 4 0 IN NNP NNP NNP IN O
ng/ml) ng/ml) 0 0 0 1 0 0 0 0 6 0 NNP NNP NNP IN CD O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNP IN CD NNP O
6 6 0 0 0 0 0 0 1 1 1 0 NNP IN CD NNP JJ O
h. h. 0 0 0 0 0 0 0 0 2 0 IN CD NNP JJ NNP O
UNS-derived UNS-derived 1 0 1 0 0 0 0 0 11 0 CD NNP JJ NNP VBD O
BMM BMM 1 1 0 0 0 0 0 0 3 0 NNP JJ NNP VBD RB O
had had 0 0 0 0 0 0 0 0 3 0 JJ NNP VBD RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP VBD RB VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBD RB VBN NN CC O
secretion secretion 0 0 0 0 0 0 0 0 9 0 RB VBN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 VBN NN CC NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 NN CC NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP CC O
IL-1β IL-1β 1 0 1 0 0 0 0 1 5 0 NN IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP VBG O
IL-6 IL-6 1 1 1 0 0 0 0 1 4 0 NNP CC NNP VBG NNP O
following following 0 0 0 0 0 0 0 0 9 0 CC NNP VBG NNP NNP O
LPS LPS 1 1 0 0 0 0 0 0 3 0 NNP VBG NNP NNP NNP O
stimulation. stimulation. 0 0 0 0 0 0 0 0 12 0 VBG NNP NNP NNP VBD O
This This 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NNP VBD VBN IN O
accompanied accompanied 0 0 0 0 0 0 0 0 11 0 NNP VBD VBN IN VBN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBN IN VBN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP NNP O
IL-1R1, IL-1R1, 1 1 1 0 1 0 0 1 7 0 NN IN NNP NNP CC O
IL-6R IL-6R 1 1 1 0 0 0 0 1 5 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
TLR4. TLR4. 1 1 0 0 0 0 0 1 5 0 NNP CC NNP NNP NNP O
Pre-weaning Pre-weaning 1 0 1 0 0 0 0 0 11 0 CC NNP NNP NNP NN O
GH GH 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NN VBD O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBD DT O
reversed reversed 0 0 0 0 0 0 0 0 8 0 NNP NN VBD DT JJ O
this this 0 0 0 0 0 0 0 0 4 0 NN VBD DT JJ NNP O
pro-inflammatory pro-inflammatory 0 0 1 0 0 0 0 0 16 0 VBD DT JJ NNP NNP O
phenotype. phenotype. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP NNP O
Furthermore Furthermore 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP NNP VBD O
UNGH UNGH 1 1 0 0 0 0 0 0 4 0 NNP NNP NNP VBD VBN O
displayed displayed 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 NNP VBD VBN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 VBD VBN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNS IN O
markers markers 0 0 0 0 0 0 0 0 7 0 NN IN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NN O
alternative alternative 0 0 0 0 0 0 0 0 11 0 NNS IN JJ NN NN O
(M2) (M2) 0 1 0 0 0 0 0 1 4 0 IN JJ NN NN NN O
macrophage macrophage 0 0 0 0 0 0 0 0 10 0 JJ NN NN NN NN O
activation, activation, 0 0 0 0 1 0 0 0 11 0 NN NN NN NN NN O
mannose mannose 0 0 0 0 0 0 0 0 7 0 NN NN NN NN CC O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NN NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
PPARγ. PPARγ. 1 0 0 0 0 0 0 0 6 0 NN CC NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NN VBZ O
study study 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBZ IN O
demonstrates demonstrates 0 0 0 0 0 0 0 0 12 0 NNP NN VBZ IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN JJ NNP O
fetal fetal 0 0 0 0 0 0 0 0 5 0 VBZ IN JJ NNP NN O
UN UN 1 1 0 0 0 0 0 0 2 0 IN JJ NNP NN VBZ O
exposure exposure 0 0 0 0 0 0 0 0 8 0 JJ NNP NN VBZ JJ O
primes primes 0 0 0 0 0 0 0 0 6 0 NNP NN VBZ JJ NN O
hematopoietic hematopoietic 0 0 0 0 0 0 0 0 13 0 NN VBZ JJ NN NNS O
immune immune 0 0 0 0 0 0 0 0 6 0 VBZ JJ NN NNS TO O
cells cells 0 0 0 0 0 0 0 0 5 0 JJ NN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO DT RBR O
a a 0 0 0 0 0 0 0 0 1 0 NNS TO DT RBR JJ O
more more 0 0 0 0 0 0 0 0 4 0 TO DT RBR JJ JJ O
potent potent 0 0 0 0 0 0 0 0 6 0 DT RBR JJ JJ NN O
pro-inflammatory pro-inflammatory 0 0 1 0 0 0 0 0 16 0 RBR JJ JJ NN IN O
phenotype phenotype 0 0 0 0 0 0 0 0 9 0 JJ JJ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJ NN O
heightened heightened 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN NN O
cytokine cytokine 0 0 0 0 0 0 0 0 8 0 IN JJ NN NN CC O
secretion secretion 0 0 0 0 0 0 0 0 9 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
receptor receptor 0 0 0 0 0 0 0 0 8 0 NN CC NN NNP NNP O
expression. expression. 0 0 0 0 0 0 0 0 11 0 CC NN NNP NNP DT O
Furthermore Furthermore 1 0 0 0 0 0 0 0 11 0 NN NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP DT NNS VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP JJ TO O
pre-disposed pre-disposed 0 0 1 0 0 0 0 0 12 0 NNS VBP JJ TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 VBP JJ TO JJ NNP O
pro-inflammatory pro-inflammatory 0 0 1 0 0 0 0 0 16 0 JJ TO JJ NNP NN O
M1 M1 1 1 0 0 0 0 0 1 2 0 TO JJ NNP NN NN O
macrophage macrophage 0 0 0 0 0 0 0 0 10 0 JJ NNP NN NN WDT O
phenotype phenotype 0 0 0 0 0 0 0 0 9 0 NNP NN NN WDT VBZ O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBZ JJ O
has has 0 0 0 0 0 0 0 0 3 0 NN WDT VBZ JJ CC O
wide-reaching wide-reaching 0 0 1 0 0 0 0 0 13 0 WDT VBZ JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 VBZ JJ CC JJ NNS O
important important 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NNS IN O
effects effects 0 0 0 0 0 0 0 0 7 0 CC JJ NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNS IN O
terms terms 0 0 0 0 0 0 0 0 5 0 NNS IN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN NN CC O
obesity obesity 0 0 0 0 0 0 0 0 7 0 NNS IN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC JJ NNP O
metabolic metabolic 0 0 0 0 0 0 0 0 9 0 NN CC JJ NNP NONE O
disease. disease. 0 0 0 0 0 0 0 0 8 0 CC JJ NNP NONE NONE O
Extraction Extraction 1 0 0 0 0 0 0 0 10 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP CC O
s- s- 0 0 1 0 0 0 0 0 2 0 NN IN NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNS IN O
N-compounds N-compounds 1 0 1 0 0 0 0 0 11 0 NNP CC NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 CC NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
mixture mixture 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
hydrocarbons hydrocarbons 0 0 0 0 0 0 0 0 12 0 NN IN NNS IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NNS O
ionic ionic 0 0 0 0 0 0 0 0 5 0 NNS IN JJ NNS IN O
liquids liquids 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNP O
selective selective 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NNP NNP O
solvents. solvents. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP NNP O
Gabrić Gabrić 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP NNP NNP O
B, B, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sander Sander 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cvjetko Cvjetko 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Bubalo Bubalo 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Macut Macut 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
D. D. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
INA-Industrija INA-Industrija 1 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
Nafte Nafte 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
d.d., d.d., 0 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Avenija Avenija 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Veceslava Veceslava 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP CD O
Holjevca Holjevca 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CD CD O
10, 10, 0 0 0 0 1 0 0 1 3 0 NNP NNP CD CD JJ O
10000 10000 0 0 0 0 0 0 1 1 5 0 NNP CD CD JJ NNP O
Zagreb, Zagreb, 1 0 0 0 1 0 0 0 7 0 CD CD JJ NNP NNP O
Croatia. Croatia. 1 0 0 0 0 0 0 0 8 0 CD JJ NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP NN O
Liquid-liquid Liquid-liquid 1 0 1 0 0 0 0 0 13 0 NNP NNP NNP NN VBZ O
extraction extraction 0 0 0 0 0 0 0 0 10 0 NNP NNP NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN VBZ DT JJ NN O
alternative alternative 0 0 0 0 0 0 0 0 11 0 VBZ DT JJ NN WDT O
method method 0 0 0 0 0 0 0 0 6 0 DT JJ NN WDT MD O
that that 0 0 0 0 0 0 0 0 4 0 JJ NN WDT MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN WDT MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 WDT MD VB VBN IN O
used used 0 0 0 0 0 0 0 0 4 0 MD VB VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VB VBN IN NN CC O
desulfurization desulfurization 0 0 0 0 0 0 0 0 15 0 VBN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN IN O
denitrification denitrification 0 0 0 0 0 0 0 0 15 0 NN CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN CC O
gasoline gasoline 0 0 0 0 0 0 0 0 8 0 NN IN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NN NNP O
diesel diesel 0 0 0 0 0 0 0 0 6 0 NN CC NN NNP NNP O
fuels. fuels. 0 0 0 0 0 0 0 0 6 0 CC NN NNP NNP VBZ O
Recent Recent 1 0 0 0 0 0 0 0 6 0 NN NNP NNP VBZ NN O
approaches approaches 0 0 0 0 0 0 0 0 10 0 NNP NNP VBZ NN NN O
employ employ 0 0 0 0 0 0 0 0 6 0 NNP VBZ NN NN JJ O
different different 0 0 0 0 0 0 0 0 9 0 VBZ NN NN JJ NNS O
ionic ionic 0 0 0 0 0 0 0 0 5 0 NN NN JJ NNS IN O
liquids liquids 0 0 0 0 0 0 0 0 7 0 NN JJ NNS IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NN O
selective selective 0 0 0 0 0 0 0 0 9 0 NNS IN JJ NN JJ O
solvents, solvents, 0 0 0 0 1 0 0 0 9 0 IN JJ NN JJ TO O
due due 0 0 0 0 0 0 0 0 3 0 JJ NN JJ TO PRP$ O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 JJ TO PRP$ JJ NN O
general general 0 0 0 0 0 0 0 0 7 0 TO PRP$ JJ NN IN O
immiscibility immiscibility 0 0 0 0 0 0 0 0 13 0 PRP$ JJ NN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN NN CC O
gasoline gasoline 0 0 0 0 0 0 0 0 8 0 NN IN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC NNP JJ O
diesel, diesel, 0 0 0 0 1 0 0 0 7 0 NN CC NNP JJ NN O
negligible negligible 0 0 0 0 0 0 0 0 10 0 CC NNP JJ NN NN O
vapor vapor 0 0 0 0 0 0 0 0 5 0 NNP JJ NN NN CC O
pressure, pressure, 0 0 0 0 1 0 0 0 9 0 JJ NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 NN CC JJ NN TO O
selectivity selectivity 0 0 0 0 0 0 0 0 11 0 CC JJ NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO NNP CC O
sulfur- sulfur- 0 0 1 0 0 0 0 0 7 0 NN TO NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 TO NNP CC JJ NNP O
nitrogen-containing nitrogen-containing 0 0 1 0 0 0 0 0 19 0 NNP CC JJ NNP NNP O
compounds. compounds. 0 0 0 0 0 0 0 0 10 0 CC JJ NNP NNP IN O
For For 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP IN -NONE- O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNP IN -NONE- CD O
reason, reason, 0 0 0 0 1 0 0 0 7 0 NNP IN -NONE- CD JJ O
five five 0 0 0 0 0 0 0 0 4 0 IN -NONE- CD JJ JJ O
imidazolium-based imidazolium-based 0 0 1 0 0 0 0 0 17 0 -NONE- CD JJ JJ NNS O
ionic ionic 0 0 0 0 0 0 0 0 5 0 CD JJ JJ NNS CC O
liquids liquids 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC CD JJ O
one one 0 0 0 0 0 0 0 0 3 0 NNS CC CD JJ JJ O
pyridinium-based pyridinium-based 0 0 1 0 0 0 0 0 16 0 CC CD JJ JJ NN O
ionic ionic 0 0 0 0 0 0 0 0 5 0 CD JJ JJ NN VBD O
liquid liquid 0 0 0 0 0 0 0 0 6 0 JJ JJ NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD VBN IN O
selected selected 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN NN IN O
extraction extraction 0 0 0 0 0 0 0 0 10 0 VBN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNP O
thiophene, thiophene, 0 0 0 0 1 0 0 0 10 0 NN IN NNP NNP CC O
dibenzothiophene, dibenzothiophene, 0 0 0 0 1 0 0 0 17 0 IN NNP NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NN IN O
pyridine pyridine 0 0 0 0 0 0 0 0 8 0 NNP CC NN IN CD O
from from 0 0 0 0 0 0 0 0 4 0 CC NN IN CD NN O
two two 0 0 0 0 0 0 0 0 3 0 NN IN CD NN NNP O
model model 0 0 0 0 0 0 0 0 5 0 IN CD NN NNP NNP O
solutions. solutions. 0 0 0 0 0 0 0 0 10 0 CD NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS IN O
influences influences 0 0 0 0 0 0 0 0 10 0 NNP NNP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ NN O
hydrodynamic hydrodynamic 0 0 0 0 0 0 0 0 12 0 NNS IN JJ NN NN O
conditions, conditions, 0 0 0 0 1 0 0 0 11 0 IN JJ NN NN NN O
mass mass 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN CC O
ratio, ratio, 0 0 0 0 1 0 0 0 6 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
number number 0 0 0 0 0 0 0 0 6 0 NN CC NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NNS VBD O
stages stages 0 0 0 0 0 0 0 0 6 0 NN IN NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 IN NNS VBD NNP NNP O
investigated. investigated. 0 0 0 0 0 0 0 0 13 0 NNS VBD NNP NNP DT O
Increasing Increasing 1 0 0 0 0 0 0 0 10 0 VBD NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN NN O
mass mass 0 0 0 0 0 0 0 0 4 0 NNP DT NN NN IN O
ratio ratio 0 0 0 0 0 0 0 0 5 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ JJ O
ionic ionic 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NN O
liquid/model liquid/model 0 0 0 1 0 0 0 0 12 0 IN JJ JJ NN CC O
fuel fuel 0 0 0 0 0 0 0 0 4 0 JJ JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
multistage multistage 0 0 0 0 0 0 0 0 10 0 NN CC NN NN VBZ O
extraction extraction 0 0 0 0 0 0 0 0 10 0 CC NN NN VBZ DT O
promotes promotes 0 0 0 0 0 0 0 0 8 0 NN NN VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBZ DT NN CC O
desulfurization desulfurization 0 0 0 0 0 0 0 0 15 0 VBZ DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN NNS O
denitrification denitrification 0 0 0 0 0 0 0 0 15 0 NN CC NN NNS IN O
abilities abilities 0 0 0 0 0 0 0 0 9 0 CC NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT VBN JJ O
examined examined 0 0 0 0 0 0 0 0 8 0 IN DT VBN JJ NNP O
ionic ionic 0 0 0 0 0 0 0 0 5 0 DT VBN JJ NNP NNP O
liquids. liquids. 0 0 0 0 0 0 0 0 8 0 VBN JJ NNP NNP VBD O
All All 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP VBD JJ O
selected selected 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD JJ NNS O
ionic ionic 0 0 0 0 0 0 0 0 5 0 NNP VBD JJ NNS MD O
liquids liquids 0 0 0 0 0 0 0 0 7 0 VBD JJ NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 JJ NNS MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB VBN CC O
reused reused 0 0 0 0 0 0 0 0 6 0 MD VB VBN CC VBN O
and and 0 0 0 0 0 0 0 0 3 0 VB VBN CC VBN IN O
regenerated regenerated 0 0 0 0 0 0 0 0 11 0 VBN CC VBN IN NNS O
by by 0 0 0 0 0 0 0 0 2 0 CC VBN IN NNS IN O
means means 0 0 0 0 0 0 0 0 5 0 VBN IN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN NN NNP O
vacuum vacuum 0 0 0 0 0 0 0 0 6 0 NNS IN NN NNP NONE O
evaporation. evaporation. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NONE NONE O
Genetic Genetic 1 0 0 0 0 0 0 0 7 0 NONE NONE JJ NNS IN O
polymorphisms polymorphisms 0 0 0 0 0 0 0 0 13 0 NONE JJ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NNS O
glutathione glutathione 0 0 0 0 0 0 0 0 11 0 NNS IN NN NNS NNP O
S-transferases S-transferases 1 0 1 0 0 0 0 0 14 0 IN NN NNS NNP NNP O
P1 P1 1 1 0 0 0 0 0 1 2 0 NN NNS NNP NNP NNP O
(GSTP1) (GSTP1) 0 1 0 0 0 0 0 1 7 0 NNS NNP NNP NNP CC O
Ile105Val Ile105Val 1 0 0 0 0 0 0 1 9 0 NNP NNP NNP CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC VB NN O
prostate prostate 0 0 0 0 0 0 0 0 8 0 NNP CC VB NN -NONE- O
cancer cancer 0 0 0 0 0 0 0 0 6 0 CC VB NN -NONE- DT O
risk: risk: 0 0 0 0 0 0 0 0 5 0 VB NN -NONE- DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN -NONE- DT JJ NN O
systematic systematic 0 0 0 0 0 0 0 0 10 0 -NONE- DT JJ NN CC O
review review 0 0 0 0 0 0 0 0 6 0 DT JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
meta-analysis. meta-analysis. 0 0 1 0 0 0 0 0 14 0 NN CC NNP NNP NNP O
Cai Cai 1 0 0 0 0 0 0 0 3 0 CC NNP NNP NNP NNP O
Q, Q, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wu Wu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Zhang Zhang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Guo Guo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
X, X, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shang Shang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Jiang Jiang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tian Tian 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Niu Niu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y. Y. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Urology, Urology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Second Second 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Tianjin Tianjin 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP NNP O
Medical Medical 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP NNP O
Tianjin Tianjin 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Urology, Urology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP CD O
Tianjin, Tianjin, 1 0 0 0 1 0 0 0 8 0 IN NNP NNP CD NNP O
300211, 300211, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP JJ O
Numerous Numerous 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP JJ NNS O
epidemiological epidemiological 0 0 0 0 0 0 0 0 15 0 NNP NNP JJ NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP JJ NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 JJ NNS VBP VBN DT O
evaluated evaluated 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBP VBN DT NN IN O
association association 0 0 0 0 0 0 0 0 11 0 VBN DT NN IN DT O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNS O
glutathione glutathione 0 0 0 0 0 0 0 0 11 0 IN DT NN NNS NNP O
S-transferases S-transferases 1 0 1 0 0 0 0 0 14 0 DT NN NNS NNP NNP O
P1 P1 1 1 0 0 0 0 0 1 2 0 NN NNS NNP NNP NNP O
(GSTP1) (GSTP1) 0 1 0 0 0 0 0 1 7 0 NNS NNP NNP NNP VBZ O
Ile105Val Ile105Val 1 0 0 0 0 0 0 1 9 0 NNP NNP NNP VBZ CC O
polymorphisms polymorphisms 0 0 0 0 0 0 0 0 13 0 NNP NNP VBZ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP VBZ CC JJ NN O
prostate prostate 0 0 0 0 0 0 0 0 8 0 VBZ CC JJ NN NN O
cancer cancer 0 0 0 0 0 0 0 0 6 0 CC JJ NN NN NNP O
(PCa) (PCa) 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNP NNP O
risk. risk. 0 0 0 0 0 0 0 0 5 0 NN NN NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNP NNP DT NNS VBP O
studies studies 0 0 0 0 0 0 0 0 7 0 NNP DT NNS VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 DT NNS VBP VBN VBG O
yielded yielded 0 0 0 0 0 0 0 0 7 0 NNS VBP VBN VBG NNP O
conflicting conflicting 0 0 0 0 0 0 0 0 11 0 VBP VBN VBG NNP DT O
results. results. 0 0 0 0 0 0 0 0 8 0 VBN VBG NNP DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 VBG NNP DT JJ NN O
comprehensive comprehensive 0 0 0 0 0 0 0 0 13 0 NNP DT JJ NN VBD O
search search 0 0 0 0 0 0 0 0 6 0 DT JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
conducted conducted 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NN O
through through 0 0 0 0 0 0 0 0 7 0 VBD VBN IN NN -NONE- O
researching researching 0 0 0 0 0 0 0 0 11 0 VBN IN NN -NONE- -NONE- O
MEDLINE, MEDLINE, 1 1 0 0 1 0 0 0 8 0 IN NN -NONE- -NONE- NNP O
PubMed, PubMed, 1 0 0 0 1 0 0 0 7 0 NN -NONE- -NONE- NNP IN O
Web Web 1 0 0 0 0 0 0 0 3 0 -NONE- -NONE- NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 -NONE- NNP IN NNP CC O
Science, Science, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP CC O
EMBASE, EMBASE, 1 1 0 0 1 0 0 0 7 0 NNP CC NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP CC DT NN IN O
total total 0 0 0 0 0 0 0 0 5 0 CC DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NNS O
13 13 0 0 0 0 0 0 1 1 2 0 NN IN CD NNS VBG O
studies studies 0 0 0 0 0 0 0 0 7 0 IN CD NNS VBG CD O
including including 0 0 0 0 0 0 0 0 9 0 CD NNS VBG CD NNS O
3,227 3,227 0 0 0 0 1 0 0 1 5 0 NNS VBG CD NNS CC O
cases cases 0 0 0 0 0 0 0 0 5 0 VBG CD NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 CD NNS CC CD NNS O
3,945 3,945 0 0 0 0 1 0 0 1 5 0 NNS CC CD NNS VBD O
controls controls 0 0 0 0 0 0 0 0 8 0 CC CD NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD NNP DT O
identified. identified. 0 0 0 0 0 0 0 0 11 0 NNS VBD NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 VBD NNP DT NN VBD O
meta-analysis meta-analysis 0 0 1 0 0 0 0 0 13 0 NNP DT NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD VBN TO O
performed performed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
obtain obtain 0 0 0 0 0 0 0 0 6 0 VBN TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ IN O
summary summary 0 0 0 0 0 0 0 0 7 0 VB DT JJ IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 DT JJ IN VBN NNS O
estimated estimated 0 0 0 0 0 0 0 0 9 0 JJ IN VBN NNS NNS O
odds odds 0 0 0 0 0 0 0 0 4 0 IN VBN NNS NNS -NONE- O
ratios ratios 0 0 0 0 0 0 0 0 6 0 VBN NNS NNS -NONE- CC O
(ORs) (ORs) 0 0 0 0 0 0 0 0 5 0 NNS NNS -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNS -NONE- CC CD NN O
95 95 0 0 0 0 0 0 1 1 2 0 -NONE- CC CD NN NN O
% % 0 0 0 0 0 0 0 0 1 0 CC CD NN NN NNS O
confidence confidence 0 0 0 0 0 0 0 0 10 0 CD NN NN NNS -NONE- O
intervals intervals 0 0 0 0 0 0 0 0 9 0 NN NN NNS -NONE- IN O
(CIs) (CIs) 0 0 0 0 0 0 0 0 5 0 NN NNS -NONE- IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNS -NONE- IN NNP NNS O
GSTP1 GSTP1 1 1 0 0 0 0 0 1 5 0 -NONE- IN NNP NNS IN O
polymorphisms polymorphisms 0 0 0 0 0 0 0 0 13 0 IN NNP NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNS IN JJ IN O
PCa, PCa, 1 0 0 0 1 0 0 0 4 0 NNS IN JJ IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN JJ IN NN TO O
attention attention 0 0 0 0 0 0 0 0 9 0 JJ IN NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NN NN O
study study 0 0 0 0 0 0 0 0 5 0 NN TO NN NN CC O
quality quality 0 0 0 0 0 0 0 0 7 0 TO NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NNP O
publication publication 0 0 0 0 0 0 0 0 11 0 NN CC NN NNP NNP O
bias. bias. 0 0 0 0 0 0 0 0 5 0 CC NN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NNP O
GSTP1 GSTP1 1 1 0 0 0 0 0 1 5 0 NNP NNP NNP NNP NN O
Ile158Val Ile158Val 1 0 0 0 0 0 0 1 9 0 NNP NNP NNP NN NNS O
variant variant 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNS VBP O
genotypes genotypes 0 0 0 0 0 0 0 0 9 0 NNP NN NNS VBP JJR O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP JJR VBN O
less less 0 0 0 0 0 0 0 0 4 0 NNS VBP JJR VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBP JJR VBN IN VBN O
with with 0 0 0 0 0 0 0 0 4 0 JJR VBN IN VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 VBN IN VBN NN IN O
risk risk 0 0 0 0 0 0 0 0 4 0 IN VBN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP IN O
PCa PCa 1 0 0 0 0 0 0 0 3 0 NN IN NNP IN DT O
for for 0 0 0 0 0 0 0 0 3 0 IN NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN NN O
homozygote homozygote 0 0 0 0 0 0 0 0 10 0 IN DT NN NN JJ O
model model 0 0 0 0 0 0 0 0 5 0 DT NN NN JJ NNS O
(Val/Val (Val/Val 0 0 0 1 0 0 0 0 8 0 NN NN JJ NNS -NONE- O
vs vs 0 0 0 0 0 0 0 0 2 0 NN JJ NNS -NONE- CC O
Ile/Ile: Ile/Ile: 1 0 0 1 0 0 0 0 8 0 JJ NNS -NONE- CC : O
OR OR 1 1 0 0 0 0 0 0 2 0 NNS -NONE- CC : CD O
= = 0 0 0 0 0 0 0 0 1 0 -NONE- CC : CD PRP O
1.42; 1.42; 0 0 0 0 0 0 0 1 5 0 CC : CD PRP CD O
I I 1 1 0 0 0 0 0 0 1 0 : CD PRP CD CD O
2 2 0 0 0 0 0 0 1 1 1 0 CD PRP CD CD CD O
= = 0 0 0 0 0 0 0 0 1 0 PRP CD CD CD CD O
63.7 63.7 0 0 0 0 0 0 0 1 4 0 CD CD CD CD CD O
%; %; 0 0 0 0 0 0 0 0 2 0 CD CD CD CD NN O
95 95 0 0 0 0 0 0 1 1 2 0 CD CD CD NN NNP O
% % 0 0 0 0 0 0 0 0 1 0 CD CD NN NNP NNP O
CI CI 1 1 0 0 0 0 0 0 2 0 CD NN NNP NNP CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NNP NNP CD CC O
1.02-1.97) 1.02-1.97) 0 0 1 0 0 0 0 1 10 0 NNP NNP CD CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD CC DT JJ NN O
recessive recessive 0 0 0 0 0 0 0 0 9 0 CC DT JJ NN NN O
model model 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN : O
(OR (OR 0 1 0 0 0 0 0 0 3 0 JJ NN NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NN : CD PRP O
1.41; 1.41; 0 0 0 0 0 0 0 1 5 0 NN : CD PRP CD O
I I 1 1 0 0 0 0 0 0 1 0 : CD PRP CD CD O
2 2 0 0 0 0 0 0 1 1 1 0 CD PRP CD CD CD O
= = 0 0 0 0 0 0 0 0 1 0 PRP CD CD CD CD O
45.5 45.5 0 0 0 0 0 0 0 1 4 0 CD CD CD CD CD O
%; %; 0 0 0 0 0 0 0 0 2 0 CD CD CD CD NN O
95 95 0 0 0 0 0 0 1 1 2 0 CD CD CD NN NNP O
% % 0 0 0 0 0 0 0 0 1 0 CD CD NN NNP NNP O
CI CI 1 1 0 0 0 0 0 0 2 0 CD NN NNP NNP NNP O
= = 0 0 0 0 0 0 0 0 1 0 NN NNP NNP NNP NNP O
1.10-1.80). 1.10-1.80). 0 0 1 0 0 0 0 1 11 0 NNP NNP NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP DT NNS O
no no 0 0 0 0 0 0 0 0 2 0 NNP NNP DT NNS VBD O
associations associations 0 0 0 0 0 0 0 0 12 0 NNP DT NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD VBN IN O
detected detected 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBD VBN IN JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 VBN IN JJ JJ NNP O
genetic genetic 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NNP NNP O
models. models. 0 0 0 0 0 0 0 0 7 0 JJ JJ NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
stratified stratified 0 0 0 0 0 0 0 0 10 0 NNP DT JJ NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ JJ O
ethnicity, ethnicity, 0 0 0 0 1 0 0 0 10 0 NN IN JJ JJ NNS O
significant significant 0 0 0 0 0 0 0 0 11 0 IN JJ JJ NNS IN O
associations associations 0 0 0 0 0 0 0 0 12 0 JJ JJ NNS IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 JJ NNS IN NNP NNP O
GSTP1 GSTP1 1 1 0 0 0 0 0 1 5 0 NNS IN NNP NNP NN O
Ile105Val Ile105Val 1 0 0 0 0 0 0 1 9 0 IN NNP NNP NN CC O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 NNP NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NN O
PCa PCa 1 0 0 0 0 0 0 0 3 0 NN CC NNP NN VBD O
risk risk 0 0 0 0 0 0 0 0 4 0 CC NNP NN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NN VBD RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NN VBD RB VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 VBD RB VBN IN NNP O
among among 0 0 0 0 0 0 0 0 5 0 RB VBN IN NNP IN O
Caucasians Caucasians 1 0 0 0 0 0 0 0 10 0 VBN IN NNP IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 IN NNP IN JJ NNS O
Val/Val Val/Val 1 0 0 1 0 0 0 0 7 0 NNP IN JJ NNS JJ O
vs vs 0 0 0 0 0 0 0 0 2 0 IN JJ NNS JJ NN O
Ile/Ile Ile/Ile 1 0 0 1 0 0 0 0 7 0 JJ NNS JJ NN NN O
comparison comparison 0 0 0 0 0 0 0 0 10 0 NNS JJ NN NN : O
(OR (OR 0 1 0 0 0 0 0 0 3 0 JJ NN NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NN : CD PRP O
1.22; 1.22; 0 0 0 0 0 0 0 1 5 0 NN : CD PRP CD O
I I 1 1 0 0 0 0 0 0 1 0 : CD PRP CD CD O
2 2 0 0 0 0 0 0 1 1 1 0 CD PRP CD CD CD O
= = 0 0 0 0 0 0 0 0 1 0 PRP CD CD CD CD O
0.0 0.0 0 0 0 0 0 0 0 1 3 0 CD CD CD CD CD O
%; %; 0 0 0 0 0 0 0 0 2 0 CD CD CD CD NN O
95 95 0 0 0 0 0 0 1 1 2 0 CD CD CD NN NNP O
% % 0 0 0 0 0 0 0 0 1 0 CD CD NN NNP NNP O
CI CI 1 1 0 0 0 0 0 0 2 0 CD NN NNP NNP CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NNP NNP CD CC O
1.02-1.47) 1.02-1.47) 0 0 1 0 0 0 0 1 10 0 NNP NNP CD CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NNP CD CC IN DT O
for for 0 0 0 0 0 0 0 0 3 0 CD CC IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC IN DT JJ NN O
recessive recessive 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN NN O
model model 0 0 0 0 0 0 0 0 5 0 DT JJ NN NN : O
(OR (OR 0 1 0 0 0 0 0 0 3 0 JJ NN NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NN : CD PRP O
1.26; 1.26; 0 0 0 0 0 0 0 1 5 0 NN : CD PRP CD O
I I 1 1 0 0 0 0 0 0 1 0 : CD PRP CD CD O
2 2 0 0 0 0 0 0 1 1 1 0 CD PRP CD CD CD O
= = 0 0 0 0 0 0 0 0 1 0 PRP CD CD CD CD O
0.0 0.0 0 0 0 0 0 0 0 1 3 0 CD CD CD CD CD O
%; %; 0 0 0 0 0 0 0 0 2 0 CD CD CD CD NN O
95 95 0 0 0 0 0 0 1 1 2 0 CD CD CD NN NNP O
% % 0 0 0 0 0 0 0 0 1 0 CD CD NN NNP NNP O
CI CI 1 1 0 0 0 0 0 0 2 0 CD NN NNP NNP CD O
= = 0 0 0 0 0 0 0 0 1 0 NN NNP NNP CD IN O
1.06-1.49), 1.06-1.49), 0 0 1 0 1 0 0 1 11 0 NNP NNP CD IN EX O
while while 0 0 0 0 0 0 0 0 5 0 NNP CD IN EX VBD O
there there 0 0 0 0 0 0 0 0 5 0 CD IN EX VBD DT O
were were 0 0 0 0 0 0 0 0 4 0 IN EX VBD DT NNS O
no no 0 0 0 0 0 0 0 0 2 0 EX VBD DT NNS VBD O
associations associations 0 0 0 0 0 0 0 0 12 0 VBD DT NNS VBD IN O
found found 0 0 0 0 0 0 0 0 5 0 DT NNS VBD IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBD IN JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 VBD IN JJ JJ NNP O
genetic genetic 0 0 0 0 0 0 0 0 7 0 IN JJ JJ NNP NNP O
models. models. 0 0 0 0 0 0 0 0 7 0 JJ JJ NNP NNP DT O
However, However, 1 0 0 0 1 0 0 0 8 0 JJ NNP NNP DT NNS O
no no 0 0 0 0 0 0 0 0 2 0 NNP NNP DT NNS VBD O
associations associations 0 0 0 0 0 0 0 0 12 0 NNP DT NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD VBN IN O
found found 0 0 0 0 0 0 0 0 5 0 NNS VBD VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP CC O
Asians Asians 1 0 0 0 0 0 0 0 6 0 VBN IN NNP CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNS IN O
African-Americans African-Americans 1 0 1 0 0 0 0 0 17 0 NNP CC NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 CC NNS IN DT JJ O
all all 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NNS O
genetic genetic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NNS WRB O
models models 0 0 0 0 0 0 0 0 6 0 DT JJ NNS WRB VBN O
when when 0 0 0 0 0 0 0 0 4 0 JJ NNS WRB VBN IN O
stratified stratified 0 0 0 0 0 0 0 0 10 0 NNS WRB VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 WRB VBN IN NNP NNP O
ethnicity. ethnicity. 0 0 0 0 0 0 0 0 10 0 VBN IN NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP PRP$ O
conclusion, conclusion, 0 0 0 0 1 0 0 0 11 0 NNP NNP NNP PRP$ NN O
our our 0 0 0 0 0 0 0 0 3 0 NNP NNP PRP$ NN VBZ O
meta-analysis meta-analysis 0 0 1 0 0 0 0 0 13 0 NNP PRP$ NN VBZ NN O
provides provides 0 0 0 0 0 0 0 0 8 0 PRP$ NN VBZ NN IN O
evidence evidence 0 0 0 0 0 0 0 0 8 0 NN VBZ NN IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 VBZ NN IN NNP NNP O
GSTP1 GSTP1 1 1 0 0 0 0 0 1 5 0 NN IN NNP NNP NN O
Ile105Val Ile105Val 1 0 0 0 0 0 0 1 9 0 IN NNP NNP NN NNS O
gene gene 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNS VBD O
polymorphisms polymorphisms 0 0 0 0 0 0 0 0 13 0 NNP NN NNS VBD TO O
contributed contributed 0 0 0 0 0 0 0 0 11 0 NN NNS VBD TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBD TO NNP NNP O
PCa PCa 1 0 0 0 0 0 0 0 3 0 VBD TO NNP NNP NONE O
susceptibility. susceptibility. 0 0 0 0 0 0 0 0 15 0 TO NNP NNP NONE NONE O
Identification Identification 1 0 0 0 0 0 0 0 14 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP DT O
(S,S)-γ-Glutamyl-(cis-S-1-propenyl)thioglycine, (S,S)-γ-Glutamyl-(cis-S-1-propenyl)thioglycine, 0 0 1 0 1 0 0 1 47 0 NN IN NNP DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 IN NNP DT NNP NNP O
Naturally Naturally 1 0 0 0 0 0 0 0 9 0 NNP DT NNP NNP NNP O
Occurring Occurring 1 0 0 0 0 0 0 0 9 0 DT NNP NNP NNP NNP O
Norcysteine Norcysteine 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP IN O
Derivative, Derivative, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NNP O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 IN DT JJ NNP NNP O
Vegetable Vegetable 1 0 0 0 0 0 0 0 9 0 DT JJ NNP NNP NNP O
Toona Toona 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNP NNP O
sinensis. sinensis. 0 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
JX, JX, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Eidman Eidman 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
K, K, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gan Gan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
XW, XW, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Haefliger Haefliger 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
OP, OP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Carroll Carroll 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
PJ, PJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Pika Pika 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J. J. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Firmenich Firmenich 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Aromatics Aromatics 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
(China) (China) 0 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Co., Co., 1 0 0 0 1 0 0 0 4 0 NNP NNP NNP NNP , O
Ltd. Ltd. 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP , DT O
, , 0 0 0 0 1 0 0 0 1 0 NNP NNP , DT CD O
No No 1 0 0 0 0 0 0 0 2 0 NNP , DT CD NNP O
3901 3901 0 0 0 0 0 0 1 1 4 0 , DT CD NNP NNP O
JinDu JinDu 1 0 0 0 0 0 0 0 5 0 DT CD NNP NNP NNP O
Road, Road, 1 0 0 0 1 0 0 0 5 0 CD NNP NNP NNP NNP O
Xinzhuang Xinzhuang 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Industry Industry 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Park, Park, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP CD O
Shanghai Shanghai 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP CD NNP O
201108, 201108, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP IN O
Extracts Extracts 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NN O
Toona Toona 1 0 0 0 0 0 0 0 5 0 NNP IN NNP NN NNS O
sinensis sinensis 0 0 0 0 0 0 0 0 8 0 IN NNP NN NNS VBD O
shoots shoots 0 0 0 0 0 0 0 0 6 0 NNP NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN TO O
studied studied 0 0 0 0 0 0 0 0 7 0 NNS VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
identify identify 0 0 0 0 0 0 0 0 8 0 VBN TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
precursors precursors 0 0 0 0 0 0 0 0 10 0 VB DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ JJ O
volatile volatile 0 0 0 0 0 0 0 0 8 0 NNS IN JJ JJ NN O
sulfur-containing sulfur-containing 0 0 1 0 0 0 0 0 17 0 IN JJ JJ NN NNP O
flavor flavor 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NNP NNP O
molecules. molecules. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP NN O
T. T. 1 1 0 0 0 0 0 0 2 0 NN NNP NNP NN VBD O
sinensis sinensis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB JJ O
contain contain 0 0 0 0 0 0 0 0 7 0 VBN TO VB JJ NNS O
new new 0 0 0 0 0 0 0 0 3 0 TO VB JJ NNS -NONE- O
compounds compounds 0 0 0 0 0 0 0 0 9 0 VB JJ NNS -NONE- CD O
(S,S)-γ-glutamyl-(cis-S-1-propenyl)thioglycine, (S,S)-γ-glutamyl-(cis-S-1-propenyl)thioglycine, 0 0 1 0 1 0 0 1 47 0 JJ NNS -NONE- CD -NONE- O
1, 1, 0 0 0 0 1 0 0 1 2 0 NNS -NONE- CD -NONE- CD O
(S,S)-γ-glutamyl-(trans-S-1-propenyl)thioglycine, (S,S)-γ-glutamyl-(trans-S-1-propenyl)thioglycine, 0 0 1 0 1 0 0 1 49 0 -NONE- CD -NONE- CD CC O
2, 2, 0 0 0 0 1 0 0 1 2 0 CD -NONE- CD CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- CD CC JJ CD O
γ-glutamyl-(cis-S-1-propenyl)-cysteine, γ-glutamyl-(cis-S-1-propenyl)-cysteine, 0 0 1 0 1 0 0 1 39 0 CD CC JJ CD DT O
3. 3. 0 0 0 0 0 0 0 1 2 0 CC JJ CD DT NNS O
The The 1 0 0 0 0 0 0 0 3 0 JJ CD DT NNS IN O
structures structures 0 0 0 0 0 0 0 0 10 0 CD DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 NNS IN DT NNS VBD O
compounds compounds 0 0 0 0 0 0 0 0 9 0 IN DT NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 DT NNS VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN IN O
interpretation interpretation 0 0 0 0 0 0 0 0 14 0 VBN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
multistage multistage 0 0 0 0 0 0 0 0 10 0 NN IN NN NN JJ O
mass mass 0 0 0 0 0 0 0 0 4 0 IN NN NN JJ NN O
spectrometric spectrometric 0 0 0 0 0 0 0 0 13 0 NN NN JJ NN CD O
(MSn), (MSn), 0 0 0 0 1 0 0 0 6 0 NN JJ NN CD CC O
1D, 1D, 0 1 0 0 1 0 0 1 3 0 JJ NN CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN CD CC CD NNP O
2D 2D 0 1 0 0 0 0 0 1 2 0 CD CC CD NNP NNP O
NMR NMR 1 1 0 0 0 0 0 0 3 0 CC CD NNP NNP NNP O
data. data. 0 0 0 0 0 0 0 0 5 0 CD NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN NN O
absolute absolute 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NN IN O
configuration configuration 0 0 0 0 0 0 0 0 13 0 NNP NN NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN CD VBD O
1 1 0 0 0 0 0 0 1 1 1 0 NN IN CD VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 IN CD VBD VBN IN O
established established 0 0 0 0 0 0 0 0 11 0 CD VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN IN O
comparison comparison 0 0 0 0 0 0 0 0 10 0 VBN IN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN JJ IN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 NN IN JJ IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 IN JJ IN JJ VBN O
computed computed 0 0 0 0 0 0 0 0 8 0 JJ IN JJ VBN CC O
infrared infrared 0 0 0 0 0 0 0 0 8 0 IN JJ VBN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ VBN CC JJ NN O
vibrational vibrational 0 0 0 0 0 0 0 0 11 0 VBN CC JJ NN NN O
circular circular 0 0 0 0 0 0 0 0 8 0 CC JJ NN NN NNP O
dichroism dichroism 0 0 0 0 0 0 0 0 9 0 JJ NN NN NNP NNP O
spectra. spectra. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP IN O
Because Because 1 0 0 0 0 0 0 0 7 0 NN NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NN IN O
flexibility flexibility 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CC O
molecule molecule 0 0 0 0 0 0 0 0 8 0 IN DT NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
novelty novelty 0 0 0 0 0 0 0 0 7 0 CC DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ DT O
structure, structure, 0 0 0 0 1 0 0 0 10 0 IN DT JJ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 DT JJ DT NN VBD O
configuration configuration 0 0 0 0 0 0 0 0 13 0 JJ DT NN VBD JJ O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD JJ VBN O
further further 0 0 0 0 0 0 0 0 7 0 NN VBD JJ VBN IN O
confirmed confirmed 0 0 0 0 0 0 0 0 9 0 VBD JJ VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 JJ VBN IN NNP NNP O
X-ray X-ray 1 0 1 0 0 0 0 0 5 0 VBN IN NNP NNP NNPS O
crystallography. crystallography. 0 0 0 0 0 0 0 0 16 0 IN NNP NNP NNPS CD O
Compounds Compounds 1 0 0 0 0 0 0 0 9 0 NNP NNP NNPS CD CC O
1 1 0 0 0 0 0 0 1 1 1 0 NNP NNPS CD CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NNPS CD CC CD VBP O
2 2 0 0 0 0 0 0 1 1 1 0 CD CC CD VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 CC CD VBP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CD VBP DT JJ NNS O
first first 0 0 0 0 0 0 0 0 5 0 VBP DT JJ NNS IN O
examples examples 0 0 0 0 0 0 0 0 8 0 DT JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ NNS O
norcysteine-containing norcysteine-containing 0 0 1 0 0 0 0 0 22 0 NNS IN JJ NNS VBD O
metabolites metabolites 0 0 0 0 0 0 0 0 11 0 IN JJ NNS VBD IN O
reported reported 0 0 0 0 0 0 0 0 8 0 JJ NNS VBD IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNP NNP O
nature. nature. 0 0 0 0 0 0 0 0 7 0 VBD IN NNP NNP MD O
They They 1 0 0 0 0 0 0 0 4 0 IN NNP NNP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NNP MD VB NNS O
release release 0 0 0 0 0 0 0 0 7 0 NNP MD VB NNS IN O
thiols thiols 0 0 0 0 0 0 0 0 6 0 MD VB NNS IN NN O
via via 0 0 0 0 0 0 0 0 3 0 VB NNS IN NN IN O
cleavage cleavage 0 0 0 0 0 0 0 0 8 0 NNS IN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
amide amide 0 0 0 0 0 0 0 0 5 0 IN DT NN NN IN O
bond bond 0 0 0 0 0 0 0 0 4 0 DT NN NN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP VBD O
proteases, proteases, 0 0 0 0 1 0 0 0 10 0 NN IN NNP VBD IN O
followed followed 0 0 0 0 0 0 0 0 8 0 IN NNP VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NNP VBD IN JJ NN O
spontaneous spontaneous 0 0 0 0 0 0 0 0 11 0 VBD IN JJ NN IN O
decomposition decomposition 0 0 0 0 0 0 0 0 13 0 IN JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT VBG JJ O
resulting resulting 0 0 0 0 0 0 0 0 9 0 IN DT VBG JJ JJ O
unstable unstable 0 0 0 0 0 0 0 0 8 0 DT VBG JJ JJ NN O
alk(en)yl alk(en)yl 0 0 0 0 0 0 0 0 9 0 VBG JJ JJ NN NNP O
norcysteine norcysteine 0 0 0 0 0 0 0 0 11 0 JJ JJ NN NNP NONE O
moiety. moiety. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NONE NONE O
Book Book 1 0 0 0 0 0 0 0 4 0 NONE NONE NNP VBD NNP O
review review 0 0 0 0 0 0 0 0 6 0 NONE NNP VBD NNP NNP O
of: of: 0 0 0 0 0 0 0 0 3 0 NNP VBD NNP NNP NNP O
"Dialysis: "Dialysis: 0 0 0 0 0 0 0 0 10 0 VBD NNP NNP NNP NNP O
History, History, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP CC O
Development Development 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Promise", Promise", 1 0 0 0 1 0 0 0 9 0 NNP CC NNP NNP IN O
Edited Edited 1 0 0 0 0 0 0 0 6 0 CC NNP NNP IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Todd Todd 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 IN NNP NNP NNP NNP O
Ing, Ing, 1 0 0 0 1 0 0 0 4 0 NNP NNP NNP NNP NNP O
Mohamed Mohamed 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
A. A. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Rahman, Rahman, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Carl Carl 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kjellstrand. Kjellstrand. 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Gallieni Gallieni 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
M. M. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Director, Director, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP CC O
Nephrology Nephrology 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Dialysis Dialysis 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP NNP O
Unit, Unit, 1 0 0 0 1 0 0 0 5 0 CC NNP NNP NNP NNP O
San San 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Carlo Carlo 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Borromeo Borromeo 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Milano, Milano, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NONE O
Italy. Italy. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NONE NONE O
Cohesin Cohesin 1 0 0 0 0 0 0 0 7 0 NONE NONE NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NONE NNP CC NNP DT O
Cdk1: Cdk1: 1 0 0 0 0 0 0 1 5 0 NNP CC NNP DT NN O
an an 0 0 0 0 0 0 0 0 2 0 CC NNP DT NN NNP O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NNP DT NN NNP NNP B_TIMEXCCP
barricade. barricade. 0 0 0 0 0 0 0 0 10 0 DT NN NNP NNP NNP O
Jones Jones 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NNP NNP O
KT. KT. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biomedical Biomedical 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
Faculty Faculty 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Health, Health, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Newcastle, Newcastle, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP CD O
NSW NSW 1 1 0 0 0 0 0 0 3 0 IN NNP NNP CD NNP O
2308, 2308, 0 0 0 0 1 0 0 1 5 0 NNP NNP CD NNP NNP O
Australia. Australia. 1 0 0 0 0 0 0 0 10 0 NNP CD NNP NNP NNP O
keith.jones@newcastle.edu.au keith.jones@newcastle.edu.au 0 0 0 0 0 0 0 0 28 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Separation Separation 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NNS O
sister sister 0 0 0 0 0 0 0 0 6 0 NNP IN NN NNS IN O
chromatids chromatids 0 0 0 0 0 0 0 0 10 0 IN NN NNS IN NN O
at at 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN IN O
anaphase anaphase 0 0 0 0 0 0 0 0 8 0 NNS IN NN IN NN B_TIMEXCCP
in in 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NNS O
metazoan metazoan 0 0 0 0 0 0 0 0 8 0 NN IN NN NNS VBZ O
cells cells 0 0 0 0 0 0 0 0 5 0 IN NN NNS VBZ RB O
requires requires 0 0 0 0 0 0 0 0 8 0 NN NNS VBZ RB DT O
only only 0 0 0 0 0 0 0 0 4 0 NNS VBZ RB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBZ RB DT NN IN O
cleavage cleavage 0 0 0 0 0 0 0 0 8 0 RB DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
kleisin kleisin 0 0 0 0 0 0 0 0 7 0 IN DT NN NN IN O
subunit subunit 0 0 0 0 0 0 0 0 7 0 DT NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
centromeric centromeric 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN CC O
cohesin, cohesin, 0 0 0 0 1 0 0 0 8 0 IN JJ NN CC JJ O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
efficient efficient 0 0 0 0 0 0 0 0 9 0 NN CC JJ NN NN O
poleward poleward 0 0 0 0 0 0 0 0 8 0 CC JJ NN NN IN O
movement movement 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN VBN NNS O
separated separated 0 0 0 0 0 0 0 0 9 0 NN IN VBN NNS VBZ O
sisters sisters 0 0 0 0 0 0 0 0 7 0 IN VBN NNS VBZ DT O
requires requires 0 0 0 0 0 0 0 0 8 0 VBN NNS VBZ DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBZ DT VBN NN O
associated associated 0 0 0 0 0 0 0 0 10 0 VBZ DT VBN NN IN O
loss loss 0 0 0 0 0 0 0 0 4 0 DT VBN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBN NN IN NNP NNP O
Cdk1 Cdk1 1 0 0 0 0 0 0 1 4 0 NN IN NNP NNP NNP O
activity. activity. 0 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP IN O
Activation Activation 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ JJ O
anaphase-promoting anaphase-promoting 0 0 1 0 0 0 0 0 18 0 IN DT JJ JJ NNS B_TIMEXCCP
complex/cyclosome complex/cyclosome 0 0 0 1 0 0 0 0 17 0 DT JJ JJ NNS DT O
ensures ensures 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 JJ NNS DT NNS VBP O
events events 0 0 0 0 0 0 0 0 6 0 NNS DT NNS VBP NNP O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP NNP NNP O
coordinated. coordinated. 0 0 0 0 0 0 0 0 12 0 NNS VBP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 VBP NNP NNP CD JJ O
20118997 20118997 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Checkpoint Checkpoint 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP NN VBZ B_TIMEXCCP
activation activation 0 0 0 0 0 0 0 0 10 0 NONE NNP NN VBZ JJ O
regulates regulates 0 0 0 0 0 0 0 0 9 0 NNP NN VBZ JJ NN O
mutagenic mutagenic 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ NN NNP O
translesion translesion 0 0 0 0 0 0 0 0 11 0 VBZ JJ NN NNP NNP O
synthesis. synthesis. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP NNP O
Kai Kai 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wang Wang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
TS. TS. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Pathology, Pathology, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
Stanford Stanford 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 NNP IN NNP NNP NNP O
Stanford, Stanford, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP CD O
California California 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP CD NNP O
94305-5324, 94305-5324, 0 0 1 0 1 0 0 1 11 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP VBP O
Cells Cells 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN NN O
evolved evolved 0 0 0 0 0 0 0 0 7 0 NNP VBP VBN NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 VBP VBN NN NNS TO B_TIMEXCCP
responses responses 0 0 0 0 0 0 0 0 9 0 VBN NN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 arrest NN NNS TO VB CC O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNS TO VB CC VB O
or or 0 0 0 0 0 0 0 0 2 0 TO VB CC VB DT O
delay delay 0 0 0 0 0 0 0 0 5 0 VB CC VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC VB DT NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VB DT NN NN NN O
cycle, cycle, 0 0 0 0 1 0 0 0 6 0 DT NN NN NN NNP O
activate activate 0 0 0 0 0 0 0 0 8 0 NN NN NN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN NN NNP NN -NONE- O
repair repair 0 0 0 0 0 0 0 0 6 0 NN NNP NN -NONE- CC O
networks, networks, 0 0 0 0 1 0 0 0 9 0 NNP NN -NONE- CC VB O
or or 0 0 0 0 0 0 0 0 2 0 NN -NONE- CC VB NN O
induce induce 0 0 0 0 0 0 0 0 6 0 -NONE- CC VB NN IN O
apoptosis apoptosis 0 0 0 0 0 0 0 0 9 0 CC VB NN IN JJ O
after after 0 0 0 0 0 0 0 0 5 0 VB NN IN JJ NNP O
genomic genomic 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNP NNP O
perturbation. perturbation. 0 0 0 0 0 0 0 0 13 0 IN JJ NNP NNP VBP O
Cells Cells 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP RB VBN O
also also 0 0 0 0 0 0 0 0 4 0 NNP VBP RB VBN DT O
evolved evolved 0 0 0 0 0 0 0 0 7 0 VBP RB VBN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB VBN DT NN NN O
translesion translesion 0 0 0 0 0 0 0 0 11 0 VBN DT NN NN NNS O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 DT NN NN NNS TO O
processes processes 0 0 0 0 0 0 0 0 9 0 NN NN NNS TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO VB JJ O
tolerate tolerate 0 0 0 0 0 0 0 0 8 0 NNS TO VB JJ NNS O
genomic genomic 0 0 0 0 0 0 0 0 7 0 TO VB JJ NNS IN O
lesions lesions 0 0 0 0 0 0 0 0 7 0 VB JJ NNS IN DT O
by by 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
either either 0 0 0 0 0 0 0 0 6 0 NNS IN DT JJ CC O
error-free error-free 0 0 1 0 0 0 0 0 10 0 IN DT JJ CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 DT JJ CC JJ NNP O
error-prone error-prone 0 0 1 0 0 0 0 0 11 0 JJ CC JJ NNP NNP O
repair. repair. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 JJ NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN IN O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN IN DT O
after after 0 0 0 0 0 0 0 0 5 0 VBP IN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 IN IN DT NN NN O
replication replication 0 0 0 0 0 0 0 0 11 0 IN DT NN NN NNS O
perturbation, perturbation, 0 0 0 0 1 0 0 0 13 0 DT NN NN NNS NN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS NN DT O
exhibit exhibit 0 0 0 0 0 0 0 0 7 0 NN NNS NN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS NN DT NN NN O
mutator mutator 0 0 0 0 0 0 0 0 7 0 NN DT NN NN WDT O
phenotype, phenotype, 0 0 0 0 1 0 0 0 10 0 DT NN NN WDT MD O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN WDT MD VB RB O
be be 0 0 0 0 0 0 0 0 2 0 WDT MD VB RB VBN O
significantly significantly 0 0 0 0 0 0 0 0 13 0 MD VB RB VBN IN O
affected affected 0 0 0 0 0 0 0 0 8 0 VB RB VBN IN NNS O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN NNS IN O
mutations mutations 0 0 0 0 0 0 0 0 9 0 VBN IN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 IN DT NN NNS NNP B_TIMEXCCP
elements elements 0 0 0 0 0 0 0 0 8 0 DT NN NNS NNP CC O
Cds1 Cds1 1 0 0 0 0 0 0 1 4 0 NN NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP CC O
Rad17 Rad17 1 0 0 0 0 0 0 1 5 0 NNP CC NNP CC NN O
or or 0 0 0 0 0 0 0 0 2 0 CC NNP CC NN NN O
translesion translesion 0 0 0 0 0 0 0 0 11 0 NNP CC NN NN NNS O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 CC NN NN NNS NNP O
polymerases polymerases 0 0 0 0 0 0 0 0 11 0 NN NN NNS NNP CC O
DinB DinB 1 0 0 0 0 0 0 0 4 0 NN NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP NNP O
Polzeta. Polzeta. 1 0 0 0 0 0 0 0 8 0 NNP CC NNP NNP NN O
Cells Cells 1 0 0 0 0 0 0 0 5 0 CC NNP NNP NN TO O
respond respond 0 0 0 0 0 0 0 0 7 0 NNP NNP NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO JJ NN O
genomic genomic 0 0 0 0 0 0 0 0 7 0 NN TO JJ NN IN O
perturbation perturbation 0 0 0 0 0 0 0 0 12 0 TO JJ NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN IN O
up-regulation up-regulation 0 0 1 0 0 0 0 0 13 0 NN IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP IN O
DinB DinB 1 0 0 0 0 0 0 0 4 0 NN IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT NN NN O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 IN DT NN NN NNP B_TIMEXCCP
activation-dependent activation-dependent 0 0 1 0 0 0 0 0 20 0 DT NN NN NNP NNP O
manner. manner. 0 0 0 0 0 0 0 0 7 0 NN NN NNP NNP NN O
Moreover, Moreover, 1 0 0 0 1 0 0 0 9 0 NN NNP NNP NN IN O
association association 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP IN O
DinB DinB 1 0 0 0 0 0 0 0 4 0 NN IN NNP IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN NN VBZ O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NNP IN NN VBZ NN O
is is 0 0 0 0 0 0 0 0 2 0 IN NN VBZ NN IN O
dependent dependent 0 0 0 0 0 0 0 0 9 0 NN VBZ NN IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 VBZ NN IN JJ NN O
functional functional 0 0 0 0 0 0 0 0 10 0 NN IN JJ NN CC O
Rad17, Rad17, 1 0 0 0 1 0 0 1 6 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP RB O
DinB DinB 1 0 0 0 0 0 0 0 4 0 NN CC NNP RB VBZ O
physically physically 0 0 0 0 0 0 0 0 10 0 CC NNP RB VBZ IN O
interacts interacts 0 0 0 0 0 0 0 0 9 0 NNP RB VBZ IN DT O
with with 0 0 0 0 0 0 0 0 4 0 RB VBZ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT JJ NNS O
checkpoint-clamp checkpoint-clamp 0 0 1 0 0 0 0 0 16 0 IN DT JJ NNS NNP B_TIMEXCCP
components components 0 0 0 0 0 0 0 0 10 0 DT JJ NNS NNP CC O
Hus1 Hus1 1 0 0 0 0 0 0 1 4 0 JJ NNS NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNS NNP CC NNP NNP O
Rad1. Rad1. 1 0 0 0 0 0 0 1 5 0 NNP CC NNP NNP NN O
Thus, Thus, 1 0 0 0 1 0 0 0 5 0 CC NNP NNP NN NN O
translesion translesion 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NN VBZ O
synthesis synthesis 0 0 0 0 0 0 0 0 9 0 NNP NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT NN IN O
part part 0 0 0 0 0 0 0 0 4 0 VBZ DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 IN DT NN NNP NNP O
response. response. 0 0 0 0 0 0 0 0 9 0 DT NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
12514100 12514100 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NN O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NN NNP O
PMCID: PMCID: 1 1 0 0 0 0 0 0 6 0 IN JJ NN NNP NONE O
PMC195967 PMC195967 1 1 0 0 0 0 0 1 9 0 JJ NN NNP NONE NONE O
Reactivation Reactivation 1 0 0 0 0 0 0 0 12 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP NN O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN IN NNP NN IN B_TIMEXCCP
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 IN NNP NN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNP O
S-phase S-phase 1 0 1 0 0 0 0 0 7 0 NN IN NN NNP NNP B_TIMEXCCP
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN NN NNP NNP NNP O
Floros Floros 1 0 0 0 0 0 0 0 6 0 NN NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Baserga Baserga 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
R. R. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBZ O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 NNP NNP NNP VBZ VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 NNP VBZ VBP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ VBP DT NN JJ O
temperature temperature 0 0 0 0 0 0 0 0 11 0 VBP DT NN JJ NN O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 DT NN JJ NN NN O
(ts) (ts) 0 0 0 0 0 0 0 0 4 0 NN JJ NN NN IN O
mutant mutant 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
BHK BHK 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN JJS O
that that 0 0 0 0 0 0 0 0 4 arrest IN NNP IN JJS IN O
arrest arrest 0 0 0 0 0 0 0 0 6 0 NNP IN JJS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 IN JJS IN NNP IN O
G1 G1 1 1 0 0 0 0 0 1 2 0 JJS IN NNP IN DT B_TIMEXCCP
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
nonpermissive nonpermissive 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN CC O
temperature temperature 0 0 0 0 0 0 0 0 11 0 DT JJ NN CC IN O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC IN NN O
after after 0 0 0 0 0 0 0 0 5 0 NN CC IN NN NNP O
serum serum 0 0 0 0 0 0 0 0 5 0 CC IN NN NNP NNP O
deprivation. deprivation. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 NN NNP NNP NNP VBD O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 NNP NNP NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD VBN IN O
fused fused 0 0 0 0 0 0 0 0 5 0 NNP VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NN O
polyethylene polyethylene 0 0 0 0 0 0 0 0 12 0 VBN IN NN NN IN O
glycol glycol 0 0 0 0 0 0 0 0 6 0 IN NN NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ NNP O
other other 0 0 0 0 0 0 0 0 5 0 NN IN JJ NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 IN JJ NNP NNP NNP O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 JJ NNP NNP NNP CC O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP CC DT NN NNS O
fusion fusion 0 0 0 0 0 0 0 0 6 0 CC DT NN NNS VBD O
products products 0 0 0 0 0 0 0 0 8 0 DT NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
incubated incubated 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
nonpermissive nonpermissive 0 0 0 0 0 0 0 0 13 0 IN DT JJ NNP NNP O
temperature. temperature. 0 0 0 0 0 0 0 0 12 0 DT JJ NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNS VBD O
homokaryons homokaryons 0 0 0 0 0 0 0 0 11 0 NNP NNP NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD JJ IN O
incapable incapable 0 0 0 0 0 0 0 0 9 0 NNS VBD JJ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBD JJ IN NN NNP O
entering entering 0 0 0 0 0 0 0 0 8 0 JJ IN NN NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase IN NN NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NN NNP NN IN DT O
under under 0 0 0 0 0 0 0 0 5 0 NNP NN IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNP NNP O
conditions. conditions. 0 0 0 0 0 0 0 0 11 0 IN DT NNP NNP WRB O
However, However, 1 0 0 0 1 0 0 0 8 0 DT NNP NNP WRB NNP O
when when 0 0 0 0 0 0 0 0 4 0 NNP NNP WRB NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNP WRB NNP NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 WRB NNP NN NNP NNS O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 NNP NN NNP NNS VBD O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NNP NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNS VBD VBN IN O
fused fused 0 0 0 0 0 0 0 0 5 0 NNS VBD VBN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 VBN IN NNP NNP NNP B_TIMEXCCP
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 IN NNP NNP NNP DT O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP DT NN O
both both 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NN IN O
nuclei nuclei 0 0 0 0 0 0 0 0 6 0 NNP DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBD O
homokaryons homokaryons 0 0 0 0 0 0 0 0 11 0 IN DT NNS VBD NNP O
entered entered 0 0 0 0 0 0 0 0 7 0 DT NNS VBD NNP NNP O
S S 1 1 0 0 0 0 0 0 1 0 NNS VBD NNP NNP RB B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 VBD NNP NNP RB WRB O
even even 0 0 0 0 0 0 0 0 4 0 NNP NNP RB WRB DT O
when when 0 0 0 0 0 0 0 0 4 0 NNP RB WRB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB WRB DT NN NNS O
fusion fusion 0 0 0 0 0 0 0 0 6 0 WRB DT NN NNS VBD O
products products 0 0 0 0 0 0 0 0 8 0 DT NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
incubated incubated 0 0 0 0 0 0 0 0 9 0 NNS VBD VBN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
nonpermissive nonpermissive 0 0 0 0 0 0 0 0 13 0 IN DT JJ NNP NNP O
temperature. temperature. 0 0 0 0 0 0 0 0 12 0 DT JJ NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN NNP O
addition addition 0 0 0 0 0 0 0 0 8 0 NNP NNP NN NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNP NN NNP NN NNP B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NN NNP NN NNP NNP O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 NNP NN NNP NNP IN O
cells, cells, 0 0 0 0 1 0 0 0 6 0 NN NNP NNP IN VBN O
if if 0 0 0 0 0 0 0 0 2 0 NNP NNP IN VBN IN O
fused fused 0 0 0 0 0 0 0 0 5 0 NNP IN VBN IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN VBN IN NN -NONE- O
chick chick 0 0 0 0 0 0 0 0 5 0 VBN IN NN -NONE- MD O
erythrocytes, erythrocytes, 0 0 0 0 1 0 0 0 13 0 IN NN -NONE- MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NN -NONE- MD VB DT O
reactivate reactivate 0 0 0 0 0 0 0 0 10 0 -NONE- MD VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT NN NN O
chick chick 0 0 0 0 0 0 0 0 5 0 VB DT NN NN RB O
nucleus, nucleus, 0 0 0 0 1 0 0 0 8 0 DT NN NN RB IN O
even even 0 0 0 0 0 0 0 0 4 0 NN NN RB IN DT O
if if 0 0 0 0 0 0 0 0 2 0 NN RB IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT NNS VBP O
heterokaryons heterokaryons 0 0 0 0 0 0 0 0 13 0 IN DT NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP VBN IN O
placed placed 0 0 0 0 0 0 0 0 6 0 NNS VBP VBN IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 VBP VBN IN JJ NNP O
nonpermissive nonpermissive 0 0 0 0 0 0 0 0 13 0 VBN IN JJ NNP NNP O
temperature. temperature. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP NNP O
Therefore Therefore 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NNP NN O
S S 1 1 0 0 0 0 0 0 1 phase NNP NNP NNP NN NN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 NNP NNP NN NN IN O
information information 0 0 0 0 0 0 0 0 11 0 NNP NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP MD O
tsAF8 tsAF8 0 0 0 0 0 0 0 1 5 0 NN IN NNP MD VB O
can can 0 0 0 0 0 0 0 0 3 0 IN NNP MD VB NNP O
induce induce 0 0 0 0 0 0 0 0 6 0 NNP MD VB NNP NNP O
DNA DNA 1 1 0 0 0 0 0 0 3 0 MD VB NNP NNP IN O
synthesis, synthesis, 0 0 0 0 1 0 0 0 10 0 VB NNP NNP IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 NNP NNP IN NNP IN O
fusion, fusion, 0 0 0 0 1 0 0 0 7 0 NNP IN NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NNP O
mammalian mammalian 0 0 0 0 0 0 0 0 9 0 NNP IN JJ NNP NNP O
G0 G0 1 1 0 0 0 0 0 1 2 0 IN JJ NNP NNP VBZ O
AF8 AF8 1 1 0 0 0 0 0 1 3 0 JJ NNP NNP VBZ CC O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP VBZ CC NN NNS O
chick chick 0 0 0 0 0 0 0 0 5 0 VBZ CC NN NNS RB O
erythrocytes erythrocytes 0 0 0 0 0 0 0 0 12 0 CC NN NNS RB WRB O
even even 0 0 0 0 0 0 0 0 4 0 NN NNS RB WRB DT O
when when 0 0 0 0 0 0 0 0 4 0 NNS RB WRB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 RB WRB DT NNS CC O
homokaryons homokaryons 0 0 0 0 0 0 0 0 11 0 WRB DT NNS CC NNS O
or or 0 0 0 0 0 0 0 0 2 0 DT NNS CC NNS VBP O
heterokaryons heterokaryons 0 0 0 0 0 0 0 0 13 0 NNS CC NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 CC NNS VBP VBN IN O
incubated incubated 0 0 0 0 0 0 0 0 9 0 NNS VBP VBN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBP VBN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT JJ NNP O
nonpermissive nonpermissive 0 0 0 0 0 0 0 0 13 0 IN DT JJ NNP NNP O
temperature. temperature. 0 0 0 0 0 0 0 0 12 0 DT JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
7388961 7388961 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
[G1 [G1 0 1 0 0 0 0 0 1 3 0 NONE NONE NN JJ NNP B_TIMEXCCP
spermatogonial spermatogonial 0 0 0 0 0 0 0 0 14 0 NONE NN JJ NNP NNP O
chalone]. chalone]. 0 0 0 0 0 0 0 0 9 0 NN JJ NNP NNP IN O
[Article [Article 0 0 0 0 0 0 0 0 8 0 JJ NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Spanish] Spanish] 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Bustos-Obregón Bustos-Obregón 1 0 1 0 0 0 0 0 14 0 IN NNP NNP NNP NNP O
E. E. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Departamento Departamento 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biología Biología 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NN O
Celular Celular 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NN -NONE- O
y y 0 0 0 0 0 0 0 0 1 0 NNP NNP NN -NONE- NNP O
Genética, Genética, 1 0 0 0 1 0 0 0 9 0 NNP NN -NONE- NNP IN O
Facultad Facultad 1 0 0 0 0 0 0 0 8 0 NN -NONE- NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 -NONE- NNP IN NNP NNP O
Medicina Medicina 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Norte, Norte, 1 0 0 0 1 0 0 0 6 0 IN NNP NNP NNP IN O
Universidad Universidad 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Chile, Chile, 1 0 0 0 1 0 0 0 6 0 NNP IN NNP NNP NNP O
Santiago. Santiago. 1 0 0 0 0 0 0 0 9 0 IN NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VBP O
Chalones Chalones 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNP VBP JJ NNS O
physiological physiological 0 0 0 0 0 0 0 0 13 0 NNP VBP JJ NNS IN O
inhibitors inhibitors 0 0 0 0 0 0 0 0 10 0 VBP JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN WDT O
proliferation proliferation 0 0 0 0 0 0 0 0 13 0 IN NN NN WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT NN DT O
act act 0 0 0 0 0 0 0 0 3 0 NN WDT NN DT IN O
either either 0 0 0 0 0 0 0 0 6 0 WDT NN DT IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN DT IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 DT IN DT NNP CC O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN DT NNP CC NNP B_TIMEXCCP
or or 0 0 0 0 0 0 0 0 2 0 DT NNP CC NNP NN O
G2 G2 1 1 0 0 0 0 0 1 2 phase NNP CC NNP NN IN B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 CC NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN NNP NNP O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 DT NN NNP NNP VBP O
They They 1 0 0 0 0 0 0 0 4 0 NN NNP NNP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 NNP NNP VBP VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBP VBN VBN IN O
described described 0 0 0 0 0 0 0 0 9 0 VBP VBN VBN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 VBN VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
variety variety 0 0 0 0 0 0 0 0 7 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN VBG O
tissues, tissues, 0 0 0 0 1 0 0 0 8 0 NN IN NN VBG DT O
including including 0 0 0 0 0 0 0 0 9 0 IN NN VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN VBG DT JJ NNP O
seminiferous seminiferous 0 0 0 0 0 0 0 0 12 0 VBG DT JJ NNP NNP O
epithelium. epithelium. 0 0 0 0 0 0 0 0 11 0 DT JJ NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN CC O
vivo vivo 0 0 0 0 0 0 0 0 4 0 NNP NNP NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN NN NN O
vitro vitro 0 0 0 0 0 0 0 0 5 0 CC IN NN NN IN O
characterization characterization 0 0 0 0 0 0 0 0 16 0 IN NN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NN NNP O
rat rat 0 0 0 0 0 0 0 0 3 0 NN IN NN NNP JJ O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN NN NNP JJ NN B_TIMEXCCP
spermatogonial spermatogonial 0 0 0 0 0 0 0 0 14 0 NN NNP JJ NN NN O
chalone chalone 0 0 0 0 0 0 0 0 7 0 NNP JJ NN NN WDT O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 JJ NN NN WDT PRP O
that that 0 0 0 0 0 0 0 0 4 0 NN NN WDT PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN WDT PRP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 WDT PRP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 PRP VBZ DT JJ NN O
glycoprotein, glycoprotein, 0 0 0 0 1 0 0 0 13 0 VBZ DT JJ NN NN O
heat-labile, heat-labile, 0 0 1 0 1 0 0 0 12 0 DT JJ NN NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 JJ NN NN NN IN O
weight weight 0 0 0 0 0 0 0 0 6 0 NN NN NN IN CD O
under under 0 0 0 0 0 0 0 0 5 0 NN NN IN CD NN O
5,000 5,000 0 0 0 0 1 0 0 1 5 0 NN IN CD NN NN O
D, D, 1 1 0 0 1 0 0 0 2 0 IN CD NN NN NN O
tissue tissue 0 0 0 0 0 0 0 0 6 0 CD NN NN NN CC O
specific specific 0 0 0 0 0 0 0 0 8 0 NN NN NN CC RB O
but but 0 0 0 0 0 0 0 0 3 0 NN NN CC RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 NN CC RB JJ JJ O
species-specific, species-specific, 0 0 1 0 1 0 0 0 17 0 CC RB JJ JJ IN O
active active 0 0 0 0 0 0 0 0 6 0 RB JJ JJ IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 JJ JJ IN JJ NN O
physiological physiological 0 0 0 0 0 0 0 0 13 0 JJ IN JJ NN IN O
pH, pH, 0 0 0 0 1 0 0 0 3 0 IN JJ NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NN IN NN NN VBN O
action action 0 0 0 0 0 0 0 0 6 0 IN NN NN VBN IN O
mediated mediated 0 0 0 0 0 0 0 0 8 0 NN NN VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBN IN JJ NNP O
cyclic cyclic 0 0 0 0 0 0 0 0 6 0 VBN IN JJ NNP NNP O
AMP. AMP. 1 1 0 0 0 0 0 0 4 0 IN JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
origin origin 0 0 0 0 0 0 0 0 6 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBP O
substance substance 0 0 0 0 0 0 0 0 9 0 IN DT NN VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 DT NN VBP DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NN VBP DT VBN NNS O
differentiated differentiated 0 0 0 0 0 0 0 0 14 0 VBP DT VBN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 DT VBN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
spermatogenesis spermatogenesis 0 0 0 0 0 0 0 0 15 0 IN DT NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 DT NN IN JJ NNS O
primary primary 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS IN O
spermatocytes spermatocytes 0 0 0 0 0 0 0 0 13 0 IN JJ NNS IN TO O
up up 0 0 0 0 0 0 0 0 2 0 JJ NNS IN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNS IN TO NN NNP O
round round 0 0 0 0 0 0 0 0 5 0 IN TO NN NNP NNP O
spermatids. spermatids. 0 0 0 0 0 0 0 0 11 0 TO NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NNS O
target target 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNS VBP O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 NN NNS VBP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT NN DT O
type type 0 0 0 0 0 0 0 0 4 0 VBP DT NN DT JJ O
A A 1 1 0 0 0 0 0 0 1 0 DT NN DT JJ RB O
(and (and 0 0 0 0 0 0 0 0 4 0 NN DT JJ RB RB O
perhaps perhaps 0 0 0 0 0 0 0 0 7 0 DT JJ RB RB DT O
only only 0 0 0 0 0 0 0 0 4 0 JJ RB RB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 RB RB DT NN NNP O
A0) A0) 1 1 0 0 0 0 0 1 3 0 RB DT NN NNP NNP O
spermatogonia. spermatogonia. 0 0 0 0 0 0 0 0 14 0 DT NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN -NONE- O
inhibitory inhibitory 0 0 0 0 0 0 0 0 10 0 NNP NNP NN -NONE- VBN O
effect, effect, 0 0 0 0 1 0 0 0 7 0 NNP NN -NONE- VBN IN O
measured measured 0 0 0 0 0 0 0 0 8 0 NN -NONE- VBN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 -NONE- VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
uptake uptake 0 0 0 0 0 0 0 0 6 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ IN O
H3-thymidine H3-thymidine 1 0 1 0 0 0 0 1 12 0 NN IN JJ IN JJ O
into into 0 0 0 0 0 0 0 0 4 0 IN JJ IN JJ JJ O
testicular testicular 0 0 0 0 0 0 0 0 10 0 JJ IN JJ JJ VBZ O
DNA, DNA, 1 1 0 0 1 0 0 0 4 0 IN JJ JJ VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 JJ JJ VBZ RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 JJ VBZ RB JJ IN O
dependent dependent 0 0 0 0 0 0 0 0 9 0 VBZ RB JJ IN JJ O
on on 0 0 0 0 0 0 0 0 2 0 RB JJ IN JJ NN O
testicular testicular 0 0 0 0 0 0 0 0 10 0 JJ IN JJ NN NNP O
steroids, steroids, 0 0 0 0 1 0 0 0 9 0 IN JJ NN NNP NN O
Sertoli Sertoli 1 0 0 0 0 0 0 0 7 0 JJ NN NNP NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NN NNP NN NNS JJ O
products products 0 0 0 0 0 0 0 0 8 0 NNP NN NNS JJ CC O
(inhibin (inhibin 0 0 0 0 0 0 0 0 8 0 NN NNS JJ CC DT O
or or 0 0 0 0 0 0 0 0 2 0 NNS JJ CC DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ CC DT JJ NN O
like) like) 0 0 0 0 0 0 0 0 5 0 CC DT JJ NN IN O
nor nor 0 0 0 0 0 0 0 0 3 0 DT JJ NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
hypothalamic-hypophyseal-gonadal hypothalamic-hypophyseal-gonadal 0 0 1 0 0 0 0 0 32 0 IN DT JJ NN IN O
axis, axis, 0 0 0 0 1 0 0 0 5 0 DT JJ NN IN PRP O
since since 0 0 0 0 0 0 0 0 5 0 JJ NN IN PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN IN PRP VBZ IN O
occurs occurs 0 0 0 0 0 0 0 0 6 0 IN PRP VBZ IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 PRP VBZ IN NNP NNP O
vitro. vitro. 0 0 0 0 0 0 0 0 6 0 VBZ IN NNP NNP DT O
In In 1 0 0 0 0 0 0 0 2 0 IN NNP NNP DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NNP DT O
mouse, mouse, 0 0 0 0 1 0 0 0 6 0 NNP DT NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 DT NNP DT JJ NN O
biological biological 0 0 0 0 0 0 0 0 10 0 NNP DT JJ NN NN O
half-life half-life 0 0 1 0 0 0 0 0 9 0 DT JJ NN NN NN O
(in (in 0 0 0 0 0 0 0 0 3 0 JJ NN NN NN IN O
vivo) vivo) 0 0 0 0 0 0 0 0 5 0 NN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP JJ O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN DT NNP JJ NN B_TIMEXCCP
spermatogonial spermatogonial 0 0 0 0 0 0 0 0 14 0 DT NNP JJ NN VBZ O
chalone chalone 0 0 0 0 0 0 0 0 7 0 NNP JJ NN VBZ IN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ IN CD O
around around 0 0 0 0 0 0 0 0 6 0 NN VBZ IN CD NNP O
14 14 0 0 0 0 0 0 1 1 2 0 VBZ IN CD NNP NNP O
hs. hs. 0 0 0 0 0 0 0 0 3 0 IN CD NNP NNP NN O
Chronic Chronic 1 0 0 0 0 0 0 0 7 0 CD NNP NNP NN IN O
administration administration 0 0 0 0 0 0 0 0 14 0 NNP NNP NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
entire entire 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN IN O
length length 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NN O
mouse mouse 0 0 0 0 0 0 0 0 5 0 NN IN NN NN VBZ O
spermatogenesis spermatogenesis 0 0 0 0 0 0 0 0 15 0 IN NN NN VBZ RB O
does does 0 0 0 0 0 0 0 0 4 0 NN NN VBZ RB VB O
not not 0 0 0 0 0 0 0 0 3 0 NN VBZ RB VB JJ O
alter alter 0 0 0 0 0 0 0 0 5 0 VBZ RB VB JJ NNS O
spermatogenic spermatogenic 0 0 0 0 0 0 0 0 13 0 RB VB JJ NNS CC O
kinetics kinetics 0 0 0 0 0 0 0 0 8 0 VB JJ NNS CC VBZ O
nor nor 0 0 0 0 0 0 0 0 3 0 JJ NNS CC VBZ PRP O
does does 0 0 0 0 0 0 0 0 4 0 NNS CC VBZ PRP VB O
it it 0 0 0 0 0 0 0 0 2 0 CC VBZ PRP VB IN O
result result 0 0 0 0 0 0 0 0 6 0 VBZ PRP VB IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 PRP VB IN NNP NNP O
azoospermia. azoospermia. 0 0 0 0 0 0 0 0 12 0 VB IN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP JJ NN O
biological biological 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 NNP JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP JJ O
G1 G1 1 1 0 0 0 0 0 1 2 0 IN DT NNP JJ NN B_TIMEXCCP
spermatogonial spermatogonial 0 0 0 0 0 0 0 0 14 0 DT NNP JJ NN MD O
chalone chalone 0 0 0 0 0 0 0 0 7 0 NNP JJ NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 JJ NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
counteracted counteracted 0 0 0 0 0 0 0 0 12 0 MD VB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 VB VBN IN NN IN O
vitro vitro 0 0 0 0 0 0 0 0 5 0 VBN IN NN IN NNS O
by by 0 0 0 0 0 0 0 0 2 0 IN NN IN NNS IN O
means means 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT NN O
an an 0 0 0 0 0 0 0 0 2 0 NNS IN DT NN NN O
immune immune 0 0 0 0 0 0 0 0 6 0 IN DT NN NN NN O
rabbit rabbit 0 0 0 0 0 0 0 0 6 0 DT NN NN NN VBD O
serum serum 0 0 0 0 0 0 0 0 5 0 NN NN NN VBD IN O
raised raised 0 0 0 0 0 0 0 0 6 0 NN NN VBD IN DT O
against against 0 0 0 0 0 0 0 0 7 0 NN VBD IN DT RB O
a a 0 0 0 0 0 0 0 0 1 0 VBD IN DT RB VBN O
partially partially 0 0 0 0 0 0 0 0 9 0 IN DT RB VBN NN O
purified purified 0 0 0 0 0 0 0 0 8 0 DT RB VBN NN NN O
rat rat 0 0 0 0 0 0 0 0 3 0 RB VBN NN NN NN O
testicular testicular 0 0 0 0 0 0 0 0 10 0 VBN NN NN NN NN O
extract extract 0 0 0 0 0 0 0 0 7 0 NN NN NN NN IN O
(source (source 0 0 0 0 0 0 0 0 7 0 NN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
chalone). chalone). 0 0 0 0 0 0 0 0 9 0 IN DT NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 DT NNP NNP CD JJ O
2533475 2533475 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NN NN O
G2-phase G2-phase 1 0 1 0 0 0 0 1 8 0 NONE DT NN NN NNP B_TIMEXCCP
DNA-damage DNA-damage 1 0 1 0 0 0 0 0 10 0 DT NN NN NNP NNP O
checkpoint. checkpoint. 0 0 0 0 0 0 0 0 11 0 NN NN NNP NNP NNP B_TIMEXCCP
O'Connell O'Connell 1 0 0 0 0 1 0 0 9 0 NN NNP NNP NNP NNP O
MJ, MJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Walworth Walworth 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
NC, NC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Carr Carr 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
AM. AM. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Trescowthick Trescowthick 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Laboratories, Laboratories, 1 0 0 0 1 0 0 0 13 0 NNP NNP NNP NNP NNP O
Peter Peter 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
MacCallum MacCallum 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Locked Locked 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CD O
Bag Bag 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP CD JJ O
1, 1, 0 0 0 0 1 0 0 1 2 0 NNP NNP CD JJ NN O
A'Beckett A'Beckett 1 0 0 0 0 1 0 0 9 0 NNP CD JJ NN NN O
Street, Street, 1 0 0 0 1 0 0 0 7 0 CD JJ NN NN NNP O
Melbourne, Melbourne, 1 0 0 0 1 0 0 0 10 0 JJ NN NN NNP CD O
Victoria Victoria 1 0 0 0 0 0 0 0 8 0 NN NN NNP CD NNP O
8006, 8006, 0 0 0 0 1 0 0 1 5 0 NN NNP CD NNP NNP O
Australia. Australia. 1 0 0 0 0 0 0 0 10 0 NNP CD NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 CD NNP NNP NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN NNS O
damage damage 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NNS JJ O
causes causes 0 0 0 0 0 0 0 0 6 0 NNP NN NNS JJ NN O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 NN NNS JJ NN IN O
delay delay 0 0 0 0 0 0 0 0 5 0 NNS JJ NN IN NNP O
before before 0 0 0 0 0 0 0 0 6 0 JJ NN IN NNP NNP O
S S 1 1 0 0 0 0 0 0 1 0 NN IN NNP NNP IN B_TIMEXCCP
phase, phase, 0 0 0 0 1 0 0 0 6 0 IN NNP NNP IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NNP NNP IN NN CC O
replication replication 0 0 0 0 0 0 0 0 11 0 NNP IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NNP O
before before 0 0 0 0 0 0 0 0 6 0 NN CC IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 CC IN NNP NNP VBZ B_TIMEXCCP
This This 1 0 0 0 0 0 0 0 4 0 IN NNP NNP VBZ DT O
involves involves 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT NN IN O
number number 0 0 0 0 0 0 0 0 6 0 VBZ DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB VBN O
highly highly 0 0 0 0 0 0 0 0 6 0 NN IN RB VBN NNS O
conserved conserved 0 0 0 0 0 0 0 0 9 0 IN RB VBN NNS IN O
proteins proteins 0 0 0 0 0 0 0 0 8 0 RB VBN NNS IN NN O
that that 0 0 0 0 0 0 0 0 4 0 VBN NNS IN NN NNP O
sense sense 0 0 0 0 0 0 0 0 5 0 NNS IN NN NNP NN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 IN NN NNP NN CC O
damage damage 0 0 0 0 0 0 0 0 6 0 NN NNP NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC JJ DT O
signal signal 0 0 0 0 0 0 0 0 6 0 NN CC JJ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC JJ DT JJ NNP O
cell-cycle cell-cycle 0 0 1 0 0 0 0 0 10 0 JJ DT JJ NNP NNP O
machinery. machinery. 0 0 0 0 0 0 0 0 10 0 DT JJ NNP NNP IN O
Kinases Kinases 1 0 0 0 0 0 0 0 7 0 JJ NNP NNP IN VBD O
that that 0 0 0 0 0 0 0 0 4 0 NNP NNP IN VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP IN VBD RB VBN O
initially initially 0 0 0 0 0 0 0 0 9 0 IN VBD RB VBN IN O
discovered discovered 0 0 0 0 0 0 0 0 10 0 VBD RB VBN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN NN O
yeast yeast 0 0 0 0 0 0 0 0 5 0 VBN IN NN NN NNS O
model model 0 0 0 0 0 0 0 0 5 0 IN NN NN NNS VBP O
systems systems 0 0 0 0 0 0 0 0 7 0 NN NN NNS VBP RB O
have have 0 0 0 0 0 0 0 0 4 0 NN NNS VBP RB VBN O
recently recently 0 0 0 0 0 0 0 0 8 0 NNS VBP RB VBN RP O
been been 0 0 0 0 0 0 0 0 4 0 VBP RB VBN RP TO O
shown shown 0 0 0 0 0 0 0 0 5 0 RB VBN RP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN RP TO VB DT O
regulate regulate 0 0 0 0 0 0 0 0 8 0 RP TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
regulators regulators 0 0 0 0 0 0 0 0 10 0 VB DT NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN JJ NNS O
cyclin-dependent cyclin-dependent 0 0 1 0 0 0 0 0 16 0 NNS IN JJ NNS CC O
kinases kinases 0 0 0 0 0 0 0 0 7 0 IN JJ NNS CC TO O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNS CC TO NN DT O
control control 0 0 0 0 0 0 0 0 7 0 CC TO NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO NN DT NN IN O
stability stability 0 0 0 0 0 0 0 0 9 0 NN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
p53. p53. 0 0 0 0 0 0 0 1 4 0 NN IN NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 IN NNP NNP VBZ DT O
shows shows 0 0 0 0 0 0 0 0 5 0 NNP NNP VBZ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT NN IN O
importance importance 0 0 0 0 0 0 0 0 10 0 VBZ DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NN IN NN NNS IN B_TIMEXCCP
proteins proteins 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN VBG NN O
maintaining maintaining 0 0 0 0 0 0 0 0 11 0 NNS IN VBG NN NNP O
genome genome 0 0 0 0 0 0 0 0 6 0 IN VBG NN NNP NNP O
stability. stability. 0 0 0 0 0 0 0 0 10 0 VBG NN NNP NNP PRP O
Here, Here, 1 0 0 0 1 0 0 0 5 0 NN NNP NNP PRP VBZ O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBZ JJ O
discuss discuss 0 0 0 0 0 0 0 0 7 0 NNP PRP VBZ JJ NNS O
recent recent 0 0 0 0 0 0 0 0 6 0 PRP VBZ JJ NNS IN O
data data 0 0 0 0 0 0 0 0 4 0 VBZ JJ NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 JJ NNS IN JJ CC O
yeast yeast 0 0 0 0 0 0 0 0 5 0 NNS IN JJ CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NNS WDT O
metazoans metazoans 0 0 0 0 0 0 0 0 9 0 JJ CC NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 CC NNS WDT VBP DT O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNS WDT VBP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 WDT VBP DT JJ NN O
remarkable remarkable 0 0 0 0 0 0 0 0 10 0 VBP DT JJ NN IN O
conservation conservation 0 0 0 0 0 0 0 0 12 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
organization organization 0 0 0 0 0 0 0 0 12 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
G2 G2 1 1 0 0 0 0 0 1 2 0 IN DT NNP NNP NN B_TIMEXCCP
DNA-damage DNA-damage 1 0 1 0 0 0 0 0 10 0 DT NNP NNP NN NNP O
checkpoint checkpoint 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NNP NNP B_TIMEXCCP
pathway. pathway. 0 0 0 0 0 0 0 0 8 0 NNP NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
10856933 10856933 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Dynamics Dynamics 1 0 0 0 0 0 0 0 8 0 NONE NONE NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNS IN NN NNS O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNS IN B_TIMEXCCP
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 IN NN NNS IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN NNS NNP O
Schizosaccharomyces Schizosaccharomyces 1 0 0 0 0 0 0 0 19 0 NNS IN NNS NNP NNP O
pombe. pombe. 0 0 0 0 0 0 0 0 6 0 IN NNS NNP NNP NNP O
Drummond Drummond 1 0 0 0 0 0 0 0 8 0 NNS NNP NNP NNP NNP O
DR, DR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Cross Cross 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
RA. RA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNPS O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNPS NNP O
Motors Motors 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS NNP NNP O
Group, Group, 1 0 0 0 1 0 0 0 6 0 NNP NNPS NNP NNP NNP O
Marie Marie 1 0 0 0 0 0 0 0 5 0 NNPS NNP NNP NNP NNP O
Curie Curie 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Institute, Institute, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chart, Chart, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Surrey, Surrey, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
UK. UK. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
BACKGROUND: BACKGROUND: 1 1 0 0 0 0 0 0 11 0 NNP NNP NNP NNP IN O
Microtubules Microtubules 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NN NNS O
interphase interphase 0 0 0 0 0 0 0 0 10 0 NNP IN NN NNS VBP B_TIMEXCCP
Schizosaccharomyces Schizosaccharomyces 1 0 0 0 0 0 0 0 19 0 IN NN NNS VBP VBP O
pombe pombe 0 0 0 0 0 0 0 0 5 0 NN NNS VBP VBP JJ O
are are 0 0 0 0 0 0 0 0 3 0 NNS VBP VBP JJ IN O
essential essential 0 0 0 0 0 0 0 0 9 0 VBP VBP JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 VBP JJ IN NN DT O
maintaining maintaining 0 0 0 0 0 0 0 0 11 0 JJ IN NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 IN NN DT NN NN O
linear linear 0 0 0 0 0 0 0 0 6 0 NN DT NN NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 DT NN NN NN IN O
habit habit 0 0 0 0 0 0 0 0 5 0 NN NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP NNS IN O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS IN RB O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN RB CC O
assembly assembly 0 0 0 0 0 0 0 0 8 0 NNS IN RB CC RB O
and and 0 0 0 0 0 0 0 0 3 0 IN RB CC RB IN O
disassembly disassembly 0 0 0 0 0 0 0 0 11 0 RB CC RB IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC RB IN DT NNS O
these these 0 0 0 0 0 0 0 0 5 0 RB IN DT NNS VBP O
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 IN DT NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 DT NNS VBP RB RB O
so so 0 0 0 0 0 0 0 0 2 0 NNS VBP RB RB NNP O
far far 0 0 0 0 0 0 0 0 3 0 VBP RB RB NNP NNP O
uncharacterised. uncharacterised. 0 0 0 0 0 0 0 0 16 0 RB RB NNP NNP NNP O
RESULTS: RESULTS: 1 1 0 0 0 0 0 0 8 0 RB NNP NNP NNP NN O
Live Live 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NN JJ O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN JJ NN O
confocal confocal 0 0 0 0 0 0 0 0 8 0 NNP NN JJ NN IN O
imaging imaging 0 0 0 0 0 0 0 0 7 0 NN JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
alpha1 alpha1 0 0 0 0 0 0 0 1 6 0 NN IN NNP NN VBD O
tubulin tubulin 0 0 0 0 0 0 0 0 7 0 IN NNP NN VBD IN O
tagged tagged 0 0 0 0 0 0 0 0 6 0 NNP NN VBD IN VBN O
with with 0 0 0 0 0 0 0 0 4 0 NN VBD IN VBN JJ O
enhanced enhanced 0 0 0 0 0 0 0 0 8 0 VBD IN VBN JJ NN O
green green 0 0 0 0 0 0 0 0 5 0 IN VBN JJ NN NN O
fluorescent fluorescent 0 0 0 0 0 0 0 0 11 0 VBN JJ NN NN VBD O
protein protein 0 0 0 0 0 0 0 0 7 0 JJ NN NN VBD RB O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN NN VBD RB JJ O
longitudinally longitudinally 0 0 0 0 0 0 0 0 14 0 NN VBD RB JJ RB O
oriented, oriented, 0 0 0 0 1 0 0 0 9 0 VBD RB JJ RB JJ O
dynamically dynamically 0 0 0 0 0 0 0 0 11 0 RB JJ RB JJ NN O
unstable unstable 0 0 0 0 0 0 0 0 8 0 JJ RB JJ NN NN O
interphase interphase 0 0 0 0 0 0 0 0 10 0 RB JJ NN NN NNS B_TIMEXCCP
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 JJ NN NN NNS NNP O
assemblies assemblies 0 0 0 0 0 0 0 0 10 0 NN NN NNS NNP NNP O
(IMAs). (IMAs). 0 0 0 0 0 0 0 0 7 0 NN NNS NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNS NNP NNP NNP VBD O
IMAs IMAs 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD RB JJ O
uniformly uniformly 0 0 0 0 0 0 0 0 9 0 NNP VBD RB JJ IN O
bright bright 0 0 0 0 0 0 0 0 6 0 VBD RB JJ IN PRP$ O
along along 0 0 0 0 0 0 0 0 5 0 RB JJ IN PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 JJ IN PRP$ NN NN O
length length 0 0 0 0 0 0 0 0 6 0 IN PRP$ NN NN IN O
apart apart 0 0 0 0 0 0 0 0 5 0 PRP$ NN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
zone zone 0 0 0 0 0 0 0 0 4 0 IN DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB RB O
approximately approximately 0 0 0 0 0 0 0 0 13 0 NN IN RB RB JJ O
doubly doubly 0 0 0 0 0 0 0 0 6 0 IN RB RB JJ NN O
intense intense 0 0 0 0 0 0 0 0 7 0 RB RB JJ NN RB O
fluorescence fluorescence 0 0 0 0 0 0 0 0 12 0 RB JJ NN RB JJ O
commonly commonly 0 0 0 0 0 0 0 0 8 0 JJ NN RB JJ NN O
present present 0 0 0 0 0 0 0 0 7 0 NN RB JJ NN TO O
close close 0 0 0 0 0 0 0 0 5 0 RB JJ NN TO PRP$ O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO PRP$ NNP O
their their 0 0 0 0 0 0 0 0 5 0 NN TO PRP$ NNP NNP O
centres. centres. 0 0 0 0 0 0 0 0 8 0 TO PRP$ NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 PRP$ NNP NNP NNS IN O
ends ends 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NNP O
each each 0 0 0 0 0 0 0 0 4 0 NNS IN DT NNP VBD O
IMA IMA 1 1 0 0 0 0 0 0 3 0 IN DT NNP VBD IN O
switched switched 0 0 0 0 0 0 0 0 8 0 DT NNP VBD IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBD IN NN : O
growth growth 0 0 0 0 0 0 0 0 6 0 VBD IN NN : RB O
( ( 0 0 0 0 0 0 0 0 1 0 IN NN : RB CD O
approximately approximately 0 0 0 0 0 0 0 0 13 0 NN : RB CD -NONE- O
3.0 3.0 0 0 0 0 0 0 0 1 3 0 : RB CD -NONE- TO O
microm/min) microm/min) 0 0 0 1 0 0 0 0 11 0 RB CD -NONE- TO VB O
to to 0 0 0 0 0 0 0 0 2 0 CD -NONE- TO VB : O
shrinkage shrinkage 0 0 0 0 0 0 0 0 9 0 -NONE- TO VB : RB O
( ( 0 0 0 0 0 0 0 0 1 0 TO VB : RB CD O
approximately approximately 0 0 0 0 0 0 0 0 13 0 VB : RB CD -NONE- O
4.5 4.5 0 0 0 0 0 0 0 1 3 0 : RB CD -NONE- IN O
microm/min) microm/min) 0 0 0 1 0 0 0 0 11 0 RB CD -NONE- IN CD O
at at 0 0 0 0 0 0 0 0 2 0 CD -NONE- IN CD NNS O
1.0 1.0 0 0 0 0 0 0 0 1 3 0 -NONE- IN CD NNS IN O
events events 0 0 0 0 0 0 0 0 6 0 IN CD NNS IN NN O
per per 0 0 0 0 0 0 0 0 3 0 CD NNS IN NN CC O
minute minute 0 0 0 0 0 0 0 0 6 0 NNS IN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC IN NN O
from from 0 0 0 0 0 0 0 0 4 0 NN CC IN NN TO O
shrinkage shrinkage 0 0 0 0 0 0 0 0 9 0 CC IN NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN TO NN IN CD O
at at 0 0 0 0 0 0 0 0 2 0 TO NN IN CD NNS O
1.9 1.9 0 0 0 0 0 0 0 1 3 0 NN IN CD NNS IN O
events events 0 0 0 0 0 0 0 0 6 0 IN CD NNS IN JJ O
per per 0 0 0 0 0 0 0 0 3 0 CD NNS IN JJ CC O
minute, minute, 0 0 0 0 1 0 0 0 7 0 NNS IN JJ CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC DT CD O
the the 0 0 0 0 0 0 0 0 3 0 JJ CC DT CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 CC DT CD NNS VBD O
ends ends 0 0 0 0 0 0 0 0 4 0 DT CD NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 CD NNS VBD RB JJ O
equivalently equivalently 0 0 0 0 0 0 0 0 12 0 NNS VBD RB JJ NN O
dynamic, dynamic, 0 0 0 0 1 0 0 0 8 0 VBD RB JJ NN NN O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 RB JJ NN NN NNP O
equivalent equivalent 0 0 0 0 0 0 0 0 10 0 JJ NN NN NNP NNP O
structure. structure. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP RB O
We We 1 0 0 0 0 0 0 0 2 0 NN NNP NNP RB VBP O
accordingly accordingly 0 0 0 0 0 0 0 0 11 0 NNP NNP RB VBP DT O
propose propose 0 0 0 0 0 0 0 0 7 0 NNP RB VBP DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 RB VBP DT JJ NN O
symmetrical symmetrical 0 0 0 0 0 0 0 0 11 0 VBP DT JJ NN IN O
model model 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NN VBG O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 NN IN NN VBG IN O
packing packing 0 0 0 0 0 0 0 0 7 0 IN NN VBG IN DT O
within within 0 0 0 0 0 0 0 0 6 0 NN VBG IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT NNP IN O
IMAs, IMAs, 1 0 0 0 1 0 0 0 5 0 IN DT NNP IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 DT NNP IN WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 NNP IN WDT NNS VBP O
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 IN WDT NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 WDT NNS VBP RB NNS O
plus plus 0 0 0 0 0 0 0 0 4 0 NNS VBP RB NNS IN O
ends ends 0 0 0 0 0 0 0 0 4 0 VBP RB NNS IN CC O
out out 0 0 0 0 0 0 0 0 3 0 RB NNS IN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNS IN CC NN NN O
overlap overlap 0 0 0 0 0 0 0 0 7 0 IN CC NN NN TO O
close close 0 0 0 0 0 0 0 0 5 0 CC NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN IN O
equator equator 0 0 0 0 0 0 0 0 7 0 TO DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NNP O
cell. cell. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NNP MD O
IMAs IMAs 1 0 0 0 0 0 0 0 4 0 DT NNP NNP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NNP NNP MD VB NN O
contain contain 0 0 0 0 0 0 0 0 7 0 NNP MD VB NN NNS O
multiple multiple 0 0 0 0 0 0 0 0 8 0 MD VB NN NNS IN O
copies copies 0 0 0 0 0 0 0 0 6 0 VB NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNS IN DT NN IN O
motif; motif; 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NNP O
if if 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP RB O
so, so, 0 0 0 0 1 0 0 0 3 0 NN IN NNP RB IN O
then then 0 0 0 0 0 0 0 0 4 0 IN NNP RB IN DT O
within within 0 0 0 0 0 0 0 0 6 0 NNP RB IN DT NNP O
each each 0 0 0 0 0 0 0 0 4 0 RB IN DT NNP NNP O
IMA IMA 1 1 0 0 0 0 0 0 3 0 IN DT NNP NNP DT O
end, end, 0 0 0 0 1 0 0 0 4 0 DT NNP NNP DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT NN VBZ O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 NNP DT NN VBZ MD O
ends ends 0 0 0 0 0 0 0 0 4 0 DT NN VBZ MD VB O
must must 0 0 0 0 0 0 0 0 4 0 NN VBZ MD VB PRP O
synchronise synchronise 0 0 0 0 0 0 0 0 11 0 VBZ MD VB PRP CC O
catastrophe catastrophe 0 0 0 0 0 0 0 0 11 0 MD VB PRP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VB PRP CC NNP NNP O
rescue. rescue. 0 0 0 0 0 0 0 0 7 0 PRP CC NNP NNP DT O
When When 1 0 0 0 0 0 0 0 4 0 CC NNP NNP DT NNS O
both both 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NNS IN O
ends ends 0 0 0 0 0 0 0 0 4 0 NNP DT NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN DT NNP O
an an 0 0 0 0 0 0 0 0 2 0 NNS IN DT NNP NN O
IMA IMA 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN IN O
lodge lodge 0 0 0 0 0 0 0 0 5 0 DT NNP NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
hemispherical hemispherical 0 0 0 0 0 0 0 0 13 0 IN DT JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN DT O
ends, ends, 0 0 0 0 1 0 0 0 5 0 JJ NN NN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN NN DT NNP NN O
IMAs IMAs 1 0 0 0 0 0 0 0 4 0 NN DT NNP NN TO O
start start 0 0 0 0 0 0 0 0 5 0 DT NNP NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO VB IN O
bend bend 0 0 0 0 0 0 0 0 4 0 NN TO VB IN NN O
under under 0 0 0 0 0 0 0 0 5 0 TO VB IN NN CC O
compression compression 0 0 0 0 0 0 0 0 11 0 VB IN NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 NN CC PRP$ JJ NN O
overall overall 0 0 0 0 0 0 0 0 7 0 CC PRP$ JJ NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 PRP$ JJ NN NN VBZ O
rate rate 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ VBN IN O
inhibited inhibited 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN IN NNP O
about about 0 0 0 0 0 0 0 0 5 0 VBZ VBN IN NNP NNP O
twofold. twofold. 0 0 0 0 0 0 0 0 8 0 VBN IN NNP NNP NN O
Similar Similar 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NN NNS O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 NNP NNP NN NNS VBD O
dynamics dynamics 0 0 0 0 0 0 0 0 8 0 NNP NN NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN NNS O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNS VBG O
cells cells 0 0 0 0 0 0 0 0 5 0 VBN IN NNS VBG IN O
ranging ranging 0 0 0 0 0 0 0 0 7 0 IN NNS VBG IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBG IN NN IN O
size size 0 0 0 0 0 0 0 0 4 0 VBG IN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 IN NN IN DT TO O
half half 0 0 0 0 0 0 0 0 4 0 NN IN DT TO NN O
to to 0 0 0 0 0 0 0 0 2 0 IN DT TO NN JJ O
twice twice 0 0 0 0 0 0 0 0 5 0 DT TO NN JJ NNP O
normal normal 0 0 0 0 0 0 0 0 6 0 TO NN JJ NNP NNP O
length. length. 0 0 0 0 0 0 0 0 7 0 NN JJ NNP NNP NN O
Patterned Patterned 1 0 0 0 0 0 0 0 9 0 JJ NNP NNP NN VBD O
photobleaching photobleaching 0 0 0 0 0 0 0 0 14 0 NNP NNP NN VBD DT O
indicated indicated 0 0 0 0 0 0 0 0 9 0 NNP NN VBD DT JJ O
no no 0 0 0 0 0 0 0 0 2 0 NN VBD DT JJ NN O
detectable detectable 0 0 0 0 0 0 0 0 10 0 VBD DT JJ NN CC O
treadmilling treadmilling 0 0 0 0 0 0 0 0 12 0 DT JJ NN CC NN O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC NN VBG O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 NN CC NN VBG IN O
sliding sliding 0 0 0 0 0 0 0 0 7 0 CC NN VBG IN NNP O
during during 0 0 0 0 0 0 0 0 6 0 NN VBG IN NNP NNP O
interphase. interphase. 0 0 0 0 0 0 0 0 11 0 VBG IN NNP NNP NNP B_TIMEXCCP
CONCLUSIONS: CONCLUSIONS: 1 1 0 0 0 0 0 0 12 0 IN NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
consequence consequence 0 0 0 0 0 0 0 0 11 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBD O
mechanisms mechanisms 0 0 0 0 0 0 0 0 10 0 IN DT NNS VBD VBZ O
described described 0 0 0 0 0 0 0 0 9 0 DT NNS VBD VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNS VBD VBZ JJ NN O
continuous continuous 0 0 0 0 0 0 0 0 10 0 VBD VBZ JJ NN IN O
recruitment recruitment 0 0 0 0 0 0 0 0 11 0 VBZ JJ NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNS O
microtubule microtubule 0 0 0 0 0 0 0 0 11 0 NN IN NN NNS TO O
ends ends 0 0 0 0 0 0 0 0 4 0 IN NN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS TO DT NNS IN O
ends ends 0 0 0 0 0 0 0 0 4 0 TO DT NNS IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 DT NNS IN VBG JJ O
growing growing 0 0 0 0 0 0 0 0 7 0 NNS IN VBG JJ NN O
cells, cells, 0 0 0 0 1 0 0 0 6 0 IN VBG JJ NN JJ O
supporting supporting 0 0 0 0 0 0 0 0 10 0 VBG JJ NN JJ NN O
microtubule-based microtubule-based 0 0 1 0 0 0 0 0 17 0 JJ NN JJ NN IN O
transport transport 0 0 0 0 0 0 0 0 9 0 NN JJ NN IN DT O
into into 0 0 0 0 0 0 0 0 4 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
cell cell 0 0 0 0 0 0 0 0 4 0 IN DT NN VBZ CC O
ends ends 0 0 0 0 0 0 0 0 4 0 DT NN VBZ CC RB O
and and 0 0 0 0 0 0 0 0 3 0 NN VBZ CC RB VBG O
qualitatively qualitatively 0 0 0 0 0 0 0 0 13 0 VBZ CC RB VBG IN O
accounting accounting 0 0 0 0 0 0 0 0 10 0 CC RB VBG IN DT O
for for 0 0 0 0 0 0 0 0 3 0 RB VBG IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT JJ NN O
essential essential 0 0 0 0 0 0 0 0 9 0 IN DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNS O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN NNS IN O
microtubules microtubules 0 0 0 0 0 0 0 0 12 0 NN IN NNS IN VBG O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN VBG NN O
directing directing 0 0 0 0 0 0 0 0 9 0 NNS IN VBG NN NN O
linear linear 0 0 0 0 0 0 0 0 6 0 IN VBG NN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 VBG NN NN NN IN O
growth growth 0 0 0 0 0 0 0 0 6 0 NN NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NNP NNP O
pombe. pombe. 0 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP IN O
Comment Comment 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cell Cell 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP DT O
polarity: polarity: 0 0 0 0 0 0 0 0 9 0 IN NNP NNP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP NNP DT NN IN O
tale tale 0 0 0 0 0 0 0 0 4 0 NNP DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NNP O
two two 0 0 0 0 0 0 0 0 3 0 NN IN CD NNP NNP O
Ts. Ts. 1 0 0 0 0 0 0 0 3 0 IN CD NNP NNP NNP O
[Curr [Curr 0 0 0 0 0 0 0 0 5 0 CD NNP NNP NNP CD O
Biol. Biol. 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP CD -NONE- O
2001] 2001] 0 0 0 0 0 0 0 1 5 0 NNP NNP CD -NONE- CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP CD -NONE- CD JJ O
10898975 10898975 0 0 0 0 0 0 1 1 8 0 CD -NONE- CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 -NONE- CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Chromokinesins: Chromokinesins: 1 0 0 0 0 0 0 0 15 0 NONE NONE NN VBD NNS O
multitalented multitalented 0 0 0 0 0 0 0 0 13 0 NONE NN VBD NNS IN O
players players 0 0 0 0 0 0 0 0 7 0 NN VBD NNS IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBD NNS IN NNP NNP O
mitosis. mitosis. 0 0 0 0 0 0 0 0 8 0 NNS IN NNP NNP NNP B_TIMEXCCP
Mazumdar Mazumdar 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Misteli Misteli 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
T. T. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
National National 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Institute/NIH, Institute/NIH, 1 0 0 1 1 0 0 0 14 0 NNP NNP NNP NNP NNP O
Bethesda, Bethesda, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP CD O
MD MD 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
20892, 20892, 0 0 0 0 1 0 0 1 6 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
mazumdam@mail.nih.gov mazumdam@mail.nih.gov 0 0 0 0 0 0 0 0 21 0 CD NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNS O
Molecular Molecular 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNS VBP O
motors motors 0 0 0 0 0 0 0 0 6 0 NNP NNP NNS VBP JJ O
generate generate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP JJ NNS O
cellular cellular 0 0 0 0 0 0 0 0 8 0 NNS VBP JJ NNS CC O
forces forces 0 0 0 0 0 0 0 0 6 0 VBP JJ NNS CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC NN IN O
act act 0 0 0 0 0 0 0 0 3 0 NNS CC NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
multitude multitude 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
intracellular intracellular 0 0 0 0 0 0 0 0 13 0 NN IN JJ NN NNP O
transport transport 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP O
processes. processes. 0 0 0 0 0 0 0 0 10 0 JJ NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBP O
chromokinesins chromokinesins 0 0 0 0 0 0 0 0 14 0 NNP NNP NNS VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 NNP NNS VBP DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS VBP DT NN IN O
subgroup subgroup 0 0 0 0 0 0 0 0 8 0 VBP DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNP O
kinesin kinesin 0 0 0 0 0 0 0 0 7 0 NN IN NN NNP NNP O
motors. motors. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP NN O
Chromokinesins Chromokinesins 1 0 0 0 0 0 0 0 14 0 NN NNP NNP NN IN O
act act 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NNS O
various various 0 0 0 0 0 0 0 0 7 0 NN IN JJ NNS IN O
steps steps 0 0 0 0 0 0 0 0 5 0 IN JJ NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN JJ VBG O
mitosis, mitosis, 0 0 0 0 1 0 0 0 8 0 NNS IN JJ VBG NN B_TIMEXCCP
including including 0 0 0 0 0 0 0 0 9 0 IN JJ VBG NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 JJ VBG NN NN NN O
condensation, condensation, 0 0 0 0 1 0 0 0 13 0 VBG NN NN NN NN O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 NN NN NN NN NN B_TIMEXCCP
alignment, alignment, 0 0 0 0 1 0 0 0 10 0 NN NN NN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN NN NN NN NN O
segregation, segregation, 0 0 0 0 1 0 0 0 12 0 NN NN NN NN CC O
cytokinesis cytokinesis 0 0 0 0 0 0 0 0 11 0 NN NN NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP VBP O
they they 0 0 0 0 0 0 0 0 4 0 NN CC PRP VBP VB O
help help 0 0 0 0 0 0 0 0 4 0 CC PRP VBP VB NN O
maintain maintain 0 0 0 0 0 0 0 0 8 0 PRP VBP VB NN NNP O
genome genome 0 0 0 0 0 0 0 0 6 0 VBP VB NN NNP NNP O
stability. stability. 0 0 0 0 0 0 0 0 10 0 VB NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN JJ O
emerging emerging 0 0 0 0 0 0 0 0 8 0 NNP NNP NN JJ NN O
multifunctional multifunctional 0 0 0 0 0 0 0 0 15 0 NNP NN JJ NN IN O
nature nature 0 0 0 0 0 0 0 0 6 0 NN JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNS VBZ O
chromokinesins chromokinesins 0 0 0 0 0 0 0 0 14 0 IN DT NNS VBZ NNS O
provides provides 0 0 0 0 0 0 0 0 8 0 DT NNS VBZ NNS IN O
insights insights 0 0 0 0 0 0 0 0 8 0 NNS VBZ NNS IN DT O
into into 0 0 0 0 0 0 0 0 4 0 VBZ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
coordination coordination 0 0 0 0 0 0 0 0 12 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN JJ O
distinct distinct 0 0 0 0 0 0 0 0 8 0 NN IN NN JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN NN JJ NN CC O
steps, steps, 0 0 0 0 1 0 0 0 6 0 NN JJ NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC PRP$ NN O
their their 0 0 0 0 0 0 0 0 5 0 NN CC PRP$ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 CC PRP$ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 PRP$ NN IN NN IN O
maintenance maintenance 0 0 0 0 0 0 0 0 11 0 NN IN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NN NN O
genome genome 0 0 0 0 0 0 0 0 6 0 NN IN NN NN VBZ O
stability stability 0 0 0 0 0 0 0 0 9 0 IN NN NN VBZ PRP O
makes makes 0 0 0 0 0 0 0 0 5 0 NN NN VBZ PRP JJ O
them them 0 0 0 0 0 0 0 0 4 0 NN VBZ PRP JJ JJ O
attractive attractive 0 0 0 0 0 0 0 0 10 0 VBZ PRP JJ JJ NNS O
potential potential 0 0 0 0 0 0 0 0 9 0 PRP JJ JJ NNS IN O
targets targets 0 0 0 0 0 0 0 0 7 0 JJ JJ NNS IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN JJ NNP O
therapeutic therapeutic 0 0 0 0 0 0 0 0 11 0 NNS IN JJ NNP NNP O
intervention. intervention. 0 0 0 0 0 0 0 0 13 0 IN JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
15946846 15946846 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Banding Banding 1 0 0 0 0 0 0 0 7 0 NONE NONE VBG CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NONE VBG CC NN IN O
spiralization spiralization 0 0 0 0 0 0 0 0 13 0 VBG CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NNP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP B_TIMEXCCP
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP NNP O
Goradia Goradia 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NNP NNP O
RY, RY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Davis Davis 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
BK. BK. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP JJ O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 NNP NNP JJ NN VBZ O
technique technique 0 0 0 0 0 0 0 0 9 0 NNP JJ NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ VBN WDT O
described described 0 0 0 0 0 0 0 0 9 0 NN VBZ VBN WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 VBZ VBN WDT NNS VBP O
produces produces 0 0 0 0 0 0 0 0 8 0 VBN WDT NNS VBP IN O
spiralization spiralization 0 0 0 0 0 0 0 0 13 0 WDT NNS VBP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNS VBP IN JJ NN O
human human 0 0 0 0 0 0 0 0 5 0 VBP IN JJ NN NNP O
metaphase metaphase 0 0 0 0 0 0 0 0 9 0 IN JJ NN NNP NNP B_TIMEXCCP
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 JJ NN NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP JJ NN O
important important 0 0 0 0 0 0 0 0 9 0 NNP NNP JJ NN VBZ O
feature feature 0 0 0 0 0 0 0 0 7 0 NNP JJ NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ VBN VBN O
heat heat 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN IN O
followed followed 0 0 0 0 0 0 0 0 8 0 VBZ VBN VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NN NNP O
trypsin trypsin 0 0 0 0 0 0 0 0 7 0 VBN IN NN NNP NNP O
treatment. treatment. 0 0 0 0 0 0 0 0 10 0 IN NN NNP NNP NN O
By By 1 0 0 0 0 0 0 0 2 0 NN NNP NNP NN -NONE- O
varying varying 0 0 0 0 0 0 0 0 7 0 NNP NNP NN -NONE- PRP O
conditions, conditions, 0 0 0 0 1 0 0 0 11 0 NNP NN -NONE- PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 NN -NONE- PRP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 -NONE- PRP VBZ JJ TO O
possible possible 0 0 0 0 0 0 0 0 8 0 PRP VBZ JJ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBZ JJ TO VB JJ O
produce produce 0 0 0 0 0 0 0 0 7 0 JJ TO VB JJ NNS O
bands, bands, 0 0 0 0 1 0 0 0 6 0 TO VB JJ NNS CC O
spirals spirals 0 0 0 0 0 0 0 0 7 0 VB JJ NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC JJ NNP O
intermediate intermediate 0 0 0 0 0 0 0 0 12 0 NNS CC JJ NNP NNP O
stages. stages. 0 0 0 0 0 0 0 0 7 0 CC JJ NNP NNP VBZ O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP VBZ DT O
provides provides 0 0 0 0 0 0 0 0 8 0 NNP NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ NN O
new new 0 0 0 0 0 0 0 0 3 0 VBZ DT JJ NN TO O
approach approach 0 0 0 0 0 0 0 0 8 0 DT JJ NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN TO DT NN IN O
understanding understanding 0 0 0 0 0 0 0 0 13 0 TO DT NN IN VBG O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBG CC O
banding banding 0 0 0 0 0 0 0 0 7 0 NN IN VBG CC NN O
and and 0 0 0 0 0 0 0 0 3 0 IN VBG CC NN NNP O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 VBG CC NN NNP NNP O
structure. structure. 0 0 0 0 0 0 0 0 10 0 CC NN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NN NNP NNP CD JJ O
67074 67074 0 0 0 0 0 0 1 1 5 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Characterization Characterization 1 0 0 0 0 0 0 0 16 0 NONE NONE NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NN IN NNP VBD O
cDNAs cDNAs 0 0 0 0 0 0 0 0 5 0 NN IN NNP VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 IN NNP VBD IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN JJ NN O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 VBD IN JJ NN IN O
prophase prophase 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NN B_TIMEXCCP
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN NNP O
lily lily 0 0 0 0 0 0 0 0 4 0 NN IN NN NNP NNP O
microsporocytes. microsporocytes. 0 0 0 0 0 0 0 0 16 0 IN NN NNP NNP NNP O
Kobayashi Kobayashi 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NNP NNP O
T, T, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kobayashi Kobayashi 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
E, E, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sato Sato 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Hotta Hotta 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Miyajima Miyajima 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
N, N, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tanaka Tanaka 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Tabata Tabata 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Biology, Biology, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Science, Science, 1 0 0 0 1 0 0 0 8 0 NNP IN NNP NNP NNP O
Nagoya Nagoya 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Furoh-cho, Furoh-cho, 1 0 1 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Japan. Japan. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP VB O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VB CC O
identify identify 0 0 0 0 0 0 0 0 8 0 NNP NNP VB CC VB O
and and 0 0 0 0 0 0 0 0 3 0 NNP VB CC VB NNS O
analyze analyze 0 0 0 0 0 0 0 0 7 0 VB CC VB NNS VBG O
genes genes 0 0 0 0 0 0 0 0 5 0 CC VB NNS VBG IN O
functioning functioning 0 0 0 0 0 0 0 0 11 0 VB NNS VBG IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NNS VBG IN JJ NN O
reproductive reproductive 0 0 0 0 0 0 0 0 12 0 VBG IN JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN IN O
formation formation 0 0 0 0 0 0 0 0 9 0 JJ NN NN IN JJR O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJR JJ O
higher higher 0 0 0 0 0 0 0 0 6 0 NN IN JJR JJ NNP O
plants, plants, 0 0 0 0 1 0 0 0 7 0 IN JJR JJ NNP NN O
cDNAs cDNAs 0 0 0 0 0 0 0 0 5 0 JJR JJ NNP NN DT O
harboring harboring 0 0 0 0 0 0 0 0 9 0 JJ NNP NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NNS VBD O
messages messages 0 0 0 0 0 0 0 0 8 0 NN DT NNS VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 DT NNS VBD IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN JJ NN O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 VBD IN JJ NN VBD O
prophase prophase 0 0 0 0 0 0 0 0 8 0 IN JJ NN VBD VBN B_TIMEXCCP
were were 0 0 0 0 0 0 0 0 4 0 JJ NN VBD VBN CC O
isolated isolated 0 0 0 0 0 0 0 0 8 0 NN VBD VBN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 VBD VBN CC NNP DT O
characterized. characterized. 0 0 0 0 0 0 0 0 14 0 VBN CC NNP DT NNP O
A A 1 1 0 0 0 0 0 0 1 0 CC NNP DT NNP NN O
cDNA cDNA 0 0 0 0 0 0 0 0 4 0 NNP DT NNP NN VBD O
library library 0 0 0 0 0 0 0 0 7 0 DT NNP NN VBD IN O
constructed constructed 0 0 0 0 0 0 0 0 11 0 NNP NN VBD IN NNS O
from from 0 0 0 0 0 0 0 0 4 0 NN VBD IN NNS IN O
microsporocytes microsporocytes 0 0 0 0 0 0 0 0 15 0 VBD IN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NN O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NN IN O
prophase prophase 0 0 0 0 0 0 0 0 8 0 IN JJ NN IN NNP B_TIMEXCCP
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP NN O
Lilium Lilium 1 0 0 0 0 0 0 0 6 0 NN IN NNP NN VBD O
longiflorum longiflorum 0 0 0 0 0 0 0 0 11 0 IN NNP NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NNP NN VBD VBN IN O
screened screened 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VBD VBN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT NN NN O
subtraction subtraction 0 0 0 0 0 0 0 0 11 0 IN DT NN NN NN O
probe probe 0 0 0 0 0 0 0 0 5 0 DT NN NN NN TO O
specific specific 0 0 0 0 0 0 0 0 8 0 NN NN NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO JJ NNP O
meiotic meiotic 0 0 0 0 0 0 0 0 7 0 NN TO JJ NNP NNP O
prophase. prophase. 0 0 0 0 0 0 0 0 9 0 TO JJ NNP NNP VBD B_TIMEXCCP
Clones Clones 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP VBD VBD O
selected selected 0 0 0 0 0 0 0 0 8 0 NNP NNP VBD VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP VBD VBD VBN IN O
classified classified 0 0 0 0 0 0 0 0 10 0 VBD VBD VBN IN CD O
into into 0 0 0 0 0 0 0 0 4 0 VBD VBN IN CD NNS O
18 18 0 0 0 0 0 0 1 1 2 0 VBN IN CD NNS IN O
groups groups 0 0 0 0 0 0 0 0 6 0 IN CD NNS IN NN O
by by 0 0 0 0 0 0 0 0 2 0 CD NNS IN NN NN O
cross cross 0 0 0 0 0 0 0 0 5 0 NNS IN NN NN CC O
hybridization hybridization 0 0 0 0 0 0 0 0 13 0 IN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NNP O
partial partial 0 0 0 0 0 0 0 0 7 0 NN CC JJ NNP NNP O
sequencing. sequencing. 0 0 0 0 0 0 0 0 11 0 CC JJ NNP NNP NN O
Northern Northern 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NN NN O
blot blot 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBD O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NN NN VBD IN O
revealed revealed 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NN VBD IN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT NNS VBG O
transcripts transcripts 0 0 0 0 0 0 0 0 11 0 IN DT NNS VBG TO O
corresponding corresponding 0 0 0 0 0 0 0 0 13 0 DT NNS VBG TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBG TO DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBG TO DT JJ NNP O
respective respective 0 0 0 0 0 0 0 0 10 0 TO DT JJ NNP NNS O
cDNA cDNA 0 0 0 0 0 0 0 0 4 0 DT JJ NNP NNS VBD O
groups groups 0 0 0 0 0 0 0 0 6 0 JJ NNP NNS VBD VBG O
began began 0 0 0 0 0 0 0 0 5 0 NNP NNS VBD VBG IN O
accumulating accumulating 0 0 0 0 0 0 0 0 12 0 NNS VBD VBG IN DT O
at at 0 0 0 0 0 0 0 0 2 0 VBD VBG IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBG IN DT JJ NNS O
early early 0 0 0 0 0 0 0 0 5 0 IN DT JJ NNS IN O
stages stages 0 0 0 0 0 0 0 0 6 0 DT JJ NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN CC O
meiosis meiosis 0 0 0 0 0 0 0 0 7 0 NNS IN NN CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBD JJ O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 NN CC VBD JJ NNS O
clone-specific clone-specific 0 0 1 0 0 0 0 0 14 0 CC VBD JJ NNS IN O
profiles profiles 0 0 0 0 0 0 0 0 8 0 VBD JJ NNS IN NN O
during during 0 0 0 0 0 0 0 0 6 0 JJ NNS IN NN CC O
meiosis meiosis 0 0 0 0 0 0 0 0 7 0 NNS IN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
spore spore 0 0 0 0 0 0 0 0 5 0 CC DT NN NN NNP O
formation formation 0 0 0 0 0 0 0 0 9 0 DT NN NN NNP NNP O
process. process. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN VBD O
amino amino 0 0 0 0 0 0 0 0 5 0 NNP NNP NN VBD NNS O
acid acid 0 0 0 0 0 0 0 0 4 0 NNP NN VBD NNS IN O
sequences sequences 0 0 0 0 0 0 0 0 9 0 NN VBD NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 VBD NNS IN DT VBN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT VBN NN O
predicted predicted 0 0 0 0 0 0 0 0 9 0 IN DT VBN NN NNS O
gene gene 0 0 0 0 0 0 0 0 4 0 DT VBN NN NNS VBD O
products products 0 0 0 0 0 0 0 0 8 0 VBN NN NNS VBD NN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NNS VBD NN IN O
similarity similarity 0 0 0 0 0 0 0 0 10 0 NNS VBD NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBD NN IN JJ NN O
known known 0 0 0 0 0 0 0 0 5 0 NN IN JJ NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN NNP O
products, products, 0 0 0 0 1 0 0 0 9 0 JJ NN NN NNP NN O
e.g. e.g. 0 0 0 0 0 0 0 0 4 0 NN NN NNP NN NN O
heat heat 0 0 0 0 0 0 0 0 4 0 NN NNP NN NN NN O
shock shock 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN NN O
proteins, proteins, 0 0 0 0 1 0 0 0 9 0 NN NN NN NN NNS O
serine serine 0 0 0 0 0 0 0 0 6 0 NN NN NN NNS IN O
proteases proteases 0 0 0 0 0 0 0 0 9 0 NN NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ CC O
Bacillus, Bacillus, 1 0 0 0 1 0 0 0 9 0 NNS IN JJ CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC NNP CD O
RAD RAD 1 1 0 0 0 0 0 0 3 0 JJ CC NNP CD NN O
51 51 0 0 0 0 0 0 1 1 2 0 CC NNP CD NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 NNP CD NN NN IN O
product product 0 0 0 0 0 0 0 0 7 0 CD NN NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
yeast. yeast. 0 0 0 0 0 0 0 0 6 0 NN IN NNP NNP IN O
Half Half 1 0 0 0 0 0 0 0 4 0 IN NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
putative putative 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NNS O
gene gene 0 0 0 0 0 0 0 0 4 0 DT JJ NN NNS VBD O
products products 0 0 0 0 0 0 0 0 8 0 JJ NN NNS VBD JJ O
had had 0 0 0 0 0 0 0 0 3 0 NN NNS VBD JJ JJ O
hydrophobic hydrophobic 0 0 0 0 0 0 0 0 11 0 NNS VBD JJ JJ NN O
N-terminal N-terminal 1 0 1 0 0 0 0 0 10 0 VBD JJ JJ NN VBG O
regions, regions, 0 0 0 0 1 0 0 0 8 0 JJ JJ NN VBG IN O
suggesting suggesting 0 0 0 0 0 0 0 0 10 0 JJ NN VBG IN PRP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBG IN PRP MD O
they they 0 0 0 0 0 0 0 0 4 0 VBG IN PRP MD VB O
may may 0 0 0 0 0 0 0 0 3 0 IN PRP MD VB IN O
function function 0 0 0 0 0 0 0 0 8 0 PRP MD VB IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 MD VB IN JJ NNP O
signal signal 0 0 0 0 0 0 0 0 6 0 VB IN JJ NNP NNP O
peptides. peptides. 0 0 0 0 0 0 0 0 9 0 IN JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
7584025 7584025 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
[Differences [Differences 0 0 0 0 0 0 0 0 12 0 NONE NONE NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 NONE NNS IN NN NN O
gene gene 0 0 0 0 0 0 0 0 4 0 NNS IN NN NN IN O
expression expression 0 0 0 0 0 0 0 0 10 0 IN NN NN IN NNP O
between between 0 0 0 0 0 0 0 0 7 0 NN NN IN NNP NN O
Taxus Taxus 1 0 0 0 0 0 0 0 5 0 NN IN NNP NN NNS O
chinensis chinensis 0 0 0 0 0 0 0 0 9 0 IN NNP NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NN NNS IN NN NN O
Taxol-synthesis Taxol-synthesis 1 0 1 0 0 0 0 0 15 phase NNS IN NN NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT IN O
those those 0 0 0 0 0 0 0 0 5 0 NN CC DT IN NN O
during during 0 0 0 0 0 0 0 0 6 0 CC DT IN NN NNP O
non-Taxol-synthesis non-Taxol-synthesis 0 0 1 0 0 0 0 0 19 0 DT IN NN NNP NNP B_TIMEXCCP
phase]. phase]. 0 0 0 0 0 0 0 0 7 0 IN NN NNP NNP IN O
[Article [Article 0 0 0 0 0 0 0 0 8 0 NN NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Chinese] Chinese] 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Hu Hu 1 0 0 0 0 0 0 0 2 0 IN NNP NNP NNP NNP O
GB, GB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Mei Mei 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
XG, XG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Gong Gong 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
W, W, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ke Ke 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
T. T. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
School School 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Life Life 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP CC O
Science Science 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Huazhong Huazhong 1 0 0 0 0 0 0 0 8 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Science Science 1 0 0 0 0 0 0 0 7 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Technology, Technology, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP CD O
Wuhan Wuhan 1 0 0 0 0 0 0 0 5 0 CC NNP NNP CD NNP O
430074, 430074, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP JJ O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP CD NNP JJ NNP O
hugbonline@263.net hugbonline@263.net 0 0 0 0 0 0 0 1 18 0 CD NNP JJ NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP NN O
plant, plant, 0 0 0 0 1 0 0 0 6 0 NNP NNP NNP NN IN O
evocation evocation 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN JJ NN O
secondary secondary 0 0 0 0 0 0 0 0 9 0 NN IN JJ NN VBZ O
metabolism metabolism 0 0 0 0 0 0 0 0 10 0 IN JJ NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 NN VBZ VBN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 VBZ VBN IN JJ JJ O
complex complex 0 0 0 0 0 0 0 0 7 0 VBN IN JJ JJ CC O
biochemical biochemical 0 0 0 0 0 0 0 0 11 0 IN JJ JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ JJ CC JJ NNS O
molecular molecular 0 0 0 0 0 0 0 0 9 0 JJ CC JJ NNS WDT O
events events 0 0 0 0 0 0 0 0 6 0 CC JJ NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 JJ NNS WDT VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNS WDT VBP VBN IN O
regulated regulated 0 0 0 0 0 0 0 0 9 0 WDT VBP VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBP VBN IN JJ CC O
developmental developmental 0 0 0 0 0 0 0 0 13 0 VBN IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNP O
environmental environmental 0 0 0 0 0 0 0 0 13 0 JJ CC JJ NNP NNP O
factors. factors. 0 0 0 0 0 0 0 0 8 0 CC JJ NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN TO O
order order 0 0 0 0 0 0 0 0 5 0 NNP NNP NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO VB JJR O
get get 0 0 0 0 0 0 0 0 3 0 NN TO VB JJR NN O
more more 0 0 0 0 0 0 0 0 4 0 TO VB JJR NN IN O
information information 0 0 0 0 0 0 0 0 11 0 VB JJR NN IN NNP O
about about 0 0 0 0 0 0 0 0 5 0 JJR NN IN NNP NNP O
Taxol Taxol 1 0 0 0 0 0 0 0 5 0 NN IN NNP NNP NN O
biosynthesis, biosynthesis, 0 0 0 0 1 0 0 0 13 0 IN NNP NNP NN IN O
comparison comparison 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNP NNS O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 NN IN NNP NNS IN O
populations populations 0 0 0 0 0 0 0 0 11 0 IN NNP NNS IN NNP O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNS IN NNP NN O
Taxus Taxus 1 0 0 0 0 0 0 0 5 0 NNS IN NNP NN NNS O
chinensis chinensis 0 0 0 0 0 0 0 0 9 0 IN NNP NN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NNP NN NNS IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NN NNS IN NN NN O
Taxol-synthesis Taxol-synthesis 1 0 1 0 0 0 0 0 15 phase NNS IN NN NN CC B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT IN O
those those 0 0 0 0 0 0 0 0 5 0 NN CC DT IN NN O
during during 0 0 0 0 0 0 0 0 6 0 CC DT IN NN NN O
non-Taxol-synthesis non-Taxol-synthesis 0 0 1 0 0 0 0 0 19 phase DT IN NN NN VBD B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 IN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN IN O
performed performed 0 0 0 0 0 0 0 0 9 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP JJ O
mRNA mRNA 0 0 0 0 0 0 0 0 4 0 VBN IN NNP JJ NNP O
differential differential 0 0 0 0 0 0 0 0 12 0 IN NNP JJ NNP NNP O
display. display. 0 0 0 0 0 0 0 0 8 0 NNP JJ NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD IN O
suggested suggested 0 0 0 0 0 0 0 0 9 0 NNP NNS VBD IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NNS RB O
genes genes 0 0 0 0 0 0 0 0 5 0 VBD IN NNS RB VBN O
specifically specifically 0 0 0 0 0 0 0 0 12 0 IN NNS RB VBN IN O
expressed expressed 0 0 0 0 0 0 0 0 9 0 NNS RB VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 RB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN NN O
Taxol-synthesis Taxol-synthesis 1 0 1 0 0 0 0 0 15 phase IN DT NN NN MD B_TIMEXCCP
phase phase 0 0 0 0 0 0 0 0 5 0 DT NN NN MD VB O
might might 0 0 0 0 0 0 0 0 5 0 NN NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 MD VB VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VB VBN IN NNP NNP O
Taxol Taxol 1 0 0 0 0 0 0 0 5 0 VBN IN NNP NNP NNP O
biosynthesis. biosynthesis. 0 0 0 0 0 0 0 0 13 0 IN NNP NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 NNP NNP NNP CD JJ O
12385255 12385255 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
Anaphase-telophase Anaphase-telophase 1 0 1 0 0 0 0 0 18 0 NONE NONE NN NN IN B_TIMEXCCP
analysis analysis 0 0 0 0 0 0 0 0 8 0 NONE NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
chromosomal chromosomal 0 0 0 0 0 0 0 0 11 0 NN IN JJ NN VBD O
damage damage 0 0 0 0 0 0 0 0 6 0 IN JJ NN VBD IN O
induced induced 0 0 0 0 0 0 0 0 7 0 JJ NN VBD IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN NNP NNP O
chemicals. chemicals. 0 0 0 0 0 0 0 0 10 0 VBD IN NNP NNP NNP O
Dulout Dulout 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
FN, FN, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Olivero Olivero 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
OA. OA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Three Three 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NN NNS O
main main 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNS VBD O
aspects aspects 0 0 0 0 0 0 0 0 7 0 NNP NN NNS VBD IN O
involved involved 0 0 0 0 0 0 0 0 8 0 NN NNS VBD IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBD IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VBD IN DT JJ NN O
chemical chemical 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NNS O
anaphase-telophase anaphase-telophase 0 0 1 0 0 0 0 0 18 0 NN IN JJ NNS IN B_TIMEXCCP
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 IN JJ NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 IN DT JJ NN IN O
mitosis mitosis 0 0 0 0 0 0 0 0 7 0 DT JJ NN IN NN B_TIMEXCCP
after after 0 0 0 0 0 0 0 0 5 0 JJ NN IN NN VBD O
treatment treatment 0 0 0 0 0 0 0 0 9 0 NN IN NN VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 IN NN VBD JJ CD O
analyzed: analyzed: 0 0 0 0 0 0 0 0 9 0 NN VBD JJ CD DT O
1) 1) 0 0 0 0 0 0 0 1 2 0 VBD JJ CD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ CD DT NN IN O
relationship relationship 0 0 0 0 0 0 0 0 12 0 CD DT NN IN DT O
between between 0 0 0 0 0 0 0 0 7 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
frequency frequency 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNS O
anaphase-telophase anaphase-telophase 0 0 1 0 0 0 0 0 18 0 NN IN JJ NNS CC B_TIMEXCCP
aberrations aberrations 0 0 0 0 0 0 0 0 11 0 IN JJ NNS CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS CC DT NN IN O
time time 0 0 0 0 0 0 0 0 4 0 CC DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN IN O
fixation fixation 0 0 0 0 0 0 0 0 8 0 NN IN NN IN NNP O
after after 0 0 0 0 0 0 0 0 5 0 IN NN IN NNP CD O
treatment; treatment; 0 0 0 0 0 0 0 0 10 0 NN IN NNP CD DT O
2) 2) 0 0 0 0 0 0 0 1 2 0 IN NNP CD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP CD DT JJ NN O
dose-response dose-response 0 0 1 0 0 0 0 0 13 0 CD DT JJ NN CC O
relationships; relationships; 0 0 0 0 0 0 0 0 14 0 DT JJ NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC CD DT O
3) 3) 0 0 0 0 0 0 0 1 2 0 NN CC CD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 CC CD DT JJ NN O
proliferative proliferative 0 0 0 0 0 0 0 0 13 0 CD DT JJ NN IN O
rate rate 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS VBN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS VBN TO O
exposed exposed 0 0 0 0 0 0 0 0 7 0 IN NNS VBN TO NNS O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO NNS WDT O
chemicals chemicals 0 0 0 0 0 0 0 0 9 0 VBN TO NNS WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 TO NNS WDT NN IN O
interact interact 0 0 0 0 0 0 0 0 8 0 NNS WDT NN IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 WDT NN IN NNP IN O
DNA DNA 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN NNP IN JJ NNP O
different different 0 0 0 0 0 0 0 0 9 0 NNP IN JJ NNP NNP O
mechanisms. mechanisms. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP VBD O
Experiments Experiments 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD VBN RP O
carried carried 0 0 0 0 0 0 0 0 7 0 NNP VBD VBN RP VBG O
out out 0 0 0 0 0 0 0 0 3 0 VBD VBN RP VBG JJ O
using using 0 0 0 0 0 0 0 0 5 0 VBN RP VBG JJ NN O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 RP VBG JJ NN NN O
hamster hamster 0 0 0 0 0 0 0 0 7 0 VBG JJ NN NN NN O
ovary ovary 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NNP O
(CHO) (CHO) 0 1 0 0 0 0 0 0 5 0 NN NN NN NNP NNP O
cells. cells. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS VBD O
compounds compounds 0 0 0 0 0 0 0 0 9 0 NNP NNP NNS VBD VBD O
examined examined 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NNS VBD VBD VBN -NONE- O
adriamycin adriamycin 0 0 0 0 0 0 0 0 10 0 VBD VBD VBN -NONE- CC O
(ADR) (ADR) 0 1 0 0 0 0 0 0 5 0 VBD VBN -NONE- CC VB O
and and 0 0 0 0 0 0 0 0 3 0 VBN -NONE- CC VB NNP O
mitomycin mitomycin 0 0 0 0 0 0 0 0 9 0 -NONE- CC VB NNP NNP O
C C 1 1 0 0 0 0 0 0 1 0 CC VB NNP NNP NNP O
(MMC). (MMC). 0 1 0 0 0 0 0 0 6 0 VB NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
frequency frequency 0 0 0 0 0 0 0 0 9 0 NNP NNP NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NN NNS O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NNS IN NN NNS CC O
bridges bridges 0 0 0 0 0 0 0 0 7 0 IN NN NNS CC IN O
or or 0 0 0 0 0 0 0 0 2 0 NN NNS CC IN VBG O
with with 0 0 0 0 0 0 0 0 4 0 NNS CC IN VBG NNS O
lagging lagging 0 0 0 0 0 0 0 0 7 0 CC IN VBG NNS IN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 IN VBG NNS IN RB O
as as 0 0 0 0 0 0 0 0 2 0 VBG NNS IN RB IN O
well well 0 0 0 0 0 0 0 0 4 0 NNS IN RB IN DT O
as as 0 0 0 0 0 0 0 0 2 0 IN RB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 RB IN DT JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN VBD B_TIMEXCCP
index index 0 0 0 0 0 0 0 0 5 0 DT JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
determined determined 0 0 0 0 0 0 0 0 10 0 NN VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNP O
each each 0 0 0 0 0 0 0 0 4 0 VBN IN DT NNP NNP O
experiment. experiment. 0 0 0 0 0 0 0 0 11 0 IN DT NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP NNS VBD O
results results 0 0 0 0 0 0 0 0 7 0 NNP NNP NNS VBD VBN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 NNP NNS VBD VBN IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NNS VBD VBN IN CD O
that that 0 0 0 0 0 0 0 0 4 0 VBD VBN IN CD NN O
1) 1) 0 0 0 0 0 0 0 1 2 0 VBN IN CD NN NNS O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 IN CD NN NNS CC O
bridges bridges 0 0 0 0 0 0 0 0 7 0 CD NN NNS CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC VBG NNS O
lagging lagging 0 0 0 0 0 0 0 0 7 0 NNS CC VBG NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 CC VBG NNS VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 VBG NNS VBP RB VBN O
apparently apparently 0 0 0 0 0 0 0 0 10 0 NNS VBP RB VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 VBP RB VBN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 RB VBN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NNP NN O
S S 1 1 0 0 0 0 0 0 1 0 IN DT NNP NN IN O
period period 0 0 0 0 0 0 0 0 6 0 DT NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
previous previous 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN CD O
interphase; interphase; 0 0 0 0 0 0 0 0 11 0 DT JJ NN CD DT B_TIMEXCCP
2) 2) 0 0 0 0 0 0 0 1 2 0 JJ NN CD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CD DT NN IN O
increase increase 0 0 0 0 0 0 0 0 8 0 CD DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
cytotoxicity cytotoxicity 0 0 0 0 0 0 0 0 12 0 IN DT NN NN JJ O
index index 0 0 0 0 0 0 0 0 5 0 DT NN NN JJ IN O
(inferred (inferred 0 0 0 0 0 0 0 0 9 0 NN NN JJ IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN JJ IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN CC O
index) index) 0 0 0 0 0 0 0 0 6 0 DT JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
frequency frequency 0 0 0 0 0 0 0 0 9 0 CC DT NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN NN O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN NN NNS O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NNS IN NN NNS CC O
bridges bridges 0 0 0 0 0 0 0 0 7 0 IN NN NNS CC VBG O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC VBG NNS O
lagging lagging 0 0 0 0 0 0 0 0 7 0 NNS CC VBG NNS VBD O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 CC VBG NNS VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 VBG NNS VBD JJ TO O
proportional proportional 0 0 0 0 0 0 0 0 12 0 NNS VBD JJ TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBD JJ TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ TO DT NN NN O
treatment treatment 0 0 0 0 0 0 0 0 9 0 TO DT NN NN CC O
lapse lapse 0 0 0 0 0 0 0 0 5 0 DT NN NN CC TO O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN CC TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC TO DT NN NN O
dose dose 0 0 0 0 0 0 0 0 4 0 TO DT NN NN CC O
employed; employed; 0 0 0 0 0 0 0 0 9 0 DT NN NN CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC CD DT O
3) 3) 0 0 0 0 0 0 0 1 2 0 NN CC CD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CC CD DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 CD DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP IN O
ADR ADR 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN NN O
on on 0 0 0 0 0 0 0 0 2 0 IN NNP IN NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP IN NN NN NNS O
growth growth 0 0 0 0 0 0 0 0 6 0 IN NN NN NNS IN O
differs differs 0 0 0 0 0 0 0 0 7 0 NN NN NNS IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NNP O
MMC. MMC. 1 1 0 0 0 0 0 0 4 0 NN IN NNP NNP NNP O
While While 1 0 0 0 0 0 0 0 5 0 IN NNP NNP NNP VBD O
ADR ADR 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP VBD DT O
decreased decreased 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBD DT JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 VBD DT JJ NN IN B_TIMEXCCP
activity activity 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 NN IN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 IN NNS IN JJ NN O
logarithmic logarithmic 0 0 0 0 0 0 0 0 11 0 NNS IN JJ NN NN O
growth growth 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN NNP O
phase, phase, 0 0 0 0 1 0 0 0 6 0 JJ NN NN NNP VBD O
MMC MMC 1 1 0 0 0 0 0 0 3 0 NN NN NNP VBD JJ O
induced induced 0 0 0 0 0 0 0 0 7 0 NN NNP VBD JJ NNP O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 NNP VBD JJ NNP NNP B_TIMEXCCP
delay. delay. 0 0 0 0 0 0 0 0 6 0 VBD JJ NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NN IN O
accordance accordance 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN DT JJ O
these these 0 0 0 0 0 0 0 0 5 0 NN IN DT JJ DT O
results, results, 0 0 0 0 1 0 0 0 8 0 IN DT JJ DT NN O
the the 0 0 0 0 0 0 0 0 3 0 DT JJ DT NN IN O
occurrence occurrence 0 0 0 0 0 0 0 0 10 0 JJ DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
chromatin chromatin 0 0 0 0 0 0 0 0 9 0 NN IN NN NNS IN O
bridges bridges 0 0 0 0 0 0 0 0 7 0 IN NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ MD O
anaphase-telophase anaphase-telophase 0 0 1 0 0 0 0 0 18 0 NNS IN JJ MD VB B_TIMEXCCP
could could 0 0 0 0 0 0 0 0 5 0 IN JJ MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 JJ MD VB VBN IN O
explained explained 0 0 0 0 0 0 0 0 9 0 MD VB VBN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 VB VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN IN NN NN NN O
stickiness stickiness 0 0 0 0 0 0 0 0 10 0 IN NN NN NN TO O
and, and, 0 0 0 0 1 0 0 0 4 0 NN NN NN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN TO DT NN NN O
lesser lesser 0 0 0 0 0 0 0 0 6 0 TO DT NN NN IN O
extent, extent, 0 0 0 0 1 0 0 0 7 0 DT NN NN IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
exchange-type exchange-type 0 0 1 0 0 0 0 0 13 0 NN IN JJ NNP NNP O
aberrations. aberrations. 0 0 0 0 0 0 0 0 12 0 IN JJ NNP NNP DT O
On On 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNP DT JJ NN O
other other 0 0 0 0 0 0 0 0 5 0 NNP DT JJ NN VBG O
hand, hand, 0 0 0 0 1 0 0 0 5 0 DT JJ NN VBG NNS O
lagging lagging 0 0 0 0 0 0 0 0 7 0 JJ NN VBG NNS VBP O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 NN VBG NNS VBP TO O
seem seem 0 0 0 0 0 0 0 0 4 0 VBG NNS VBP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBP TO VB DT O
be be 0 0 0 0 0 0 0 0 2 0 VBP TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
result result 0 0 0 0 0 0 0 0 6 0 VB DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN CC O
chromatid chromatid 0 0 0 0 0 0 0 0 9 0 NN IN NN CC VB O
or or 0 0 0 0 0 0 0 0 2 0 IN NN CC VB NNS O
chromosome chromosome 0 0 0 0 0 0 0 0 10 0 NN CC VB NNS IN O
breaks breaks 0 0 0 0 0 0 0 0 6 0 CC VB NNS IN DT O
because because 0 0 0 0 0 0 0 0 7 0 VB NNS IN DT VBG O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT VBG NNS O
lagging lagging 0 0 0 0 0 0 0 0 7 0 IN DT VBG NNS VBN O
chromosomes chromosomes 0 0 0 0 0 0 0 0 11 0 DT VBG NNS VBN VBD O
observed observed 0 0 0 0 0 0 0 0 8 0 VBG NNS VBN VBD -NONE- O
were were 0 0 0 0 0 0 0 0 4 0 NNS VBN VBD -NONE- IN O
primarily, primarily, 0 0 0 0 1 0 0 0 10 0 VBN VBD -NONE- IN RB O
if if 0 0 0 0 0 0 0 0 2 0 VBD -NONE- IN RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 -NONE- IN RB JJ NNS O
all, all, 0 0 0 0 1 0 0 0 4 0 IN RB JJ NNS CC O
fragments fragments 0 0 0 0 0 0 0 0 9 0 RB JJ NNS CC RB O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNS CC RB JJ O
not not 0 0 0 0 0 0 0 0 3 0 NNS CC RB JJ NNP O
whole whole 0 0 0 0 0 0 0 0 5 0 CC RB JJ NNP NNP O
chromosomes. chromosomes. 0 0 0 0 0 0 0 0 12 0 RB JJ NNP NNP NN O
Our Our 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN IN O
evaluation evaluation 0 0 0 0 0 0 0 0 10 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
anaphase-telophase anaphase-telophase 0 0 1 0 0 0 0 0 18 0 IN DT JJ NN VBZ B_TIMEXCCP
test test 0 0 0 0 0 0 0 0 4 0 DT JJ NN VBZ IN O
indicates indicates 0 0 0 0 0 0 0 0 9 0 JJ NN VBZ IN PRP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN PRP VBZ O
it it 0 0 0 0 0 0 0 0 2 0 VBZ IN PRP VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 IN PRP VBZ RB JJ O
very very 0 0 0 0 0 0 0 0 4 0 PRP VBZ RB JJ NN O
sensitive sensitive 0 0 0 0 0 0 0 0 9 0 VBZ RB JJ NN IN O
method method 0 0 0 0 0 0 0 0 6 0 RB JJ NN IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
detection detection 0 0 0 0 0 0 0 0 9 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
chemical chemical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN CC O
clastogens, clastogens, 0 0 0 0 1 0 0 0 11 0 IN JJ NN CC JJ O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ JJ O
other other 0 0 0 0 0 0 0 0 5 0 NN CC JJ JJ JJ O
factors, factors, 0 0 0 0 1 0 0 0 8 0 CC JJ JJ JJ IN O
such such 0 0 0 0 0 0 0 0 4 0 JJ JJ JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 JJ JJ IN JJ NN O
mitotic mitotic 0 0 0 0 0 0 0 0 7 0 JJ IN JJ NN MD B_TIMEXCCP
depression, depression, 0 0 0 0 1 0 0 0 11 0 IN JJ NN MD VB O
must must 0 0 0 0 0 0 0 0 4 0 JJ NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN IN O
taken taken 0 0 0 0 0 0 0 0 5 0 MD VB VBN IN NN O
into into 0 0 0 0 0 0 0 0 4 0 VB VBN IN NN TO O
account account 0 0 0 0 0 0 0 0 7 0 VBN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB JJ O
avoid avoid 0 0 0 0 0 0 0 0 5 0 NN TO VB JJ NNP O
false-negative false-negative 0 0 1 0 0 0 0 0 14 0 TO VB JJ NNP NNP O
results. results. 0 0 0 0 0 0 0 0 8 0 VB JJ NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 JJ NNP NNP CD JJ O
6428871 6428871 0 0 0 0 0 0 1 1 7 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : VBN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : VBN IN O
indexed indexed 0 0 0 0 0 0 0 0 7 0 JJ : VBN IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 : VBN IN JJ NONE O
MEDLINE] MEDLINE] 1 1 0 0 0 0 0 0 8 0 VBN IN JJ NONE NONE O
The The 1 0 0 0 0 0 0 0 3 0 NONE NONE DT NNP IN O
Influence Influence 1 0 0 0 0 0 0 0 9 0 NONE DT NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NNP IN NNP NNP O
g.19124G>A g.19124G>A 0 0 0 0 0 0 0 1 10 0 NNP IN NNP NNP NNP O
Genetic Genetic 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP IN O
Polymorphism Polymorphism 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT NNP NNP O
OPG OPG 1 1 0 0 0 0 0 0 3 0 IN DT NNP NNP IN O
Gene Gene 1 0 0 0 0 0 0 0 4 0 DT NNP NNP IN NNP O
on on 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Bone Bone 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Mineral Mineral 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP IN O
Density Density 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN JJ NNP O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 NNP IN JJ NNP NNP O
Women. Women. 1 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP NNP O
Zhu Zhu 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Luo Luo 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Z, Z, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cao Cao 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Yu Yu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Peng Peng 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Huang Huang 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
D. D. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Emergency, Emergency, 1 0 0 0 1 0 0 0 10 0 NNP IN NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 IN NNP NNP NNP NNP O
Second Second 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Affiliated Affiliated 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
Hospital, Hospital, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
Sun Sun 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yat-sen Yat-sen 1 0 1 0 0 0 0 0 7 0 NNP NNP NNP NNP , O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP , NNP O
, , 0 0 0 0 1 0 0 0 1 0 NNP NNP , NNP NNP O
Guangzhou, Guangzhou, 1 0 0 0 1 0 0 0 10 0 NNP , NNP NNP NNP O
Guangdong Guangdong 1 0 0 0 0 0 0 0 9 0 , NNP NNP NNP NNP O
Province, Province, 1 0 0 0 1 0 0 0 9 0 NNP NNP NNP NNP NNP O
People's People's 1 0 0 0 0 1 0 0 8 0 NNP NNP NNP NNP IN O
Republic Republic 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP . O
China China 1 0 0 0 0 0 0 0 5 0 NNP IN NNP . NNP O
. . 0 0 0 0 0 0 0 0 1 0 IN NNP . NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP . NNP NNP NNP O
Objective: Objective: 1 0 0 0 0 0 0 0 10 0 . NNP NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 IN DT NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 DT NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
detect detect 0 0 0 0 0 0 0 0 6 0 VBD TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
influence influence 0 0 0 0 0 0 0 0 9 0 VB DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP JJ O
g.19124G>A g.19124G>A 0 0 0 0 0 0 0 1 10 0 NN IN NNP JJ NN O
genetic genetic 0 0 0 0 0 0 0 0 7 0 IN NNP JJ NN IN O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 NNP JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
osteoprotegerin osteoprotegerin 0 0 0 0 0 0 0 0 15 0 IN DT NN NN NN O
(OPG) (OPG) 0 1 0 0 0 0 0 0 5 0 DT NN NN NN IN O
gene gene 0 0 0 0 0 0 0 0 4 0 NN NN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN NN JJ O
bone bone 0 0 0 0 0 0 0 0 4 0 NN IN NN JJ NN O
mineral mineral 0 0 0 0 0 0 0 0 7 0 IN NN JJ NN NN O
density density 0 0 0 0 0 0 0 0 7 0 NN JJ NN NN CC O
(BMD) (BMD) 0 1 0 0 0 0 0 0 5 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
osteoporosis osteoporosis 0 0 0 0 0 0 0 0 12 0 NN CC NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NN O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 NN IN NNP NN NNP O
postmenopausal postmenopausal 0 0 0 0 0 0 0 0 14 0 IN NNP NN NNP NNP O
women. women. 0 0 0 0 0 0 0 0 6 0 NNP NN NNP NNP NNP O
Methods: Methods: 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN IN O
total total 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN CD JJ O
403 403 0 0 0 0 0 0 1 1 3 0 NN IN CD JJ NN O
primary primary 0 0 0 0 0 0 0 0 7 0 IN CD JJ NN NNS O
osteoporosis osteoporosis 0 0 0 0 0 0 0 0 12 0 CD JJ NN NNS CC O
subjects subjects 0 0 0 0 0 0 0 0 8 0 JJ NN NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC CD JJ O
409 409 0 0 0 0 0 0 1 1 3 0 NNS CC CD JJ NNS O
healthy healthy 0 0 0 0 0 0 0 0 7 0 CC CD JJ NNS VBD O
controls controls 0 0 0 0 0 0 0 0 8 0 CD JJ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 JJ NNS VBD VBN IN O
enrolled enrolled 0 0 0 0 0 0 0 0 8 0 NNS VBD VBN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 VBN IN DT NNP NNP O
study. study. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 DT NNP NNP NNP NN O
BMD BMD 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NN IN O
value value 0 0 0 0 0 0 0 0 5 0 NNP NNP NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
femoral femoral 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
neck neck 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN NN O
hip, hip, 0 0 0 0 1 0 0 0 4 0 JJ NN NN NN NN O
lumbar lumbar 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
spine spine 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
(L2-4), (L2-4), 0 1 1 0 1 0 0 1 7 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 NN CC JJ NN VBD O
hip hip 0 0 0 0 0 0 0 0 3 0 CC JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN IN O
analyzed analyzed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN NNP O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NNP NNP O
Norland Norland 1 0 0 0 0 0 0 0 7 0 VBN IN NNP NNP JJ O
XR-46 XR-46 1 1 1 0 0 0 0 1 5 0 IN NNP NNP JJ NN O
dual dual 0 0 0 0 0 0 0 0 4 0 NNP NNP JJ NN NN O
energy energy 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NN NNP O
X-ray X-ray 1 0 1 0 0 0 0 0 5 0 JJ NN NN NNP NNP O
absorptiometry. absorptiometry. 0 0 0 0 0 0 0 0 15 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NN O
polymerase polymerase 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN NN O
chain chain 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN NN O
reaction-restriction reaction-restriction 0 0 1 0 0 0 0 0 20 0 NN NN NN NN NN O
fragment fragment 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NN O
length length 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 NN NN NN NN VBD O
method method 0 0 0 0 0 0 0 0 6 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN TO O
utilized utilized 0 0 0 0 0 0 0 0 8 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBN TO VB DT NN O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NN IN O
genotype genotype 0 0 0 0 0 0 0 0 8 0 VB DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP JJ O
g.19124G>A g.19124G>A 0 0 0 0 0 0 0 1 10 0 NN IN NNP JJ NNP O
genetic genetic 0 0 0 0 0 0 0 0 7 0 IN NNP JJ NNP NNP O
polymorphism. polymorphism. 0 0 0 0 0 0 0 0 13 0 NNP JJ NNP NNP NNP O
Results: Results: 1 0 0 0 0 0 0 0 8 0 JJ NNP NNP NNP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP VBD JJ O
found found 0 0 0 0 0 0 0 0 5 0 NNP NNP VBD JJ NNS O
significant significant 0 0 0 0 0 0 0 0 11 0 NNP VBD JJ NNS IN O
differences differences 0 0 0 0 0 0 0 0 11 0 VBD JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
femoral femoral 0 0 0 0 0 0 0 0 7 0 IN DT JJ NN NN O
neck neck 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN NN O
hip, hip, 0 0 0 0 1 0 0 0 4 0 JJ NN NN NN NN O
lumbar lumbar 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
spine spine 0 0 0 0 0 0 0 0 5 0 NN NN NN NN CC O
(L2-4), (L2-4), 0 1 1 0 1 0 0 1 7 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
total total 0 0 0 0 0 0 0 0 5 0 NN CC JJ NN IN O
hip hip 0 0 0 0 0 0 0 0 3 0 CC JJ NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
BMD BMD 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN JJ O
among among 0 0 0 0 0 0 0 0 5 0 IN NNP IN JJ NNS O
different different 0 0 0 0 0 0 0 0 9 0 NNP IN JJ NNS IN O
genotypes genotypes 0 0 0 0 0 0 0 0 9 0 IN JJ NNS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NNP JJ O
g.19124G>A g.19124G>A 0 0 0 0 0 0 0 1 10 0 NNS IN NNP JJ NN O
genetic genetic 0 0 0 0 0 0 0 0 7 0 IN NNP JJ NN NNS O
polymorphism, polymorphism, 0 0 0 0 1 0 0 0 13 0 NNP JJ NN NNS IN O
individuals individuals 0 0 0 0 0 0 0 0 11 0 JJ NN NNS IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NNP O
genotype genotype 0 0 0 0 0 0 0 0 8 0 IN DT NN NNP VBD O
GG GG 1 1 0 0 0 0 0 0 2 0 DT NN NNP VBD RB O
had had 0 0 0 0 0 0 0 0 3 0 NN NNP VBD RB JJR O
significantly significantly 0 0 0 0 0 0 0 0 13 0 NNP VBD RB JJR NNP O
higher higher 0 0 0 0 0 0 0 0 6 0 VBD RB JJR NNP IN O
BMD BMD 1 1 0 0 0 0 0 0 3 0 RB JJR NNP IN DT O
than than 0 0 0 0 0 0 0 0 4 0 JJR NNP IN DT IN O
those those 0 0 0 0 0 0 0 0 5 0 NNP IN DT IN NN O
of of 0 0 0 0 0 0 0 0 2 0 IN DT IN NN NNP O
genotype genotype 0 0 0 0 0 0 0 0 8 0 DT IN NN NNP CC O
GA GA 1 1 0 0 0 0 0 0 2 0 IN NN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NNP CC NNP NNP O
AA AA 1 1 0 0 0 0 0 0 2 0 NNP CC NNP NNP NNP O
(p<0.05). (p<0.05). 0 0 0 0 0 0 0 1 9 0 CC NNP NNP NNP NNP O
Conclusion: Conclusion: 1 0 0 0 0 0 0 0 11 0 NNP NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS VBP O
findings findings 0 0 0 0 0 0 0 0 8 0 NNP NNP NNS VBP IN O
indicate indicate 0 0 0 0 0 0 0 0 8 0 NNP NNS VBP IN DT O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBP IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBP IN DT NNP JJ O
g.19124G>A g.19124G>A 0 0 0 0 0 0 0 1 10 0 IN DT NNP JJ NN O
genetic genetic 0 0 0 0 0 0 0 0 7 0 DT NNP JJ NN IN O
polymorphism polymorphism 0 0 0 0 0 0 0 0 12 0 NNP JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP NN O
OPG OPG 1 1 0 0 0 0 0 0 3 0 IN DT NNP NN VBZ O
gene gene 0 0 0 0 0 0 0 0 4 0 DT NNP NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ RB VBN O
potentially potentially 0 0 0 0 0 0 0 0 11 0 NN VBZ RB VBN TO O
related related 0 0 0 0 0 0 0 0 7 0 VBZ RB VBN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 RB VBN TO NNP CC O
BMD BMD 1 1 0 0 0 0 0 0 3 0 VBN TO NNP CC NN O
and and 0 0 0 0 0 0 0 0 3 0 TO NNP CC NN IN O
osteoporosis osteoporosis 0 0 0 0 0 0 0 0 12 0 NNP CC NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN NNP NN O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 NN IN NNP NN -NONE- O
postmenopausal postmenopausal 0 0 0 0 0 0 0 0 14 0 IN NNP NN -NONE- CC O
women, women, 0 0 0 0 1 0 0 0 6 0 NNP NN -NONE- CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 -NONE- CC DT NN DT O
allele allele 0 0 0 0 0 0 0 0 6 0 CC DT NN DT MD O
A A 1 1 0 0 0 0 0 0 1 0 DT NN DT MD VB O
could could 0 0 0 0 0 0 0 0 5 0 NN DT MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 DT MD VB VBN IN O
associated associated 0 0 0 0 0 0 0 0 10 0 MD VB VBN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 VB VBN IN DT JJR O
a a 0 0 0 0 0 0 0 0 1 0 VBN IN DT JJR NNP O
lower lower 0 0 0 0 0 0 0 0 5 0 IN DT JJR NNP CC O
BMD BMD 1 1 0 0 0 0 0 0 3 0 DT JJR NNP CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJR NNP CC DT VBN O
an an 0 0 0 0 0 0 0 0 2 0 NNP CC DT VBN NN O
increased increased 0 0 0 0 0 0 0 0 9 0 CC DT VBN NN NN O
risk risk 0 0 0 0 0 0 0 0 4 0 DT VBN NN NN IN O
factor factor 0 0 0 0 0 0 0 0 6 0 VBN NN NN IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 NN NN IN NNP NNP O
osteoporosis. osteoporosis. 0 0 0 0 0 0 0 0 13 0 NN IN NNP NNP CD O
PMID: PMID: 1 1 0 0 0 0 0 0 5 0 IN NNP NNP CD JJ O
23837846 23837846 0 0 0 0 0 0 1 1 8 0 NNP NNP CD JJ : O
[PubMed [PubMed 0 0 0 0 0 0 0 0 7 0 NNP CD JJ : IN O
- - 0 0 1 0 0 0 0 0 1 0 CD JJ : IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 JJ : IN JJ IN O
supplied supplied 0 0 0 0 0 0 0 0 8 0 : IN JJ IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 IN JJ IN JJ NONE O
publisher] publisher] 0 0 0 0 0 0 0 0 10 0 JJ IN JJ NONE NONE O
3D 3D 0 1 0 0 0 0 0 1 2 0 NONE NONE JJ VBN JJ O
pulsed pulsed 0 0 0 0 0 0 0 0 6 0 NONE JJ VBN JJ JJ O
laser-triggered laser-triggered 0 0 1 0 0 0 0 0 15 0 JJ VBN JJ JJ JJ O
high-speed high-speed 0 0 1 0 0 0 0 0 10 0 VBN JJ JJ JJ JJ O
microfluidic microfluidic 0 0 0 0 0 0 0 0 12 0 JJ JJ JJ JJ NN O
fluorescence-activated fluorescence-activated 0 0 1 0 0 0 0 0 22 0 JJ JJ JJ NN NNP O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NNP NNP O
sorter. sorter. 0 0 0 0 0 0 0 0 7 0 JJ NN NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NN NNP NNP NNP NNP O
Y, Y, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Wu Wu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
TH, TH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Kung Kung 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
YC, YC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Teitell Teitell 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
MA, MA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chiou Chiou 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
PY. PY. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Mechanical Mechanical 1 0 0 0 0 0 0 0 10 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Aerospace Aerospace 1 0 0 0 0 0 0 0 9 0 NNP CC NNP NNP NNP O
Engineering, Engineering, 1 0 0 0 1 0 0 0 12 0 CC NNP NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
California California 1 0 0 0 0 0 0 0 10 0 NNP IN NNP IN NNP O
at at 0 0 0 0 0 0 0 0 2 0 IN NNP IN NNP NNP O
Los Los 1 0 0 0 0 0 0 0 3 0 NNP IN NNP NNP NNP O
Angeles Angeles 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP CD O
(UCLA), (UCLA), 0 1 0 0 1 0 0 0 7 0 NNP NNP NNP CD NNP O
43-147 43-147 0 0 1 0 0 0 0 1 6 0 NNP NNP CD NNP NNP O
Eng. Eng. 1 0 0 0 0 0 0 0 4 0 NNP CD NNP NNP CD O
IV, IV, 1 1 0 0 1 0 0 0 3 0 CD NNP NNP CD NNP O
420 420 0 0 0 0 0 0 1 1 3 0 NNP NNP CD NNP NNP O
Westwood Westwood 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Plaza, Plaza, 1 0 0 0 1 0 0 0 6 0 CD NNP NNP NNP NNP O
Los Los 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Angeles, Angeles, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP CD O
CA CA 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP CD NNP O
90095-1597, 90095-1597, 0 0 1 0 1 0 0 1 11 0 NNP NNP CD NNP NNP O
USA. USA. 1 1 0 0 0 0 0 0 4 0 NNP CD NNP NNP NNP O
pychiou@seas.ucla.edu pychiou@seas.ucla.edu 0 0 0 0 0 0 0 0 21 0 CD NNP NNP NNP NNP O
katechen@ucla.edu. katechen@ucla.edu. 0 0 0 0 0 0 0 0 18 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
We We 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN DT O
report report 0 0 0 0 0 0 0 0 6 0 NNP NNP NN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP NN DT JJ JJ O
3D 3D 0 1 0 0 0 0 0 1 2 0 NN DT JJ JJ VBN O
microfluidic microfluidic 0 0 0 0 0 0 0 0 12 0 DT JJ JJ VBN JJ O
pulsed pulsed 0 0 0 0 0 0 0 0 6 0 JJ JJ VBN JJ JJ O
laser-triggered laser-triggered 0 0 1 0 0 0 0 0 15 0 JJ VBN JJ JJ NN O
fluorescence-activated fluorescence-activated 0 0 1 0 0 0 0 0 22 0 VBN JJ JJ NN NN O
cell cell 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN JJ O
sorter sorter 0 0 0 0 0 0 0 0 6 0 JJ NN NN JJ IN O
capable capable 0 0 0 0 0 0 0 0 7 0 NN NN JJ IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN JJ IN NN IN O
sorting sorting 0 0 0 0 0 0 0 0 7 0 JJ IN NN IN DT O
at at 0 0 0 0 0 0 0 0 2 0 IN NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
throughput throughput 0 0 0 0 0 0 0 0 10 0 IN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD CD O
23 23 0 0 0 0 0 0 1 1 2 0 NN IN CD CD NNS O
000 000 0 0 0 0 0 0 1 1 3 0 IN CD CD NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 CD CD NNS IN NNS O
per per 0 0 0 0 0 0 0 0 3 0 CD NNS IN NNS IN O
s s 0 0 0 0 0 0 0 0 1 0 NNS IN NNS IN CD O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN CD NN O
90% 90% 0 0 0 0 0 0 0 1 3 0 NNS IN CD NN IN O
purity purity 0 0 0 0 0 0 0 0 6 0 IN CD NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NN NN O
high-purity high-purity 0 0 1 0 0 0 0 0 11 0 NN IN NN NN CC O
mode mode 0 0 0 0 0 0 0 0 4 0 IN NN NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC IN DT O
at at 0 0 0 0 0 0 0 0 2 0 NN CC IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 CC IN DT NN IN O
throughput throughput 0 0 0 0 0 0 0 0 10 0 IN DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD CD O
45 45 0 0 0 0 0 0 1 1 2 0 NN IN CD CD NNS O
000 000 0 0 0 0 0 0 1 1 3 0 IN CD CD NNS IN O
cells cells 0 0 0 0 0 0 0 0 5 0 CD CD NNS IN NNS O
per per 0 0 0 0 0 0 0 0 3 0 CD NNS IN NNS IN O
s s 0 0 0 0 0 0 0 0 1 0 NNS IN NNS IN CD O
with with 0 0 0 0 0 0 0 0 4 0 IN NNS IN CD NN O
45% 45% 0 0 0 0 0 0 0 1 3 0 NNS IN CD NN IN O
purity purity 0 0 0 0 0 0 0 0 6 0 IN CD NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 CD NN IN NN NN O
enrichment enrichment 0 0 0 0 0 0 0 0 10 0 NN IN NN NN IN O
mode mode 0 0 0 0 0 0 0 0 4 0 IN NN NN IN CD O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 NN IN CD NN CC O
stage stage 0 0 0 0 0 0 0 0 5 0 IN CD NN CC IN O
and and 0 0 0 0 0 0 0 0 3 0 CD NN CC IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN CC IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 CC IN DT JJ NNP O
single single 0 0 0 0 0 0 0 0 6 0 IN DT JJ NNP NNP O
channel. channel. 0 0 0 0 0 0 0 0 8 0 DT JJ NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NN VBZ O
performance performance 0 0 0 0 0 0 0 0 11 0 NNP NNP NN VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ VBN IN O
realized realized 0 0 0 0 0 0 0 0 8 0 NN VBZ VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBZ VBN IN JJ JJ O
exciting exciting 0 0 0 0 0 0 0 0 8 0 VBN IN JJ JJ NN O
laser-induced laser-induced 0 0 1 0 0 0 0 0 13 0 IN JJ JJ NN NNS O
cavitation cavitation 0 0 0 0 0 0 0 0 10 0 JJ JJ NN NNS IN O
bubbles bubbles 0 0 0 0 0 0 0 0 7 0 JJ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT JJ NNP O
3D 3D 0 1 0 0 0 0 0 1 2 0 IN DT JJ NNP JJ O
PDMS PDMS 1 1 0 0 0 0 0 0 4 0 DT JJ NNP JJ NN O
microfluidic microfluidic 0 0 0 0 0 0 0 0 12 0 JJ NNP JJ NN TO O
channel channel 0 0 0 0 0 0 0 0 7 0 NNP JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB JJ O
generate generate 0 0 0 0 0 0 0 0 8 0 NN TO VB JJ NN O
high-speed high-speed 0 0 1 0 0 0 0 0 10 0 TO VB JJ NN NNS O
liquid liquid 0 0 0 0 0 0 0 0 6 0 VB JJ NN NNS WDT O
jets jets 0 0 0 0 0 0 0 0 4 0 JJ NN NNS WDT NN O
that that 0 0 0 0 0 0 0 0 4 0 NN NNS WDT NN VBD O
deflect deflect 0 0 0 0 0 0 0 0 7 0 NNS WDT NN VBD NN O
detected detected 0 0 0 0 0 0 0 0 8 0 WDT NN VBD NN NNS O
fluorescent fluorescent 0 0 0 0 0 0 0 0 11 0 NN VBD NN NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 VBD NN NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC NNS VBD O
particles particles 0 0 0 0 0 0 0 0 9 0 NNS CC NNS VBD IN O
focused focused 0 0 0 0 0 0 0 0 7 0 CC NNS VBD IN CD O
by by 0 0 0 0 0 0 0 0 2 0 NNS VBD IN CD NN O
3D 3D 0 1 0 0 0 0 0 1 2 0 VBD IN CD NN NNP O
sheath sheath 0 0 0 0 0 0 0 0 6 0 IN CD NN NNP NNP O
flows. flows. 0 0 0 0 0 0 0 0 6 0 CD NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN VBG O
ultrafast ultrafast 0 0 0 0 0 0 0 0 9 0 NNP NNP NN VBG NN O
switching switching 0 0 0 0 0 0 0 0 9 0 NNP NN VBG NN -NONE- O
mechanism mechanism 0 0 0 0 0 0 0 0 9 0 NN VBG NN -NONE- VBZ O
(20 (20 0 0 0 0 0 0 0 1 3 0 VBG NN -NONE- VBZ JJ O
μs μs 0 0 0 0 0 0 0 0 2 0 NN -NONE- VBZ JJ NN O
complete complete 0 0 0 0 0 0 0 0 8 0 -NONE- VBZ JJ NN NN O
on-off on-off 0 0 1 0 0 0 0 0 6 0 VBZ JJ NN NN JJ O
cycle), cycle), 0 0 0 0 1 0 0 0 7 0 JJ NN NN JJ NN O
small small 0 0 0 0 0 0 0 0 5 0 NN NN JJ NN NN O
liquid liquid 0 0 0 0 0 0 0 0 6 0 NN JJ NN NN NN O
jet jet 0 0 0 0 0 0 0 0 3 0 JJ NN NN NN NN O
perturbation perturbation 0 0 0 0 0 0 0 0 12 0 NN NN NN NN CC O
volume, volume, 0 0 0 0 1 0 0 0 7 0 NN NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ NN O
three-dimensional three-dimensional 0 0 1 0 0 0 0 0 17 0 NN CC JJ NN NN O
sheath sheath 0 0 0 0 0 0 0 0 6 0 CC JJ NN NN VBG O
flow flow 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBG IN O
focusing focusing 0 0 0 0 0 0 0 0 8 0 NN NN VBG IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 NN VBG IN JJ NN O
accurate accurate 0 0 0 0 0 0 0 0 8 0 VBG IN JJ NN NN O
timing timing 0 0 0 0 0 0 0 0 6 0 IN JJ NN NN IN O
control control 0 0 0 0 0 0 0 0 7 0 JJ NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
fast fast 0 0 0 0 0 0 0 0 4 0 NN IN JJ NN NN O
(1.5 (1.5 0 0 0 0 0 0 0 1 4 0 IN JJ NN NN NN O
m m 0 0 0 0 0 0 0 0 1 0 JJ NN NN NN VBG O
s-1) s-1) 0 0 1 0 0 0 0 1 4 0 NN NN NN VBG NNS O
passing passing 0 0 0 0 0 0 0 0 7 0 NN NN VBG NNS CC O
cells cells 0 0 0 0 0 0 0 0 5 0 NN VBG NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 VBG NNS CC NNS VBP O
particles particles 0 0 0 0 0 0 0 0 9 0 NNS CC NNS VBP CD O
are are 0 0 0 0 0 0 0 0 3 0 CC NNS VBP CD JJ O
three three 0 0 0 0 0 0 0 0 5 0 NNS VBP CD JJ NNS O
critical critical 0 0 0 0 0 0 0 0 8 0 VBP CD JJ NNS VBG O
factors factors 0 0 0 0 0 0 0 0 7 0 CD JJ NNS VBG NN O
enabling enabling 0 0 0 0 0 0 0 0 8 0 JJ NNS VBG NN VBG O
high-purity high-purity 0 0 1 0 0 0 0 0 11 0 NNS VBG NN VBG IN O
sorting sorting 0 0 0 0 0 0 0 0 7 0 VBG NN VBG IN JJ O
at at 0 0 0 0 0 0 0 0 2 0 NN VBG IN JJ IN O
high-throughput high-throughput 0 0 1 0 0 0 0 0 15 0 VBG IN JJ IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN JJ IN DT NNP O
this this 0 0 0 0 0 0 0 0 4 0 JJ IN DT NNP NONE O
sorter. sorter. 0 0 0 0 0 0 0 0 7 0 IN DT NNP NONE NONE O
Brain-derived Brain-derived 1 0 1 0 0 0 0 0 13 0 NONE NONE JJ JJ NN O
neurotrophic neurotrophic 0 0 0 0 0 0 0 0 12 0 NONE JJ JJ NN VBZ O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ JJ NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 JJ NN VBZ JJ IN O
up-regulated up-regulated 0 0 1 0 0 0 0 0 12 0 NN VBZ JJ IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBZ JJ IN JJ NN O
severe severe 0 0 0 0 0 0 0 0 6 0 JJ IN JJ NN NN O
acute acute 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NN O
cauda cauda 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NN O
equina equina 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
syndrome syndrome 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NNP O
dog dog 0 0 0 0 0 0 0 0 3 0 NN NN NN NNP NNP O
model. model. 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NNP O
Tan Tan 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNP NNP O
JM, JM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wu Wu 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Shi Shi 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
JG, JG, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Shi Shi 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
GD, GD, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
YL, YL, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Liu Liu 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
XH, XH, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Wan Wan 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
CY, CY, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Chen Chen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
DC, DC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Xing Xing 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
SM, SM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Shen Shen 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
LB, LB, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Jia Jia 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
LS, LS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ye Ye 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
XJ, XJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Li Li 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
JS. JS. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Center Center 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Trauma Trauma 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP CC O
Repair Repair 1 0 0 0 0 0 0 0 6 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
Reconstruction Reconstruction 1 0 0 0 0 0 0 0 14 0 NNP CC NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NNP IN JJ NNP O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 NNP IN JJ NNP CC O
PLA PLA 1 1 0 0 0 0 0 0 3 0 IN JJ NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NNP CC NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP CC NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 CC NNP IN NNP IN O
Orthopedics Orthopedics 1 0 0 0 0 0 0 0 11 0 NNP IN NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NNP O
98th 98th 0 0 0 0 0 0 0 1 4 0 IN DT JJ NNP IN O
Hospital Hospital 1 0 0 0 0 0 0 0 8 0 DT JJ NNP IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNP IN JJ NNP O
Chinese Chinese 1 0 0 0 0 0 0 0 7 0 NNP IN JJ NNP NNP O
PLA PLA 1 1 0 0 0 0 0 0 3 0 IN JJ NNP NNP CD O
Huzhou Huzhou 1 0 0 0 0 0 0 0 6 0 JJ NNP NNP CD NNP O
313000, 313000, 0 0 0 0 1 0 0 1 7 0 NNP NNP CD NNP NNP O
Zhejiang Zhejiang 1 0 0 0 0 0 0 0 8 0 NNP CD NNP NNP NNP O
Province, Province, 1 0 0 0 1 0 0 0 9 0 CD NNP NNP NNP NNP O
China. China. 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
To To 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NN DT O
determine determine 0 0 0 0 0 0 0 0 9 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN IN O
level level 0 0 0 0 0 0 0 0 5 0 NN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ JJ O
brain-derived brain-derived 0 0 1 0 0 0 0 0 13 0 NN IN JJ JJ NN O
neurotrophic neurotrophic 0 0 0 0 0 0 0 0 12 0 IN JJ JJ NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN IN O
(BDNF) (BDNF) 0 1 0 0 0 0 0 0 6 0 JJ NN NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 NN IN JJ NN NN O
dog dog 0 0 0 0 0 0 0 0 3 0 IN JJ NN NN IN O
model model 0 0 0 0 0 0 0 0 5 0 JJ NN NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN JJ NN O
severe severe 0 0 0 0 0 0 0 0 6 0 NN IN JJ NN NN O
acute acute 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN NN O
cauda cauda 0 0 0 0 0 0 0 0 5 0 JJ NN NN NN NN O
equina equina 0 0 0 0 0 0 0 0 6 0 NN NN NN NN WDT O
syndrome, syndrome, 0 0 0 0 1 0 0 0 9 0 NN NN NN WDT VBD O
which which 0 0 0 0 0 0 0 0 5 0 NN NN WDT VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN WDT VBD VBN IN O
induced induced 0 0 0 0 0 0 0 0 7 0 WDT VBD VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 VBN IN NN NN NN O
cauda cauda 0 0 0 0 0 0 0 0 5 0 IN NN NN NN NNS O
equina equina 0 0 0 0 0 0 0 0 6 0 NN NN NN NNS IN O
constrictions constrictions 0 0 0 0 0 0 0 0 13 0 NN NN NNS IN DT O
throughout throughout 0 0 0 0 0 0 0 0 10 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ NN O
entire entire 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN NN O
lumbar lumbar 0 0 0 0 0 0 0 0 6 0 DT JJ NN NN JJ O
(L), (L), 0 1 0 0 1 0 0 0 4 0 JJ NN NN JJ NN O
sacral sacral 0 0 0 0 0 0 0 0 6 0 NN NN JJ NN CC O
(S) (S) 0 1 0 0 0 0 0 0 3 0 NN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
coccygeal coccygeal 0 0 0 0 0 0 0 0 9 0 NN CC NN NN JJ O
(Co) (Co) 0 0 0 0 0 0 0 0 4 0 CC NN NN JJ NN O
spinal spinal 0 0 0 0 0 0 0 0 6 0 NN NN JJ NN CC O
cord cord 0 0 0 0 0 0 0 0 4 0 NN JJ NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC PRP$ JJ O
their their 0 0 0 0 0 0 0 0 5 0 NN CC PRP$ JJ NNS O
central central 0 0 0 0 0 0 0 0 7 0 CC PRP$ JJ NNS IN O
processes processes 0 0 0 0 0 0 0 0 9 0 PRP$ JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN NN O
dorsal dorsal 0 0 0 0 0 0 0 0 6 0 IN DT NN NN NN O
root root 0 0 0 0 0 0 0 0 4 0 DT NN NN NN NNP O
ganglia ganglia 0 0 0 0 0 0 0 0 7 0 NN NN NN NNP NNP O
neurons. neurons. 0 0 0 0 0 0 0 0 8 0 NN NN NNP NNP NN O
Adult Adult 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NN NN O
male male 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN NNS O
mongrel mongrel 0 0 0 0 0 0 0 0 7 0 NNP NN NN NNS VBD O
dogs dogs 0 0 0 0 0 0 0 0 4 0 NN NN NNS VBD RB O
were were 0 0 0 0 0 0 0 0 4 0 NN NNS VBD RB VBN O
randomly randomly 0 0 0 0 0 0 0 0 8 0 NNS VBD RB VBN IN O
divided divided 0 0 0 0 0 0 0 0 7 0 VBD RB VBN IN CD O
into into 0 0 0 0 0 0 0 0 4 0 RB VBN IN CD NNP O
2 2 0 0 0 0 0 0 1 1 1 0 VBN IN CD NNP NNP O
groups. groups. 0 0 0 0 0 0 0 0 7 0 IN CD NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 CD NNP NNP NN NN O
experiment experiment 0 0 0 0 0 0 0 0 10 0 NNP NNP NN NN NN O
group group 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN VBD O
(n=4) (n=4) 0 0 0 0 0 0 0 1 5 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN TO O
subjected subjected 0 0 0 0 0 0 0 0 9 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 VBN TO VB NN NN O
cauda cauda 0 0 0 0 0 0 0 0 5 0 TO VB NN NN NNP O
equina equina 0 0 0 0 0 0 0 0 6 0 VB NN NN NNP NNP O
constrictions. constrictions. 0 0 0 0 0 0 0 0 14 0 NN NN NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN NN O
control control 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN NN O
group group 0 0 0 0 0 0 0 0 5 0 NNP NN NN NN VBD O
(n=4) (n=4) 0 0 0 0 0 0 0 1 5 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN TO O
subjected subjected 0 0 0 0 0 0 0 0 9 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB NN O
cauda cauda 0 0 0 0 0 0 0 0 5 0 VBN TO VB NN NN O
equina equina 0 0 0 0 0 0 0 0 6 0 TO VB NN NN IN O
exposure exposure 0 0 0 0 0 0 0 0 8 0 VB NN NN IN NNP O
without without 0 0 0 0 0 0 0 0 7 0 NN NN IN NNP NNP O
constrictions. constrictions. 0 0 0 0 0 0 0 0 14 0 NN IN NNP NNP IN O
Level Level 1 0 0 0 0 0 0 0 5 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP IN O
BDNF BDNF 1 1 0 0 0 0 0 0 4 0 NNP IN NNP IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
spinal spinal 0 0 0 0 0 0 0 0 6 0 IN DT JJ NN CC O
cord cord 0 0 0 0 0 0 0 0 4 0 DT JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN NN O
dorsal dorsal 0 0 0 0 0 0 0 0 6 0 CC DT NN NN NN O
root root 0 0 0 0 0 0 0 0 4 0 DT NN NN NN NNS O
ganglion ganglion 0 0 0 0 0 0 0 0 8 0 NN NN NN NNS -NONE- O
cells cells 0 0 0 0 0 0 0 0 5 0 NN NN NNS -NONE- -NONE- O
(L7, (L7, 0 1 0 0 1 0 0 1 4 0 NN NNS -NONE- -NONE- VBD O
S1-S3) S1-S3) 1 1 1 0 0 0 0 1 6 0 NNS -NONE- -NONE- VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- VBD VBN CD O
assessed assessed 0 0 0 0 0 0 0 0 8 0 -NONE- VBD VBN CD NNS O
48 48 0 0 0 0 0 0 1 1 2 0 VBD VBN CD NNS IN O
hours hours 0 0 0 0 0 0 0 0 5 0 VBN CD NNS IN NN O
after after 0 0 0 0 0 0 0 0 5 0 CD NNS IN NN NNS O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NNS IN NN NNS IN O
constrictions constrictions 0 0 0 0 0 0 0 0 13 0 IN NN NNS IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ CC O
immunohistochemical immunohistochemical 0 0 0 0 0 0 0 0 19 0 NNS IN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC JJ NNP O
histopathological histopathological 0 0 0 0 0 0 0 0 17 0 JJ CC JJ NNP CD O
analyses. analyses. 0 0 0 0 0 0 0 0 9 0 CC JJ NNP CD NNS O
48 48 0 0 0 0 0 0 1 1 2 0 JJ NNP CD NNS IN O
hours hours 0 0 0 0 0 0 0 0 5 0 NNP CD NNS IN NN O
after after 0 0 0 0 0 0 0 0 5 0 CD NNS IN NN NNS O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NNS IN NN NNS IN O
constrictions constrictions 0 0 0 0 0 0 0 0 13 0 IN NN NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN NN NN O
cauda cauda 0 0 0 0 0 0 0 0 5 0 NNS IN NN NN NN O
equina, equina, 0 0 0 0 1 0 0 0 7 0 IN NN NN NN IN O
up-regulation up-regulation 0 0 1 0 0 0 0 0 13 0 NN NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP IN O
BDNF BDNF 1 1 0 0 0 0 0 0 4 0 NN IN NNP IN JJ O
within within 0 0 0 0 0 0 0 0 6 0 IN NNP IN JJ NN O
lumbosacral lumbosacral 0 0 0 0 0 0 0 0 11 0 NNP IN JJ NN JJ O
(L7-S3) (L7-S3) 0 1 1 0 0 0 0 1 7 0 IN JJ NN JJ NN O
spinal spinal 0 0 0 0 0 0 0 0 6 0 JJ NN JJ NN CC O
cord cord 0 0 0 0 0 0 0 0 4 0 NN JJ NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NN NN O
dorsal dorsal 0 0 0 0 0 0 0 0 6 0 NN CC NN NN NN O
root root 0 0 0 0 0 0 0 0 4 0 CC NN NN NN VBD O
ganglion ganglion 0 0 0 0 0 0 0 0 8 0 NN NN NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD VBN IN O
observed observed 0 0 0 0 0 0 0 0 8 0 NN VBD VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
experimental experimental 0 0 0 0 0 0 0 0 12 0 VBN IN JJ NN IN O
group group 0 0 0 0 0 0 0 0 5 0 IN JJ NN IN VBN O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 NN IN VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 IN VBN TO NN NNP O
control control 0 0 0 0 0 0 0 0 7 0 VBN TO NN NNP NNP O
group. group. 0 0 0 0 0 0 0 0 6 0 TO NN NNP NNP NN O
Our Our 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NN VBZ O
result result 0 0 0 0 0 0 0 0 6 0 NNP NNP NN VBZ IN O
suggests suggests 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN NNP MD O
BDNF BDNF 1 1 0 0 0 0 0 0 4 0 VBZ IN NNP MD VB O
might might 0 0 0 0 0 0 0 0 5 0 IN NNP MD VB DT O
play play 0 0 0 0 0 0 0 0 4 0 NNP MD VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 MD VB DT NN IN O
role role 0 0 0 0 0 0 0 0 4 0 VB DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CC O
inflammatory inflammatory 0 0 0 0 0 0 0 0 12 0 IN DT NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC JJ NN O
neuropathic neuropathic 0 0 0 0 0 0 0 0 11 0 NN CC JJ NN IN O
pain pain 0 0 0 0 0 0 0 0 4 0 CC JJ NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN IN O
result result 0 0 0 0 0 0 0 0 6 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NN O
cauda cauda 0 0 0 0 0 0 0 0 5 0 IN NN NN NN NNP O
equina equina 0 0 0 0 0 0 0 0 6 0 NN NN NN NNP NNP O
constrictions. constrictions. 0 0 0 0 0 0 0 0 14 0 NN NN NNP NNP IN O
Regulation Regulation 1 0 0 0 0 0 0 0 10 0 NN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NN O
BDNF BDNF 1 1 0 0 0 0 0 0 4 0 NNP IN NNP NN MD O
level level 0 0 0 0 0 0 0 0 5 0 IN NNP NN MD RB O
could could 0 0 0 0 0 0 0 0 5 0 NNP NN MD RB VB O
potentially potentially 0 0 0 0 0 0 0 0 11 0 NN MD RB VB DT O
provide provide 0 0 0 0 0 0 0 0 7 0 MD RB VB DT NN O
a a 0 0 0 0 0 0 0 0 1 0 RB VB DT NN IN O
therapy therapy 0 0 0 0 0 0 0 0 7 0 VB DT NN IN NN O
for for 0 0 0 0 0 0 0 0 3 0 DT NN IN NN NN O
treating treating 0 0 0 0 0 0 0 0 8 0 NN IN NN NN NN O
cauda cauda 0 0 0 0 0 0 0 0 5 0 IN NN NN NN NNP O
equina equina 0 0 0 0 0 0 0 0 6 0 NN NN NN NNP NNP O
syndrome. syndrome. 0 0 0 0 0 0 0 0 9 0 NN NN NNP NNP NNP O
KEYWORDS: KEYWORDS: 1 1 0 0 0 0 0 0 9 0 NN NNP NNP NNP NN O
Cauda Cauda 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NN NN O
equina equina 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN NN O
syndrome syndrome 0 0 0 0 0 0 0 0 8 0 NNP NN NN NN JJ O
(CES), (CES), 0 1 0 0 1 0 0 0 6 0 NN NN NN JJ JJ O
brain-derived brain-derived 0 0 1 0 0 0 0 0 13 0 NN NN JJ JJ NN O
neurotrophic neurotrophic 0 0 0 0 0 0 0 0 12 0 NN JJ JJ NN NN O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ JJ NN NN NN O
(BDNF), (BDNF), 0 1 0 0 1 0 0 0 7 0 JJ NN NN NN NN O
dorsal dorsal 0 0 0 0 0 0 0 0 6 0 NN NN NN NN NN O
root root 0 0 0 0 0 0 0 0 4 0 NN NN NN NN NN O
ganglion ganglion 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NN O
(DRG), (DRG), 0 1 0 0 1 0 0 0 6 0 NN NN NN NN NN O
multiple multiple 0 0 0 0 0 0 0 0 8 0 NN NN NN NN NN O
cauda cauda 0 0 0 0 0 0 0 0 5 0 NN NN NN NN NNS O
equina equina 0 0 0 0 0 0 0 0 6 0 NN NN NN NNS -NONE- O
constrictions constrictions 0 0 0 0 0 0 0 0 13 0 NN NN NNS -NONE- JJ O
(MCEC), (MCEC), 0 1 0 0 1 0 0 0 7 0 NN NNS -NONE- JJ NNS O
neurotrophic neurotrophic 0 0 0 0 0 0 0 0 12 0 NNS -NONE- JJ NNS -NONE- O
factors factors 0 0 0 0 0 0 0 0 7 0 -NONE- JJ NNS -NONE- NONE O
(NFs) (NFs) 0 0 0 0 0 0 0 0 5 0 JJ NNS -NONE- NONE NONE O
Pyruvate Pyruvate 1 0 0 0 0 0 0 0 8 0 NONE NONE NNP NNP NNPS O
Oxidase Oxidase 1 0 0 0 0 0 0 0 7 0 NONE NNP NNP NNPS DT O
Influences Influences 1 0 0 0 0 0 0 0 10 0 NNP NNP NNPS DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNP NNPS DT NNP NNP O
Sugar Sugar 1 0 0 0 0 0 0 0 5 0 NNPS DT NNP NNP NNP O
Utilization Utilization 1 0 0 0 0 0 0 0 11 0 DT NNP NNP NNP CC O
Pattern Pattern 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Capsule Capsule 1 0 0 0 0 0 0 0 7 0 NNP CC NNP NNP IN O
Production Production 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Streptococcus Streptococcus 1 0 0 0 0 0 0 0 13 0 NNP IN NNP NNP NNP O
pneumoniae. pneumoniae. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP NNP O
Carvalho Carvalho 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
SM, SM, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Farshchi Farshchi 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Andisi Andisi 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
V, V, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gradstedt Gradstedt 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
H, H, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Neef Neef 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Kuipers Kuipers 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
OP, OP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Neves Neves 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
AR, AR, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Bijlsma Bijlsma 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
JJ. JJ. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Instituto Instituto 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Tecnologia Tecnologia 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NN O
Química Química 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NN -NONE- O
e e 0 0 0 0 0 0 0 0 1 0 NNP NNP NN -NONE- NNP O
Biológica, Biológica, 1 0 0 0 1 0 0 0 10 0 NNP NN -NONE- NNP NNP O
Universidade Universidade 1 0 0 0 0 0 0 0 12 0 NN -NONE- NNP NNP IN O
Nova Nova 1 0 0 0 0 0 0 0 4 0 -NONE- NNP NNP IN NNP O
de de 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Lisboa, Lisboa, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP NNP O
Oeiras, Oeiras, 1 0 0 0 1 0 0 0 7 0 IN NNP NNP NNP NNP O
Portugal. Portugal. 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Pyruvate Pyruvate 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NN VBZ O
oxidase oxidase 0 0 0 0 0 0 0 0 7 0 NNP NNP NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
key key 0 0 0 0 0 0 0 0 3 0 VBZ DT JJ NN IN O
function function 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN CC O
metabolism metabolism 0 0 0 0 0 0 0 0 10 0 IN DT NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 DT NN CC NN IN O
lifestyle lifestyle 0 0 0 0 0 0 0 0 9 0 NN CC NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ JJ O
many many 0 0 0 0 0 0 0 0 4 0 NN IN JJ JJ NN O
lactic lactic 0 0 0 0 0 0 0 0 6 0 IN JJ JJ NN NN O
acid acid 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NN CC O
bacteria bacteria 0 0 0 0 0 0 0 0 8 0 JJ NN NN CC PRP$ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP$ NN O
its its 0 0 0 0 0 0 0 0 3 0 NN CC PRP$ NN NNS O
activity activity 0 0 0 0 0 0 0 0 8 0 CC PRP$ NN NNS IN O
depends depends 0 0 0 0 0 0 0 0 7 0 PRP$ NN NNS IN DT O
on on 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
presence presence 0 0 0 0 0 0 0 0 8 0 IN DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NNP O
environmental environmental 0 0 0 0 0 0 0 0 13 0 NN IN JJ NNP NNP O
oxygen. oxygen. 0 0 0 0 0 0 0 0 7 0 IN JJ NNP NNP NNP O
In In 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP NNP NN O
Streptococcus Streptococcus 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NN DT O
pneumoniae pneumoniae 0 0 0 0 0 0 0 0 10 0 NNP NNP NN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNP NN DT NN VBZ O
protein protein 0 0 0 0 0 0 0 0 7 0 NN DT NN VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 DT NN VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NN VBZ VBN VBN TO O
suggested suggested 0 0 0 0 0 0 0 0 9 0 VBZ VBN VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBN VBN TO VB DT O
play play 0 0 0 0 0 0 0 0 4 0 VBN TO VB DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 TO VB DT JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 VB DT JJ NN IN O
role role 0 0 0 0 0 0 0 0 4 0 DT JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN CC O
metabolism metabolism 0 0 0 0 0 0 0 0 10 0 NN IN NN CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 IN NN CC VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NN CC VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 CC VBZ VBN VBN IN O
implicated implicated 0 0 0 0 0 0 0 0 10 0 VBZ VBN VBN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 VBN VBN IN NNP JJ O
virulence, virulence, 0 0 0 0 1 0 0 0 10 0 VBN IN NNP JJ NN O
oxidative oxidative 0 0 0 0 0 0 0 0 9 0 IN NNP JJ NN NN O
stress stress 0 0 0 0 0 0 0 0 6 0 NNP JJ NN NN CC O
survival survival 0 0 0 0 0 0 0 0 8 0 JJ NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN IN O
death death 0 0 0 0 0 0 0 0 5 0 NN CC NN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 CC NN IN JJ NNP O
stationary stationary 0 0 0 0 0 0 0 0 10 0 NN IN JJ NNP NNP O
phase. phase. 0 0 0 0 0 0 0 0 6 0 IN JJ NNP NNP JJ O
Under Under 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP JJ NN O
semi-aerobic semi-aerobic 0 0 1 0 0 0 0 0 12 0 NNP NNP JJ NN JJ O
conditions, conditions, 0 0 0 0 1 0 0 0 11 0 NNP JJ NN JJ CC O
transcriptomic transcriptomic 0 0 0 0 0 0 0 0 14 0 JJ NN JJ CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN JJ CC JJ NN O
metabolite metabolite 0 0 0 0 0 0 0 0 10 0 JJ CC JJ NN NN O
profiling profiling 0 0 0 0 0 0 0 0 9 0 CC JJ NN NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN DT NNP O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NNP NN O
spxB spxB 0 0 0 0 0 0 0 0 4 0 IN DT NNP NN NN O
mutant mutant 0 0 0 0 0 0 0 0 6 0 DT NNP NN NN IN O
grown grown 0 0 0 0 0 0 0 0 5 0 NNP NN NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NN NN IN NN VBD O
glucose glucose 0 0 0 0 0 0 0 0 7 0 NN IN NN VBD JJ O
showed showed 0 0 0 0 0 0 0 0 6 0 IN NN VBD JJ NNS O
minor minor 0 0 0 0 0 0 0 0 5 0 NN VBD JJ NNS VBN O
changes changes 0 0 0 0 0 0 0 0 7 0 VBD JJ NNS VBN TO O
compared compared 0 0 0 0 0 0 0 0 8 0 JJ NNS VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NNS VBN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NN NN O
wild wild 0 0 0 0 0 0 0 0 4 0 TO DT NN NN NN O
type, type, 0 0 0 0 1 0 0 0 5 0 DT NN NN NN IN O
apart apart 0 0 0 0 0 0 0 0 5 0 NN NN NN IN DT O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
significant significant 0 0 0 0 0 0 0 0 11 0 IN DT JJ NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN CD NNS O
two two 0 0 0 0 0 0 0 0 3 0 NN IN CD NNS VBN O
operons operons 0 0 0 0 0 0 0 0 7 0 IN CD NNS VBN IN O
involved involved 0 0 0 0 0 0 0 0 8 0 CD NNS VBN IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNS VBN IN JJ NN O
carbohydrate carbohydrate 0 0 0 0 0 0 0 0 12 0 VBN IN JJ NN CC O
uptake uptake 0 0 0 0 0 0 0 0 6 0 IN JJ NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC NNP NNP O
processing. processing. 0 0 0 0 0 0 0 0 11 0 NN CC NNP NNP NN O
This This 1 0 0 0 0 0 0 0 4 0 CC NNP NNP NN NNS O
induction induction 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NNS TO O
leads leads 0 0 0 0 0 0 0 0 5 0 NNP NN NNS TO DT O
to to 0 0 0 0 0 0 0 0 2 0 NN NNS TO DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS TO DT NN IN O
change change 0 0 0 0 0 0 0 0 6 0 TO DT NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
sugar sugar 0 0 0 0 0 0 0 0 5 0 IN DT NN NN NNS O
utilization utilization 0 0 0 0 0 0 0 0 11 0 DT NN NN NNS IN O
capabilities capabilities 0 0 0 0 0 0 0 0 12 0 NN NN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ IN O
bacterium, bacterium, 0 0 0 0 1 0 0 0 10 0 IN DT JJ IN JJ O
as as 0 0 0 0 0 0 0 0 2 0 DT JJ IN JJ IN O
indicated indicated 0 0 0 0 0 0 0 0 9 0 JJ IN JJ IN DT O
by by 0 0 0 0 0 0 0 0 2 0 IN JJ IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 JJ IN DT NN IN O
analysis analysis 0 0 0 0 0 0 0 0 8 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN VBZ O
growth growth 0 0 0 0 0 0 0 0 6 0 IN DT NN VBZ IN O
profiles profiles 0 0 0 0 0 0 0 0 8 0 DT NN VBZ IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NN VBZ IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VBZ IN DT NNP NN O
D39 D39 1 1 0 0 0 0 0 1 3 0 IN DT NNP NN CC O
parent parent 0 0 0 0 0 0 0 0 6 0 DT NNP NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NNP NN O
spxB spxB 0 0 0 0 0 0 0 0 4 0 NN CC NNP NN IN O
mutant mutant 0 0 0 0 0 0 0 0 6 0 CC NNP NN IN NN O
on on 0 0 0 0 0 0 0 0 2 0 NNP NN IN NN NNP O
alternative alternative 0 0 0 0 0 0 0 0 11 0 NN IN NN NNP NNP O
carbohydrates. carbohydrates. 0 0 0 0 0 0 0 0 14 0 IN NN NNP NNP NN O
Metabolic Metabolic 1 0 0 0 0 0 0 0 9 0 NN NNP NNP NN CC O
analysis analysis 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP NN CC NN NNS O
growth growth 0 0 0 0 0 0 0 0 6 0 NN CC NN NNS VBD O
experiments experiments 0 0 0 0 0 0 0 0 11 0 CC NN NNS VBD IN O
showed showed 0 0 0 0 0 0 0 0 6 0 NN NNS VBD IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NNS VBD IN NN IN O
inactivation inactivation 0 0 0 0 0 0 0 0 12 0 VBD IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP VBZ O
SpxB SpxB 1 0 0 0 0 0 0 0 4 0 NN IN NNP VBZ DT O
has has 0 0 0 0 0 0 0 0 3 0 IN NNP VBZ DT NN O
no no 0 0 0 0 0 0 0 0 2 0 NNP VBZ DT NN IN O
effect effect 0 0 0 0 0 0 0 0 6 0 VBZ DT NN IN DT O
on on 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
glucose glucose 0 0 0 0 0 0 0 0 7 0 IN DT NN NN NN O
fermentation fermentation 0 0 0 0 0 0 0 0 12 0 DT NN NN NN IN O
pattern, pattern, 0 0 0 0 1 0 0 0 8 0 NN NN NN IN IN O
except except 0 0 0 0 0 0 0 0 6 0 NN NN IN IN JJ O
under under 0 0 0 0 0 0 0 0 5 0 NN IN IN JJ NNP O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 IN IN JJ NNP NNP O
conditions. conditions. 0 0 0 0 0 0 0 0 11 0 IN JJ NNP NNP NNP O
More More 1 0 0 0 0 0 0 0 4 0 JJ NNP NNP NNP PRP O
importantly, importantly, 0 0 0 0 1 0 0 0 12 0 NNP NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
show show 0 0 0 0 0 0 0 0 4 0 NNP PRP VBP IN NN O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN NN IN O
mutation mutation 0 0 0 0 0 0 0 0 8 0 VBP IN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 IN NN IN NNP NNS O
spxB spxB 0 0 0 0 0 0 0 0 4 0 NN IN NNP NNS IN O
results results 0 0 0 0 0 0 0 0 7 0 IN NNP NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NNP NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
production production 0 0 0 0 0 0 0 0 10 0 IN DT NN IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN VBN NNS O
increased increased 0 0 0 0 0 0 0 0 9 0 NN IN VBN NNS IN O
amounts amounts 0 0 0 0 0 0 0 0 7 0 IN VBN NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN JJ DT O
capsule, capsule, 0 0 0 0 1 0 0 0 8 0 NNS IN JJ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN JJ DT JJ NN O
major major 0 0 0 0 0 0 0 0 5 0 JJ DT JJ NN NN O
virulence virulence 0 0 0 0 0 0 0 0 9 0 DT JJ NN NN IN O
factor factor 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
S. S. 1 1 0 0 0 0 0 0 2 0 NN IN NNP NNP NNP O
pneumoniae. pneumoniae. 0 0 0 0 0 0 0 0 11 0 IN NNP NNP NNP IN O
Part Part 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP IN DT O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NNP IN DT NN MD O
increase increase 0 0 0 0 0 0 0 0 8 0 IN DT NN MD VB O
can can 0 0 0 0 0 0 0 0 3 0 DT NN MD VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 NN MD VB VBN TO O
attributed attributed 0 0 0 0 0 0 0 0 10 0 MD VB VBN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO NN IN O
induction induction 0 0 0 0 0 0 0 0 9 0 VBN TO NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 TO NN IN NN NN O
capsule capsule 0 0 0 0 0 0 0 0 7 0 NN IN NN NN NN O
operon operon 0 0 0 0 0 0 0 0 6 0 IN NN NN NN NNP O
(cps) (cps) 0 0 0 0 0 0 0 0 5 0 NN NN NN NNP NNP O
transcription. transcription. 0 0 0 0 0 0 0 0 14 0 NN NN NNP NNP PRP O
Therefore, Therefore, 1 0 0 0 1 0 0 0 10 0 NN NNP NNP PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NNP NNP PRP VBP IN O
propose propose 0 0 0 0 0 0 0 0 7 0 NNP PRP VBP IN NNP O
that that 0 0 0 0 0 0 0 0 4 0 PRP VBP IN NNP NN O
S. S. 1 1 0 0 0 0 0 0 2 0 VBP IN NNP NN VBZ O
pneumoniae pneumoniae 0 0 0 0 0 0 0 0 10 0 IN NNP NN VBZ JJ O
utilizes utilizes 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ JJ NN O
pyruvate pyruvate 0 0 0 0 0 0 0 0 8 0 NN VBZ JJ NN IN O
oxidase oxidase 0 0 0 0 0 0 0 0 7 0 VBZ JJ NN IN DT O
as as 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NN IN DT JJ NN O
indirect indirect 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN IN O
sensor sensor 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
oxygenation oxygenation 0 0 0 0 0 0 0 0 11 0 IN DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT JJ NN O
environment, environment, 0 0 0 0 1 0 0 0 12 0 IN DT JJ NN IN O
resulting resulting 0 0 0 0 0 0 0 0 9 0 DT JJ NN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN IN O
adaption adaption 0 0 0 0 0 0 0 0 8 0 IN DT NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN PRP$ JJ O
its its 0 0 0 0 0 0 0 0 3 0 NN IN PRP$ JJ NN O
nutritional nutritional 0 0 0 0 0 0 0 0 11 0 IN PRP$ JJ NN CC O
capability capability 0 0 0 0 0 0 0 0 10 0 PRP$ JJ NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
amount amount 0 0 0 0 0 0 0 0 6 0 CC DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN TO O
capsule capsule 0 0 0 0 0 0 0 0 7 0 NN IN NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO VB IN O
survive survive 0 0 0 0 0 0 0 0 7 0 NN TO VB IN DT O
in in 0 0 0 0 0 0 0 0 2 0 TO VB IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT NNP NONE O
host. host. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NONE NONE O
Plant Plant 1 0 0 0 0 0 0 0 5 0 NONE NONE NNP NNP NNP O
Water Water 1 0 0 0 0 0 0 0 5 0 NONE NNP NNP NNP NNP O
Use Use 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Efficiency Efficiency 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
over over 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNP NNP O
Geological Geological 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP : O
Time Time 1 0 0 0 0 0 0 0 4 0 IN NNP NNP : NNP O
- - 0 0 1 0 0 0 0 0 1 0 NNP NNP : NNP IN O
Evolution Evolution 1 0 0 0 0 0 0 0 9 0 NNP : NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 : NNP IN NNP NNP O
Leaf Leaf 1 0 0 0 0 0 0 0 4 0 NNP IN NNP NNP NNP O
Stomata Stomata 1 0 0 0 0 0 0 0 7 0 IN NNP NNP NNP NNP O
Configurations Configurations 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
Affecting Affecting 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Plant Plant 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Gas Gas 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Exchange. Exchange. 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
Assouline Assouline 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP NNP NNP O
S, S, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Or Or 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
D. D. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Environmental Environmental 1 0 0 0 0 0 0 0 13 0 NNP IN NNP NNP CC O
Physics Physics 1 0 0 0 0 0 0 0 7 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Irrigation, Irrigation, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Soil, Soil, 1 0 0 0 1 0 0 0 5 0 NNP IN NNP NNP CC O
Water Water 1 0 0 0 0 0 0 0 5 0 IN NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Environmental Environmental 1 0 0 0 0 0 0 0 13 0 NNP CC NNP NNP NNP O
Sciences, Sciences, 1 0 0 0 1 0 0 0 9 0 CC NNP NNP NNP NNP O
A.R.O.-Volcani A.R.O.-Volcani 1 0 1 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
Center, Center, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Bet Bet 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Dagan, Dagan, 1 0 0 0 1 0 0 0 6 0 NNP NNP NNP NNP NNP O
Israel. Israel. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
Plant Plant 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NN NN O
gas gas 0 0 0 0 0 0 0 0 3 0 NNP NNP NN NN VBZ O
exchange exchange 0 0 0 0 0 0 0 0 8 0 NNP NN NN VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NN VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN VBZ DT JJ NN O
key key 0 0 0 0 0 0 0 0 3 0 VBZ DT JJ NN VBG O
process process 0 0 0 0 0 0 0 0 7 0 DT JJ NN VBG JJ O
shaping shaping 0 0 0 0 0 0 0 0 7 0 JJ NN VBG JJ JJ O
global global 0 0 0 0 0 0 0 0 6 0 NN VBG JJ JJ CC O
hydrological hydrological 0 0 0 0 0 0 0 0 12 0 VBG JJ JJ CC NN O
and and 0 0 0 0 0 0 0 0 3 0 JJ JJ CC NN NNS O
carbon carbon 0 0 0 0 0 0 0 0 6 0 JJ CC NN NNS CC O
cycles cycles 0 0 0 0 0 0 0 0 6 0 CC NN NNS CC VBZ O
and and 0 0 0 0 0 0 0 0 3 0 NN NNS CC VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 NNS CC VBZ RB VBN O
often often 0 0 0 0 0 0 0 0 5 0 CC VBZ RB VBN IN O
characterized characterized 0 0 0 0 0 0 0 0 13 0 VBZ RB VBN IN NN O
by by 0 0 0 0 0 0 0 0 2 0 RB VBN IN NN NN O
plant plant 0 0 0 0 0 0 0 0 5 0 VBN IN NN NN NN O
water water 0 0 0 0 0 0 0 0 5 0 IN NN NN NN NN O
use use 0 0 0 0 0 0 0 0 3 0 NN NN NN NN NN O
efficiency efficiency 0 0 0 0 0 0 0 0 10 0 NN NN NN NN : O
(WUE (WUE 0 1 0 0 0 0 0 0 4 0 NN NN NN : DT O
- - 0 0 1 0 0 0 0 0 1 0 NN NN : DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN : DT NN IN O
ratio ratio 0 0 0 0 0 0 0 0 5 0 : DT NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NNP NN O
CO2 CO2 1 1 0 0 0 0 0 1 3 0 NN IN NNP NN TO O
gain gain 0 0 0 0 0 0 0 0 4 0 IN NNP NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NNP NN TO NN NN O
water water 0 0 0 0 0 0 0 0 5 0 NN TO NN NN NNP O
vapor vapor 0 0 0 0 0 0 0 0 5 0 TO NN NN NNP NNP O
loss). loss). 0 0 0 0 0 0 0 0 6 0 NN NN NNP NNP NN O
Plant Plant 1 0 0 0 0 0 0 0 5 0 NN NNP NNP NN NN O
fossil fossil 0 0 0 0 0 0 0 0 6 0 NNP NNP NN NN VBZ O
record record 0 0 0 0 0 0 0 0 6 0 NNP NN NN VBZ IN O
suggests suggests 0 0 0 0 0 0 0 0 8 0 NN NN VBZ IN NN O
that that 0 0 0 0 0 0 0 0 4 0 NN VBZ IN NN NN O
plant plant 0 0 0 0 0 0 0 0 5 0 VBZ IN NN NN TO O
adaptation adaptation 0 0 0 0 0 0 0 0 10 0 IN NN NN TO VBG O
to to 0 0 0 0 0 0 0 0 2 0 NN NN TO VBG JJ O
changing changing 0 0 0 0 0 0 0 0 8 0 NN TO VBG JJ NNP O
atmospheric atmospheric 0 0 0 0 0 0 0 0 11 0 TO VBG JJ NNP VBD O
CO2 CO2 1 1 0 0 0 0 0 1 3 0 VBG JJ NNP VBD VBN O
involved involved 0 0 0 0 0 0 0 0 8 0 JJ NNP VBD VBN NN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NNP VBD VBN NN IN O
evolution evolution 0 0 0 0 0 0 0 0 9 0 VBD VBN NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 VBN NN IN NN NN O
stomata stomata 0 0 0 0 0 0 0 0 7 0 NN IN NN NN NN O
density density 0 0 0 0 0 0 0 0 7 0 IN NN NN NN CC O
(d) (d) 0 0 0 0 0 0 0 0 3 0 NN NN NN CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NN NN O
size size 0 0 0 0 0 0 0 0 4 0 NN CC NN NN CC O
(s), (s), 0 0 0 0 1 0 0 0 4 0 CC NN NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC JJ JJ O
related related 0 0 0 0 0 0 0 0 7 0 NN CC JJ JJ NN O
maximal maximal 0 0 0 0 0 0 0 0 7 0 CC JJ JJ NN NN O
aperture, aperture, 0 0 0 0 1 0 0 0 9 0 JJ JJ NN NN . O
amax amax 0 0 0 0 0 0 0 0 4 0 JJ NN NN . PRP O
. . 0 0 0 0 0 0 0 0 1 0 NN NN . PRP VBD O
We We 1 0 0 0 0 0 0 0 2 0 NN . PRP VBD DT O
interpreted interpreted 0 0 0 0 0 0 0 0 11 0 . PRP VBD DT NN O
the the 0 0 0 0 0 0 0 0 3 0 PRP VBD DT NN NN O
fossil fossil 0 0 0 0 0 0 0 0 6 0 VBD DT NN NN IN O
record record 0 0 0 0 0 0 0 0 6 0 DT NN NN IN NNS O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNS CC O
s s 0 0 0 0 0 0 0 0 1 0 NN IN NNS CC VBD O
and and 0 0 0 0 0 0 0 0 3 0 IN NNS CC VBD VBN O
d d 0 0 0 0 0 0 0 0 1 0 NNS CC VBD VBN NN O
correlated correlated 0 0 0 0 0 0 0 0 10 0 CC VBD VBN NN IN O
evolution evolution 0 0 0 0 0 0 0 0 9 0 VBD VBN NN IN DT O
during during 0 0 0 0 0 0 0 0 6 0 VBN NN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NNP TO O
Phanerozoic Phanerozoic 1 0 0 0 0 0 0 0 11 0 IN DT NNP TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NNP TO VB NNS O
quantify quantify 0 0 0 0 0 0 0 0 8 0 NNP TO VB NNS IN O
impacts impacts 0 0 0 0 0 0 0 0 7 0 TO VB NNS IN NN O
on on 0 0 0 0 0 0 0 0 2 0 VB NNS IN NN NN O
gas gas 0 0 0 0 0 0 0 0 3 0 NNS IN NN NN VBG O
conductance conductance 0 0 0 0 0 0 0 0 11 0 IN NN NN VBG NN O
affecting affecting 0 0 0 0 0 0 0 0 9 0 NN NN VBG NN -NONE- O
plant plant 0 0 0 0 0 0 0 0 5 0 NN VBG NN -NONE- -NONE- O
transpiration, transpiration, 0 0 0 0 1 0 0 0 14 0 VBG NN -NONE- -NONE- CC O
E, E, 1 1 0 0 1 0 0 0 2 0 NN -NONE- -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- -NONE- CC NNP NNP O
CO2 CO2 1 1 0 0 0 0 0 1 3 0 -NONE- CC NNP NNP NNP O
uptake, uptake, 0 0 0 0 1 0 0 0 7 0 CC NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP CC O
independently, independently, 0 0 0 0 1 0 0 0 14 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP IN O
consequently, consequently, 0 0 0 0 1 0 0 0 13 0 NNP CC NNP IN NN O
on on 0 0 0 0 0 0 0 0 2 0 CC NNP IN NN NNP O
plant plant 0 0 0 0 0 0 0 0 5 0 NNP IN NN NNP DT O
WUE. WUE. 1 1 0 0 0 0 0 0 4 0 IN NN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT NN IN O
shift shift 0 0 0 0 0 0 0 0 5 0 NNP DT NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NN O
stomata stomata 0 0 0 0 0 0 0 0 7 0 NN IN NN NN IN O
configuration configuration 0 0 0 0 0 0 0 0 13 0 IN NN NN IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN NN IN JJ JJ O
large large 0 0 0 0 0 0 0 0 5 0 NN IN JJ JJ NN O
s-low s-low 0 0 1 0 0 0 0 0 5 0 IN JJ JJ NN TO O
d d 0 0 0 0 0 0 0 0 1 0 JJ JJ NN TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO JJ JJ O
small small 0 0 0 0 0 0 0 0 5 0 NN TO JJ JJ NN O
s-high s-high 0 0 1 0 0 0 0 0 6 0 TO JJ JJ NN IN O
d d 0 0 0 0 0 0 0 0 1 0 JJ JJ NN IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NN TO O
response response 0 0 0 0 0 0 0 0 8 0 NN IN NN TO NN O
to to 0 0 0 0 0 0 0 0 2 0 IN NN TO NN JJ O
decreasing decreasing 0 0 0 0 0 0 0 0 10 0 NN TO NN JJ NNP O
atmospheric atmospheric 0 0 0 0 0 0 0 0 11 0 TO NN JJ NNP VBD O
CO2 CO2 1 1 0 0 0 0 0 1 3 0 NN JJ NNP VBD IN O
resulted resulted 0 0 0 0 0 0 0 0 8 0 JJ NNP VBD IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NNP VBD IN JJ NNS O
large large 0 0 0 0 0 0 0 0 5 0 VBD IN JJ NNS IN O
changes changes 0 0 0 0 0 0 0 0 7 0 IN JJ NNS IN NN O
in in 0 0 0 0 0 0 0 0 2 0 JJ NNS IN NN NN O
plant plant 0 0 0 0 0 0 0 0 5 0 NNS IN NN NN NN O
gas gas 0 0 0 0 0 0 0 0 3 0 IN NN NN NN NNP O
exchange exchange 0 0 0 0 0 0 0 0 8 0 NN NN NN NNP NNP O
characteristics. characteristics. 0 0 0 0 0 0 0 0 16 0 NN NN NNP NNP NNS O
The The 1 0 0 0 0 0 0 0 3 0 NN NNP NNP NNS IN O
relationships relationships 0 0 0 0 0 0 0 0 13 0 NNP NNP NNS IN NN O
between between 0 0 0 0 0 0 0 0 7 0 NNP NNS IN NN NN O
gas gas 0 0 0 0 0 0 0 0 3 0 NNS IN NN NN VBZ O
conductance, conductance, 0 0 0 0 1 0 0 0 12 0 IN NN NN VBZ , O
gws gws 0 0 0 0 0 0 0 0 3 0 NN NN VBZ , DT O
, , 0 0 0 0 1 0 0 0 1 0 NN VBZ , DT CC O
A A 1 1 0 0 0 0 0 0 1 0 VBZ , DT CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 , DT CC NNP CC O
E E 1 1 0 0 0 0 0 0 1 0 DT CC NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 CC NNP CC JJ JJ O
maximal maximal 0 0 0 0 0 0 0 0 7 0 NNP CC JJ JJ NN O
relative relative 0 0 0 0 0 0 0 0 8 0 CC JJ JJ NN NN O
transpiring transpiring 0 0 0 0 0 0 0 0 11 0 JJ JJ NN NN NN O
leaf leaf 0 0 0 0 0 0 0 0 4 0 JJ NN NN NN NN O
area, area, 0 0 0 0 1 0 0 0 5 0 NN NN NN NN NN O
(amax (amax 0 0 0 0 0 0 0 0 5 0 NN NN NN NN VBD O
⋅d), ⋅d), 0 0 0 0 1 0 0 0 4 0 NN NN NN VBD JJ O
exhibited exhibited 0 0 0 0 0 0 0 0 9 0 NN NN VBD JJ NNP O
hysteretic-like hysteretic-like 0 0 1 0 0 0 0 0 15 0 NN VBD JJ NNP NNP O
behavior. behavior. 0 0 0 0 0 0 0 0 9 0 VBD JJ NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP JJ NNP O
new new 0 0 0 0 0 0 0 0 3 0 NNP NNP JJ NNP NN O
WUE WUE 1 1 0 0 0 0 0 0 3 0 NNP JJ NNP NN VBD O
trend trend 0 0 0 0 0 0 0 0 5 0 JJ NNP NN VBD IN O
derived derived 0 0 0 0 0 0 0 0 7 0 NNP NN VBD IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NN VBD IN JJ NNS O
independent independent 0 0 0 0 0 0 0 0 11 0 VBD IN JJ NNS IN O
estimates estimates 0 0 0 0 0 0 0 0 9 0 IN JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT CC O
A A 1 1 0 0 0 0 0 0 1 0 NNS IN DT CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN DT CC NNP NNS O
E E 1 1 0 0 0 0 0 0 1 0 DT CC NNP NNS IN O
differs differs 0 0 0 0 0 0 0 0 7 0 CC NNP NNS IN JJ O
from from 0 0 0 0 0 0 0 0 4 0 NNP NNS IN JJ -NONE- O
established established 0 0 0 0 0 0 0 0 11 0 NNS IN JJ -NONE- VBZ O
WUE-CO2 WUE-CO2 1 1 1 0 0 0 0 1 7 0 IN JJ -NONE- VBZ IN O
trends trends 0 0 0 0 0 0 0 0 6 0 JJ -NONE- VBZ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 -NONE- VBZ IN JJ NNP O
atmospheric atmospheric 0 0 0 0 0 0 0 0 11 0 VBZ IN JJ NNP NNS O
CO2 CO2 1 1 0 0 0 0 0 1 3 0 IN JJ NNP NNS VBG O
concentrations concentrations 0 0 0 0 0 0 0 0 14 0 JJ NNP NNS VBG CD O
exceeding exceeding 0 0 0 0 0 0 0 0 9 0 NNP NNS VBG CD NNP O
1,200 1,200 0 0 0 0 1 0 0 1 5 0 NNS VBG CD NNP NNP O
ppm. ppm. 0 0 0 0 0 0 0 0 4 0 VBG CD NNP NNP NN O
In In 1 0 0 0 0 0 0 0 2 0 CD NNP NNP NN IN O
contrast contrast 0 0 0 0 0 0 0 0 8 0 NNP NNP NN IN DT O
with with 0 0 0 0 0 0 0 0 4 0 NNP NN IN DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT JJ NN O
nearly-linear nearly-linear 0 0 1 0 0 0 0 0 13 0 IN DT JJ NN IN O
decrease decrease 0 0 0 0 0 0 0 0 8 0 DT JJ NN IN NNP O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN NNP IN O
WUE WUE 1 1 0 0 0 0 0 0 3 0 NN IN NNP IN VBG O
with with 0 0 0 0 0 0 0 0 4 0 IN NNP IN VBG NNP O
decreasing decreasing 0 0 0 0 0 0 0 0 10 0 NNP IN VBG NNP VBD O
CO2 CO2 1 1 0 0 0 0 0 1 3 0 IN VBG NNP VBD IN O
obtained obtained 0 0 0 0 0 0 0 0 8 0 VBG NNP VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NNP VBD IN JJ NN O
standard standard 0 0 0 0 0 0 0 0 8 0 VBD IN JJ NN DT O
methods, methods, 0 0 0 0 1 0 0 0 8 0 IN JJ NN DT RB O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT RB VBN O
newly newly 0 0 0 0 0 0 0 0 5 0 NN DT RB VBN NNP O
estimated estimated 0 0 0 0 0 0 0 0 9 0 DT RB VBN NNP NN O
WUE WUE 1 1 0 0 0 0 0 0 3 0 RB VBN NNP NN VBZ O
trend trend 0 0 0 0 0 0 0 0 5 0 VBN NNP NN VBZ RB O
exhibits exhibits 0 0 0 0 0 0 0 0 8 0 NNP NN VBZ RB JJ O
remarkably remarkably 0 0 0 0 0 0 0 0 10 0 NN VBZ RB JJ NNS O
stable stable 0 0 0 0 0 0 0 0 6 0 VBZ RB JJ NNS IN O
values values 0 0 0 0 0 0 0 0 6 0 RB JJ NNS IN DT O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN DT JJ O
an an 0 0 0 0 0 0 0 0 2 0 NNS IN DT JJ NN O
extended extended 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN NN O
geologic geologic 0 0 0 0 0 0 0 0 8 0 DT JJ NN NN IN O
period period 0 0 0 0 0 0 0 0 6 0 JJ NN NN IN WDT O
during during 0 0 0 0 0 0 0 0 6 0 NN NN IN WDT JJ O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT JJ NNP O
atmospheric atmospheric 0 0 0 0 0 0 0 0 11 0 IN WDT JJ NNP VBD O
CO2 CO2 1 1 0 0 0 0 0 1 3 0 WDT JJ NNP VBD IN O
dropped dropped 0 0 0 0 0 0 0 0 7 0 JJ NNP VBD IN CD O
from from 0 0 0 0 0 0 0 0 4 0 NNP VBD IN CD TO O
3,500 3,500 0 0 0 0 1 0 0 1 5 0 VBD IN CD TO CD O
to to 0 0 0 0 0 0 0 0 2 0 IN CD TO CD NNP O
1,200 1,200 0 0 0 0 1 0 0 1 5 0 CD TO CD NNP NNP O
ppm. ppm. 0 0 0 0 0 0 0 0 4 0 TO CD NNP NNP JJ O
Pending Pending 1 0 0 0 0 0 0 0 7 0 CD NNP NNP JJ NN O
additional additional 0 0 0 0 0 0 0 0 10 0 NNP NNP JJ NN DT O
tests, tests, 0 0 0 0 1 0 0 0 6 0 NNP JJ NN DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 JJ NN DT NNS MD O
findings findings 0 0 0 0 0 0 0 0 8 0 NN DT NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 DT NNS MD VB VBN O
affect affect 0 0 0 0 0 0 0 0 6 0 NNS MD VB VBN NNS O
projected projected 0 0 0 0 0 0 0 0 9 0 MD VB VBN NNS IN O
impacts impacts 0 0 0 0 0 0 0 0 7 0 VB VBN NNS IN VBN O
of of 0 0 0 0 0 0 0 0 2 0 VBN NNS IN VBN JJ O
increased increased 0 0 0 0 0 0 0 0 9 0 NNS IN VBN JJ NNP O
atmospheric atmospheric 0 0 0 0 0 0 0 0 11 0 IN VBN JJ NNP IN O
CO2 CO2 1 1 0 0 0 0 0 1 3 0 VBN JJ NNP IN NNS O
on on 0 0 0 0 0 0 0 0 2 0 JJ NNP IN NNS IN O
components components 0 0 0 0 0 0 0 0 10 0 NNP IN NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 IN NNS IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT JJ JJ O
global global 0 0 0 0 0 0 0 0 6 0 IN DT JJ JJ NNP O
hydrological hydrological 0 0 0 0 0 0 0 0 12 0 DT JJ JJ NNP NONE O
cycle. cycle. 0 0 0 0 0 0 0 0 6 0 JJ JJ NNP NONE NONE O
Kurt Kurt 1 0 0 0 0 0 0 0 4 0 NONE NONE NNP NNP NNP O
Hellmann Hellmann 1 0 0 0 0 0 0 0 8 0 NONE NNP NNP NNP NNP O
D. D. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
M., M., 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
D. D. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Phil. Phil. 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
Oxon Oxon 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
1922–2013. 1922–2013. 0 0 0 0 0 0 0 1 10 0 NNP NNP NNP NNP NNP O
Eccles Eccles 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
SA. SA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Tumour Tumour 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP CC O
Biology Biology 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNP O
Metastasis, Metastasis, 1 0 0 0 1 0 0 0 11 0 NNP CC NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 CC NNP NNP NNP NNP O
Research Research 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
UK UK 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Therapeutics Therapeutics 1 0 0 0 0 0 0 0 12 0 NNP NNP NNP NNP NNP O
Unit, Unit, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
The The 1 0 0 0 0 0 0 0 3 0 NNP NNP NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Cancer Cancer 1 0 0 0 0 0 0 0 6 0 NNP IN NNP NNP NNP O
Research, Research, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Sutton, Sutton, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Surrey, Surrey, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
UK. UK. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NONE O
Sue.Eccles@icr.ac.uk Sue.Eccles@icr.ac.uk 1 0 0 0 0 0 0 0 20 0 NNP NNP NNP NONE NONE O
Topological Topological 1 0 0 0 0 0 0 0 11 0 NONE NONE JJ NN NNS O
edge edge 0 0 0 0 0 0 0 0 4 0 NONE JJ NN NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 JJ NN NNS IN -NONE- O
of of 0 0 0 0 0 0 0 0 2 0 NN NNS IN -NONE- NN O
C60+12 C60+12 1 1 0 0 0 0 0 1 6 0 NNS IN -NONE- NN NNP O
n n 0 0 0 0 0 0 0 0 1 0 IN -NONE- NN NNP NNP O
fullerenes. fullerenes. 0 0 0 0 0 0 0 0 11 0 -NONE- NN NNP NNP NNP O
Mottaghi Mottaghi 1 0 0 0 0 0 0 0 8 0 NN NNP NNP NNP NNP O
A, A, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ashrafi Ashrafi 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
AR. AR. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Nanocomputing, Nanocomputing, 1 0 0 0 1 0 0 0 14 0 NNP IN NNP NNP IN O
Institute Institute 1 0 0 0 0 0 0 0 9 0 IN NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP CC O
Nanoscience Nanoscience 1 0 0 0 0 0 0 0 11 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Nanotechnology, Nanotechnology, 1 0 0 0 1 0 0 0 15 0 NNP CC NNP NNP IN O
University University 1 0 0 0 0 0 0 0 10 0 CC NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Kashan, Kashan, 1 0 0 0 1 0 0 0 7 0 NNP IN NNP NNP CD O
Kashan Kashan 1 0 0 0 0 0 0 0 6 0 IN NNP NNP CD PRP O
87317-51167, 87317-51167, 0 0 1 0 1 0 0 1 12 0 NNP NNP CD PRP NNP O
I I 1 1 0 0 0 0 0 0 1 0 NNP CD PRP NNP NNP O
R R 1 1 0 0 0 0 0 0 1 0 CD PRP NNP NNP NNP O
Iran. Iran. 1 0 0 0 0 0 0 0 5 0 PRP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NN O
A A 1 1 0 0 0 0 0 0 1 0 NNP NNP NNP NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN NNP O
graph graph 0 0 0 0 0 0 0 0 5 0 NNP NN NN NNP VBZ O
M M 1 1 0 0 0 0 0 0 1 0 NN NN NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 NN NNP VBZ DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NNP VBZ DT JJ NN O
simple simple 0 0 0 0 0 0 0 0 6 0 VBZ DT JJ NN IN O
graph graph 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN WDT O
in in 0 0 0 0 0 0 0 0 2 0 JJ NN IN WDT NNS O
which which 0 0 0 0 0 0 0 0 5 0 NN IN WDT NNS CC O
atoms atoms 0 0 0 0 0 0 0 0 5 0 IN WDT NNS CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 WDT NNS CC JJ NNS O
chemical chemical 0 0 0 0 0 0 0 0 8 0 NNS CC JJ NNS VBP O
bonds bonds 0 0 0 0 0 0 0 0 5 0 CC JJ NNS VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 JJ NNS VBP DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 NNS VBP DT NNS CC O
vertices vertices 0 0 0 0 0 0 0 0 8 0 VBP DT NNS CC NNS O
and and 0 0 0 0 0 0 0 0 3 0 DT NNS CC NNS IN O
edges edges 0 0 0 0 0 0 0 0 5 0 NNS CC NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 CC NNS IN JJ NNP O
M, M, 1 1 0 0 1 0 0 0 2 0 NNS IN JJ NNP NNP O
respectively. respectively. 0 0 0 0 0 0 0 0 13 0 IN JJ NNP NNP NN O
The The 1 0 0 0 0 0 0 0 3 0 JJ NNP NNP NN NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 NNP NNP NN NN NNP O
graph graph 0 0 0 0 0 0 0 0 5 0 NNP NN NN NNP VBZ O
M M 1 1 0 0 0 0 0 0 1 0 NN NN NNP VBZ VBN O
is is 0 0 0 0 0 0 0 0 2 0 NN NNP VBZ VBN DT O
called called 0 0 0 0 0 0 0 0 6 0 NNP VBZ VBN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 VBZ VBN DT NN NN O
fullerene fullerene 0 0 0 0 0 0 0 0 9 0 VBN DT NN NN IN O
graph, graph, 0 0 0 0 1 0 0 0 6 0 DT NN NN IN NNP O
if if 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP VBZ O
M M 1 1 0 0 0 0 0 0 1 0 NN IN NNP VBZ DT O
is is 0 0 0 0 0 0 0 0 2 0 IN NNP VBZ DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP VBZ DT JJ NN O
molecular molecular 0 0 0 0 0 0 0 0 9 0 VBZ DT JJ NN IN O
graph graph 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NN IN DT NN NNP O
fullerene fullerene 0 0 0 0 0 0 0 0 9 0 IN DT NN NNP NNP O
molecule. molecule. 0 0 0 0 0 0 0 0 9 0 DT NN NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 NN NNP NNP VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NNP VBZ JJ IN O
well-known well-known 0 0 1 0 0 0 0 0 10 0 NNP VBZ JJ IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 VBZ JJ IN JJ NNS O
such such 0 0 0 0 0 0 0 0 4 0 JJ IN JJ NNS VBP O
molecules molecules 0 0 0 0 0 0 0 0 9 0 IN JJ NNS VBP IN O
exist exist 0 0 0 0 0 0 0 0 5 0 JJ NNS VBP IN RB O
for for 0 0 0 0 0 0 0 0 3 0 NNS VBP IN RB NNS O
even even 0 0 0 0 0 0 0 0 4 0 VBP IN RB NNS VBP O
integers integers 0 0 0 0 0 0 0 0 8 0 IN RB NNS VBP : O
n n 0 0 0 0 0 0 0 0 1 0 RB NNS VBP : CD O
≥ ≥ 0 0 0 0 0 0 0 0 1 0 NNS VBP : CD CC O
24 24 0 0 0 0 0 0 1 1 2 0 VBP : CD CC NN O
or or 0 0 0 0 0 0 0 0 2 0 : CD CC NN : O
n n 0 0 0 0 0 0 0 0 1 0 CD CC NN : CD O
= = 0 0 0 0 0 0 0 0 1 0 CC NN : CD DT O
20. 20. 0 0 0 0 0 0 0 1 3 0 NN : CD DT NN O
The The 1 0 0 0 0 0 0 0 3 0 : CD DT NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 CD DT NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN DT NN O
this this 0 0 0 0 0 0 0 0 4 0 NN IN DT NN VBZ O
paper paper 0 0 0 0 0 0 0 0 5 0 IN DT NN VBZ TO O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBZ TO VB DT O
investigate investigate 0 0 0 0 0 0 0 0 11 0 VBZ TO VB DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT JJ NNS O
topological topological 0 0 0 0 0 0 0 0 11 0 VB DT JJ NNS IN O
properties properties 0 0 0 0 0 0 0 0 10 0 DT JJ NNS IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NNS IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNS IN DT NN IN O
class class 0 0 0 0 0 0 0 0 5 0 IN DT NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN NN NNS O
fullerene fullerene 0 0 0 0 0 0 0 0 9 0 NN IN NN NNS VBG O
molecules molecules 0 0 0 0 0 0 0 0 9 0 IN NN NNS VBG CD O
containing containing 0 0 0 0 0 0 0 0 10 0 NN NNS VBG CD CD O
60 60 0 0 0 0 0 0 1 1 2 0 NNS VBG CD CD CD O
+ + 0 0 0 0 0 0 0 0 1 0 VBG CD CD CD NN O
12n 12n 0 0 0 0 0 0 0 1 3 0 CD CD CD NN NNP O
carbon carbon 0 0 0 0 0 0 0 0 6 0 CD CD NN NNP NONE O
atoms. atoms. 0 0 0 0 0 0 0 0 6 0 CD NN NNP NONE NONE O
Field Field 1 0 0 0 0 0 0 0 5 0 NONE NONE NNP NNS IN O
tests tests 0 0 0 0 0 0 0 0 5 0 NONE NNP NNS IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 NNP NNS IN VBG DT O
evaluating evaluating 0 0 0 0 0 0 0 0 10 0 NNS IN VBG DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 IN VBG DT JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 VBG DT JJ NN NN O
work work 0 0 0 0 0 0 0 0 4 0 DT JJ NN NN IN O
capacity capacity 0 0 0 0 0 0 0 0 8 0 JJ NN NN IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NN NN IN NNP NNP O
firefighters. firefighters. 0 0 0 0 0 0 0 0 13 0 NN IN NNP NNP NNP O
Lindberg Lindberg 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP NNP O
AS, AS, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Oksa Oksa 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
J, J, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Gavhed Gavhed 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Malm Malm 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
C. C. 1 1 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Sports Sports 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
Medicine Medicine 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP NNP O
Unit, Unit, 1 0 0 0 1 0 0 0 5 0 NNP NNP NNP NNP NNP O
Umeå Umeå 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
University, University, 1 0 0 0 1 0 0 0 11 0 NNP NNP NNP NNP : O
Sweden Sweden 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP : NNP O
; ; 0 0 0 0 0 0 0 0 1 0 NNP NNP : NNP NNP O
Winternet, Winternet, 1 0 0 0 1 0 0 0 10 0 NNP : NNP NNP NNP O
Boden, Boden, 1 0 0 0 1 0 0 0 6 0 : NNP NNP NNP NNP O
Sweden. Sweden. 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP IN O
Working Working 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP IN DT O
as as 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT NN O
a a 0 0 0 0 0 0 0 0 1 0 NNP IN DT NN VBZ O
firefighter firefighter 0 0 0 0 0 0 0 0 11 0 IN DT NN VBZ RB O
is is 0 0 0 0 0 0 0 0 2 0 DT NN VBZ RB -NONE- O
physically physically 0 0 0 0 0 0 0 0 10 0 NN VBZ RB -NONE- CC O
strenuous, strenuous, 0 0 0 0 1 0 0 0 10 0 VBZ RB -NONE- CC DT O
and and 0 0 0 0 0 0 0 0 3 0 RB -NONE- CC DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 -NONE- CC DT JJ NN O
high high 0 0 0 0 0 0 0 0 4 0 CC DT JJ NN IN O
level level 0 0 0 0 0 0 0 0 5 0 DT JJ NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN JJ NN O
physical physical 0 0 0 0 0 0 0 0 8 0 NN IN JJ NN NNS O
fitness fitness 0 0 0 0 0 0 0 0 7 0 IN JJ NN NNS DT O
increases increases 0 0 0 0 0 0 0 0 9 0 JJ NN NNS DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 NN NNS DT JJ NN O
firefighter's firefighter's 0 0 0 0 0 1 0 0 13 0 NNS DT JJ NN TO O
ability ability 0 0 0 0 0 0 0 0 7 0 DT JJ NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 JJ NN TO VB IN O
cope cope 0 0 0 0 0 0 0 0 4 0 NN TO VB IN DT O
with with 0 0 0 0 0 0 0 0 4 0 TO VB IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 VB IN DT JJ NN O
physical physical 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN IN O
stress stress 0 0 0 0 0 0 0 0 6 0 DT JJ NN IN PRP$ O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN PRP$ NNP O
their their 0 0 0 0 0 0 0 0 5 0 NN IN PRP$ NNP NNP O
profession. profession. 0 0 0 0 0 0 0 0 11 0 IN PRP$ NNP NNP NNS O
Direct Direct 1 0 0 0 0 0 0 0 6 0 PRP$ NNP NNP NNS IN O
measurements measurements 0 0 0 0 0 0 0 0 12 0 NNP NNP NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNS IN JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 NNS IN JJ NN NN O
capacity, capacity, 0 0 0 0 1 0 0 0 9 0 IN JJ NN NN VBP O
however, however, 0 0 0 0 1 0 0 0 8 0 JJ NN NN VBP RB O
are are 0 0 0 0 0 0 0 0 3 0 NN NN VBP RB JJ O
often often 0 0 0 0 0 0 0 0 5 0 NN VBP RB JJ NN O
complicated, complicated, 0 0 0 0 1 0 0 0 12 0 VBP RB JJ NN NN O
time time 0 0 0 0 0 0 0 0 4 0 RB JJ NN NN CC O
consuming, consuming, 0 0 0 0 1 0 0 0 10 0 JJ NN NN CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC NNP NNP O
expensive. expensive. 0 0 0 0 0 0 0 0 10 0 NN CC NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 CC NNP NNP JJ NN O
first first 0 0 0 0 0 0 0 0 5 0 NNP NNP JJ NN IN O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP JJ NN IN DT O
of of 0 0 0 0 0 0 0 0 2 0 JJ NN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN IN DT NN NN O
present present 0 0 0 0 0 0 0 0 7 0 IN DT NN NN VBD O
study study 0 0 0 0 0 0 0 0 5 0 DT NN NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 NN NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB DT O
evaluate evaluate 0 0 0 0 0 0 0 0 8 0 VBD TO VB DT NNS O
the the 0 0 0 0 0 0 0 0 3 0 TO VB DT NNS IN O
correlations correlations 0 0 0 0 0 0 0 0 12 0 VB DT NNS IN JJ O
between between 0 0 0 0 0 0 0 0 7 0 DT NNS IN JJ NN O
direct direct 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NN CC O
(laboratory) (laboratory) 0 0 0 0 0 0 0 0 12 0 IN JJ NN CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 JJ NN CC JJ NN O
indirect indirect 0 0 0 0 0 0 0 0 8 0 NN CC JJ NN JJ O
(field) (field) 0 0 0 0 0 0 0 0 7 0 CC JJ NN JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 JJ NN JJ NN NNS O
capacity capacity 0 0 0 0 0 0 0 0 8 0 NN JJ NN NNS IN O
tests tests 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN NNS IN JJ CC O
common common 0 0 0 0 0 0 0 0 6 0 NNS IN JJ CC RB O
and and 0 0 0 0 0 0 0 0 3 0 IN JJ CC RB VBG O
physically physically 0 0 0 0 0 0 0 0 10 0 JJ CC RB VBG VBG O
demanding demanding 0 0 0 0 0 0 0 0 9 0 CC RB VBG VBG NNP O
firefighting firefighting 0 0 0 0 0 0 0 0 12 0 RB VBG VBG NNP NNP O
tasks. tasks. 0 0 0 0 0 0 0 0 6 0 VBG VBG NNP NNP JJ O
The The 1 0 0 0 0 0 0 0 3 0 VBG NNP NNP JJ NN O
second second 0 0 0 0 0 0 0 0 6 0 NNP NNP JJ NN VBD O
aim aim 0 0 0 0 0 0 0 0 3 0 NNP JJ NN VBD TO O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD TO VB O
to to 0 0 0 0 0 0 0 0 2 0 NN VBD TO VB NNS O
give give 0 0 0 0 0 0 0 0 4 0 VBD TO VB NNS IN O
recommendations recommendations 0 0 0 0 0 0 0 0 15 0 TO VB NNS IN TO O
as as 0 0 0 0 0 0 0 0 2 0 VB NNS IN TO WDT O
to to 0 0 0 0 0 0 0 0 2 0 NNS IN TO WDT NN O
which which 0 0 0 0 0 0 0 0 5 0 IN TO WDT NN NNS O
field field 0 0 0 0 0 0 0 0 5 0 TO WDT NN NNS MD O
tests tests 0 0 0 0 0 0 0 0 5 0 WDT NN NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB DT O
be be 0 0 0 0 0 0 0 0 2 0 NNS MD VB DT JJS O
the the 0 0 0 0 0 0 0 0 3 0 MD VB DT JJS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VB DT JJS JJ IN O
useful useful 0 0 0 0 0 0 0 0 6 0 DT JJS JJ IN NN O
for for 0 0 0 0 0 0 0 0 3 0 JJS JJ IN NN -NONE- O
evaluating evaluating 0 0 0 0 0 0 0 0 10 0 JJ IN NN -NONE- JJ O
firefighters' firefighters' 0 0 0 0 0 1 0 0 13 0 IN NN -NONE- JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 NN -NONE- JJ NN NNP O
work work 0 0 0 0 0 0 0 0 4 0 -NONE- JJ NN NNP DT O
capacity. capacity. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP DT NN O
A A 1 1 0 0 0 0 0 0 1 0 NN NNP DT NN IN O
total total 0 0 0 0 0 0 0 0 5 0 NNP DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NNS O
38 38 0 0 0 0 0 0 1 1 2 0 NN IN CD NNS -NONE- O
subjects subjects 0 0 0 0 0 0 0 0 8 0 IN CD NNS -NONE- NNS O
(26 (26 0 0 0 0 0 0 0 1 3 0 CD NNS -NONE- NNS CC O
men men 0 0 0 0 0 0 0 0 3 0 NNS -NONE- NNS CC CD O
and and 0 0 0 0 0 0 0 0 3 0 -NONE- NNS CC CD NN O
12 12 0 0 0 0 0 0 1 1 2 0 NNS CC CD NN VBD O
women) women) 0 0 0 0 0 0 0 0 6 0 CC CD NN VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 CD NN VBD NNP NNP O
included. included. 0 0 0 0 0 0 0 0 9 0 NN VBD NNP NNP JJ O
Two Two 1 0 0 0 0 0 0 0 3 0 VBD NNP NNP JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 NNP NNP JJ NN NN O
capacity capacity 0 0 0 0 0 0 0 0 8 0 NNP JJ NN NN CD O
tests, tests, 0 0 0 0 1 0 0 0 6 0 JJ NN NN CD NN O
six six 0 0 0 0 0 0 0 0 3 0 NN NN CD NN -NONE- O
field field 0 0 0 0 0 0 0 0 5 0 NN CD NN -NONE- CC O
tests, tests, 0 0 0 0 1 0 0 0 6 0 CD NN -NONE- CC CD O
and and 0 0 0 0 0 0 0 0 3 0 NN -NONE- CC CD VBG O
seven seven 0 0 0 0 0 0 0 0 5 0 -NONE- CC CD VBG NNS O
firefighting firefighting 0 0 0 0 0 0 0 0 12 0 CC CD VBG NNS VBD O
tasks tasks 0 0 0 0 0 0 0 0 5 0 CD VBG NNS VBD NNP O
were were 0 0 0 0 0 0 0 0 4 0 VBG NNS VBD NNP NNP O
performed. performed. 0 0 0 0 0 0 0 0 10 0 NNS VBD NNP NNP VBD O
Lactate Lactate 1 0 0 0 0 0 0 0 7 0 VBD NNP NNP VBD CC O
threshold threshold 0 0 0 0 0 0 0 0 9 0 NNP NNP VBD CC NN O
and and 0 0 0 0 0 0 0 0 3 0 NNP VBD CC NN IN O
onset onset 0 0 0 0 0 0 0 0 5 0 VBD CC NN IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CC NN IN NN NN O
blood blood 0 0 0 0 0 0 0 0 5 0 NN IN NN NN NN O
lactate lactate 0 0 0 0 0 0 0 0 7 0 IN NN NN NN VBD O
accumulation accumulation 0 0 0 0 0 0 0 0 12 0 NN NN NN VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 NN NN VBD VBN TO O
found found 0 0 0 0 0 0 0 0 5 0 NN VBD VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO VB VBN O
be be 0 0 0 0 0 0 0 0 2 0 VBN TO VB VBN TO O
correlated correlated 0 0 0 0 0 0 0 0 10 0 TO VB VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VB VBN TO DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN TO DT NN IN O
performance performance 0 0 0 0 0 0 0 0 11 0 TO DT NN IN CD O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN CD NN O
one one 0 0 0 0 0 0 0 0 3 0 NN IN CD NN NN O
work work 0 0 0 0 0 0 0 0 4 0 IN CD NN NN NNS O
task task 0 0 0 0 0 0 0 0 4 0 CD NN NN NNS : O
(rs (rs 0 0 0 0 0 0 0 0 3 0 NN NN NNS : -NONE- O
= = 0 0 0 0 0 0 0 0 1 0 NN NNS : -NONE- CC O
-0.65 -0.65 0 0 1 0 0 0 0 1 5 0 NNS : -NONE- CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 : -NONE- CC NNP NNP O
-0.63, -0.63, 0 0 1 0 1 0 0 1 6 0 -NONE- CC NNP NNP NNP O
p<0.01, p<0.01, 0 0 0 0 1 0 0 1 7 0 CC NNP NNP NNP NNP O
respectively). respectively). 0 0 0 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
Absolute Absolute 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP NNP CC O
(mL·min(-1)) (mL·min(-1)) 0 0 1 0 0 0 0 1 12 0 NNP NNP NNP CC JJ O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC JJ NN O
relative relative 0 0 0 0 0 0 0 0 8 0 NNP CC JJ NN JJ O
(mL·kg(-1)·min(-1)) (mL·kg(-1)·min(-1)) 0 0 1 0 0 0 0 1 19 0 CC JJ NN JJ JJ O
maximal maximal 0 0 0 0 0 0 0 0 7 0 JJ NN JJ JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 NN JJ JJ NN VBD O
capacity capacity 0 0 0 0 0 0 0 0 8 0 JJ JJ NN VBD VBN O
was was 0 0 0 0 0 0 0 0 3 0 JJ NN VBD VBN TO O
correlated correlated 0 0 0 0 0 0 0 0 10 0 NN VBD VBN TO DT O
to to 0 0 0 0 0 0 0 0 2 0 VBD VBN TO DT CC O
all all 0 0 0 0 0 0 0 0 3 0 VBN TO DT CC CD O
but but 0 0 0 0 0 0 0 0 3 0 TO DT CC CD IN O
one one 0 0 0 0 0 0 0 0 3 0 DT CC CD IN DT O
of of 0 0 0 0 0 0 0 0 2 0 CC CD IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD IN DT NN VBZ O
work work 0 0 0 0 0 0 0 0 4 0 IN DT NN VBZ NNS O
tasks tasks 0 0 0 0 0 0 0 0 5 0 DT NN VBZ NNS : O
(rs (rs 0 0 0 0 0 0 0 0 3 0 NN VBZ NNS : -NONE- O
= = 0 0 0 0 0 0 0 0 1 0 VBZ NNS : -NONE- TO O
-0.79 -0.79 0 0 1 0 0 0 0 1 5 0 NNS : -NONE- TO CD O
to to 0 0 0 0 0 0 0 0 2 0 : -NONE- TO CD CC O
0.55 0.55 0 0 0 0 0 0 0 1 4 0 -NONE- TO CD CC -NONE- O
and and 0 0 0 0 0 0 0 0 3 0 TO CD CC -NONE- TO O
-0.74 -0.74 0 0 1 0 0 0 0 1 5 0 CD CC -NONE- TO CD O
to to 0 0 0 0 0 0 0 0 2 0 CC -NONE- TO CD NN O
0.47, 0.47, 0 0 0 0 1 0 0 1 5 0 -NONE- TO CD NN NNP O
p<0.01, p<0.01, 0 0 0 0 1 0 0 1 7 0 TO CD NN NNP NNP O
respectively). respectively). 0 0 0 0 0 0 0 0 14 0 CD NN NNP NNP NN O
Aerobic Aerobic 1 0 0 0 0 0 0 0 7 0 NN NNP NNP NN VBZ O
capacity capacity 0 0 0 0 0 0 0 0 8 0 NNP NNP NN VBZ JJ O
is is 0 0 0 0 0 0 0 0 2 0 NNP NN VBZ JJ IN O
important important 0 0 0 0 0 0 0 0 9 0 NN VBZ JJ IN JJ O
for for 0 0 0 0 0 0 0 0 3 0 VBZ JJ IN JJ NN O
firefighters' firefighters' 0 0 0 0 0 1 0 0 13 0 JJ IN JJ NN NN O
work work 0 0 0 0 0 0 0 0 4 0 IN JJ NN NN CC O
performance, performance, 0 0 0 0 1 0 0 0 12 0 JJ NN NN CC PRP O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC PRP VBP O
we we 0 0 0 0 0 0 0 0 2 0 NN CC PRP VBP VBN O
have have 0 0 0 0 0 0 0 0 4 0 CC PRP VBP VBN IN O
concluded concluded 0 0 0 0 0 0 0 0 9 0 PRP VBP VBN IN DT O
that that 0 0 0 0 0 0 0 0 4 0 VBP VBN IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 VBN IN DT NN TO O
time time 0 0 0 0 0 0 0 0 4 0 IN DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB CD O
row row 0 0 0 0 0 0 0 0 3 0 NN TO VB CD -NONE- O
500 500 0 0 0 0 0 0 1 1 3 0 TO VB CD -NONE- DT O
m, m, 0 0 0 0 1 0 0 0 2 0 VB CD -NONE- DT NN O
the the 0 0 0 0 0 0 0 0 3 0 CD -NONE- DT NN TO O
time time 0 0 0 0 0 0 0 0 4 0 -NONE- DT NN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 DT NN TO VB CD O
run run 0 0 0 0 0 0 0 0 3 0 NN TO VB CD NN O
3000 3000 0 0 0 0 0 0 1 1 4 0 TO VB CD NN JJ O
m m 0 0 0 0 0 0 0 0 1 0 VB CD NN JJ TO O
relative relative 0 0 0 0 0 0 0 0 8 0 CD NN JJ TO NN O
to to 0 0 0 0 0 0 0 0 2 0 NN JJ TO NN NN O
body body 0 0 0 0 0 0 0 0 4 0 JJ TO NN NN NN O
weight weight 0 0 0 0 0 0 0 0 6 0 TO NN NN NN CC O
(s·kg(-1)), (s·kg(-1)), 0 0 1 0 1 0 0 1 11 0 NN NN NN CC DT O
and and 0 0 0 0 0 0 0 0 3 0 NN NN CC DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NN CC DT NN IN O
percent percent 0 0 0 0 0 0 0 0 7 0 CC DT NN IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN JJ NN O
maximal maximal 0 0 0 0 0 0 0 0 7 0 NN IN JJ NN NN O
heart heart 0 0 0 0 0 0 0 0 5 0 IN JJ NN NN VBD O
rate rate 0 0 0 0 0 0 0 0 4 0 JJ NN NN VBD IN O
achieved achieved 0 0 0 0 0 0 0 0 8 0 NN NN VBD IN NN O
during during 0 0 0 0 0 0 0 0 6 0 NN VBD IN NN VBG O
treadmill treadmill 0 0 0 0 0 0 0 0 9 0 VBD IN NN VBG VBP O
walking walking 0 0 0 0 0 0 0 0 7 0 IN NN VBG VBP DT O
are are 0 0 0 0 0 0 0 0 3 0 NN VBG VBP DT RBS O
the the 0 0 0 0 0 0 0 0 3 0 VBG VBP DT RBS JJ O
most most 0 0 0 0 0 0 0 0 4 0 VBP DT RBS JJ NN O
valid valid 0 0 0 0 0 0 0 0 5 0 DT RBS JJ NN NNS O
field field 0 0 0 0 0 0 0 0 5 0 RBS JJ NN NNS IN O
tests tests 0 0 0 0 0 0 0 0 5 0 JJ NN NNS IN VBG O
for for 0 0 0 0 0 0 0 0 3 0 NN NNS IN VBG DT O
evaluating evaluating 0 0 0 0 0 0 0 0 10 0 NNS IN VBG DT JJ O
a a 0 0 0 0 0 0 0 0 1 0 IN VBG DT JJ JJ O
firefighter's firefighter's 0 0 0 0 0 1 0 0 13 0 VBG DT JJ JJ NN O
aerobic aerobic 0 0 0 0 0 0 0 0 7 0 DT JJ JJ NN NNP O
work work 0 0 0 0 0 0 0 0 4 0 JJ JJ NN NNP NONE O
capacity. capacity. 0 0 0 0 0 0 0 0 9 0 JJ NN NNP NONE NONE O
Comparison Comparison 1 0 0 0 0 0 0 0 10 0 NONE NONE NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NONE NNP IN NNP CC O
Systemic Systemic 1 0 0 0 0 0 0 0 8 0 NNP IN NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 IN NNP CC NNP NNP O
Mucosal Mucosal 1 0 0 0 0 0 0 0 7 0 NNP CC NNP NNP IN O
Immunization Immunization 1 0 0 0 0 0 0 0 12 0 CC NNP NNP IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN JJ NNS O
Helper-Dependent Helper-Dependent 1 0 1 0 0 0 0 0 16 0 NNP IN JJ NNS IN O
Adenoviruses Adenoviruses 1 0 0 0 0 0 0 0 12 0 IN JJ NNS IN NNP O
for for 0 0 0 0 0 0 0 0 3 0 JJ NNS IN NNP IN O
Vaccination Vaccination 1 0 0 0 0 0 0 0 11 0 NNS IN NNP IN NNP O
against against 0 0 0 0 0 0 0 0 7 0 IN NNP IN NNP NNP O
Mucosal Mucosal 1 0 0 0 0 0 0 0 7 0 NNP IN NNP NNP IN O
Challenge Challenge 1 0 0 0 0 0 0 0 9 0 IN NNP NNP IN NNP O
with with 0 0 0 0 0 0 0 0 4 0 NNP NNP IN NNP NNP O
SHIV. SHIV. 1 1 0 0 0 0 0 0 5 0 NNP IN NNP NNP NNP O
Weaver Weaver 1 0 0 0 0 0 0 0 6 0 IN NNP NNP NNP NNP O
EA, EA, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Nehete Nehete 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
PN, PN, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Nehete Nehete 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
BP, BP, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Yang Yang 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Buchl Buchl 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
SJ, SJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Hanley Hanley 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
PW, PW, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Palmer Palmer 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
D, D, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Montefiori Montefiori 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP NNP NNP O
DC, DC, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Ferrari Ferrari 1 0 0 0 0 0 0 0 7 0 NNP NNP NNP NNP NNP O
G, G, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Ng Ng 1 0 0 0 0 0 0 0 2 0 NNP NNP NNP NNP NNP O
P, P, 1 1 0 0 1 0 0 0 2 0 NNP NNP NNP NNP NNP O
Sastry Sastry 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP NNP O
KJ, KJ, 1 1 0 0 1 0 0 0 3 0 NNP NNP NNP NNP NNP O
Barry Barry 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNP NNP O
MA. MA. 1 1 0 0 0 0 0 0 3 0 NNP NNP NNP NNP NNP O
Source Source 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Internal Internal 1 0 0 0 0 0 0 0 8 0 NNP IN NNP NNP NNP O
Medicine, Medicine, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP IN O
Division Division 1 0 0 0 0 0 0 0 8 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Infectious Infectious 1 0 0 0 0 0 0 0 10 0 NNP IN NNP NNP NNP O
Diseases, Diseases, 1 0 0 0 1 0 0 0 9 0 IN NNP NNP NNP NNP O
Translational Translational 1 0 0 0 0 0 0 0 13 0 NNP NNP NNP NNP NNP O
Immunovirology Immunovirology 1 0 0 0 0 0 0 0 14 0 NNP NNP NNP NNP NNP O
Program, Program, 1 0 0 0 1 0 0 0 8 0 NNP NNP NNP NNP IN O
Department Department 1 0 0 0 0 0 0 0 10 0 NNP NNP NNP IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNP IN NNP NNP O
Immunology, Immunology, 1 0 0 0 1 0 0 0 11 0 NNP IN NNP NNP NNP O
Mayo Mayo 1 0 0 0 0 0 0 0 4 0 IN NNP NNP NNP NNP O
Clinic, Clinic, 1 0 0 0 1 0 0 0 7 0 NNP NNP NNP NNP NNP O
Rochester, Rochester, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNP O
Minnesota, Minnesota, 1 0 0 0 1 0 0 0 10 0 NNP NNP NNP NNP NNPS O
United United 1 0 0 0 0 0 0 0 6 0 NNP NNP NNP NNPS IN O
States States 1 0 0 0 0 0 0 0 6 0 NNP NNP NNPS IN NNP O
of of 0 0 0 0 0 0 0 0 2 0 NNP NNPS IN NNP NNP O
America. America. 1 0 0 0 0 0 0 0 8 0 NNPS IN NNP NNP NNP O
Abstract Abstract 1 0 0 0 0 0 0 0 8 0 IN NNP NNP NNP -NONE- O
Most Most 1 0 0 0 0 0 0 0 4 0 NNP NNP NNP -NONE- NNS O
HIV-1 HIV-1 1 1 1 0 0 0 0 1 5 0 NNP NNP -NONE- NNS VBP O
infections infections 0 0 0 0 0 0 0 0 10 0 NNP -NONE- NNS VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 -NONE- NNS VBP VBN TO O
thought thought 0 0 0 0 0 0 0 0 7 0 NNS VBP VBN TO VB O
to to 0 0 0 0 0 0 0 0 2 0 VBP VBN TO VB IN O
occur occur 0 0 0 0 0 0 0 0 5 0 VBN TO VB IN NN O
at at 0 0 0 0 0 0 0 0 2 0 TO VB IN NN NNS O
mucosal mucosal 0 0 0 0 0 0 0 0 7 0 VB IN NN NNS IN O
surfaces surfaces 0 0 0 0 0 0 0 0 8 0 IN NN NNS IN JJ O
during during 0 0 0 0 0 0 0 0 6 0 NN NNS IN JJ NNP O
sexual sexual 0 0 0 0 0 0 0 0 6 0 NNS IN JJ NNP NNP O
contact. contact. 0 0 0 0 0 0 0 0 8 0 IN JJ NNP NNP VBZ O
It It 1 0 0 0 0 0 0 0 2 0 JJ NNP NNP VBZ VBN O
has has 0 0 0 0 0 0 0 0 3 0 NNP NNP VBZ VBN VBN O
been been 0 0 0 0 0 0 0 0 4 0 NNP VBZ VBN VBN IN O
hypothesized hypothesized 0 0 0 0 0 0 0 0 12 0 VBZ VBN VBN IN NNS O
that that 0 0 0 0 0 0 0 0 4 0 VBN VBN IN NNS VBN O
vaccines vaccines 0 0 0 0 0 0 0 0 8 0 VBN IN NNS VBN IN O
delivered delivered 0 0 0 0 0 0 0 0 9 0 IN NNS VBN IN NN O
at at 0 0 0 0 0 0 0 0 2 0 NNS VBN IN NN NNS O
mucosal mucosal 0 0 0 0 0 0 0 0 7 0 VBN IN NN NNS MD O
surfaces surfaces 0 0 0 0 0 0 0 0 8 0 IN NN NNS MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NNS MD VB JJR O
mediate mediate 0 0 0 0 0 0 0 0 7 0 NNS MD VB JJR NN O
better better 0 0 0 0 0 0 0 0 6 0 MD VB JJR NN IN O
protection protection 0 0 0 0 0 0 0 0 10 0 VB JJR NN IN -NONE- O
against against 0 0 0 0 0 0 0 0 7 0 JJR NN IN -NONE- IN O
HIV-1 HIV-1 1 1 1 0 0 0 0 1 5 0 NN IN -NONE- IN NNS O
than than 0 0 0 0 0 0 0 0 4 0 IN -NONE- IN NNS WDT O
vaccines vaccines 0 0 0 0 0 0 0 0 8 0 -NONE- IN NNS WDT VBP O
that that 0 0 0 0 0 0 0 0 4 0 IN NNS WDT VBP VBN O
are are 0 0 0 0 0 0 0 0 3 0 NNS WDT VBP VBN NNP O
delivered delivered 0 0 0 0 0 0 0 0 9 0 WDT VBP VBN NNP NNP O
systemically. systemically. 0 0 0 0 0 0 0 0 13 0 VBP VBN NNP NNP NN O
To To 1 0 0 0 0 0 0 0 2 0 VBN NNP NNP NN NN O
test test 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NN VBZ O
this, this, 0 0 0 0 1 0 0 0 5 0 NNP NN NN VBZ NNS O
rhesus rhesus 0 0 0 0 0 0 0 0 6 0 NN NN VBZ NNS VBD O
macaques macaques 0 0 0 0 0 0 0 0 8 0 NN VBZ NNS VBD VBN O
were were 0 0 0 0 0 0 0 0 4 0 VBZ NNS VBD VBN IN O
vaccinated vaccinated 0 0 0 0 0 0 0 0 10 0 NNS VBD VBN IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 VBD VBN IN JJ NN O
intramuscular intramuscular 0 0 0 0 0 0 0 0 13 0 VBN IN JJ NN CC O
(i.m.) (i.m.) 0 0 0 0 0 0 0 0 6 0 IN JJ NN CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 JJ NN CC JJ NN O
intravaginal intravaginal 0 0 0 0 0 0 0 0 12 0 NN CC JJ NN VBZ O
(ivag.) (ivag.) 0 0 0 0 0 0 0 0 7 0 CC JJ NN VBZ IN O
routes routes 0 0 0 0 0 0 0 0 6 0 JJ NN VBZ IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 NN VBZ IN JJ JJ O
helper-dependent helper-dependent 0 0 1 0 0 0 0 0 16 0 VBZ IN JJ JJ NN O
adenoviral adenoviral 0 0 0 0 0 0 0 0 10 0 IN JJ JJ NN NNS O
(HD-Ad) (HD-Ad) 0 0 1 0 0 0 0 0 7 0 JJ JJ NN NNS VBG O
vectors vectors 0 0 0 0 0 0 0 0 7 0 JJ NN NNS VBG -NONE- O
expressing expressing 0 0 0 0 0 0 0 0 10 0 NN NNS VBG -NONE- NNP O
HIV-1 HIV-1 1 1 1 0 0 0 0 1 5 0 NNS VBG -NONE- NNP NNP O
envelope. envelope. 0 0 0 0 0 0 0 0 9 0 VBG -NONE- NNP NNP VBD O
Macaques Macaques 1 0 0 0 0 0 0 0 8 0 -NONE- NNP NNP VBD JJ O
were were 0 0 0 0 0 0 0 0 4 0 NNP NNP VBD JJ VBN O
first first 0 0 0 0 0 0 0 0 5 0 NNP VBD JJ VBN RB O
immunized immunized 0 0 0 0 0 0 0 0 9 0 VBD JJ VBN RB IN O
intranasally intranasally 0 0 0 0 0 0 0 0 12 0 JJ VBN RB IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 VBN RB IN NNS NNP O
species species 0 0 0 0 0 0 0 0 7 0 RB IN NNS NNP NNP O
C C 1 1 0 0 0 0 0 0 1 0 IN NNS NNP NNP NN O
Ad Ad 1 0 0 0 0 0 0 0 2 0 NNS NNP NNP NN CD O
serotype serotype 0 0 0 0 0 0 0 0 8 0 NNP NNP NN CD NN O
5 5 0 0 0 0 0 0 1 1 1 0 NNP NN CD NN RB O
(Ad5) (Ad5) 0 0 0 0 0 0 0 1 5 0 NN CD NN RB TO O
prior prior 0 0 0 0 0 0 0 0 5 0 CD NN RB TO JJ O
to to 0 0 0 0 0 0 0 0 2 0 NN RB TO JJ IN O
serotype-switching serotype-switching 0 0 1 0 0 0 0 0 18 0 RB TO JJ IN NNS O
with with 0 0 0 0 0 0 0 0 4 0 TO JJ IN NNS NNP O
species species 0 0 0 0 0 0 0 0 7 0 JJ IN NNS NNP NNP O
C C 1 1 0 0 0 0 0 0 1 0 IN NNS NNP NNP NNP O
HD-Ad6, HD-Ad6, 1 0 1 0 1 0 0 1 7 0 NNS NNP NNP NNP NNP O
Ad1, Ad1, 1 0 0 0 1 0 0 1 4 0 NNP NNP NNP NNP CC O
Ad5, Ad5, 1 0 0 0 1 0 0 1 4 0 NNP NNP NNP CC NNP O
and and 0 0 0 0 0 0 0 0 3 0 NNP NNP CC NNP NNS O
Ad2 Ad2 1 0 0 0 0 0 0 1 3 0 NNP CC NNP NNS VBG O
vectors vectors 0 0 0 0 0 0 0 0 7 0 CC NNP NNS VBG NN O
expressing expressing 0 0 0 0 0 0 0 0 10 0 NNP NNS VBG NN VBD O
env env 0 0 0 0 0 0 0 0 3 0 NNS VBG NN VBD IN O
followed followed 0 0 0 0 0 0 0 0 8 0 VBG NN VBD IN JJ O
by by 0 0 0 0 0 0 0 0 2 0 NN VBD IN JJ NN O
rectal rectal 0 0 0 0 0 0 0 0 6 0 VBD IN JJ NN IN O
challenge challenge 0 0 0 0 0 0 0 0 9 0 IN JJ NN IN JJ O
with with 0 0 0 0 0 0 0 0 4 0 JJ NN IN JJ NNP O
CCR5-tropic CCR5-tropic 1 0 1 0 0 0 0 1 11 0 NN IN JJ NNP NNP O
SHIV-SF162P3. SHIV-SF162P3. 1 1 1 0 0 0 0 1 13 0 IN JJ NNP NNP IN O
Vaccination Vaccination 1 0 0 0 0 0 0 0 11 0 JJ NNP NNP IN DT O
by by 0 0 0 0 0 0 0 0 2 0 NNP NNP IN DT JJ O
the the 0 0 0 0 0 0 0 0 3 0 NNP IN DT JJ NN O
systemic systemic 0 0 0 0 0 0 0 0 8 0 IN DT JJ NN VBN O
route route 0 0 0 0 0 0 0 0 5 0 DT JJ NN VBN JJR O
generated generated 0 0 0 0 0 0 0 0 9 0 JJ NN VBN JJR JJ O
stronger stronger 0 0 0 0 0 0 0 0 8 0 NN VBN JJR JJ NNP O
systemic systemic 0 0 0 0 0 0 0 0 8 0 VBN JJR JJ NNP NNP O
CD8 CD8 1 1 0 0 0 0 0 1 3 0 JJR JJ NNP NNP NN O
T T 1 1 0 0 0 0 0 0 1 0 JJ NNP NNP NN NNS O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN NNS IN O
responses responses 0 0 0 0 0 0 0 0 9 0 NNP NN NNS IN JJ O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN JJ CC O
PBMC, PBMC, 1 1 0 0 1 0 0 0 5 0 NNS IN JJ CC NN O
but but 0 0 0 0 0 0 0 0 3 0 IN JJ CC NN NN O
weaker weaker 0 0 0 0 0 0 0 0 6 0 JJ CC NN NN NNP O
mucosal mucosal 0 0 0 0 0 0 0 0 7 0 CC NN NN NNP NNP O
responses. responses. 0 0 0 0 0 0 0 0 10 0 NN NN NNP NNP NN O
Conversely, Conversely, 1 0 0 0 1 0 0 0 11 0 NN NNP NNP NN NN O
mucosal mucosal 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NN VBD O
immunization immunization 0 0 0 0 0 0 0 0 12 0 NNP NN NN VBD JJR O
generated generated 0 0 0 0 0 0 0 0 9 0 NN NN VBD JJR NNP O
stronger stronger 0 0 0 0 0 0 0 0 8 0 NN VBD JJR NNP NNP O
CD4 CD4 1 1 0 0 0 0 0 1 3 0 VBD JJR NNP NNP NN O
T T 1 1 0 0 0 0 0 0 1 0 JJR NNP NNP NN JJ O
cell cell 0 0 0 0 0 0 0 0 4 0 NNP NNP NN JJ NN O
central central 0 0 0 0 0 0 0 0 7 0 NNP NN JJ NN NN O
memory memory 0 0 0 0 0 0 0 0 6 0 NN JJ NN NN NNS O
(Tcm) (Tcm) 0 0 0 0 0 0 0 0 5 0 JJ NN NN NNS IN O
responses responses 0 0 0 0 0 0 0 0 9 0 NN NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NNP O
colon. colon. 0 0 0 0 0 0 0 0 6 0 IN DT NNP NNP NN O
Intramuscular Intramuscular 1 0 0 0 0 0 0 0 13 0 DT NNP NNP NN VBD O
immunization immunization 0 0 0 0 0 0 0 0 12 0 NNP NNP NN VBD JJR O
generated generated 0 0 0 0 0 0 0 0 9 0 NNP NN VBD JJR NNS O
higher higher 0 0 0 0 0 0 0 0 6 0 NN VBD JJR NNS IN O
levels levels 0 0 0 0 0 0 0 0 6 0 VBD JJR NNS IN JJ O
of of 0 0 0 0 0 0 0 0 2 0 JJR NNS IN JJ NN O
env-binding env-binding 0 0 1 0 0 0 0 0 11 0 NNS IN JJ NN CC O
antibodies, antibodies, 0 0 0 0 1 0 0 0 11 0 IN JJ NN CC DT O
but but 0 0 0 0 0 0 0 0 3 0 JJ NN CC DT VBN O
neither neither 0 0 0 0 0 0 0 0 7 0 NN CC DT VBN VBG O
produced produced 0 0 0 0 0 0 0 0 8 0 CC DT VBN VBG CC O
neutralizing neutralizing 0 0 0 0 0 0 0 0 12 0 DT VBN VBG CC JJ O
or or 0 0 0 0 0 0 0 0 2 0 VBN VBG CC JJ NNP O
cytotoxic cytotoxic 0 0 0 0 0 0 0 0 9 0 VBG CC JJ NNP NNP O
antibodies. antibodies. 0 0 0 0 0 0 0 0 11 0 CC JJ NNP NNP NN O
After After 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NN NNP O
mucosal mucosal 0 0 0 0 0 0 0 0 7 0 NNP NNP NN NNP NNP O
SHIV SHIV 1 1 0 0 0 0 0 0 4 0 NNP NN NNP NNP DT O
challenge, challenge, 0 0 0 0 1 0 0 0 10 0 NN NNP NNP DT NNS O
both both 0 0 0 0 0 0 0 0 4 0 NNP NNP DT NNS VBD O
groups groups 0 0 0 0 0 0 0 0 6 0 NNP DT NNS VBD NNP O
controlled controlled 0 0 0 0 0 0 0 0 10 0 DT NNS VBD NNP NN O
SHIV SHIV 1 1 0 0 0 0 0 0 4 0 NNS VBD NNP NN IN O
better better 0 0 0 0 0 0 0 0 6 0 VBD NNP NN IN NN O
than than 0 0 0 0 0 0 0 0 4 0 NNP NN IN NN NNP O
control control 0 0 0 0 0 0 0 0 7 0 NN IN NN NNP NNP O
animals. animals. 0 0 0 0 0 0 0 0 8 0 IN NN NNP NNP JJR O
However, However, 1 0 0 0 1 0 0 0 8 0 NN NNP NNP JJR NNS O
more more 0 0 0 0 0 0 0 0 4 0 NNP NNP JJR NNS IN O
animals animals 0 0 0 0 0 0 0 0 7 0 NNP JJR NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 JJR NNS IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NNP NN O
ivag. ivag. 0 0 0 0 0 0 0 0 5 0 IN DT NNP NN VBD O
group group 0 0 0 0 0 0 0 0 5 0 DT NNP NN VBD JJR O
had had 0 0 0 0 0 0 0 0 3 0 NNP NN VBD JJR JJ O
lower lower 0 0 0 0 0 0 0 0 5 0 NN VBD JJR JJ NN O
viral viral 0 0 0 0 0 0 0 0 5 0 VBD JJR JJ NN NNS O
set set 0 0 0 0 0 0 0 0 3 0 JJR JJ NN NNS IN O
points points 0 0 0 0 0 0 0 0 6 0 JJ NN NNS IN IN O
than than 0 0 0 0 0 0 0 0 4 0 NN NNS IN IN IN O
in in 0 0 0 0 0 0 0 0 2 0 NNS IN IN IN DT O
in in 0 0 0 0 0 0 0 0 2 0 IN IN IN DT NNP O
the the 0 0 0 0 0 0 0 0 3 0 IN IN DT NNP NNP O
i.m. i.m. 0 0 0 0 0 0 0 0 4 0 IN DT NNP NNP NNP O
group. group. 0 0 0 0 0 0 0 0 6 0 DT NNP NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 NNP NNP NNP NNS VBP O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS VBP NN O
suggest suggest 0 0 0 0 0 0 0 0 7 0 NNP NNS VBP NN NN O
mucosal mucosal 0 0 0 0 0 0 0 0 7 0 NNS VBP NN NN MD O
vaccination vaccination 0 0 0 0 0 0 0 0 11 0 VBP NN NN MD VB O
may may 0 0 0 0 0 0 0 0 3 0 NN NN MD VB VB O
have have 0 0 0 0 0 0 0 0 4 0 NN MD VB VB NN O
improve improve 0 0 0 0 0 0 0 0 7 0 MD VB VB NN IN O
protection protection 0 0 0 0 0 0 0 0 10 0 VB VB NN IN JJ O
against against 0 0 0 0 0 0 0 0 7 0 VB NN IN JJ NNP O
sexually-transmitted sexually-transmitted 0 0 1 0 0 0 0 0 20 0 NN IN JJ NNP NNP O
HIV. HIV. 1 1 0 0 0 0 0 0 4 0 IN JJ NNP NNP NNS O
These These 1 0 0 0 0 0 0 0 5 0 JJ NNP NNP NNS RB O
data data 0 0 0 0 0 0 0 0 4 0 NNP NNP NNS RB VBP O
also also 0 0 0 0 0 0 0 0 4 0 NNP NNS RB VBP IN O
demonstrate demonstrate 0 0 0 0 0 0 0 0 11 0 NNS RB VBP IN JJ O
that that 0 0 0 0 0 0 0 0 4 0 RB VBP IN JJ NNP O
helper-dependent helper-dependent 0 0 1 0 0 0 0 0 16 0 VBP IN JJ NNP NNS O
Ad Ad 1 0 0 0 0 0 0 0 2 0 IN JJ NNP NNS MD O
vaccines vaccines 0 0 0 0 0 0 0 0 8 0 JJ NNP NNS MD VB O
can can 0 0 0 0 0 0 0 0 3 0 NNP NNS MD VB JJ O
mediate mediate 0 0 0 0 0 0 0 0 7 0 NNS MD VB JJ NN O
robust robust 0 0 0 0 0 0 0 0 6 0 MD VB JJ NN NNS O
vaccine vaccine 0 0 0 0 0 0 0 0 7 0 VB JJ NN NNS IN O
responses responses 0 0 0 0 0 0 0 0 9 0 JJ NN NNS IN DT O
in in 0 0 0 0 0 0 0 0 2 0 NN NNS IN DT NN O
the the 0 0 0 0 0 0 0 0 3 0 NNS IN DT NN IN O
face face 0 0 0 0 0 0 0 0 4 0 IN DT NN IN RB O
of of 0 0 0 0 0 0 0 0 2 0 DT NN IN RB NN O
prior prior 0 0 0 0 0 0 0 0 5 0 NN IN RB NN TO O
immunity immunity 0 0 0 0 0 0 0 0 8 0 IN RB NN TO NNP O
to to 0 0 0 0 0 0 0 0 2 0 RB NN TO NNP CC O
Ad5 Ad5 1 0 0 0 0 0 0 1 3 0 NN TO NNP CC IN O
and and 0 0 0 0 0 0 0 0 3 0 TO NNP CC IN CD O
during during 0 0 0 0 0 0 0 0 6 0 NNP CC IN CD NNS O
four four 0 0 0 0 0 0 0 0 4 0 CC IN CD NNS IN O
rounds rounds 0 0 0 0 0 0 0 0 6 0 IN CD NNS IN NN O
of of 0 0 0 0 0 0 0 0 2 0 CD NNS IN NN NNP O
adenovirus adenovirus 0 0 0 0 0 0 0 0 10 0 NNS IN NN NNP NONE O
vaccination. vaccination. 0 0 0 0 0 0 0 0 12 0 IN NN NNP NONE NONE O
